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Abstract 
Background 
Major depressive disorder (MDD) has been previously recognized as a severely impacting disorder. 
Although effective intervention strategies exist, access to treatment remains low, particularly in 
low- to middle-income countries. The purpose of this thesis was to formulate a complete 
epidemiological profile for MDD. This involved investigating (1) the global distribution of MDD; 
(2) the global burden of MDD in terms of disability-adjusted life years (DALYs), years lived with 
disability (YLDs) and years lost to premature mortality (YLLs) for the Global Burden of Disease 
Study 2010 (GBD 2010); (3) the contribution of MDD as a risk factor to the distribution and burden 
of suicide and ischemic heart disease; and (4) the risk factors of MDD and related avenues for 
further research. Such an epidemiological profile assists in identifying the size of the population 
who may need intervention for MDD. It provides policy-makers with information that can, along 
with considerations of cost-effectiveness and equity, be used in resource allocation within the health 
sector. For researchers, it identifies where the gaps in the literature exist regarding the epidemiology 
of MDD which need to be addressed with future research. 
 
Methods 
A systematic literature review was conducted to capture studies of the prevalence, incidence, 
duration, and excess-mortality associated with MDD. Data points were integrated into a statistical 
disease model using DisMod-MR, a Bayesian meta-regression tool. DisMod-MR predicts 
epidemiological data for parameters and parts of the world with no raw data and also accommodates 
known methodological and ecological determinants of MDD.  
 
To estimate burden, disability weights measuring the severity of health loss from MDD were 
obtained from population survey data. These were combined with DisMod-MR prevalence data to 
calculate YLDs for MDD by age, sex, year, and country. To calculate YLLs, comparative risk 
assessment methodology was used to explore MDD as a risk factor for both suicide and ischemic 
heart disease. Data from additional systematic literature reviews and meta-analyses were used to 
obtain the pooled relative-risk of (1) ischemic heart disease in those exposed to MDD, and (2) 
suicide in those exposed to select mental and substance use disorders including MDD. For each risk 
factor-outcome pairing, population attributable fractions were calculated from the pooled relative-
risks and DisMod-MR prevalence data. These were then used to calculate the proportion of DALYs 
originally allocated to ischemic heart disease and suicide in GBD 2010 which could be re-assigned 
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to MDD.  Finally, an investigation into the risk factors for MDD was presented, with a working 
example of how two previously established risk factors, child sexual abuse (CSA) and intimate 
partner violence (IPV), can impact on the distribution of MDD.  
 
Results 
The literature search for epidemiological data identified 116 prevalence, 4 incidence, 5 duration, 
and 11 excess-mortality studies. DisMod-MR estimated over 298 million point prevalence cases of 
MDD globally in 2010. The global point prevalence was very similar across time, although higher 
in low- to middle-income countries and females aged 25 to 34 years. The annual incidence of an 
episode of MDD followed a similar age and regional pattern to prevalence but was about one and a 
half times higher; consistent with an average duration of 37.7 weeks.  
 
When compared to the 290 other diseases and injuries in GBD 2010, MDD was ranked as the 
second leading cause of YLDs; accounting for 8.2% (5.9%–10.8%) of global YLDs in 2010. MDD 
was also a leading cause of DALYs, accounting for 2.5% (1.9%–3.2%) of global DALYs. 
Additionally, MDD explained 4 million ischemic heart disease DALYs and 16 million suicide 
YLLs. Out of 22.5 million (14.8-29.8 million) suicide YLLs attributable to all mental and substance 
use disorders identified as risk factors for suicide, MDD was responsible for the largest proportion 
(46.1%, 28.0%-60.8%).   
 
Data on the risk factors of MDD were sparse and incomplete however there was sufficient evidence 
to quantify the respective effect of conflict, CSA and IPV on MDD. CSA and IPV had the potential 
to explain up to 63·7% (46·2%-80·2%) of the sex difference in MDD however this finding was 
deemed preliminary given uncertainty and omissions in this data. Further research is required to 
investigate this further, particularly around how the observed effect of CSA and IPV on the sex 
difference of MDD interacts with other risk factors and changes across age, place and time. 
 
Conclusion 
MDD is a common and disabling disorder which imposes significant disease burden on the 
population. It also contributes substantially to the burden allocated to suicide and ischemic heart 
disease. These findings emphasize the importance of including MDD as a public-health priority and 
implementing cost-effectiveness interventions to reduce its burden. There was a paucity of data 
exploring the risk factors for MDD. However, data that were available underlined the importance of 
investigating how interventions to ameliorate the increased risk of MDD from abuse, war, and 
violence can be incorporated into prevention programs.  
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Chapter One: Relevance, aims, and outline of the thesis 
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Context for the thesis 
Major depressive disorder (MDD) has been previously recognised as a severely impacting disorder 
(1). However, although effective intervention strategies exist (2, 3), access to treatment remains 
exceedingly low; particularly in low to middle income countries. Even in high income countries, 
those receiving treatment typically do so many years after the onset of the disorder and few receive 
optimal treatment strategies (2-4).  This has important implications for both national and global 
health agendas, given that increased life expectancy due to better reproductive health, nutrition and 
control of communicable diseases means that more of the population are living to the age where 
MDD is most prevalent (5, 6). 
 
The purpose of this PhD was to formulate an epidemiological profile for MDD. Epidemiology is the 
study of the distribution and determinants of diseases and injuries in a given population, and the 
application of this study to regulate these diseases and injuries (7). By extension, an 
epidemiological profile of MDD describes and quantifies who in the general population has the 
disorder, has recovered, and died as a result of MDD. It identifies characteristics of those with and 
without MDD, behaviours that place people at risk, and their health outcomes. This information 
assists in the identification of people in need of prevention and care services, and ultimately 
facilitates the setting of health policies and service planning for MDD.  
 
Whilst there is considerable literature on the different elements of the epidemiology of MDD, there 
has been little effort placed in integrating these into a comprehensive global epidemiological profile 
for the disorder (8). For the purposes of this PhD, this involved investigating the following areas; 
 The global distribution of MDD in terms of the prevalence, incidence, duration, and excess 
mortality associated with the disorder. 
 The extent to which the distribution of MDD impacts on the health of the population 
compared to other diseases and injuries.  
 The contribution of MDD to other diseases and injuries, namely suicide and ischemic heart 
disease (IHD).  
 The risk factors of MDD and related avenues for further research. 
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Figure 1 illustrates the epidemiological profile of MDD formulated in this thesis. Due to certain 
exposures or risk factors (many of which have yet to be fully understood), people in the general 
population meet diagnostic criteria for MDD and contribute to the incidence of the disease. Incident 
cases go on to inform the number of prevalent cases.  Cases are removed from the prevalence pool 
as they recover (and contribute to the remission rate) or as they die due to MDD (and contribute to 
the cause-specific mortality rate) or other causes  (9). 
 
To reliably quantify the extent to which MDD impacts on the health of the population in its own 
right, as well as in comparison to other diseases, the epidemiological data generated here were used 
to estimate the burden of MDD in the Global Burden of Disease (GBD) Study 2010 (GBD 2010) (5, 
6, 10-13). GBD 2010 estimated the burden associated with 291 diseases (including 20 mental and 
substance use disorders) and 63 risk factors, in terms of disability-adjusted life years (DALYs). 
DALYs provide a consistent unit of measurement to compare the fatal and non-fatal health loss 
associated with different diseases and injuries, across different populations, settings, and years. 
They can directly inform priority setting exercises in national and global health agendas; as well as 
provide the basis from which the effectiveness of existing intervention strategies for MDD and 
other diseases can be monitored over time (5).  
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Figure 1. Illustration of the epidemiological profile of MDD formulated in this thesis. 
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Thesis aims, relevance, and applicability 
Aim One 
Aim one was to formulate a comprehensive model of the global distribution of MDD.  This task 
was separated into two parts; 
 First, it involved conducting a systematic review of the literature to establish the global 
prevalence, incidence, duration and excess mortality associated with MDD; and from this, 
identifying sources of heterogeneity in the data that were ‘real’ versus heterogeneity due to 
differences in study methodology and design. 
 Second, it involved the application of Bayesian meta-regression techniques to model the 
distribution of MDD and adequately adjust for the established sources of heterogeneity in 
the data. 
 
Relevance and applicability 
Information on the epidemiological distribution of a given disease typically forms the empirical 
underpinning for investigating the public health and clinical impact of the disease in the population 
(14). In this case, it provided the basis for investigating all subsequent thesis aims. That said, 
interpretation and generalizability of the available literature on the distribution of MDD (as 
captured in the first part of aim one) was restricted by significant variability in the data obtained 
between studies, missing data, or unequally distributed data across settings, age groups, years and, 
parameters. Bayesian meta-regression statistical modelling techniques (13)  were used here (for the 
second part of aim one) to address these limitations and model the prevalence, incidence, duration 
and excess mortality of MDD for males and females, 20 age groups, 187 countries, 21 world 
regions and, 3 time points. 
 
Aim two 
Aim two was to quantify the global burden of MDD. This aim was conducted as a GBD 2010 
deliverable and involved the use of epidemiological output from aim one. 
 
Relevance and applicability 
The first global burden of disease study in 1990 (GBD 1990) (1) and its updates by the World 
Health Organization (WHO) between 2000 and 2005 (GBD 2000/05) (15, 16) identified depression 
as the leading cause of disability. Although this made notable contributions to shifting international 
focus onto depression as a leading cause of burden, the global prevalence of MDD remains high (8, 
17) and treatment rates remain low (4). 
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To respond to this, it is important to make available comparable estimates of burden, reflective 
of recent statistical and epidemiological advancements in mental health research. This provides 
us with an empirical basis to;  
 Compare and contrast burden due to MDD with burden due to other diseases. 
 Compare and contrast burden due to MDD between countries, regions, sex, age and 
year. 
 Further explore the status of MDD as a leading cause of disease burden and the extent to 
which MDD intervention strategies need to be prioritized in health management plans. 
 Evaluate the effectiveness of existing health policies and services in improving the 
health of individuals with MDD and ultimately reducing its burden. 
 
Aim three 
Aim three was to quantify the burden attributable to MDD and other mental and substance use 
disorders as risk factors for suicide. This involved conducting a literature review to assess and 
compile evidence for mental and substance use disorders as risk factors for suicide. Then, 
estimating (using GBD 2010’s comparative risk assessment (CRA) methodology) the proportion of 
suicide DALYs from GBD 2010 that could be re-assigned to these mental and substance use 
disorders as a result. This work also used the output from aims one and two. 
 
Relevance and applicability 
In spite of evidence showing excess mortality attributable to the majority of mental and substance 
use disorders (18), this cannot be entirely reflected in burden of disease estimations. Mental and 
substance use disorders are rarely identified as primary causes of death in vital registrations (used to 
estimate deaths in GBD 2010) as this typically involves the problematic task of unraveling the 
effect of multiple mental, substance and physical disorders to find the primary cause of death. 
Investigating mental and substance use disorders as  risk factors for fatal outcomes like suicide 
allows us to circumvent this problem (10, 19). 
 
Furthermore, GBD 2010 estimated ‘direct burden’ where mental and substance use disorders were 
the direct cause of health loss, but excluded the excess (attributable) burden resulting from the 
increased risk of mortality and disability due to subsequent health outcomes associated with the 
disorders (19). Here, we expand on the published GBD 2010 findings by estimating the additional 
burden attributable to MDD as well as other mental and substance use disorders as risk factors for 
suicide. Simultaneously considering the direct and the attributable burden of mental and substance 
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use disorders provides a more comprehensive estimation of total burden.  It quantifies the 
relationship between these disorders and their health outcomes which is imperative to the 
identification of the leading (and potentially modifiable) drivers of disability and mortality.  
 
Aim four 
Aim four was to explore the risk factors of MDD, an area of unexplained variability in the 
epidemiological profile of MDD proposed in the thesis.  A key constraint in any form of mental 
health research is dealing with missing (or incomplete) data and sources of unexplained variability 
(14). To deal with missing data in this thesis, methods were put into place to explore gaps in the 
literature, estimate where possible missing data, correct for any inconsistencies due to missing data 
and, incorporate the effect of missing data within the bounds of uncertainty estimated for all high 
level findings. In spite of this, it was not possible to quantify all sources of unexplained variability. 
One of the key areas of unexplained variability pertained to the risk factors of MDD and how these 
impact its global distribution. Although there is considerable literature on the risk factors of mental 
disorders, for most of these risk factors there are insufficient data to fully quantify their association 
with MDD (20-25). The aim here was to identify risk factors for which there was sufficient data to 
quantify their association with MDD, discuss how these risk factors can impact on the global 
distribution of MDD, and highlight areas of this literature requiring further research. 
 
Relevance and applicability 
Quantifying the risk factors of MDD can make key contributions towards the prevention and 
treatment of MDD in vulnerable populations. Effective intervention strategies targeting reductions 
in the duration, severity and deaths associated with MDD exist but can only reduce burden by 10% 
to 30% (3, 26, 27). Although this highlights MDD as a condition where disease prevention can be 
critical, there is also much left to establish by way of effective prevention strategies (28). Aside 
from highlighting opportunities for the further development of the epidemiological model of MDD 
proposed in this thesis, this aim also responds to the lack of research on preventative strategies for 
MDD. 
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Thesis outline 
This thesis is partly comprised by publications. It includes four chapters, each made up of one peer 
reviewed publication attending to aims one to three, and a discussion chapter attending to aim four. 
It also includes a series of additional publications designed to complement this work. Primary 
collection of data was not required. Instead, a series of systematic reviews of the literature was 
conducted to capture studies reporting on the epidemiology of MDD. The thesis is structured as 
follows (see Figure S1 in Appendix One for an illustration of this): 
 
 Chapter One summarizes the context, aims, relevance and, outline of the thesis.  
 
 Chapter Two presents a literature review of the epidemiology of MDD, highlighting the 
gaps and limitations in the literature addressed in the thesis. 
 
 Chapters Three to Seven present the original work conducted as part of the thesis.  Chapter 
Three summarizes available data on the global distribution of MDD; Chapter Four makes 
use of this data to model the distribution of MDD by country, region, age, sex and year; 
Chapter Five quantifies the global burden of MDD for GBD 2010; Chapter Six investigates 
suicide as an outcome of MDD and quantifies the additional burden that can be re-assigned 
to MDD as a result of this; and Chapter Seven explores the available literature on the risk 
factors of MDD, investigates how two of these risk factors can impact on the global 
distribution of MDD, and highlights areas of this literature requiring further research. 
 
 Chapter Eight presents a conclusion for the thesis, highlighting the strengths, limitations and 
implications of the findings, as well as areas for further research. 
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Chapter Two: Literature review 
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Chapter summary 
This literature review is divided into 5 sections pertaining to the aims of the thesis. It provides the 
standard definition for MDD used; then reviews the available literature on the global distribution, 
burden, risk factors, and outcomes of MDD. It also highlights the gaps in the literature which will 
be addressed in the thesis. 
 
Case definition 
For many diseases, the presence of underlying pathogens has been identified and as a result, disease 
definitions and diagnostic tests have been established.  Unfortunately, for mental disorders like 
MDD underlying mechanisms are complex and remain difficult to operationalise.  In Western 
classificatory systems, a diagnosis of MDD is derived by formulating a prognosis based on a set of 
behavioural symptoms and one’s interpretation of associated levels of impairments. Although there 
has been much debate around the generalisability of these definitions to non-Western cultures, it is 
largely accepted that psychological and behavioural disturbances in human populations are present 
in almost all cultures (29, 30). What tends to differ between cultures is the manifestation of these 
psychological and behavioural disturbances as this is reliant on the individual or cultural 
interpretation (31). A relevant example here would be the fact that although some cultures have a 
word to describe ‘sadness’, the concept of depression as a disorder does not exist.  As such, 
individuals are more likely to interpret MDD symptoms as a physical illness (32-35). 
 
For the purposes of this thesis, past conventions (8) were followed in setting a case definition for 
MDD and ‘universalism’ was assumed. Universalism in this context refers to the position that 
although culture may influence their development and display, basic human characteristics such as 
mental disorders are common across all human societies (36, 37). Had it been possible here, a cross-
culturally comparable definition and survey instrument for MDD would have been used to explore 
its global distribution. Unfortunately, (as demonstrated in the next chapter) although Western 
diagnostic systems and survey instruments exist, these are not fully validated in non-Western 
cultures where culturally relevant definitions have yet to be developed (32, 36). Consequently, the 
definition of MDD used in this thesis was based on diagnostic nomenclature from the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-IV-TR) (38) and the International Classification 
of Diseases (ICD-10) (39), two established but predominantly Western-based classificatory systems 
for mental disorders. The alternative would be to exclude from analyses, any country where DSM 
and ICD diagnostic classifications are suspected to be inadequate. Not only is it unclear which 
countries would need to be excluded, but this exclusion means that subsequent burden analyses 
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would essentially assume that the burden due to MDD in these countries is zero, a position 
considered to be indefensible (8). 
 
According to the DSM-IV-TR, MDD (DSM-IV-TR: 296.2) forms part of the depressive disorders 
sub-group of mood disorders which also includes dysthymia (DSM-IV-TR: 300.4) and depression 
not otherwise specified (NOS) (DSM-IV-TR: 311). MDD is an episodic disorder characterized by at 
least one major depressive episode (MDE). A MDE involves symptoms of depressed mood and/or 
loss of interest causing clinically significant impairment in the main areas of functioning (38). The 
equivalence as defined by the ICD-10 is characterized by at least 2 of the following symptoms; 
depressed mood, loss of interest and /or fatigue (ICD-10: F-32) (39).  Dysthymia is also 
characterized by symptoms of depressive mood but differentiated from MDD by severity, and 
chronicity. To meet a diagnosis of MDD, depressed mood must be experienced mostly all day and 
every day for a minimum of 2 weeks. To meet a diagnosis of dysthymia depressed mood must be 
experienced for some but not necessarily all days over a minimum period of 2 years. Depression 
NOS is characterized by clinically significant presentations of depressed mood which do not meet 
criteria for MDD or dysthymia (38). 
 
MDD cases can also be categorized in terms of severity. The DSM-IV-TR defines the severity of 
MDD in terms of whether the symptoms experienced lead to mild, moderate or severe impairment 
to occupational and social functioning. Severe episodes can also include psychotic features such as 
delusions and hallucinations (38).  The ICD-10 on the other hand, defines the severity of MDD in 
terms of both impairment and the number of symptoms experienced. A mild state involves 2 or 3 
symptoms with minimal distress to daily activities. A moderate state involves 4 or more symptoms 
with great difficulty in continuing daily activities. A severe state involves the presence of numerous 
symptoms which are all distressing to daily activities, with suicidal thoughts and psychosis often 
present (39). 
 
There are slight differences in how the DSM-IV and ICD-10 define MDD but they were both 
included here to allow for maximum data inclusion. Restricting data inclusion to either one of these 
diagnostic sources would significantly reduce the global representativeness of findings. However, to 
further ensure comparability, the effect of diagnostic criteria (i.e. DSM vs. ICD diagnoses) on 
prevalence was investigated.  
 
Differences in definition aside, both ICD and DSM make use of relatively precise and homogenous 
criteria (based on the presenting clinical features of a given disorder) to diagnose a mental disorder 
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(38, 39). Although this categorical approach to defining depression has made significant 
contributions towards formulating an adequate nosological system for the disorder (40), some 
limitations exist.  It’s been argued that in diagnosing MDD, DSM/ICD criteria attempt to impose 
boundaries upon what is essentially a continuum of depressive symptoms. Applying artificial 
cutoffs to dimensional features such as symptom frequency, severity and duration may lead to 
measurement error (40-42). This can have important implications to establishing the epidemiology 
of MDD. For instance, it affects whether a proportion of  what is currently classified as 
‘substhreshold cases’  of depression by DSM and ICD classifications should be considered while 
quantifying the global distribution, risk factors and outcomes  of MDD.   
 
Another challenge with DSM and ICD definitions of MDD is that they change over time. In 2014, 
DSM-5, the updated version of DSM-IV was published (43). Although the same categorical 
approach to diagnosing depression was used in DSM-5, some key changes to the criteria were 
made. Notably, the ‘bereavement exclusion’ criterion present in DSM-IV was omitted in DSM-5. 
This criterion stipulated that a diagnosis of MDD could only be made following bereavement if 
symptoms were present for longer than two months, included  significant functional impairment, 
suicide ideation, psychotic symptoms, or psychomotor retardation (38). Instead of making use of 
this criterion, the text in DSM-5 seeks to differentiate between a MDE and a normal or expected 
response to a significant loss, but essentially, individuals diagnosed with severe depression in 
response to bereavement can be treated as having a mental disorder (43). The clinical and 
epidemiological  impacts of this change in criteria have already been subjected to much debate (44) 
but new population surveys of prevalence, incidence, remission, duration of MDD using DSM-V 
rather than DSM-IV criteria are required before  they can be included in the present thesis. 
Similarly, a new version of ICD-10 is also underway (45). The extent to which the definition of 
MDD will differ from the current ICD-10 definition has yet to be determined. 
 
Although limitations to DSM-IV and ICD-10 definitions of MDD exist, their use ensured a level of 
consistency and comparability between the definitions of MDD used between studies. That being 
said, it is important to acknowledge here that the concept of MDD as a disease entity may be more 
heterogeneous than what has been investigated in the thesis. As more data are made available on the 
distribution of MDD following DSM-5 or alternative culturally-sensitive definitions of MDD, the 
baseline estimates presented here using DSM-IV and ICD-10 can be expanded upon. 
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The global distribution of major depressive disorder 
Aim one of this thesis was to formulate a comprehensive model of the global distribution of MDD.  
The distribution of a disease in the population is typically quantified in terms of its prevalence, 
incidence, duration and associated excess-mortality (7, 14). Table 1 describes each of these 
epidemiological parameters in relation to MDD. 
 
Table 1. Summary of parameters investigated for the global distribution of MDD 
 
Parameter Definition 
Prevalence The proportion of the population with  MDD at a specific point in time 
(point/current/past month prevalence) or during a specified time period (6-, 12-
month prevalence) (14) 
Incidence The number of new cases of MDD in the population in one year (7). 
 
Duration The average length of a MDE (46). 
 
Excess 
mortality 
rate 
The rate of dying in people with MDD compared to the general population. This 
can be presented as a relative-risk (RR, ratio of observed death in the sample to 
expected death in the population) or a standardised mortality ratio  (SMR, ratio 
of observed deaths in the sample to expected death in a population of standard 
composition in terms of age, sex, etc.) (14). 
 
 
A review of the literature on the global distribution of MDD revealed that although there are 
numerous publications on MDD epidemiology, the global representativeness and quality of the data 
were limited. Interpretation and synthesis of the data were difficult given variations in the choice of 
instruments used to capture MDD in the population, sampling methodology and statistical analyses 
used between studies. Gaps in data availability also limited interpretation.   
 
For instance, a review by Paykel and collaborators reported that the pooled 12-month prevalence of 
MDD in Europe (Spain, Italy, France, Belgium, Netherlands, Germany, Finland, and United 
Kingdom) was 5%.  Although a set of inclusion criteria enforced a minimum quality on the studies 
included, limitations remained.  The geographic representativeness, age range, survey instrument 
and prevalence type used to capture the data varied between studies, introducing heterogeneity in 
the pooled prevalence estimate.  Another major obstacle was the paucity of data, particularly from 
Eastern European countries, limiting representativeness (47).  Another survey of the prevalence of 
MDD in Belgium, France, Germany, Netherlands, Spain, and United Kingdom reported that the 
pooled 6-month prevalence of MDD was higher at 6.9% (48). It too was restricted to a Western 
European sample.   
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A review of MDD in the Asia Pacific region (Australia, China, Hong Kong, Japan, Malaysia, 
Singapore, Taiwan, Thailand and Korea) reported that point prevalence ranged between 1.3% and 
5.5%, 12-month prevalence ranged between 1.7% and 6.7%, and lifetime prevalence ranged 
between 1.1% and 19.9%. The availability of data from Asian countries was poor and the data 
available often used very different definitions of MDD (49). A more global review summarizing the 
prevalence of MDD in the United States, Canada, Puerto Rico, France, West Germany, Italy, 
Lebanon, Taiwan, Korea, and New Zealand reported that the 12-month prevalence varied between 
0.8% in Taiwan and 5.8% in New Zealand. Although there were significant cross-national 
differences in prevalence, females consistently had higher prevalence than males and the mean age 
of onset was consistently in the mid to late twenties (50). Again, the age range, sample size, and 
response rate varied substantially between survey sites. 
 
In most cases, the epidemiological studies reviewed were not designed to be systematically 
compared with one another, but instead, to inform local decisions in priority setting and evaluation 
(51). Consequently, it remained unclear whether the differences in prevalence reported were ‘real’ 
or whether they were driven by between-study differences in methodology and design.  A solution 
to this would be to carry out a cross-national survey which captured the prevalence of MDD using 
consistent methodology for data collection and assessment. The closest we have to this gold 
standard for MDD is the World Mental Health Survey (WMHS) Consortium, which conducted 
representative population surveys of common mental disorders in 28 countries (17). That said, the 
variability in the prevalence of MDD between WMHS sites is far from trivial (19). For instance, the 
12-month prevalence of MDD ranged from 1.1% of adults in Nigeria to 10.4% of adults in Brazil - 
São Paulo. Women had higher prevalence than men and the mean duration of a MDE ranged from 
23.1 to 33.8 weeks depending on the sample (17, 52). It is possible that these represented true 
variability in the global distribution of MDD however despite using a standard cross-national study 
protocol,  differences remained in the methodology used to capture data between sites (17). The 
national representativeness of samples varied between survey sites. For instance, surveys conducted 
in Brazil, India, Japan, Nigeria, and the People’s Republic of China used regionally- rather than 
nationally-representative samples. The amount of missing data and response rates were also 
different between sites. The WMHS relied on the WHO Composite International Diagnostic 
Interview (CIDI) to capture cases of MDD.  Although the CIDI has been extensively used in 
Western countries, its reliability and validity in non-Western countries remains unclear. It has been 
argued that the prevalence of MDD, as captured by the CIDI is likely to be underestimated in non-
Western countries as the CIDI is not sensitive to cross-cultural presentations of this disorder (53-
55).  Furthermore, in the WMHS, the CIDI was administered by lay as opposed to clinically trained 
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interviewers, the latter of which has been found to be more sensitive to capturing non-Western 
presentations of mental disorders (56-58).  This has also been found to the case for other diagnostic 
instruments which like the CIDI, can be mapped to DSM/ICD definitions but have yet to be fully 
validated in non-Western contexts (32). As previously explained, due to limitations in the available 
definition for MDD, a standard case definition was derived using DSM and ICD classifications and 
only diagnostic tools which could map to these definitions were considered in the thesis. To further 
ensure comparability, differences in the surveyed prevalence of MDD between countries, 
instruments, classificatory systems, and interviewer type were investigated. 
 
The problem of heterogeneity between studies (or survey sites) is also apparent while comparing 
literature on the excess mortality of MDD. Evidence for  an increased risk of death for those with 
MDD compared to the risk of death in the general population has been based on aggregated data 
from studies with considerably different methodology (18, 59-62).  For instance, previous meta-
analyses of all-cause mortality due to MDD in community-based samples reported pooled effect 
sizes ranging from 1.56 to 1.81 [36, 38, 40]. The definition of depression used also varied between 
studies, with estimates derived from both clinically defined depression (i.e. MDD based on 
DSM/ICD criteria) and sub-clinical MDD captured through symptom scales (59). Assuming that the 
severity of MDD has a significant effect on the risk mortality, the inclusion of sub-clinical MDD 
may bias findings (59). 
A search for studies on the incidence and duration of MDD introduced the issue of inconsistent 
data. Paykel and collaborators concluded that the overall incidence of MDD was unclear because of 
a lack of longitudinal follow-up of cases available (47). The few longitudinal studies that do report 
incidence data (63-67) suggest that MDD has an annual incidence rate of between 1.6 and 7.4 per 
100 person years. As many of these surveys excluded those diagnosed with MDD at baseline, new 
episodes of MDD in people with previous episodes were not counted. Given that the DSM-IV-TR 
and ICD-10 define MDD as an episodic disorder, where the individual can experience more than 
one MDE, the incidence of MDD would have been underestimated in these studies. As the data on 
how long depressive episodes persist is also limited, this also makes it difficult to derive globally 
representative estimates of the duration of a MDE (46, 68). Expert consensus sets the average 
duration of MDE at approximately 0.50 of a year (46, 68). Although this is useful, it does not 
replace high quality raw data. 
 
Overall, we can conclude from the literature that there are more data available on the prevalence of 
MDD compared to its incidence, duration and excess mortality. There are less data available from 
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low to middle income countries and the data available are unequally distributed between age, sex, 
and year or, are limited in terms of study methodology and design (17, 48, 69, 70). These 
limitations would restrict the epidemiological profile of MDD formulated for this thesis. As such, 
measures needed to be put in place to supplement them, in the absence of more reliable data. These 
measures are discussed in greater detail in Chapters Three and Four.  
 
The global burden of major depressive disorder 
Aim two of the thesis was to quantify the global burden of MDD. In order to improve the health 
outcomes of people with MDD, we must understand not only the distribution of those with MDD 
between countries but also its ‘disease burden’ i.e. the extent of the health loss caused by MDD in a 
given population compared with health loss due to other diseases and injuries. Historically, 
decisions around which diseases and injuries to prioritise in global and national health agendas were 
informed by mortality statistics. Although this enhanced our understanding of diseases and injuries 
causing premature mortality, the lack of emphasis on morbidity underestimated the contribution of 
prevalent and disabling diseases associated with lower rates of mortality (such as MDD)  (71, 72). 
As a result, our understanding of the comparative global epidemiology as well as the identification 
of the cost effective interventions strategies for MDD (and other mental and substance use 
disorders) has been considerably limited compared to other diseases. 
 
The initiative to quantify and compare the global burden of diseases in terms of both mortality and 
morbidity was introduced by the World Bank in their 1993 World Development Report (71). The 
report proposed a new generic summary measure of health - the DALY- to capture the burden 
attributable to diseases and injuries. DALYs represent a ‘health gap’. They quantify the current state 
of a population’s health compared to a gold standard, which is for the entire population to live with 
perfect health for the duration of the standard life expectancy. One DALY corresponds to the loss of 
one healthy year of life. They are calculated by summing years lost to premature mortality (YLLs) 
and years lived with disability (YLDs) (5, 72).  
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In order to calculate YLDs, the prevalence or incidence of a given disease in the population is 
multiplied by the average disability associated with the disease. Disability is limited to ‘within the 
skin’ decrements in functioning (such as body functions, senses, cognition and ambulation) and is 
quantified using a ‘disability weight’ ranging from 0 (perfect health) to 1 (death) (12, 13). 
 
                
P= number of prevalent cases; I=number of incident cases 
DW = disability weight 
 
 
To estimate YLLs, the number of deaths attributable to the disease is multiplied by the standard life 
expectancy at the age at which death occurs. The standard life expectancy reflects the lowest death 
rates recorded in a given year (11).  
 
             
N = number of deaths attributable to the disease 
L = standard life expectancy at age of death (in years). 
 
The first GBD study (GBD 1990) estimated DALYs for 107 diseases and injuries for 8 world 
regions (1). This included the burden of ‘unipolar depression’, an amalgamation of single-episode 
depression (ICD-10: F 32; DSM IV TR: 296.2), recurrent depression (ICD 10: F 33; DSM IV TR: 
296.3) and dysthymia (ICD 10:F34.1; DSM IV TR: 300.4) (1, 38, 39, 73). Unipolar depression 
explained 3.7% of global DALYs, making it the 4th leading cause of burden worldwide (1, 38, 39).  
GBD 1990 was followed by a series of updates with partial revisions of the data inputs between 
2000 and 2005 (GBD 2000/05), by the WHO.  GBD 2000/05 was however still largely based on the 
GBD 1990’s methodology. It provided us with burden estimates for 135 diseases and injuries for 6 
world regions and 14 sub regions (16). Unipolar depression explained 4.3% of DALYs, elevating 
itself to the 3rd leading cause of burden worldwide from the GBD 1990 results. It was also the 
primary cause of disability, explaining 13.4% of YLDs in women and 8.3% in men  (15). 
 
Both GBD 1990 and 2000/05 highlighted unipolar depression as a leading contributor of disease 
burden, with its burden exceeding that of diseases such as cerebrovascular disease and cancer (1, 
15). This finding made notable contributions to shifting international focus onto depression in 
public health agendas and the addition of mental health interventions to health management plans 
(74). That said, in spite of this effort, treatment rates remain low for depression, particularly in low- 
to middle income countries (4). For this reason, it remains important to make available comparable 
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estimates of burden, which incorporate current statistical and epidemiological advancements in 
mental health research.  
 
Furthermore, a review of the literature for responses to GBD 1990 and 2000/05 findings revealed 
parts of the burden estimation methodology in need of further improvement. Unipolar depression, 
as defined by GBD 1990 and 2000/05 was found to be too heterogeneous. Recent investigation into 
the presentation of depressive disorders shows that the illness occurs across of wide spectrum of 
severity and course. Consequently a ‘one-size-fits-all’ approach as used in GBD 1990 and 2000/05 
is not suitable (75).  There is also debate around the suitability of epidemiological data used in the 
estimation of YLDs for unipolar depression in GBD 1990 and 2000/05. Datasets were based on 
selected ‘best’ data sources rather than from a systematic review of the literature (1, 15).  Brhlikova 
and collaborators argued that the epidemiological studies included in the GBD 2000/05 study for 
unipolar depression were  limited in study design and methodology and in some instances violated 
GBD inclusion criteria (69).  Disability weights for unipolar depression were derived by health 
professionals using the person trade off method. This involved a trade-off exercise where target 
individuals traded off years lived with and without different disabilities first individually, then as a 
group consensus. This exercise was purposefully designed to be deliberative so that participants 
could be as comprehensive as possible in their evaluations (1). Kruijshaar and collaborators argued 
that this was not the most informed method to make complex comparisons about the disability 
attributable to depression. Health professionals likely made judgments based on the clinical 
presentation of depression which is typically more severe than the presentation of depression in the 
general population, thereby inflating disability and subsequently burden (76). 
 
In late 2012, high-level findings from GBD 2010, the latest iteration of the GBD studies were 
released. GBD 2010 included an all-inclusive re-analysis of burden for 291 diseases and injuries 
and 63 risk factors, across 187 countries, 21 world regions, males and females, 1990, 2005, 2010, 
and 20 different age groups. It represented the most comprehensive analysis of disease burden to 
date (5, 6, 10-13). Aim two of the thesis focused on estimating the global burden of depressive 
disorders. Analysis of data for this thesis aim was conducted concurrently to GBD 2010 and served 
as a deliverable for the study. The methodology for estimating the burden of MDD was re-evaluated 
with considerations given to the mentioned limitations. Chapter Five presents the method used and 
burden findings for both MDD and dysthymia. The inclusion of the latter disorder enabled 
comparison of the extent to which MDD contributes to disease burden to other forms of depression.  
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The health outcomes of major depressive disorder   
Aim three of the thesis was to quantify the burden attributable to MDD as a risk factor for other 
fatal health outcomes. The term ‘risk factor’ in this thesis refers to an entity (in this case MDD) that 
increases the likelihood of disease, injury or death (10). 
 
Two pathways have been proposed in explaining health outcomes associated with MDD. The first 
relates to an increased likelihood of adverse health behaviors in individuals with MDD compared to 
the general population (59). For instance, depression has been linked with an increased risk of 
substance use (77-81) and other life threatening behavior (82, 83). The second pathway relates to 
individuals with MDD having a biological predisposition to certain health outcomes (84). For 
instance, depression has been linked to an increased risk of cancer (84) and  IHD (85). 
A literature review by Baxter and collaborators investigating the adequacy of available data 
required to establish causality (as per Bradford Hill’s criteria (86, 87))  between mental and 
substance use disorders and other health outcomes concluded that although there was a broad array 
of literature linking MDD to other health consequences the quality and representativeness of this 
literature was lacking. For most health outcomes (cancers, diabetes, injuries), data were restricted in 
terms of inconsistent definition of cases, risk factors and outcomes, poor generalizability of 
findings, and little or no consideration given to confounding factors (88). There was however 
sufficient evidence to confidently infer an association between (1) MDD and IHD and (2) a 
selection of mental and substance use disorders (including MDD) and suicide. 
 
Charlson and collaborators’ systematic review quantifying the association between MDD and IHD 
concluded that pooled relative-risk (RR) of developing IHD in those with depression was 1.56 
(1.30- 1.87). There was sufficient data to establish a temporal and dose–response relationship 
between depression and IHD, as well as plausible behavioral and biological pathways (85, 89). 
 
 The relationship between mental and substance use disorders and suicide has also been well studied 
(18, 74, 82, 83, 88, 90-92). Studies using a case cohort/series design have consistently shown an 
increased risk of suicide in those with mental and substance use disorders compared to the general 
population. Although it varies by sex and disorder type, this association remains significant after 
adjusting for the presence of other risk factors such as adverse marital and employment status. 
Overall, the pooled RR of suicide has been found to be approximately 7.5 (6.2-9.0) times higher in 
males and 11.7 (9.7-14.1) times higher in females with a mental disorder compared to males and 
females with no mental disorder (83). Mood disorders such as MDD are typically associated with 
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greater risk than other disorders such as schizophrenia, substance abuse, anxiety disorder and 
personality disorders (82, 83). 
 
In spite of the evidence for MDD as a risk factor for IHD and suicide, only substance use disorders, 
anorexia nervosa, and schizophrenia are documented as causes of death in the ICD-10 cause of 
death guidelines (39). ICD-10 stipulates that deaths can only be assigned to a given condition when 
the disorder is considered as the direct cause of death. As such, IHD or suicide deaths occurring as a 
result of MDD are coded to cardiovascular disease and self-imposed injuries respectively. Even for 
those few mental and substance disorders recognised as direct causes of death, vital registrations 
typically assign very few deaths due to them as it is not always possible to separate the effect of 
various mental, substance and physical disorders to ascertain the principal cause of death. Given 
that the estimation of deaths and YLLs in GBD studies are derived from vital registry data, previous 
GBD studies as well as GBD 2010 presented  no YLLs for MDD and very few for other mental and 
substance use disorders. Instead, deaths due to mental and substance use disorders were captured 
elsewhere in the GBD’s mutually exclusive list of diseases and injuries (11, 19). 
 
Investigating mental and substance use disorders as risk factors for fatal outcomes allows us to 
circumvent this problem by making use of a CRA methodology (10). Rather than rely on 
certification and coding practices in mortality registration systems, this method quantifies the 
difference in population health given a counterfactual with a theoretical minimum level of exposure 
(10).  In addition to estimating the burden of diseases and injuries as a ‘direct’ cause of health loss, 
GBD studies make use of this CRA methodology to quantify  the excess (attributable) burden 
resulting from diseases and injuries being risk factors for other health outcomes.  However, despite 
the fact that GBD 2010 presented on the direct burden of 20 mental and substance use disorders, 
only substance use disorders were investigated as risk factors (10).  
 
The purpose of aim three of the thesis was to estimate the additional burden attributable to MDD as 
a risk factor for other fatal health outcomes. This work was intended to (1) supplement the lack of 
deaths and YLLs recorded for MDD in spite of evidence of excess-mortality associated with the 
disorder, for instance in the form of suicide and IHD; and (2) estimate the additional burden due to 
MDD as a risk factor for other health outcomes. These are useful as they offer an estimation of the 
putative causal relationships between MDD and other health outcomes. They also help explain the 
disability and mortality that potentially can be modified by interventions to prevent and treat MDD. 
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Although both IHD and suicide were investigated as outcomes of MDD and went on to inform the 
epidemiological profile being formulated in this thesis, MDD as a risk factor for IHD was not 
considered a core PhD deliverable as the work undertaken was shared between multiple researchers 
(85, 89). Instead (1) the magnitude of the risk of suicide due to all mental and substance use 
disorders; and (2) the contribution of MDD on suicide within this group, were investigated. Other 
mental and substance use disorders were included here as it is important from a public health 
perspective to not only estimate the burden attributable to MDD as a risk factor for other health 
outcomes, but also to consider the relative impact of MDD compared to other mental and substance 
use disorders.  
 
The risk factors of major depressive disorder 
Aim four was to explore the risk factors of MDD. One of the key areas of unexplained variability in 
mental health research pertains to the risk factors of mental disorders. Diseases (such as HIV/AIDs) 
are diagnosed based on the presence of a virus or pathogen regardless of symptoms or their impact 
on the individual. Mental disorders on the other hand, are diagnosed (to date) based on a set of 
behavioural symptoms and our interpretation of associated levels of impairment. This makes the 
risk factors of mental disorders more difficult to assess and quantify (93). 
 
Nonetheless, a complete epidemiological profile of MDD also requires an understanding of how 
ecological factors (e.g. environmental, cultural and biological factors) influence the distribution of 
the disorder. This has enabled better understanding of  causal pathways for other disorders like 
schizophrenia, cancers, auto-immune diseases, and infectious diseases (93). It has also contributed 
to both clinical and public health domains by providing evidence based rationale for explaining and 
controlling the occurrence of diseases in the population (94).   
 
Although there have been a number of ecological variables identified as risk factors for MDD (20-
25), for most of these risk factors there are insufficient data to fully quantify their association with 
MDD and/or establish causality (88). GBD 2010’s review of the published and unpublished 
literature for risk factor-outcome pairings concluded that there was sufficient evidence  to estimate 
attributable burden for two accepted risk factors of MDD ― child sexual abuse (CSA)  and intimate 
partner violence (IPV) (10). Merits for inclusion of these risk factors were assessed using criteria 
(e.g. (1) relevance of the risk factor to disease burden or policy; (2) availability of data to estimate 
the global distribution of the risk factor and effect sizes; (3) availability and strength of the evidence 
for causal effects) which were in line with accepted frameworks for establishing causality in 
epidemiological research (86). 
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CSA is defined as all forms of sexual abuse occurring before the age of 18. This includes both 
contact forms (e.g. rape) and non-contact forms (e.g. non-contact exposure of genitalia, threatened 
sexual violence) (95).  IPV is defined as violence where the victim is 15 years or older and the 
perpetrator is the current or ex-intimate partner of the victim (96). The association between both 
risk factors and MDD has been well established and includes evidence from longitudinal twin 
studies (which typically offer robust means of assessing confounding effects between early life risk 
factors), quantifying the link between traumatic events and an increased risk of MDD (97-99).  
In GBD 2010, the previously defined CRA methodology was used to quantify the global proportion 
of MDD cases attributable to CSA and IPV respectively. In this instance, the proportion of MDD 
prevalent cases averted given a counterfactual absence of ever having experienced CSA or IPV in 
the population (10) was investigated. Findings showed that  CSA accounted for 5.1% and IPV for 
11.4%  of MDD DALYs respectively (10). With MDD established as one of the leading causes of 
burden worldwide by GBD 2010 (5, 13), this has salient implications for effectively reducing its 
ubiquitous burden.  
 
In many countries, particularly low to middle income countries where there are high levels of 
gender inequality, women are considerably more likely to be exposed to CSA and IPV than men. 
Furthermore, women are likely to experience more chronic patterns of abuse and violence, more 
controlling and threatening behaviour and are more likely to be injured and killed by abuse and 
violence  than men (100-102) .  
It is conceivable that the sex difference in exposure to CSA and IPV also impacts on the sex 
difference in MDD. Females are up to two times more likely to have MDD than males. This finding 
has been replicated in many cross-national epidemiological surveys (103-107) and has been linked 
to the incidence of depression rather than its duration or re-occurrence (103, 105, 106). Explanatory 
models consisting of biological, social and psychological pathways have been proposed but have 
yet to be fully quantified (103, 107-110). For instance, it has been suggested that women may be 
more susceptible to depression due to changes in body chemistry and hormonal systems during the 
reproductive years, gender-role associated stress or, exposure to traumatic life events which activate 
stress hormones and affect the balance of neurotransmitters in the brain (103, 107).  
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The purpose of aim four of the thesis was to explore the risk factors of MDD, an area of 
unexplained variability in the epidemiological profile of MDD proposed. This involved 
investigating how two established risk factors of MDD (CSA and IPV) can impact on its global 
distribution. This work can contribute further to quantifying the heterogeneity within the 
epidemiology of MDD i.e. investigating how much of the variability is ‘real’ and how much can be 
explained by methodological factors. Further work on establishing potentially avertable risk factors 
to MDD will also inform the setting of  preventative intervention strategies for MDD which is 
currently lacking (28). 
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Chapter review 
This chapter reviewed the available literature on the epidemiology of MDD. Despite the many 
publications on this topic, there remains significant gaps in the literature, with more to be learnt for 
instance about the risk factors of MDD, differences in its distribution between countries, how it 
impacts on the population, and how it compares to other diseases and injuries. Upcoming chapters 
present the original research undertaken in this thesis, focused on responding to these research 
questions and aims of the thesis. Chapter Three pertains to aim one, which was to review the 
available data and summarise the global distribution of MDD.  
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Chapter Three: Global variation in the prevalence and incidence of major depressive 
disorder: A systematic review of the epidemiological literature 
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Chapter summary 
Background 
Summarising the epidemiology of MDD at a global level is complicated by significant 
heterogeneity in the data. The aim of this study is to present a global summary of the prevalence 
and incidence of MDD, accounting for sources of bias, and dealing with heterogeneity. Findings are 
informing MDD burden quantification in GBD 2010.   
 
Method 
A systematic review of prevalence and incidence of MDD was undertaken. Electronic databases 
Medline, PsycInfo and EMBASE were searched. Community-representative studies adhering to 
suitable diagnostic nomenclature were included. A meta-regression was conducted to explore 
sources of heterogeneity in prevalence and guide the stratification of data in a meta-analysis. 
 
Results 
The literature search identified 116 prevalence and 4 incidence studies. Prevalence period, sex, year 
of study, depression subtype, survey instrument, age and region were significant determinants of 
prevalence, explaining 57.7% of the variability between studies. The global point prevalence of 
MDD, adjusting for methodological differences was 4.7% (4.4%-5.0%). The pooled annual 
incidence was 3.0% (2.4%-3.8%), clearly at odds with the pooled prevalence estimates and the 
previously reported average duration of 30 weeks for an episode of MDD.  
 
Conclusion 
 Our findings provide a comprehensive and up-to-date profile of the prevalence of MDD globally. 
Region and study methodology influenced the prevalence of MDD. This needs to be considered in 
the GBD 2010 study and in investigations into the ecological determinants of MDD. Good quality 
estimates from low/middle income countries were sparse. More accurate data on incidence are also 
required.  
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Introduction 
Depressive disorders as defined by the DSM-IV-TR typically present in adolescence or early adult 
life, can be chronic or episodic and are frequently recurrent and comorbid with substance abuse or 
other mental and physical health conditions (38). The burden attributed to depressive disorders 
worldwide is a major public health concern. The GBD study measures disease burden in terms of 
the DALY. This is the sum of YLLs and YLDs (1). The GBD 1990 study reported that depressive 
disorders were the 4th leading cause of burden, accounting for 3.7% of DALYs in 1990 (1).  By 
2000/05 they were the 3rd leading cause of burden accounting for 4.3% of DALYs, and the leading 
cause of disability, accounting for 13.4% of YLDs in women and 8.3% in men  (15). 
 
Our understanding of the public health importance of mental disorders, including their impact on 
other health conditions (74, 111) will be enhanced by the GBD 2010 study currently underway 
(112). This will quantify burden for over 220 diseases (including 11 mental disorders) by country 
and 21 world regions for the years 1990, 2005 and 2010. It will use significantly improved 
methodology compared to the GBD 1990 study, including more representative disability weight 
estimations (see:  http://www.globalburden.org/).  In the GBD 2010 study, a dimensional approach 
is being taken, with burden being calculated for major MDD i.e. one or more MDEs using three 
severity levels, and dysthymia separately. This will enable burden estimates to encapsulate 
differences in morbidity within and between depressive disorder subtypes (113-115). 
 
To quantify the morbidity (i.e. YLD) attributable to MDD in the GBD 2010 study, epidemiological 
data were required to describe the disease occurrence and course of illness (see Table S1, Appendix 
Two for definitions of the data required). Although there is a wealth of literature on the different 
epidemiological parameters of MDD, this has yet to be systematically summarised at a global level. 
Aside from informing the GBD 2010 study, such an integrated summary has both clinical and 
public health applications (116-118). However, this task is complicated by the presence of 
significant heterogeneity in the data. Heterogeneity refers to both the variability in epidemiological 
estimates resulting from true differences in the epidemiology of MDD and the variability produced 
by differences in the methodology used to capture data (51, 52) 
 
 Literature reviews on the prevalence and incidence of MDD have consistently raised the issue of 
heterogeneity. The GBD 2000/05 update estimated that the 12-month prevalence of a MDE was 
1.6% in males and 2.5% in females. Predicted (from prevalence estimates) annual incidence was 
3.2% in males and 4.9% in females (15). An analytical review of the GBD 2000/05 update 
28 
 
concluded that there was a lack of data on unipolar depression and significant heterogeneity across 
epidemiological estimates (69). 
 
Paykel and collaborators’ review of MDD in Europe reporting a 12-month prevalence of 5% also 
revealed significant gaps in the literature.  The incidence of MDD was unclear because of the lack 
of longitudinal follow-up of cases and there was limited data from Eastern Europe (47). Another 
review investigating the prevalence of MDD in the United States, Canada, Puerto Rico, France, 
West Germany, Italy, Lebanon, Taiwan, Korea, and New Zealand revealed significant regional 
variation in prevalence. The 12-month prevalence of MDD ranged from 0.8% in Taiwan to 5.8% in 
New Zealand (50). Explaining this regional variation is difficult given differences in the 
methodology used by the different studies (51). 
 
In an attempt to control for this, the WMHS Consortium conducted population surveys in 28 
countries using a standard protocol for data collection and assessment. The CIDI was used to 
diagnose cases of MDE (52) Results revealed regional variation in the 12-month prevalence of a 
MDE, ranging from 2.2% in Japan to 10.4% in Brazil with similar averages of 5.5% in developed 
and 5.9% in developing countries. The average duration of an episode estimated from WMHS 
ranged from 23.1 to 33.8 weeks (17, 52, 119).These differences may reflect true regional variability 
in the epidemiology of MDE. However, despite WMHS’ standardised procedure, some limitations 
were reported. Notably, validation exercises involving the CIDI have been completed almost 
entirely in Western countries; hence its cross-cultural reliability and validity remains unclear (4, 52, 
120). 
 
The aim of this paper is to summarise the global prevalence and incidence of MDD exploring the 
global distribution and sources of heterogeneity and, where feasible, adjusting for variability caused 
by differences in study methodology and design. This will help identify true differences in the 
global distribution of MDD that need to be considered in the integration of the epidemiological 
data. This work was undertaken by the GBD Mental Disorders Research Group 
(http://www.qcmhr.uq.edu. au/ BODP). 
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Methods 
Literature review                                                                                                                                                                            
The systematic review adhered to guidelines recommended by the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement (121). Electronic databases Medline 
(via CSA), PsycInfo and EMBASE were used. Search strings were derived in consultation with a 
research librarian. For more information on the search strings, see    
http://www.gbd.unsw.edu.au/gbdweb.nsf/resources/MD_Pt2_SearchStrings/$file/MDSearch+string
s_2.pdf. Publications in languages other than English were included. Although the search was 
limited to studies published between 1980 and 2007, continuing perusal of the literature and 
correspondence with experts in the field allowed us to capture additional studies up to 2011.   
 
Inclusion and exclusion. Population based surveys representative of the community, region or 
country were included. Non-representative subsets of the population such as samples based on in-
patient admissions or treatment trials were excluded. Studies adhering to DSM or ICD diagnostic 
classifications were preferred to allow for better consistency in the measurement of MDD; however 
studies using symptom scales that only broadly map on to DSM/ICD diagnostic thresholds were 
included for comparison.  Where the same data were reported across different papers the most 
informative paper was selected. 
 
For prevalence, we included studies reporting point (i.e. current or past-month prevalence), 6- 
and/or 12-month prevalence. Lifetime estimates were excluded as these are more prone to recall 
bias (122-125). Estimates of MDD were the focus; however if studies reported estimates of 
depression NOS these were included for comparison. Studies reporting incidence hazards were 
included (i.e. those with person years of follow-up in the denominator). Estimates of probability 
such as cumulative incidence based on longer risk intervals were excluded.  
 
Extraction. Data extracted included information on the country and year of study, parameter value 
and type (e.g. point or 12-month prevalence), sample coverage (community, regional, national), 
sample urbanicity (rural, urban, mixed), sex (male, female, persons), age range, case ascertainment 
period (recorded as the midyear time point), response rate, depression subtype (MDD or MDD + 
depression NOS), diagnostic criteria (ICD, DSM) and survey instrument (diagnostic instruments, 
symptom scales). Countries were stratified into regions based on the GBD categorisation of regions 
(see http://www.globalburden.com.au/project-description). Forced entry of key variables was 
required for quality assurance. A random sample of papers was reviewed by two researchers to 
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check consistency of data extraction. Where differences occurred, reviewers discussed these with 
the study’s primary investigator (HAW) to arrive at a consensus. 
 
Uncertainty (standard error (SE) or confidence interval) pertaining to each prevalence or incidence 
estimate was extracted if reported or otherwise calculated. If the denominator (sex- and/or age-
specific sample size) was reported, SE was calculated using SE = √2.1*(P*(1–P)/N) where P is the 
proportion of cases reported, 2.1 is the average design effect and N is the denominator. The average 
design effect accounted for any increase in uncertainty produced by a study’s sampling 
methodology. It was calculated based on a sample of 110 design effects from the GBD Mental 
Disorders Research Group’s affective disorders dataset. If the denominator was not reported by age 
and sex, the United Nation’s country-, sex-, age- and year-specific population size was used to 
distribute the overall sample size across age and sex categories (126). 
 
Analysis 
Prevalence. For prevalence, Stata II.2 software (http://www.stata.com/) was used to conduct a 
meta-regression (127) to help explain the variability between studies.  We based our statistical 
methodology on previous applications of meta-regression to explore the effect of methodological 
and ecological variables on prevalence (127-129). Since the distribution of prevalence estimates 
was positively skewed, logarithmic transformation (natural log) was applied to meet the parametric 
assumption of normality (130). 
 
Results from the meta-regression guided the stratification of pooled prevalence estimates in the 
subsequent meta-analysis (127). As it is essential for GBD purposes to avoid any overestimation in 
burden estimates, point prevalence is considered as the gold standard as it is less susceptible to 
recall bias compared to estimates of period prevalence (113-115). For this reason, it was also set as 
the primary summary measure here as well as in the upcoming GBD disease modelling of MDD for 
which this literature review was undertaken.  
 
Statistical heterogeneity was quantified using the I
2
 statistic, which indicates the total variation in 
the data attributable to heterogeneity (131). A random effects model was selected over the fixed 
effects model to accommodate for heterogeneity (132, 133). We used the post-estimation ‘predict’ 
command to estimate overall prevalence by region, accommodating for methodological factors. 
This command fitted a value to each reported prevalence estimate and the associated SE based on 
the coefficients from the meta-regression (134). 
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Incidence. Similar methods of pooling incidence were used as described for prevalence. However, 
the paucity of incidence estimates did not permit us to conduct a meta-regression.  
 
Results 
Out of 32,579 data sources on the epidemiology of MDD only 120 studies fitted the inclusion 
criteria for prevalence and incidence. The search and main reasons for exclusion are summarised in 
figure 2. A summary of the studies included for each parameter is given in Tables S2 and S3, 
Appendix Two.        
  
Prevalence                                                                                                                                                                                   
One hundred and sixteen studies reporting the prevalence of MDD were included, the majority of 
which were from Western countries i.e. Europe and North America (n=74). We identified 11 studies 
reporting both MDD and depression NOS and 22 studies using a symptom scale. There was 
considerable variability between estimates. Point prevalence ranged from 0.05% in males from 
Japan aged 65 years or older (135) to 73% in females from Afghanistan aged 15 years or older 
(136). 
 
To maximise inclusion, potential outliers in the dataset with no salient methodological limitation 
were retained and investigated further through the meta-regression. To ensure independence of 
observations, where person as well as sex-specific estimates were reported by the same study only 
the latter were included in analyses. Where age-specific and overall-age estimates were reported, 
only the latter were included. Where only age-specific estimates were reported, these were 
combined to calculate the overall-age prevalence i.e. the summed number of cases across each age 
group was divided by the summed denominator across each age group. This reduced the final 
dataset from 783 to 274 prevalence estimates. To investigate the effect of age on prevalence, 
estimates were grouped into 4 broad categories: whole age range (e.g. 0 to 99 years), <18 years, 18-
65 years and >65 years. Where reported age ranges could fit into more than one category they were 
allocated to the most representative one on a case-by-case basis. 
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Records identified through electronic database 
search  (n = 32,579 )
PsycINFO (n =14,110) 
Medline (n =17,268) 
Embase (n =7,481)
 6,280 Duplicates removed
Additional records identified 
through other sources (n = 36)
Sources found post 2007 (n =7)
Grey literature (n = 6 )
World Mental Health Surveys (n = 23)
Full text articles assessed for eligibility 
(n = 936)
Studies included in quantitative analysis 
(n= 120)
Prevalence
(n = 116)
Incidence
(n = 4)
Records excluded after abstract/title 
search 
e.g. sample not representative, 
not primary data, epidemiological 
estimates not reported  
( n = 31,643)
Papers excluded after full-text review.
e.g.  lifetime prevalence reported, 
prevalence could not be calculated, 
clinical diagnostic criteria not used, 
duplicated studies
(n = 852)
 
 
Figure 2. Flowchart showing results of the systematic review for the prevalence and incidence of 
MDD. 
 
In the meta-regression, study-level variables were inserted  in the model first (model 1), and the 
country-level variable (region) second (model 2). Coverage and urbanicity variables were excluded 
from both models  as they were signficantly correlated with the majority of other variables, 
particularly with the region variable, which is a major focus of this paper. Model 1 explained 43.1% 
of the between study variance (Adjusted R
2
  43.1%, F(11, 265)= 16.9, p<0.001). Prevalence type, 
sex, midyear of case ascertainment, age range, depression subtype and survey instrument were 
statistically significant determinants of reported prevalence (table 2). Diagnostic criteria were not 
significantly associated with prevalence. 
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Prevalence was statistically higher for past year prevalence compared to point, in females compared 
to males and persons, in studies capturing MDD and depression NOS  compared to MDD alone, 
and in studies with more recent case ascertainments. Persons under 18 years had lower prevalence 
than persons across the overall age group and studies that used symptom scales reported a higher  
prevalence than studies where DSM or ICD criteria were used. The survey instrument variable was 
originally made up of 8 categories, summarising the most frequent instruments in the dataset. The 
CIDI was used as the reference as it was the most commonly reported. This variable was 
dichotomised in the final model because symptom scales were the only instruments to yield 
signicantly different prevalence estimates at p<0.001. Results were similar when clinical interview 
(interviews conducted by a clinician) were used instead of the CIDI as the reference, with only 
symptoms scales (p<0.001) and the Geriatric Mental State Schedule (p<0.041) yielding statistically 
significant results. 
 
The inclusion of the region variable in model 2 explained an additional 14.6% of the between study 
variance. The overall variance explained by study- and country-level variables combined was 
57.7% (Adjusted R
2
  57.7%, F(19, 257)=16.5, p<0.001). Prevalence period, sex, midyear of case 
ascertainment, depression subtype, survey instrument and age range remained statistically 
significant determinants of reported prevalence in model 2. When Western Europe, the region with 
the most data, was set as the reference, a statistically significant effect of region emerged  such that 
prevalence from South America, South Asia and Africa/Middle East was statistically higher than 
prevalence from Western Europe. Estimates from  East/Southeast Asia and Asia Pacific, High 
Income were statistically lower. Similar results were obtained when North America was used as the 
reference, except that South America and North Africa/Middle East no longer yielded statistically 
higher prevalence.  
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Table 2. Results of meta-regression models showing odds ratios for reported prevalence by study- 
and country-level determinants. 
 
 Unadjusted
a 
Adjusted (Model 1)
b 
Adjusted (Model 2)
c 
Determinant Odds ratio  
(95% uncertainty) 
p value 
< 
Odds ratio  
(95% 
uncertainty) 
p value < Odds ratio  
(95% 
uncertainty) 
p 
value 
< 
Prevalence period Reference: Point      
12 month 
prevalence 
1.02 (0.79-1.32) 0.853 1.2 (1.0-1.5)* 0.048* 1.3 (1.1-1.6) 0.007
* 
Sex Reference: Female      
Male 0.6 (0.5-0.7)* 0.001* 0.6 (0.5-0.7)* 0.001* 0.6 (0.5-0.7) 0.001
* 
Total 0.7 (0.5-0.9)* 0.009* 0.7 (0.6-0.9)* 0.012* 0.7 (0.6-0.9) 0.008
* 
Midyear of case 
ascertainment
d
  
1.03 (1.01-1.05)* 0.003* 1.02 (1.00-
1.03)* 
0.036* 1.02 (1.01-1.04) 0.002
* 
Age (years) Reference: Overall age 
groups (0-99 years) 
     
18-65 1.02 (0.78-1.34) 0.864 1.2 (0.9-1.5) 0.145 1.2 (0.9-1.5) 0.067 
<18 0.7 (0.5-1.0)* 0.025* 0.6 (0.4-0.7)* 0.001* 0.6 (0.4-0.7) 0.001
* 
>65 0.5 (0.4-0.7)* 0.001* 0.98 (0.73-
1.33) 
0.913 1.1 (0.8-1.4) 0.568 
Depression 
subtype 
Reference: MDD only      
MDD + 
Depression NOS 
0.6 (0.4-0.8)* 0.002* 1.96 (1.47-
2.62)* 
0.001* 2.1 (1.6-2.8) 0.001
* 
Diagnostic 
criteria 
Reference: DSM      
ICD 0.8 (0.6-1.2) 0.281 0.95  (0.72-
1.25) 
0.697 0.9 (0.7-1.2) 0.390 
Not specified 3.3 (1.9-5.8)* 0.001* 1.5 (0.9-2.5) 0.145 1.5 (0.9-2.5) 0.106 
Survey 
instrument 
Reference: DSM/ICD 
tools 
     
Symptom scale 3.4 (2.6-4.6)* 0.001* 3.6 (2.6-5.0)* 0.001* 2.9 (2.1-4.0) 0.001
* 
Region Reference: Western 
Europe 
     
Central/Eastern 
Europe 
1.5 (0.9-2.4) 0.132   1.3 (0.9-2.0) 0.143 
North America 0.9 (0.6-1.3) 0.563   1.2 (0.9-1.6) 0.200 
South America 1.3 (0.9-1.9) 0.148   1.6 (1.5-2.1)* 0.004
* 
Australasia 0.8 (0.5-1.2) 0.281   0.9 (0.6-1.3) 0.580 
East/Southeast 
Asia 
0.4 (0.3 -0.6) 0.001*   0.4 (0.3-0.6)* 0.001
* 
South Asia 3.3 (1.8-6.2) 0.001*   2.1 (1.2-3.6)* 0.006
* 
Asia Pacific, High 
Income 
0.6 (0.3-1.0) 0.045*   0.4 (0.3-0.7)* 0.001
* 
Africa/Middle East 1.9 (1.4-2.7) 0.001*   1.4 (1.1-1.8)* 0.042
* 
Note. The response rate variable was exlcuded from the model as it did not contribute to the overall variance explained. 
a
Unadjusted results represent meta-regression ran on indiviual variables without countrolling for the effect of others. 
b
Adjusted model 1 results represent meta-regression ran on study-level variables only. 
c
Adjusted model 2 results 
represent meta-regression ran on study- and country-level variables. 
d
Midyear of case ascertainment modelled as a 
continuous variable. *Statistical significance at p<0.05. 
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A series of meta-analyses was used to further illustrate the effect of statistically significant 
determinants of prevalence. Reported prevalence was pooled according to each statistically 
significant study-level determinant (table 3). For each determinant, reported prevalence was also 
pooled by sex, but there was insuffient data to simultaneously stratify prevalence by all other 
determinants. To address this limitation, prevalence was also predicted for each region while 
adjusting for the effects of study-level determinants  in model 2 (figure 3). Although reduced, cross-
national differences in prevalence persisted after adjusting for study-level determinants of 
prevalence. Notably, although adjusted downwards, estimates from South Asia and Africa/Middle 
East remained the highest in the dataset, and although adjusted upwards, estimates from 
East/Southeast Asia remained amongst the lowest. Estimates from Asia Pacific were no longer 
amongst the lowest. The adjusted and unadjusted prevalence by region is summarised in Table S4, 
Appendix Two. 
 
Table 3.Pooled reported prevalence stratified by study-level determinants statistically associated 
with prevalence. 
 Female (n= 82) Male (n=79) Person (n=34) 
Determinant  Prevalence 
 (95% CI) 
Prevalence 
(95% CI) 
Prevalence            
(95% CI) 
Prevalence period      
Point (n=82) 5.9 (4.7-7.5) 3.8 (3.2-4.5) 4.7 (3.7-5.5) 
12 months (n=47) 7.2 (6.0-8.9) 3.9 (3.0-5.1) 3.7 (2.7-5.0) 
Depression subtype      
MDD only (n=105) 5.8 (4.7-7.1) 3.5 (2.9-4.2) 4.2 (3.4-5.2) 
MDD + depression NOS (n=11) 10.2 (8.9-12.1) 6.4 (5.2-7.9) 7.2 (4.3-11.8) 
Survey instrument      
DSM/ICD tool (n=94) 5.4 (4.9-6.1) 3.1 (2.7-3.6) 3.8 (3.1-4.6) 
Symptom scale (n=22) 17.03 (11.46-
25.28) 
11.6 (7.5-18.0) 12.1 (9.3-15.7) 
Note. For each determinant, prevalence was additionally pooled only by sex hence did not account for the effect of all 
other determinants of prevalence. All I
2
 statistics were >90%; n: number of studies in each group; CI:Confidence 
interval. 
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Note. Map derived using MapInfo Professional. Version 10.5.2. (2010) Pitney Bowes Software Inc. Troy, New York; 
Map Projection: Robinson WGS84. 
Figure 3. Predicted point prevalence by region, adjusted for study level determinants. 
 
Incidence                                                                                                                                                                         
Only 4 studies (64-67)  reporting annual incidence rates of MDD from USA, Canada and Ethiopia 
were identified. Estimates ranged from 1.6% in females aged 18 years or above to 7.1% in females 
aged 15 to 19 years, from the USA. Male and female estimates across overall age groups were 
pooled to calculate an overall estimate of annual incidence (table 4). Total estimates were only 
included if sex-specific estimates were not reported. Although pooled female estimates were higher 
than pooled male estimates,  there was no statistically significant effect of sex. Since there were 
only 3 estimates in each group, more data is required to make a definitive statement on whether a 
difference exists. 
 
Table 4. Pooled estimates of annual incidence. 
 
Sex Incidence (95% CI) Weight (%)
a 
Female (n=3) 3.4 (1.9-6.3) 48.0 
Male (n=3) 2.7 (2.0-3.7) 49.1 
Total (n=1) 2.4 (0.7-8.4) 2.9 
Overall (n=7) 3.0 (2.4-3.8) 100.00 
Note. All I
2
 statistics were  >86%; n is the number of estimates in each group; CI:Confidence interval; 
a
Random effects 
weights. 
 
Discussion 
The majority of the literature on prevalence was from Western Europe and North America with 
much less from non-Western regions. Prevalence data were highly sensitive to elements of study 
design and methodology. Consistent with existing literature, prevalence in females was higher than 
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in males (107, 137, 138) and 12-month prevalence was higher than point prevalence (139-141).  
Given these results, it would be reasonable to assume that when pooled by gender and prevalence 
type simultaneously, pooled 12-month prevalence would be higher than pooled point prevalence; 
however this was not the case. For persons pooled 12-month prevalence was lower than pooled 
point prevalence although this result was not statistically significant.  Pursuing the reason for this 
finding was outside the scope of this study however, similar unanticipated results have been 
reported in literature pertaining to the prevalence of schizophrenia (142). It must also be noted that 
prevalence was pooled by prevalence type and sex only due to lack of data. Controlling for the other 
significant study-level determinants of prevalence as was done in the meta-regression may have 
yielded different results.  
 
 Symptom scales were the only survey instruments significantly associated with prevalence, 
suggesting adequate consistency between the other diagnostic tools in the MDD literature. There 
has been continuous debate as to whether symptom scales are better suited to measuring mental 
disorder symptoms or psychological distress (143-145) . In this case, we found that symptom scales 
inflated the overall prevalence of MDD. That said, they were often the only tools used to capture 
prevalence, particularly in conflict settings where epidemiological data is sparse (146). In order to 
maximize the global representativeness of our findings we chose to include prevalence estimates 
derived from symptoms scales. We adjusted for any inflation to pooled prevalence by specifying 
that prevalence derived from diagnostic tools was the gold standard. This is consistent with the 
methodology used by other authors specifying that data from symptoms scales need to be 
‘recalibrated’ relative to data from diagnostic tools (145, 147, 148). Despite some differences in the 
DSM and ICD definitions of MDD, diagnostic criteria did not have a statistically significant effect 
on prevalence. 
 
We detected a time effect suggesting that the prevalence of MDD had increased over time. This was 
based on an ecological comparison of the midpoint of the case ascertainment period, as a 
continuous variable. It’s possible that this finding represented a true increase in prevalence. 
Alternatively, it could be due to other methodological or ecological differences across time that we 
were unable to capture. More in-depth investigation is required to confirm this finding. The only 
age effect found was from the <18 years age group, which yielded lower estimates compared to 
estimates across the entire lifespan. This was likely due to estimates from very young children (e.g. 
8-9 years) in the <18 year old group. However, drawing conclusions from this variable is also 
problematic given that we could only categorize age using 4 broad age categories and some age 
ranges could be allocated to multiple categories. We used broad as opposed to age-specific 
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estimates as the latter would violate the parametric assumption of independent observations 
required in a meta-regression. A more detailed comparison of prevalence across the lifespan is 
required for better conclusions 
We detected considerable regional differences in the prevalence of MDD, some of which were 
reduced when study-level sources of variability were controlled for. Although our finding of higher 
prevalence of MDD in developing regions (except for Asia East/Southeast) compared to developed 
regions corresponded to WMHS results,  our overall adjusted point prevalence of 4.7% was higher 
than the WMHS finding of 1.8% point prevalence in developed countries and 2.6% in developing 
countries. Instead, it was closer to the 5.5% 12-month prevalence in developed countries (52). The 
higher point prevalence obtained here may be due to the adjustments made for differences in study 
methodology. Despite WMHS efforts to enforce a standardised methodology, differences still 
occurred. Response rates and the amount of missing data varied substantially across countries which 
may have reduced the representativeness of some samples (4, 52, 120). The WMHS used data 
collected by the CIDI only. Our broader focus allowed us to include data from countries that were 
not part of the WMHS, using other diagnostic instruments. That said, our inclusion of prevalence 
derived from symptom scales must be treated with caution given the possibility of inflating final 
results with presentations of MDD symptoms rather than diagnoses.  
Estimates from East/Southeast Asia remained much lower than other regions even after adjusting 
for methodological differences. This may reflect a true difference in the global distribution of 
MDD. Alternatively, it may be due to unidentified sources of measurement bias that we were 
unable to control for.  One possibility is that DSM/ICD diagnostic criteria are not sensitive to cross 
cultural presentations of MDD (4, 52, 120).  Another is that MDD may be mis-coded as depression 
NOS in less developed countries (53, 55), underestimating prevalence.  We recommend that in 
upcoming GBD burden calculation this limitation be addressed through the inclusion of estimates of 
depression NOS as was done here.  
Ecological factors may also contribute to regional differences in prevalence. Consistently high 
prevalence in Africa/Middle East and South Asia raises the possibility that conflict in countries such 
as Afghanistan, Iraq and Sudan increase the prevalence of MDD. This is consistent with literature 
suggesting that exposure to torture and other trauma in conflict settings increase the prevalence of 
depression and post-traumatic stress disorder (148). Based on this, we also recommend that the 
effect of conflict status be investigated further.  
39 
 
Whilst we found numerous naturalistic studies of the annual incidence of MDD, very few follow-up 
studies using representative community samples were available. The GBD 2000/05 update 
predicted an average incidence of 3.2% in males and 4.9% in females (15, 73) which was higher 
than our results of 2.7% in males and 3.4% in females. If a duration of 30 weeks for an episode of 
MDD (27) is taken into account, there is a clear inconsistency between the few incidence estimates 
we obtained and our adjusted prevalence estimate, in that incidence was lower than prevalence 
instead of higher. This problem illustrates the importance of internal consistency between 
epidemiological parameters. While summaries of individual epidemiological parameters of MDD 
are useful, they may be inaccurate, particularly where data are limited. In this case, parameters need 
to be considered simultaneously for an internally consistent epidemiological profile of MDD. The 
upcoming GBD disease modelling of the epidemiology of MDD will help clarify this (149). In the 
meantime, our incidence findings are indicative only. More cross-national data are required for 
stronger conclusions. Although more data were available for prevalence, there were few good 
quality estimates from less developed parts of the world. This prevented us from conducting region-
specific analyses of variance. We were also unable to control for all sources of variability in 
prevalence. Further investigation into other determinants of prevalence, for instance human 
development indicators outside the scope of this review, is required.  
 
Our literature review addressed a range of issues central to the epidemiology of MDD. It identified 
the data sources required for burden estimation in the GBD 2010 study. It also provided an 
epidemiological summary of MDD, considering, where feasible, sources of heterogeneity in the 
data. We recommend that the statistically significant study-level determinants of prevalence 
identified be considered when generating other ecological models of MDD prevalence. We were 
also able to identify salient gaps in the literature that need further consideration. There were very 
little incidence data and very few studies from non-developed parts of the world across all 
parameters. We were also unable to comprehensively assess the effect of age on prevalence. Further 
investigation of these limitations is required for a clearer epidemiological profile of MDD. 
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Chapter review 
Chapter Three focused on reviewing the available data on the global distribution of MDD (Thesis 
aim one, part one). The focus was primarily on analysing the available prevalence and incidence 
data, although duration and excess-mortality data were also discussed and will be presented in 
greater detail in the next chapter. 
 
The summary of prevalence data presented in Chapter Three was incomplete given missing data, as 
well as considerable variability between data points from different studies. An analysis of incidence 
data revealed inconsistency between reported incidence, prevalence and duration data, likely due to 
restrictions in how incidence was surveyed.  Rather than rely on these data points to inform the 
epidemiological profile of MDD, in Chapter Four, statistical modelling was used to assemble them 
into an internally consistent disease model. This made is possible to estimate epidemiological data  
for ages, years and countries for which raw data was not available, while adjusting for the sources 
of variability identified in Chapter Three.  
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Chapter Four: The epidemiological modelling of major depressive disorder: Application for 
the global burden of disease study 2010.  
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Chapter summary 
Background 
 Although the detrimental impact of MDD at the individual level has been described, its global 
epidemiology remains unclear given limitations in the data. Here we present the modelled 
epidemiological profile of MDD dealing with heterogeneity in the data, enforcing internal 
consistency between epidemiological parameters and making estimates for world regions with no 
empirical data.  These estimates were used to quantify the burden of MDD for GBD 2010.  
 
Method 
Analyses drew on data from our existing literature review of the epidemiology of MDD.  DisMod-
MR, the latest version of the generic disease modelling system redesigned as a Bayesian meta-
regression tool, derived prevalence by age, year and sex for 21 regions. Prior epidemiological 
knowledge, study- and country-level covariates adjusted sub-optimal raw data.  
 
Results 
There were over 298 million cases of MDD globally at any point in time in 2010, with the highest 
proportion of cases occurring between 25 and 34 years. Global point prevalence was very similar 
across time (4.4% (95% uncertainty: 4.2-4.7%) in 1990, 4.4% (4.1-4.7%) in 2005 and 2010), but 
higher in females (5.5% (5.0-6.0%) compared to males (3.2% (3.0-3.6%) in 2010. Regions in 
conflict had higher prevalence than those with no conflict. The annual incidence of an episode of 
MDD followed a similar age and regional pattern to prevalence but was about one and a half times 
higher, consistent with an average duration of 37.7 weeks.  
 
Conclusion 
We were able to integrate available data, including those from high quality surveys and sub-optimal 
studies, into a model adjusting for known methodological sources of heterogeneity.  We were also 
able to estimate the epidemiology of MDD in regions with no available data. This informed GBD 
2010 and the public health field, with a clearer understanding of the global distribution of MDD.   
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Introduction 
Quantitative summaries of disease epidemiology are essential inputs to generating health indicators 
such as burden of disease estimates. They have also made significant contributions to health policy, 
service planning, and funding priorities in public-health (116-118). That said, epidemiological data 
can be costly and difficult to assemble. As a result global data are limited and sometimes unreliable, 
in which case supplementary measures to accurately compile the data are required.  
 
GBD 1990 and its update in 2000/05 quantified burden in terms of DALYs which are the sum of 
YLDs and YLLs (1, 16). In 1990, depressive disorders were the 4th leading cause of burden (1). In 
2000, they were the 3
rd
 leading cause of burden as well as the leading cause of disability (15). This 
has made the estimation of burden for depressive disorders a critical component of the GBD 2010 
study. GBD 2010 is a comprehensive re-assessment of disease burden and draws on a wide range of 
data sources and expertise to quantify burden for 291 diseases and injuries, 21 world regions and 
the years 1990, 2005 and 2010. Main findings from this study were published in 2012 in a series of 
publications (5, 6, 10-13). 
 
The GBD 2010 mental disorders research group (see: http://www.globalburden.com.au/) oversaw 
the burden quantification process for 20 mental disorders, including MDD and dysthymia. For each 
mental disorder, this involved: (1) conducting a literature review of the disorder’s epidemiology; (2) 
evaluating the extracted data in a disease model; and (3) producing estimates of prevalence for 
calculating disease burden (13). A major point of difference of GBD 2010 from previous versions is 
that results were presented without discounting, without the previously used age weights and with 
prevalent rather than incident YLDs (13). This paper follows our literature review of the raw global 
epidemiological data for MDD(150), representing step 1 of the burden calculation process. Here, we 
present an integrated and complete epidemiological model of MDD (step 2). The epidemiological 
review and modelling of dysthymia is being reported separately (151). 
 
 For GBD purposes, epidemiological data on prevalence, incidence, remission, duration and excess 
mortality are required (13). Summarising these parameters for MDD: (1) there are more data 
available for prevalence than for other parameters; (2) there are sparse data from low and middle 
income countries; and (3) there is considerable between-study variability in the epidemiology of 
MDD(27, 59, 150). This epidemiological variability may be an artefact of differences in data 
collection and assessment or, alternatively, due to ‘real’ differences in the disorder’s epidemiology 
(51, 152, 153). The aim is to correct for the former and to retain the latter in order to present an 
accurate epidemiological profile of the burden of MDD.   
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Existing reviews of the global prevalence of MDD suggest that the 12-month prevalence ranges 
between 0.8% and 5.8% (50) or between 2.2% and 10.4% (17), depending on study methodology  
and sampling. Given that GBD focuses on capturing people who are experiencing disability within 
the year of interest, period prevalence is not the ideal measure for quantifying disease burden(13). 
Our review estimated that the global point (defined as current or past-month) prevalence of MDD 
was  4.7% (4.4%-5.0%) ranging from 3.7% (3.1%-4.3%) in North America to 8.6% (5.2%-14.0%) 
in South Asia, a region which included prevalence from countries in conflict. Study methodology 
and geographic location explained 57.7% of the variability in prevalence, noting that lack of data 
for certain parts of the world limited findings (150). Our pooled estimate of  annual incidence 
derived from studies identified in the systematic review was 3.0% (2.4%-3.8%). As the estimated 
average duration of a MDE is less than a year (27), it is clear that the prevalence and incidence 
findings were ‘inconsistent’ as logically, incidence of MDD episodes should be higher than 
prevalence. 
 
Internal consistency can be achieved by making use of an incidence-prevalence-mortality model 
(Figure 4) to check for, and force consistency between epidemiological parameters. This is when 
final prevalence, incidence, duration and excess-mortality estimates simultaneously adhere to the 
generic relationships in the incidence-prevalence-mortality model for a single time, place, and sex 
(9, 13, 154). More specifically, people in the general population are at risk of becoming ill and after 
incidence, become prevalent cases of MDD.  They are then at risk of dying as a result of MDD and 
contributing to the cause-specific mortality rate or they may recover, contributing to the remission 
rate. People with and without MDD are also at risk of dying from other causes. Internal consistency 
is met if there is a corresponding incident case for every prevalent case of MDD; and if the total 
number of prevalent cases for MDD reflects not only prevalent and incident cases but also 
individuals that have died (as a result of MDD or other causes) and individuals that have recovered 
from MDD. 
 
 
 
 
 
 
 
 
45 
 
 
 
General population
Deaths in the general population 
from causes other than MDD 
Existing cases of MDD 
(prevalence)
Excess deaths in MDD cases 
New cases of MDD 
(incidence)
Cases recovered from MDD 
(remission)
Deaths in people with MDD attributable 
to other causes
  
Note. Figure adapted from an existing incidence-prevalence-mortality model (9). 
 
Figure  4. Incidence-prevalence-mortality model 
 
Supplementing this model with expert knowledge also helps address other limitations in the 
empirical data. For instance, identifying relevant covariates from study design and methodology 
(e.g. prevalence period) helps to adjust sub-optimal data. Making predictions based on the raw data 
and identifying relevant ecological covariates (e.g. conflict status) enables us to estimate data for 
parameters and world regions with no available data. Excluding these parts of the world from GBD 
estimations would assume no burden from those countries hence exclude them from the global 
priority setting exercises intended for GBD 2010 findings. Conscious of the importance of 
accurately representing all world regions in global health agendas, the GBD 2010 approach was not 
only to predict epidemiological data for parts of the world with missing data but to also ensure that 
the resulting uncertainty around these predicted estimates was incorporated into final burden results.  
 
In this paper we present an internally consistent epidemiological profile of MDD generated by 
DisMod-MR, a Bayesian meta-regression tool (13, 154) that predicts epidemiological data for 
parameters and parts of the world with no raw data and accommodates known methodological and 
ecological determinants of MDD through the use of covariates. Aside from informing GBD 2010 
burden estimates, this work contributes to the wider MDD literature by providing a more accurate 
and complete depiction of the global distribution of MDD.  
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Methods 
Case definition 
The DSM-IV-TR characterises MDD by one or more MDEs, lasting for at least 2 weeks (38), a 
definition resembling that of recurrent depressive disorder in the ICD-10 (39). A MDE involves 
symptoms of depressed mood and/or loss of interest or pleasure in all or almost all activities 
occurring most of the day and nearly every day. Consistent with the methodology proposed by Vos 
and collaborators (155, 156) as well as Ustun and collaborators (46), we modelled MDD as an 
episodic disorder, with the incidence and average length (i.e. duration) of an episode specified. We 
also incorporated prevalence estimates of depression NOS. This was in response to literature 
suggesting that MDD is often coded as depression NOS in non-Western regions because DSM/ICD 
diagnostic criteria are less sensitive to non-Western presentations of the disorder (52, 53, 55). 
 
Search strategy  
Estimates of prevalence, incidence, duration and excess mortality were searched for in a systematic 
review of the literature. This methodology has been outlined in greater detail elsewhere (27, 59, 
150) with the PRISMA checklist and flowchart (121) summarised in supporting Text S1, Appendix 
Three. In summary, electronic databases Medline, PsycInfo and EMBASE were searched from 
1980 onwards and studies were included if prevalence, incidence, duration and/or excess mortality 
of MDD were reported and if they were representative of the community, region or country. DSM 
or ICD diagnostic categorisations were required although if studies used symptom scales that 
broadly mapped to DSM/ICD thresholds, these were also included for prevalence due to lack of 
data in low to middle income regions. For prevalence we also required past year or point estimates. 
Even though point prevalence is the more representative measure for GBD purposes as it measures 
actual disability, 12-month prevalence was accepted to maximise inclusion. Lifetime estimates were 
excluded as they are most susceptible to recall bias (122-125). Given these allowances made to the 
inclusion criteria, we then looked at ways to adjust sub-optimal estimates (e.g. estimates derived 
from symptom scales and based on 12-month prevalence) towards optimal estimates (e.g. estimates 
derived from diagnostic instrument  and based on point prevalence) to minimise the methodological 
heterogeneity in the dataset (see covariates section). For incidence we used hazard rates, with 
person years of follow-up in the denominator; for duration we used estimates based on follow-up 
studies reporting the natural history of MDD in community samples; for excess mortality we used 
RR (i.e. deaths in people with MDD compared to people without MDD) or standardized mortality 
ratio (SMRs, i.e. deaths in people with MDD compared to deaths in the general population).   
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Epidemiological data were extracted into a Microsoft Excel spreadsheet. Along with information 
pertaining to the study methodology, design, parameter type and value, an estimate of uncertainty 
SE or 95% confidence interval) was extracted if reported. If not reported, uncertainty was calculated 
using SE = √2.1*(P*(1–P)/N) where P is the proportion of cases reported and  2.1 is an average 
design effect calculated using 110 design effects from the GBD Mental Disorders Research Group’s 
affective disorders dataset. N is the age- and sex-specific denominator which, if not reported, was  
estimated using United Nation’s country-, sex-, age- and year-specific population size to apportion 
the study sample size across age and sex categories  (126). 
  
The country in which each study was conducted was coded according to the 21 world regions (see: 
http://www.globalburden.com.au/project-description) used for GBD 2010. This regional grouping 
was based on broad geographic regions or continents where each region comprised of no fewer than 
two countries, grouped according to country-specific child/adult mortality levels and major causes 
of death (13, 154). Seven ‘super-regions’ were also defined which grouped regions according to 
cause of death patterns (Super-region 0: high income regions-Asia Pacific High Income, 
Australasia, Western Europe, Latin America South and North America High Income; Super-region 
1: Central and Eastern Europe and Central Asia; Super-region 2: West, East, Central and Southern 
Sub-Saharan Africa; Super-region 3: North Africa and Middle East; Super-region 4: Asia South; 
Super-region 5: East and Southeast Asia and Oceania; Super-region 6: Central, Andean and 
Tropical Latin America and Caribbean). The aim of this was to categorise countries into regions and 
regions into super regions approximating more epidemiologically homogeneous groups. These were 
used to guide the estimation of missing data informed by data from surrounding countries and/or 
regions (13, 154). 
 
Empirical data 
The systematic literature review identified 136 relevant studies covering 17 GBD world regions.  
Epidemiological estimates were reported for males, females and/or persons, across broad and/or 
specific age groups. Sex- and age-specific estimates were preferable. Figure 5 summarises the raw 
epidemiological data used as inputs in the disease modelling process. A more comprehensive 
summary of the included studies has been reported elsewhere (27, 59, 150). 
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Pooled prevalence, incidence, duration and excess mortality data 
Overall 
prevalence 
(%) 
4.7 (4.4-5.0) 
Point 
prevalence 
by region 
(%) 
North 
America
: 3.7 
(3.1-4.3) 
 
South 
America: 
4.1 
(3.5-4.7) 
Western 
Europe: 
4.7 
(4.2-
5.1) 
Eastern/Central 
Europe: 
5.1 
(4.2-6.1) 
Australasia: 
4.1 
(2.9-5.7) 
Africa/Middle 
East: 
6.6 
(5.3-8.3) 
East/Southeast 
Asia: 
3.96 
(3.4-4.6) 
Asia 
South: 
8.6 
(5.2-
14.0) 
Asia 
Pacific: 
5.6 
(4.2-
7.4) 
Overall 
incidence  
(per 100 
person years) 
3.1 (2.4-3.8) 
Average 
duration of 
an episode 
37.7 weeks 
Excess risk of 
mortality 
1.9 (1.7-2.2) 
Note: This figure summarises findings from previous work (27, 59, 150) and represents the raw data included in 
DisMod-MR analyses; The map shows the number of studies available for each world region where P: Prevalence; 
I:Incidence; D: Duration; EM: Excess-mortality; Although the literature review found 136 studies overall, some studies 
have been counted more than once in the map as they reported data for multiple countries/regions. 
 
Figure 5. Summary of the raw data on prevalence (P), incidence (I), duration (D) and excess 
mortality (EM) of MDD 
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For prevalence, we found 116 studies (556 data points) from 53 countries and 17 regions. After 
further consideration, 3 prevalence studies were excluded as outliers in the dataset (157-159). 
Estimates from these studies were well over 2 times higher than other estimates from the same 
country and/or region, and stood out as outliers in the initial stages of the modelling process. This 
reduced the prevalence dataset to 113 studies (544 data points). For incidence we found 4 studies 
(19 data points) on annual incidence from 3 countries and 2 regions (150).  For duration, we found 4 
studies from USA (65, 160-163) and 1 study from the Netherlands (68) reporting a median duration 
of between 6 to 12 weeks. We replicated the methodology used by Vos and collaborators to 
estimate an average duration from a best fit curve between the data points available from all 5 
studies reporting on time to end of an episode (27). For excess-mortality we found 11 studies (14 
data points) from 7 countries and 4 regions as compiled by Baxter and collaborators (59). 
 
Analyses 
DisMod-MR was used to model the epidemiology of MDD. DisMod-MR is the latest iteration of 
the generic disease modelling system (9) but redesigned as a Bayesian meta-regression tool (13, 
154). The Bayesian approach is one of several interpretations of statistical probability in which 
existing data is used to inform the probability of a given hypothesis i.e. the data is considered as 
fixed and the hypothesis as random. This is different to the frequentist approach for instance which 
quantifies the probability (or frequency) of the data given the hypothesis i.e. the data is considered 
random and the hypothesis fixed (164); A meta-regression can be understood as an extension of a 
meta-analysis whereby data from different studies are pooled into a weighted average, adjusting for 
sources of variability between studies (165). DisMod-MR has the capability to combine 
epidemiological data from multiple sources, reconcile data that are inconsistent and forecast data for 
regions and parameters with no or little data. It applies a negative-binomial model of disease 
prevalence, incidence, remission, and case-fatality rates and fits models with a randomized Markov-
Chain Monte Carlo algorithm (13, 154). Non-fatal burden estimates for all disorders in GBD 2010 
were calculated using DisMod-MR with the exception of a few conditions for which a customised 
model had to be created (13). 
 
DisMod-MR works in two stages. At stage 1 it pools raw data for each parameter while 
incorporating prior expert knowledge of the disease (based on empirical evidence and expert 
knowledge of the distribution of MDD in the population). In the absence of sufficient data to show 
age-pattern variation, DisMod-MR imposes a common age pattern based on evaluating age-specific 
input data available for the disorder. This stage also includes a first consistency check at the global 
level.  At stage 2, DisMod-MR simultaneously integrates the input data from all parameters as well 
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as the output from stage 1 to derive internally consistent epidemiological estimates for 187 
countries, 21 GBD world regions for 1990, 2005 and 2010, carrying forward uncertainty from 
primary data sources (13, 154). These 3 time periods were chosen to enable analysis of time trends 
and enable comparisons between different time periods using the same methodology. It would not 
be possible to compare time trends using GBD 1990 estimates from the original study as 
methodology is different. If the period of data collection was before and including 1997 (the 
midpoint between 1990 and 2005) then those studies contributed to the 1990 estimates. Studies with 
data collected after 1997 contributed to the 2005 and 2010 estimates. Although the year 2000 would 
have also been a sensible alternative to categorise estimates as it is the midpoint between 1990 and 
2010, there was insufficient data to detect any difference in the current findings if the latter option 
had been used. Where relevant, year-specific country-level covariates informed the difference 
between 1990, 2005 and 2010 estimates. Regions without primary data borrowed strength from 
other regions in a super-region through random effects. If a whole super-region had no data, 
epidemiological estimates defaulted to the global average unless country-level covariates were 
specified (13, 154) 
 
Adjustments to the data 
As per the Bayesian approach, a range of adjustments were implemented during the modelling 
phase to account for prior knowledge of disease patterns. A mimimum age of onset of 3 years was 
selected based on literature and expert advice suggesting that despite difficulties in diagnosing early 
childhood depression,  cases of MDD manifest as early as 3 years  (166). Adjustments were also 
used to supplement gaps in the raw data. After running sensitivity analyses with and without the 
incidence data included in the DisMod-MR model (see results section), it was deemed necessary to 
exclude the few data points showing low rates of MDD incidence in the population. MDD was 
modelled as an episodic disorder (as per how it’s defined in DSM-IV-TR)/ICD-10), as such we 
required data on the incidence and duration of a MDE in the DisMod-MR modelling of MDD.  In 
our review of the literature, we found that the average duration of a MDE was less than a year. 
Based on this, we would expect the incidence of a MDE to be higher than the prevalence of MDD. 
In the four studies we had available for incidence, new MDEs in people with previous episodes 
were either excluded at baseline (66, 67), discussed but not included in the final incidence estimate 
(64), or alternatively reported but limited to a narrow teenage sample where the incidence of new 
episodes comes close to total incidence (previous plus current episodes) (65). This meant that for 
our purposes, incidence was underestimated and ‘inconsistent’ with prevalence and duration data.  
Given this limitation, we excluded the few incidence estimates available and instead, allowed 
DisMod-MR to predict incidence based on the data from all other parameters. The estimate of 
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average duration was applied equally to all regions, sex and years given that there were only 5 
follow-up studies available with information on time to end of an episode and none of those 5 
studies found statistically significant sex differences in episode duration. 
 
Covariates                                                                                                                                                                               
Study-level covariates. The prevalence dataset included estimates of point and past-year prevalence 
based on varying survey instruments, response rates and sample coverage (150). Study-level 
covariates were applied to adjust sub-optimal estimates to the desired level of each of these 
variables (Table 5). Our meta-regression of the raw prevalence data outside of DisMod-MR  (150) 
guided the selection of these study-level covariates.  
 
Table 5. Study-level covariates used in the statistical modelling of MDD. 
 
Study-level covariates 
Covariate Gold-standard Rationale 
Prevalence type  Point prevalence GBD methodology requires point rather than 12-month prevalence. Given 
their structure, diagnostic interviews capturing 12-month prevalence may 
also be insensitive to past MDEs, leading to the underestimation of 
prevalence. 
Survey intrument Instruments using 
DSM/ICD 
diagnostic 
thresholds 
Symptom scales are likely to over-estimate prevalence relative to diagnostic 
instruments using DSM/ICD thresholds (150). Prevalence estimates based 
on symptom scales are adjusted to the level of those using DSM/ICD 
diagnostic thresholds 
Sample coverage: National coverage This study level covariate adjusts prevalence ascertained from a local 
community sample to the level of prevalence from a more representative 
regional or national sample.  
Study response 
rate 
response rate ≥60% This study level covariate adjusts prevalence from samples with poor 
response rate (<60%) to the level of those with better response rate (≥60%).  
Country-level covariates 
Covariate - Definition 
Conflict  - The natural log of mortality due to war or conflict in any country and year. 
Post conflict - The natural log of mortality due to war or conflict in the past ten years, in 
any country and year. 
 
Country-level covariates. Country-level covariates guided the DisMod-MR estimation of 
prevalence, particularly in the prediction of missing data. As described in previous work (147, 148, 
167, 168), conflict status is associated with an increase in the incidence (and therefore prevalence) 
of MDD. We also found evidence for this while comparing pooled prevalence across regions 
including countries in  current or past conflict(150). To improve the predictive power of the model 
for regions with no data, we included conflict and post conflict covariates in the modelling of 
prevalence. These covariates used the natural log of GBD 2010 mortality rates due to war or 
conflict in any country and year (Table 5).  
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Results 
To demonstrate the effect of the DisMod-MR modelling process on the epidemiological data, the 
first section of results compares the input data to the final DisMod-MR output.  In spite of being 
limited by data on the incidence, duration, and excess-mortality of MDD, we discuss the DisMod-
MR output for all parameters here in the interest of illustrating internal consistency. The next 
section focuses exclusively on the prevalence output given that the majority of our data was for 
prevalence and GBD 2010 calculated prevalent YLDs. More information on the DisMod-MR 
output can be obtained by contacting the corresponding author (AJF). 
 
Comparing data points with final DisMod-MR output                                                                                                   
Figure 6 shows the adjustments made to prevalence based on the effect of covariates. Study-level 
covariates for data points of past-year prevalence and using symptom scales had statistically 
significant positive values. Those data points were adjusted downwards to reflect an equivalent 
value if the studies would have measured point prevalence, using formal diagnostic instruments. 
The study response rate and community coverage covariates did not significantly impact on 
prevalence. There was however a positive effect of conflict whereby prevalence from countries in 
current conflict was higher than prevalence from countries in no conflict. This effect guided the 
prediction of prevalence for regions with missing data.  
 
 
 
Figure 6. Country- and study-level covariate adjustments for MDD 
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Figures 7 and 8 further illustrate the adjustments applied to the input data by summarising the input 
data and DisMod-MR output for females in 2010 from North Africa/Middle East (figure 7) and 
North America, High income (figure 8), regions for which we had few and considerable data points, 
respectively. Similar plots for all 21 GBD regions have been included in supporting table S1, 
Appendix Three. Each plot in figure 7, shows the minimum age of onset of 3 years (solid red line), 
the prevalence data points (blue crosses) and the final pooled prevalence output (solid blue line) 
before (plot 1) and after (plot 2) they were adjusted by study-level covariates. The difference 
between the two plots reflects adjustments made by study level covariates. Note how the prevalence 
data points were adjusted downwards (from plot 1 to plot 2) to reflect an equivalent value if the 
studies would have measured point prevalence, using formal diagnostic instruments.  
 
The first plot in figure 8 shows the prevalence data and the second plot shows the incidence data 
with their respective pooled DisMod-MR output. As previously explained, incidence data points 
(pink crosses) in plot 2 were not included in the modelling process. However, it is worth noting here 
how much lower they were in comparison to the incidence calculated by DisMod-MR (solid pink 
line), using data from all other parameters. In dealing with the previously noted inconsistency 
between incidence, prevalence and duration data, the final incidence output was also greater than 
the final prevalence output in plot 1. Incidence was greater by a fixed amount as we applied the 
same estimate of average duration across all regions, sex, age and year. The third plot from figure 8 
shows the single duration data point used (grey cross). The last plot shows prevalence by excess 
mortality which represents the mortality rate at the population level due to the (all-cause) excess 
mortality experienced by people with MDD. 
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Plot 1. Prevalence before covariate adjustments 
 
 
Plot 2. Prevalence after covariate adjustments 
 
 
Note. Blue crosses show the individual, sex-specific data points available for that region, with the horizontal line 
showing the age range for the data point and the vertical line showing the range of uncertainty around the data point; 
grey crosses in the first plot show non sex-specific data points which are converted into sex-specific data points in the 
second plot as per a sex-ratio of 0.59 (0.54-0.64); the dotted line shows prevalence output from stage 1 of the modelling 
process. This is the line of best fit based on data for that parameter only; the numerous blue vertical lines show 
uncertainty around stage 1 estimates; the solid blue line shows output from stage 2 of the modelling process. This is the 
line of best fit based on data from all parameters and represents the final output for that parameter; the grey area 
shows uncertainty around stage 2 estimates; the solid red line represents ages below the minimum age of onset applied. 
 
Figure 7. Prevalence of MDD before and after covariate adjustments for females from North 
Africa/Middle East, 2010. 
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Plot 1. Prevalence 
 
Plot 2. Incidence 
 
Plot 3. Duration 
 
Plot 4. Prevalence times excesss 
mortality 
 
Note. Crosses show the individual data points available for that region, with the horizontal line showing the age range 
for the data point and the vertical line showing the range of uncertainty around the data points; solid lines show output 
from stage  2 of the modelling process. This is the line of best fit based on data from all parameters and represents the 
final output for that parameter; grey areas represent the range of uncertainty around the final output. 
 
Figure 8. Prevalence, incidence, duration and excess-mortality of MDD in females from North 
America, High income, 2010. 
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Final prevalence output 
Figure 9 shows the final prevalence estimates by age, sex and region, for 2010. The equivalent data 
for 2005 and 1990 are summarised in supporting figures S1 and S2, Appendix Three. When 
prevalence was aggregated by year (standardised by population age and sex (169)), the prevalence 
of MDD was very consistent between 1990 (4.4% (95% uncertainty: 4.2-4.7%)), 2005 (4.4% (4.1-
4.7%) and 2010 (4.4% (4.1-4.7%)). Given the lack of time trend, the rest of the results will focus on 
the 2010 DisMod-MR output.  
 
Prevalence in 2010 was higher in females at 5.5% (5.0-6.0%) compared to males at 3.2% (3.0-
3.6%), equivalent to a male: female prevalence ratio of 0.59 (0.54-0.64). When observed across the 
lifespan, prevalence increased steadily between 3 and 19 years; peaked between 20 and 64 years; 
decreased between 65 to 74 years; and showed a smaller increase in the oldest age group. Plot 1 in 
figure 10 summarises the age differences in the global prevalence of MDD.  Note, for most age 
groups, estimates were within overlapping bounds of uncertainty. Plot 2 summarises the regional 
differences in the global prevalence of MDD. There was a 3-fold difference between North 
Africa/Middle East, the region with the highest prevalence and Asia Pacific, High income, the 
region with the lowest prevalence. Although this suggests considerable regional differences, the 
overlap in uncertainty intervals across regions is worth noting. 
 
When multiplied with United Nation’s region-, sex-, year- and age-specific population size (170), 
the overall prevalence of MDD in 2010 corresponded to over 111 million male and 187 million 
female prevalent cases of MDD. The majority of cases appeared between 25 and 34 years at over 57 
million cases and the least number of cases between 1 and 4 years at 19 thousand cases. Given their 
population size, Asia East and Asia-South yielded the highest number of prevalence cases at over 
44 million and 62 million cases respectively. Prevalent cases by age and region have been 
summarised further in figure 11.  
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Note. Prevalence interpreted as a proportion where 0.01 equates to 1% 
 
Figure 9. Regional point prevalence of MDD by age and sex, 2010. 
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High income 
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Carribean 
Global prevalence          and it 95% uncertainty interval  
Note. Global and regional prevalence estimates have been standardised by population  age and sex; AP-HI: Asia 
Pacific, High Income, As-C: Asia Central, AS-E: Asia East, AS-S: Asia South, A-SE: Asia Southeast, Aus: Australasia, 
Caribb: Caribbean, Eur-C: Europe Central, Eur-E: Europe Eastern, Eur-W: Europe Western, LA-An: Latin America, 
Andean, LA-C: Latin America, Central, LA-Sth: Latin America, Southern, LA-Trop: Latin America, Tropical, Nafr-ME: 
North Africa/Middle East, Nam-HI: North America, High Income, Oc: Oceania, SSA-C: Sub-Saharan Africa, Central, 
SSA-E: Sub-Saharan Africa, East, SSA-S: Sub-Saharan Africa Southern, SSA-W: Sub-Saharan Africa, West                                                    
 
Figure 10. The overall point prevalence of MDD and 95% uncertainty by region and age, 2010. 
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Note. All prevalent cases where divided by 1000000 to facilitate presentation; AP-HI: Asia Pacific, High Income, As-C: 
Asia Central, AS-E: Asia East, AS-S: Asia South, A-SE: Asia Southeast, Aus: Australasia, Caribb: Caribbean, Eur-C: 
Europe Central, Eur-E: Europe Eastern, Eur-W: Europe Western, LA-An: Latin America, Andean, LA-C: Latin 
America, Central, LA-Sth: Latin America, Southern, LA-Trop: Latin America, Tropical, Nafr-ME: North Africa/Middle 
East, Nam-HI: North America, High Income, Oc: Oceania, SSA-C: Sub-Saharan Africa, Central, SSA-E: Sub-Saharan 
Africa, East, SSA-S: Sub-Saharan Africa Southern, SSA-W: Sub-Saharan Africa, West.  
                                   
Figure 11. The number of point prevalent cases (in millions) of MDD by region, age and sex, 2010. 
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Discussion 
 
Consistent with previous reports, the prevalence of MDD (as estimated by DisMod-MR) was higher 
in females compared to males (107, 137, 138). However, unlike our meta-regression outside of 
DisMod-MR which found that prevalence increased significantly over time (150), our findings 
differed; suggesting that the former could have been an artefact of measurement bias rather than a 
‘real’ difference in the disorder’s epidemiology.  
 
The pooled prevalence estimate derived by DisMod-MR was also more conservative than that from 
our meta-regression (4.4% (4.1-4.7%) vs., 4.7% (4.4-5.0%)). This difference was likely due to the 
differences in the age range for which estimates were pooled. In the meta-regression we aggregated 
data from different studies all using different age ranges (from 0-9 through to 65 to 99 years). 
DisMod-MR was much more versatile in this respect as it was able to aggregate estimates with 
different age ranges into the most plausible age pattern for the entire lifespan. This allowed us to 
more consistently measure differences in prevalence across the lifespan which was not possible in 
our analyses outside of DisMod-MR where we could only classify age using 4 broad age groups 
with some age ranges fitting into several groups. According to DisMod-MR findings, prevalence 
was lowest, but still evident in early childhood and highest between 20 and 64 years. There was an 
increase in prevalence between 75 and 85 years (5.1%(4.7-5.4%) and onwards (5.2%(4.9-5.6%), 
well within the prevalence range  (4.6 to 9.3%) obtained by Luppa and collaborators’ in their recent 
review and meta-analysis of the prevalence of MDD in those aged 75 years or above (171). This age 
group is not always represented in population surveys as they tend to exclude people in residential 
care or non-private households (70, 172, 173). Consequently, this finding has important 
implications for the burden calculation of MDD which as a result incorporated prevalent cases of 
MDD across the entire lifespan.  
 
Also important for burden calculations was the ability to estimate prevalence (and therefore burden) 
for all 21 GBD regions, including regions like Oceania, Sub-Saharan-Africa Central, Latin 
America-Andean and Asia Central from where we had no empirical data. The regional pattern of 
prevalence was similar to that derived in our meta-regression (150), where prevalence from high 
income regions was lower than prevalence from low to middle income regions, particularly regions 
in conflict.  Calculating the number of prevalent cases across world regions helps to emphasize the 
challenge confronting health services in responding to MDD. For instance, Asian regions which do 
not have the highest prevalence in comparison to other regions have the most prevalent cases due to 
their population size. That said, the low prevalence rate of MDD, in all Asian regions needs to be 
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noted. Although the inclusion of depression NOS cases helped capture non-Western presentations 
of MDD likely missed by DSM/ICD diagnostic criteria, it could be that it did not completely 
account for this limitation. This is especially true for studies where lay rather than clinically trained 
interviewers were used to diagnose cases (55). Further investigation into the cross-cultural validity 
of DSM/ICD diagnostic criteria is required for clearer conclusions.  
 
The process of modelling epidemiological parameters by GBD region necessarily dilutes the effects 
of conflict on prevalence of mental disorders which may otherwise be clearly demonstrated in 
country or local level surveys. Despite this, and combined with the fact that we found very few data 
points from populations in current or past conflict, we were still able to detect an increase in 
prevalence in those settings. Prevalence was highest in North Africa/Middle East which includes 
conflict countries such as Afghanistan, Iraq and Lebanon. This highlights the importance for future 
mental health research to provide comparable assessments of mental disorders in conflict-affected 
populations. The conflict covariates together with the survey instrument and prevalence type study-
level covariates allowed us to accommodate for some, but not all of the variability in the 
epidemiological data available for MDD as DisMod-MR assumes the same level of adjustment for 
covariates across regions. The data presented here is reflective of the current state of this literature. 
With ongoing work on the global epidemiology and determinants of this disorder, we hope to 
explain more of the uncertainty around our final estimates. 
 
With the emphasis on providing a ‘data driven’ epidemiological profile of MDD, we would have 
preferred to have incidence data inform our DisMod-MR output. Our search for data on the 
incidence of MDD revealed very low rates of MDD incidence in the population. An explanation for 
this is that the few longitudinal studies reporting on the incidence of MDD typically focused on 
capturing the incidence of MDD, rather than the incidence of MDEs (63-67). Given that MDD is 
being modelled as an episodic disorder for GBD, this means that new episodes in people with 
previous episodes were not counted and incidence was underestimated. By relying on prevalence, 
duration and excess-mortality data to calculate incidence, DisMod-MR derived incidence estimates 
which were higher than prevalence, illustrating much better internal consistency between the 
prevalence, incidence and duration output.  
 
We used an average duration of 37.7 weeks which was higher than the 30.1 weeks reported by Vos 
and collaborators (27, 67). This difference was due to the inclusion of data from the Netherlands 
(68) previously excluded by Vos and collaborators on the basis that it included cases of 
subsyndromal depression and dysthymia. Given the lack of available duration data for all parts of 
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the world except USA and that the median duration yielded by this study (12 weeks) was 
comparable to the median duration from other included studies (6-12 weeks) (160-163), we chose to 
include it. However, even with this inclusion, we did not have enough data to investigate and adjust 
for any age, sex and cross-national differences in the duration of a MDE. This highlights the need 
for more studies following up community identified cases of MDD and measuring course of 
episode, particularly in low to middle income countries. 
Rather than rely solely on sub-optimal estimates of prevalence, incidence, duration and excess 
mortality, we were able to model these into an internally consistent epidemiological profile of 
MDD. This will contribute to GBD 2010 and the MDD literature at large by providing global 
estimates for MDD which go beyond mere tabulation and pooling of epidemiological data. For 
some parameters, DisMod-MR had to rely on data from only a small number of studies, limiting the 
accuracy and generalisability of findings. This has been represented through large and at times, 
overlapping bounds of uncertainty which need to be considered while interpreting DisMod-MR 
estimates. As more evidence accumulates, the approach taken here will become increasingly 
sophisticated in its ability to synthesize available information and to project intelligent estimates 
into areas where data are not available.  
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Chapter review 
Chapter Four made use of the raw data on the distribution of MDD to estimate prevalence, 
incidence, remission, duration and excess-mortality by location, age, sex, year (thesis aim one, part 
two). This data on the distribution of MDD is useful in its own right. For instance, it can assist in 
establishing groups in the population most at risk for MDD and which type of intervention strategy 
(treatment, rehabilitation, prevention, and promotion) should be prioritized. That said, it is also 
important for decision makers to know how health losses due to MDD compares to other diseases 
and injuries. 
 
For this reason, the prevalence output presented in this chapter was used in the estimation of burden 
(DALYs, YLDs, and YLLs) for MDD in Chapter Five. Although it would have been preferable to 
make use of high quality raw data for all countries, years and age groups in burden estimation, this 
was not possible given the limitations in the data discussed in Chapters Three and Four.  The 
estimation of missing data in this chapter made it possible to include countries, years and age 
groups in the burden estimation which would have otherwise been ignored. A comparison between 
burden due to MDD and dysthymia was also presented in Chapter Five. This was done to enhance 
our understanding of how MDD contributes to disease burden compared to other forms of 
depression.  
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Chapter Five: Burden of depressive disorders by country, sex, age and year: Findings from 
the global burden of disease study 2010 
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Chapter summary 
Background 
Depressive disorders were a leading cause of burden in the GBD 1990 and 2000/05 studies. Here, 
we analyse the burden of depressive disorders in GBD 2010 and present severity proportions, 
burden by country, region, age, sex, and year, as well as burden of depressive disorders as a risk 
factor for suicide and IHD. 
 
Methods 
Burden was calculated for MDD and dysthymia. A systematic review of epidemiological data was 
conducted. The data were pooled using a Bayesian meta-regression. Disability weights from 
population survey data quantified the severity of health loss from depressive disorders. These 
weights were used to calculate YLDs and DALYs. Separate DALYs were estimated for suicide and 
IHD attributable to depressive disorders.  
 
Results 
Depressive disorders were the second leading cause of YLDs in 2010. MDD accounted for 8.2% 
(5.9%–10.8%) of global YLDs and dysthymia for 1.4% (0.9%–2.0%). Depressive disorders were a 
leading cause of DALYs even though no mortality was attributed to them as the underlying cause. 
MDD accounted for 2.5% (1.9%–3.2%) of global DALYs and dysthymia for 0.5% (0.3%–0.6%). 
There was more regional variation in burden for MDD than for dysthymia; with higher estimates in 
females, and adults of working age. Whilst burden increased by 37.5% between 1990 and 2010, this 
was due to population growth and ageing. MDD explained 16 million suicide DALYs and almost 4 
million IHD DALYs. This attributable burden would increase the overall burden of depressive 
disorders from 3.0% (2.2%–3.8%) to 3.8% (3.0%–4.7%) of global DALYs.  
 
Conclusion 
GBD 2010 identified depressive disorders as a leading cause of burden. MDD was also a 
contributor of burden allocated to suicide and IHD. These findings emphasize the importance of 
including depressive disorders as a public-health priority and implementing cost-effectiveness 
interventions to reduce its burden. 
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Introduction 
Depressive disorders are common mental disorders, occurring as early as 3 years of age and across 
all world regions (150, 151). Previous GBD studies in 1990 (1) and 2000/05 (16, 174) made notable 
contributions to shifting international focus towards depressive disorders as a leading cause of 
burden in its own right and also in comparison to more recognized physical disorders. 
 
Using an approach first proposed in the World Development Report of (71), GBD 1990 and 
2000/05 used DALYs to quantify the global burden attributable to diseases and injuries. One DALY 
represents the loss of a healthy year of life and aggregates the YLDs with the YLLs (1, 16, 174). 
GBD 1990 ranked depressive disorders as the fourth leading cause of burden worldwide (equivalent 
to 3.7% of all DALYs) after lower respiratory infections, diarrhoeal diseases, and conditions arising 
during the perinatal period (1). In GBD 2000/05, depressive disorders were the third leading cause 
of burden (equivalent to 4.3% of all DALYs) after lower respiratory infections and diarrhoeal 
diseases. It was also the leading cause of disability, responsible for 13.4% of YLDs in women and 
8.3% in men (15). 
 
These results have since made significant contributions to prioritising depressive disorders, and 
mental disorders as a group, in global public health agendas; particularly in promoting the addition 
of mental health interventions to health management plans (74). For this purpose, it has also 
become important to provide comparable estimates of burden, reflective of recent statistical and 
epidemiological advancements in mental health research. This was a focus of the latest iteration of 
GBD (GBD 2010), which involved a substantial expansion of the GBD framework. GBD 2010 
quantified the direct burden of 291 diseases and injuries, in parallel with the quantification of 
burden attributable to 67 risk factors. It included a complete epidemiological re-assessment of all 
diseases, injuries, and risk factors, across 187 countries, 21 world regions, males and females, 1990, 
2005, 2010, and 20 different age groups. Unlike previous GBD studies, which estimated the burden 
of “unipolar depression” (i.e., a combination of the DSM (38) and the ICD (39) categories (15, 73)), 
GBD 2010 quantified burden separately for MDD and dysthymia; this was done to better 
accommodate differences in burden between the subtypes of depression. Rather than rely on a 
selective sample of data points (as was the case in previous GBD studies), burden estimation was 
based on a systematic review of the literature to obtain all available epidemiological data on MDD 
and dysthymia. Furthermore, revised estimation methods utilized modernized new statistical 
methods to model these epidemiological disease parameters, quantify disability, adjust for 
comorbidity between diseases, and propagate uncertainty into final burden estimates (5). 
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This article follows the GBD 2010 capstone papers on the overarching methodology and findings of 
the study for all 291 diseases and injuries (5, 6, 10-13), and also the GBD 2010 mental and illicit 
drug use disorders research group’s publication focusing on how mental and substance use 
disorders performed in comparison to other disease groups in GBD 2010 (see Figure S1, Appendix 
Four for an illustration of the GBD 2010 publications hierarchy) (19). Here we focus on presenting 
the burden of MDD and dysthymia specifically. Analyzing burden estimates at the national, 
regional, and individual characteristic level is important from both a clinical and population-health 
perspective to identify populations most at risk. We summarise the updated methodology and inputs 
used for the computation of YLDs, YLLs, and DALYs and present an analysis of country-, region-, 
age-, sex-, and, year-specific trends in the burden of depressive disorders. We also address a 
criticism of previous GBD studies (74) by estimating the additional burden attributable to MDD as 
a risk factor for other health outcomes.  
 
Methods 
Case Definition 
The DSM-IV-TR (38) describes MDD (296.21–24, 296.31–34), as an episodic disorder with a 
chronic outcome and an elevated risk of mortality, equivalent to ICD-10’s description of recurrent 
depressive disorder (F32.0–9, F33.0–9) (39). It involves the presence of at least one MDE, which is 
the experience of depressed mood almost all day, every day, for at least 2 weeks. As dysthymia 
(DSM-IV-TR: 300.4; ICD-10: F34.1) involves a less severely depressed mood compared to MDD 
and a duration of at least 2 years, it is described as chronic rather than episodic, with low rates of 
remission and no elevated risk of mortality (38, 39).  
 
Calculation of Direct Burden-YLDs 
The estimation of YLDs for a given disorder can be understood as a synthesis of epidemiological 
data that not only accommodates the number of people affected but also the severity and disability 
associated with their symptoms (13). In GBD 2010, prevalent rather than incident YLDs were 
calculated, without age-weighting and discounting (13). This means that for GBD 2010, YLDs were 
calculated by multiplying the prevalence of a given disorder by its corresponding severity- and 
comorbidity-adjusted disability weight. As these choices fundamentally change the metric, YLDs 
for 1990 were re-estimated using the same methods to allow meaningful comparisons of changes 
over time.  
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Epidemiological inputs. For MDD and dysthymia, prevalence, incidence, remission or duration, and 
excess mortality data were captured through a systematic review of the literature between 1st 
January 1980 and 31st December 2008 and continued perusal of the literature until 31st December 
2011. A search of relevant online databases (Medline, PsycInfo, and EMBASE) was conducted as 
per the PRISMA statement (121). To be eligible for inclusion studies needed to report estimates: of 
prevalence, incidence, duration, and/or excess mortality from 1980 onwards; representative of the 
community, region, or country under investigation; and based on DSM or ICD definitions of MDD 
and dysthymia. For prevalence, we required point (current/past month) or past year prevalence 
estimates. Lifetime estimates were excluded as recall bias invalidates them as credible measures of 
disease burden (27, 59, 151, 175). For incidence, we used hazard rates with person years of follow-
up as the denominator. Given the episodic presentation of MDD, we used data on the duration of 
MDEs from follow-up studies of the natural history of the disorder. For dysthymia we used 
remission data from follow-up studies capturing cases no longer fulfilling diagnostic criteria for the 
disorder. For excess-mortality, we used estimates of RR or SMR. Information on this systematic 
review can be accessed in previous publications (27, 59, 151, 175) with the main findings 
highlighted in Tables 6 and S1. 
 
Disease modelling. For each disorder, epidemiological estimates from the literature review were 
pooled using DisMod-MR, a Bayesian meta-regression tool developed specifically for GBD 2010 
(154). DisMod-MR is based on a generalized negative binomial model that: (1) uses an Incidence-
Prevalence-Mortality mathematical model (9, 154) to enforce internal consistency between 
estimates from different epidemiological parameters; (2) estimates data for countries and world 
regions with no or few available input data based on random effects for country, regions, and their 
corresponding super-region groupings; (3) deals with variability in the data due to measurement 
bias or alternatively ecological factors through the use of study- and country-level covariates; and 
(4) propagates uncertainty around the raw epidemiological data through to the final estimates (154). 
The DisMod-MR output required for YLD estimations were prevalence estimates (including their 
respective 95% uncertainty intervals) for 187 countries, 21 world regions, males and females, 1990, 
2005, and 2010, for 20 age groups. The global point prevalence output has been summarised in 
Table 6 and the country-level output in Table S2, Appendix Four. Given that the focus of this article 
was to report on the burden of depressive disorders, we have only summarised the disease 
modelling process here. More details on the disorder-specific modelling methodology, output, and, 
sensitivity analyses around final estimates have been reported in separate publications (151, 175). 
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Disability weights. The GBD 2010 framework describes disability as any short-term or long-term 
loss of health associated with a given health state (12). Unlike GBD 1990, which estimated 
disability weights by expert deliberation (1), GBD 2010 captured community-representative data 
through population surveys in Bangladesh, Indonesia, Peru, Tanzania, and the United States of 
America (14,710 participants) and an open-access internet survey available in English, Spanish, and 
Mandarin (16,328 participants). Each survey included lay descriptions of 220 health states, which 
together parsimoniously described the non-fatal consequences of all diseases and injuries in GBD 
2010. These were presented as paired-comparison questions asking participants to decide which of 
two randomly selected health states they considered the healthier. Responses were anchored on a 
scale of 0 (healthy) to 1 (death) with some additional “population health equivalence” questions, 
which compared the overall health benefits of different life saving or disease prevention programs, 
to derive disability weights (12). 
 
Severity distribution. In order to capture the range of severity in the presentation of MDD, disability 
weights were estimated for mild, moderate, and severe states of MDD. The choice of health states 
and their lay descriptions (Table 6) were formulated by members of the GBD mental disorders 
expert group, under the guidance of the GBD core group. The aim here was to encapsulate the main 
features of MDD and dysthymia (as described by DSM-IV and ICD-10 (38, 39)), using consistent, 
brief, and clear wording across each health state. Given the milder and more stable presentation of 
dysthymia, it was allocated the same disability weight as that for mild MDD. 
 
Information on the distribution of mild, moderate, and severe cases of MDD was obtained from the 
US Medical Expenditure Panel Survey (MEPS) 2000–2009 (176), the US National Epidemiological 
Survey on Alcohol and Related Conditions (NESARC) 2000–2001 and 2004–2005 (177), and the 
Australian National Survey of Mental Health and Wellbeing of Adults (NSMHWB) 1997 (178); 
these surveys captured the prevalence of multiple mental and physical disorders included in GBD 
2010 (156 in MEPS; 32 in NESARC; 20 in NSMHWB) as well as health status information 
measured by the Short Form 12-item (SF-12)  (179). 
 
A crosswalk between a score on the SF-12 and the GBD 2010 disability weights was derived from a 
convenience sample of participants asked to fill in the SF-12 to reflect 62 lay descriptions of health 
states of varying severity. From a mathematical relationship between SF-12 summary scores and 
disability weights, SF-12 values were translated into disability weights for all respondents in the 
MEPS, NESARC, and NSMHWB reflecting the combined severity of any comorbid condition. 
Next, a regression with random effects for all comorbid health states was run to parse disability in 
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each individual to each comorbid health state (13). Once disability attributable to comorbid 
disorders was portioned out, 14% of MDD cases and 29% of dysthymia cases had no disability (i.e., 
a disability weight of 0) at the time of the survey. Cases scoring a disability weight of >0 counted as 
symptomatic. For MDD, symptomatic cases were further disaggregated into mild, moderate, and 
severe where cases scoring a disability weight of >0 to halfway between a corresponding score of 
mild and moderate on the SF-12 counted as mild; cases scoring from there to halfway between a 
corresponding SF-12 score of moderate and severe counted as moderate; and those scoring from 
there onwards counted as severe. The proportion of cases in each state was then multiplied by its 
disability weight and summed to obtain an overall disability weight for MDD. Overall, the 
proportion of cases in asymptomatic, mild, moderate, and severe states over the course of MDD was 
almost identical across MEPS, NESARC, and NSMHWB for 12-month prevalence. As the 
NSMHWB was the only survey with one-month diagnoses and the SF-12 questions pertain to 
severity in the past month we used the distribution of severity from the NSMHWB for one-month 
diagnoses. Table 6 summarises the resulting health state proportions and disability weights. More 
details on this methodology have also been provided elsewhere (12, 13). 
 
Comorbidity adjustment. GBD 2010 YLD estimates were adjusted for the effect of comorbidity 
between diseases. Hypothetical populations by age, sex, year, and country were estimated using 
microsimulation. For each individual in the hypothetical population: (1) prevalence data for all 
GBD sequelae were used to estimate the probability of experiencing no, one, or more than one 
disabling condition (i.e., health state); (2) from this, a combined disability weight capturing 
disability attributable to each comorbid condition was estimated with a multiplicative function and; 
(3) re-distributed to individual conditions in a manner that was proportional to the disability weight 
of each condition in isolation; (4) the decrease between the original disability weights for MDD and 
dysthymia and the adjusted disability weights was considered as the “comorbidity correction” for 
YLDs. As we were unable to find sufficiently large datasets to explore and quantify the difference 
in disability due to comorbidities that were dependent versus independent of each other, only the 
latter was taken into consideration here. In support for this step, the severity adjustments using 
MEPS data showed that estimating independent comorbidity (i.e., assuming no correlation between 
comorbid conditions), using a multiplicative approach, explained most of the modulating effect of 
comorbidity on disability. The GBD 2010 approach to comorbidity has been discussed in greater 
detail elsewhere (13). 
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Table 6. Summary of data used to calculate YLDs for depressive disorders. 
 
Parameter MDD Dysthymia Source 
Epidemiological inputs    
Number of data points (and studies)  
 
Systematic review of the literature (150, 151). 
 Prevalence 544 (116) 141 (36) 
 Incidence 19 (4)
a 
3 (2)
a 
 Remission — 3 (2) 
 Duration 1 (5)
b — 
 Excess-mortality 14 (11) 5 (2)
c
 
DisMod-MR point prevalence % (95% 
UI) and cases  
   
Global prevalence 4.4% (4.1%–4.7%); 298 million cases 1.55% (1.5%–1.6%); 106 million 
cases 
DisMod-MR epidemiological modelling (151, 
175). 
Males 3.2% (3.0%–3.6%); 111 million cases 1.3% (1.2%–1.4%); 44 million cases 
Females 5.5% (5.0%–6.0%);187 million cases 1.8% (1.7%–1.9%); 62 million cases 
Disability weights    
Health state lay descriptions   Derived by GBD core group and mental disorders 
expert group for the GBD 2010 disability weight 
survey (12). 
Mild Has constant sadness and has lost interest in usual activities. The 
person can still function in daily life with extra effort, but sleeps 
badly, feels tired, and has trouble concentrating 
 
Moderate  
  
 
Has constant sadness and has lost interest in usual activities. The 
person has some difficulty in daily life, sleeps badly, has trouble 
concentrating, and sometimes thinks about harming himself (or 
herself). 
 
Severe Has overwhelming, constant sadness and cannot function in daily 
life. The person sometimes loses touch with reality and wants to 
harm or kill himself (or herself) 
 
Raw disability weights (95% UI)     
Mild 0.16 (0.11–0.22) 0.16 (0.11–0.22) d   GBD 2010 disability weight Survey (12) 
Moderate 0.41 (0.28–0.55)   
Severe 0.66 (0.47–0.82)   
Severity distribution %(95% UI)    
Asymptomatic 13.9% (10.2%–17.7%) 29.2% (24.9%–33.6%) Based on SF–12 data from MEPS, NSMHWB, and 
NESARC (13). Mild MDD/Symptomatic dysthymia 58.8% (48.0%–68.5%) 70.8% (66.4%–75.1%) 
Moderate 16.5% (12.1%– 21.0%)  
Severe 10.8% (3.8%–20.3%)  
Average disability weight (95% UI)    
 0.23 (0.18– 0.30) 0.11 (0.07–0.15) Based on severity proportions from MEPS, 
NSMHWB, and NESARC data, applied to weights 
from GBD 2010 disability weights survey (13). 
Note. 
a
Incidence data were excluded for MDD and dysthymia as they were not consistent with the prevalence and duration/remission data; 
b
The one data point for duration of 37.7 
weeks was an estimate of average duration calculated from a best fit curve between the data points available from five studies; 
c
Both studies reported no elevated risk of mortality in 
those with dysthymia; 
d
The disability weight for mild-MDD was applied to dysthymia; 95% UI:  95% uncertainty interval. 
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Time trend analysis. We replicated the methodology presented in the GBD 2010 capstone YLD 
paper (13) to disaggregate the change in YLDs between 1990 and 2010 into changes due to 
population growth, population age and sex structure, and YLD rates (i.e., the disorder’s 
epidemiology). This process involved estimating the total YLDs anticipated in 2010 if: (1) 
population growth increased to 2010 levels but the population age/sex structure and YLD rates 
remained the same as in 1990; and (2) the age/sex-population structure was at 2010 levels but the 
YLD rates remained the same as in 1990.  
 
Calculation of Direct Burden—DALYs 
We calculated DALYs as the sum of YLDs and YLLs. YLLs are calculated by multiplying the 
number of deaths due to the given disorder at a particular age by the standard life expectancy at that 
age. However, death records used in GBD 2010 followed ICD-10 rules for categorical attribution of 
cause of death to a single underlying cause (39) and, therefore, did not document any deaths due to 
depressive disorders. As such, we were unable to calculate disorder-specific YLLs for depressive 
disorders. Instead, associated deaths were captured under other causes in the GBD cause list and 
needed to be re-attributed to depressive disorders. 
 
Calculation of Attributable Burden  
The CRA component of GBD 2010 quantified the burden attributable to each risk factor exposure 
compared to an alternative (counterfactual) exposure distribution (10). Diseases, like MDD, can 
also be considered risk factors for loss of health if associated with elevated risk of mortality or 
disability from other diseases or injuries. We replicated the GBD 2010 CRA methodology to 
investigate the additional burden attributable to depressive disorders as a risk factor for other health 
outcomes. The burden of disease attributable to depressive disorders was estimated by comparing 
the current health status with a theoretical-minimum-risk exposure distribution, the optimum 
exposure distribution with the lowest possible risk. For depressive disorders the theoretical 
minimum was defined by the counterfactual status of absence of the disease. This process involved 
(1) the selection of health outcomes attributable to MDD and dysthymia based on data availability 
and adherence to criteria about causality; (2) conducting systematic reviews of the literature and 
meta-analyses of effect sizes of the disorder-outcome pairing (the gold standard for effect measure 
was RR estimates by year and sex derived from prospective cohort studies with a naturalistic 
follow-up of cases, representative of the general population); (3) combining the pooled RR 
estimates with the DisMod-MR prevalence output for the disorder to calculate population 
attributable fractions (PAFs); and (4) multiplying PAFs by the corresponding cause-specific 
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DALYs for the outcome under investigation to calculate attributable burden. The process allowed 
us to estimate attributable burden by sex, age, year, region, and country. Out of the comprehensive 
list of health outcomes originally investigated for mental disorders (88), there was sufficient 
evidence for causal effects to quantify the burden attributable to MDD as a risk factor for suicide 
and IHD. These literature searches have been reported in greater detail elsewhere (83, 85) with the 
main results highlighted in Table 7. 
 
Table 7. Summary of data used to calculate burden attributable to MDD as a risk factor for suicide 
and ischemic heart disease. 
 
Outcome Suicide IHD 
Number of data points (and studies) 4 (3) 13 (8) 
Number countries 2 2 
Pooled RR (95% UI)
a 19.9 (9.5–41.7) 1.6 (1.3–1.9) 
Note. 
a
RR estimates were pooled using meta-analytic strategies (83, 85); 95% UI:  95% uncertainty interval. 
 
Where we report comparisons of prevalence, YLDs, or DALYs by country or region we use ISO 
3166-1 alpha 3 codes (http://www.iso.org/iso/home/standards/country_codes.htm) and age-
standardised values using direct standardisation to the global standard population proposed by the 
WHO in 2001 (http://www.who.int/healthinfo/paper31.pdf). 
 
Results 
Direct Burden of Depressive Disorders 
Out of a total of 2.5 billion DALYs generated in the year 2010, mental and substance use disorders 
accounted for 7.4% (95% uncertainty interval: 6.3%–8.6%), depressive disorders for 3.0% (2.2%–
3.8%), MDD for 2.5% (1.9%–3.2%), and dysthymia for 0.5% (0.3%–0.6%). MDD ranked as the 
11th and dysthymia as the 51st leading cause of global DALYs in 2010. DALYs for both MDD and 
dysthymia were based solely on YLDs as there were no disorder-specific deaths (and therefore 
YLLs) recorded for either disorder. MDD was the second leading cause explaining 8.2% (5.9%–
10.8%) of all YLDs, after low back pain. Dysthymia ranked as the 19th leading cause, explaining 
1.4% (0.9%–2.0%) of all YLDs in 2010. 
 
Although the global YLD rankings were the same in 1990, depressive disorders caused only 9.3% 
(6.7%–12.2%) of all YLDs, corresponding with a 37.5% increase in YLDs between 1990 and 2010 
(see Table 8). The increase was entirely accounted for by population growth and ageing with no 
substantial change in age-specific prevalence.  
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Table 8. Change in depressive disorder YLDs between 1990 and 2010. 
 
Total YLDs in 1990 and 2010 MDD Dysthymia Depressive 
Disorders 
Total YLDs in 1990  46,138,600 7,870,700 54,009,300 
Total YLDs in 2010  63,179,247 11,084,100 74,261,500 
Total YLDs generated from 2010 population, 1990 population age 
structure, 1990 YLD rates (step 1) 
59,904,870 10,067,939 69,972,809 
Total YLDs generated from 2010 population, 2010 population age 
structure, 1990 YLD rates (step 2) 
64,537,300 11,061,231 75,598,531 
Total change in YLDs between 1990 and 2010 36.9% 40.8% 37.5% 
Change in YLDs between 1990 and 2010 due to population growth 29.8% 27.9% 29.6% 
Change in YLDs between 1990 and 2010 due to population aging  10.0% 12.6% 10.4% 
Change in YLDs between 1990 and 2010 due to prevalence 
increase  
−2.9% 0.3% −2.5% 
Note. The difference between total YLDs in 1990 and YLDs at step 1 represents the change in YLDs due to population 
growth; the difference between YLDs at step 1 and YLDs at step 2 represents the change in YLDs due to population 
aging; the difference between total YLDs in 2010 and YLDs at step 2 represents the change in YLDs due to changes in 
prevalence. 
 
Figure 12 shows the composition of YLDs by age and sex for MDD and dysthymia in 1990 and 
2010. YLDs were consistently higher for MDD compared to dysthymia and also in females 
compared to males. There were changes across the lifespan with YLDs peaking in the twenties and 
gradually decreasing into the older ages. Globally in 2010, the largest proportion of YLDs from 
depressive disorders occurred at working ages (15 to 64 years) with 60.4 million YLDs, followed 
by the 0 to 14 year age group with 7.8 million YLDs, and the 65 and over age group with 6.1 
million YLDs. 
 
Figure 13 shows the composition of YLD rates by region for MDD and dysthymia in 1990 and 
2010. Although dysthymia YLD rates were consistent between regions, there were differences for 
MDD. While the focus of GBD 2010 publications so far has largely been on reporting regional and 
global burden estimates, all analyses were primarily conducted at the country level. On the basis of 
these country-level analyses, Figure 14 shows the composition of YLD rates in 2010 (with the 
corresponding 1990 estimates presented in Figure S2, Appendix Four) by country for MDD and 
dysthymia combined (plot 1) and countries with statistically higher or lower YLD rates than the 
global mean (plot 2); the latter of which also needs to be considered while interpreting country-level 
findings. Most of the regional, and country-level differences in YLDs, were within wide and 
overlapping ranges of uncertainty, with only a few countries with statistically higher or lower YLD 
rates compared to the global mean. YLD rates were highest in Afghanistan (included in North 
Africa/Middle East) and lowest in Japan (included in the Asia Pacific, high income).  
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Figure 12. YLDs by age and sex for major depressive disorder and dysthymia in 1990 and 2010. 
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Table 9 summarises the regional YLD and DALY rankings for MDD and dysthymia in 2010 (with 
the corresponding 1990 rankings presented in Table S3, Appendix Four). This information 
highlights how MDD and dysthymia ranked in burden in comparison to other diseases and injuries 
in GBD 2010. MDD ranked as the 11th leading cause of DALYs globally but was as high as third 
in North Africa/Middle East and Latin America, Andean, and as low as 19th in sub-Saharan Africa, 
West. Although these regional rankings differed substantially to their corresponding global ranking, 
the overlapping 95% uncertainty intervals around some mean ranks also need to be considered.  
 
Attributable Burden 
The above estimates reflect direct disability where MDD is selected as the underlying cause but 
exclude the excess deaths resulting from the increased risk of mortality from suicide and burden 
from IHD attributed to MDD as a risk factor. In 2010, MDD explained a further 16 million DALYs 
when it was considered as a risk factor for suicide. Overall, close to half (46.1% [28.03%–60.8%]) 
of DALYs originally allocated to suicide (included as intentional injuries in the GBD cause list) 
could be re-attributed to MDD. In addition to this, 2.9% (1.5%–4.5%) of IHD DALYs (3.8 million 
DALYs of which 93.5% were YLLs) was attributable to MDD. Adding these to MDD would have 
increased the overall burden of MDD from 2.5% (1.9%–3.2%) to 3.4% (2.7%–4.2%) of global 
DALYs and the overall burden of depressive disorders from 3.0% (2.2%–3.8%) to 3.8% (3.0%–
4.7%) of global DALYs. The global burden rankings of MDD in the GBD cause list would have 
increased from 11th to eighth place, surpassing road injury, chronic obstructive pulmonary disease, 
and preterm birth complications. 
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Note. 95% UI: 95% uncertainty interval; AP-HI: Asia Pacific, High Income, As-C: Asia Central, AS-E: Asia East, AS-S: Asia South, A-SE: Asia Southeast, Aus: Australasia, Caribb: 
Caribbean, Eur-C: Europe Central, Eur-E: Europe Eastern, Eur-W: Europe Western, LA-An: Latin America, Andean, LA-C: Latin America, Central, LA-Sth: Latin America, 
Southern, LA-Trop: Latin America, Tropical, Nafr-ME: North Africa/Middle East, Nam-HI: North America, High Income, Oc: Oceania, SSA-C: Sub-Saharan Africa, Central, SSA-
E: Sub-Saharan Africa, East, SSA-S: Sub-Saharan Africa Southern, SSA-W: Sub-Saharan Africa, West.  
 
Figure 13. YLD rates (per 100,000) by region for major depressive disorder and dysthymia in 1990 and 2010. 
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Plot 1: World map showing age-standardised YLD rates (per 100,000) by country 
 
Plot 2: World map marking countries with statistically higher or lower YLD rates compared to the global mean 
 
Note. Low: statistically lower YLD rates compared to global mean; Middle: YLD rates not statistically different to 
global mean; High: statistically higher YLD rates compared to global mean. 
 
Figure 14. YLD rates (per 100,000) by country for depressive disorders in 2010. 
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Table 9. Regional DALY and YLD rankings with 95% uncertainty intervals for depressive 
disorders in 2010. 
 
Region YLDs DALYs 
MDD Dysthymia MDD Dysthymia 
Orde
r  
Mean 
Rank 
(95% UI) 
Orde
r  
Mean Rank  
(95% UI) 
Orde
r  
Mean 
Rank 
(95% UI) 
Orde
r 
Mean Rank  
(95% UI) 
Global 2 1.9 (1–3) 19 18.6 (13–26) 11 10.8 (7–
14) 
51 51.2 (42–
62.5) 
Asia Pacific, high 
income 
4 4.3 (2–7) 22 21.1 (14–28) 12 11.5 (6–
17) 
35 35.9 (27–47) 
Asia Central 1 1.5 (1–3) 19 19.4 (14–26) 6 7.2 (4–12) 46 46.7 (38–56) 
Asia East 2 2.3 (1–3) 16 15.1 (9–21) 8 8.4 (5–12) 33 32.4 (22–
42.5) 
Asia South 3 2.9 (1–4) 20 19.8 (11–29) 14 13.3 (8–
18) 
55 54.7 (41–70) 
Asia Southeast 1 1.4 (1–2) 19 17.9 (10–26) 6 6.7 (3–11) 44 45.1 (36–57) 
Australasia 2 2.9 (2–7) 21 20.8 (14–28) 4 6.1 (3–14) 33 34.5 (23–47) 
Caribbean 2 2.3 (1–4) 22 23 (18–33) 7 8.6 (4–13) 52 52.1 (41–65) 
Europe Central 2 2.2 (2–4) 20 19.2 (13–26) 5 6.6 (4–10) 36 37.4 (28–52) 
Europe Eastern 2 1.8 (1–2) 20 19.3 (14–26) 5 5.6 (3–9.5) 43 45.2 (35–
59.5) 
Europe Western 2 2.1 (2–3) 20 20.7 (15–28) 4 4.2 (3–8) 36 36.7 (27–51) 
Latin America, 
Andean 
1 1.7 (1–3) 22 20.9 (15–28) 3 4.6 (2–
10.5) 
42 43.5 (35–57) 
Latin America, 
Central 
1 1.3 (1–2) 19 19.1 (13–26) 5 5.2 (3–10) 41 40.1 (31–52) 
Latin America, 
Southern 
2 1.6 (1–3) 20 20.2 (13–28) 4 3.4 (2–6.5) 41 42.0 (32–58) 
Latin America, 
Tropical 
2 1.8 (1–2) 20 20.2 (14.5–
27) 
6 5 (2.5–7) 42 42.8 (35–53) 
North Africa/Middle 
East 
2 1.9 (1–2) 19 19.6 (15–28) 3 3.8 (2–8) 44 42.9 (32.5–
55) 
North America, high 
income 
2 2.1 (1–4) 21 20.2 (14–27) 5 5.0 (2–10) 38 38.1 (30–50) 
Oceania 1 1.6 (1–4) 23 22.4 (15–32) 12 13.4 (6–
23.5) 
65 63.1 (51–75) 
Sub-Saharan Africa, 
Central 
2 2.0 (1–3) 31 28.0 (18–37) 17 17.9 (12–
24) 
64 61.8 (50–75) 
Sub-Saharan Africa, 
East 
2 2.0 (1–3) 20 22.5 (14–35) 13 14.2 (11–
18) 
54 55.5 (43–75) 
Sub-Saharan Africa 
Southern 
2 2.5 (1–5) 22 22.6 (14–32) 10 10.4 (6–
16) 
52 52.3 (43–64) 
Sub-Saharan Africa, 
West 
3 3.1 (2–4) 27 26.1 (18–34) 19 19.7 (14–
26) 
58 58.4 (46–72) 
Note. Mean rank, YLD and DALY ranks were estimated for MDD and dysthymia then simulated 1,000 times to estimate 
95% uncertainty ranges. The 95% bounds of uncertainty represent the 25th and 975th value of the 1,000 draws; order, 
regional YLDs and DALYs for MDD and dysthymia were ordered by their mean rank across 1,000 draws. 
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Discussion 
GBD 2010 has identified depressive disorders as one of the leading causes of YLDs. In spite of the 
lack of disorder-specific YLLs, it was also a leading cause of DALYs, emphasizing the importance 
of non-fatal health outcomes in the quantification of disease burden. Within depressive disorders, 
MDD was the main contributor to burden, accounting for 85% of YLDs and DALYs in 2010. This 
finding was driven by high prevalence estimates with 298 million MDD cases in 2010 (175) and 
106 million cases of dysthymia (151). Discounting and age-weighting in previous GBD studies 
contributed in part to the high ranking of mental disorders. Despite not discounting (and therefore 
giving greater weight to mortality than disability) and not age-weighting (and therefore giving less 
weight to disabling conditions in young and middle aged adults) depressive disorders are still a 
leading cause of disability. 
  
GBD 2010 quantified burden for 1990, 2005, and 2010 allowing comparisons of estimates over 
time based on comparable methods. Contrary to recent literature on the topic (180, 181), our 
findings suggest that the epidemiology of both MDD and dysthymia remained relatively stable over 
time. There was a slight decrease in the prevalence rate of MDD between 1990 and 2010 but this 
was too small to allow for any explicit interpretation. As noted earlier there was a 37.5% increase in 
YLDs between 1990 and 2010 due to population growth and ageing. This has important 
implications for global health, especially in developing countries where increased life expectancy 
due to better reproductive health, nutrition, and control of childhood infectious diseases means more 
of the population are living to the age where depressive disorders are prevalent.  
 
Our findings not only emphasize depressive disorders as a global health priority, but also highlight 
the importance of understanding the variations both between and within regions when setting global 
health objectives. Variations in burden rankings between regions can be masked while considering 
global-level findings. For instance, some regional DALY rankings of MDD and dysthymia were 
considerably different than their corresponding global ranking. In the case of North Africa/Middle 
East, conflict in the region increased the prevalence of MDD, leading to a higher burden ranking for 
MDD. In sub-Saharan Africa on the other hand, the larger burden of communicable diseases such as 
malaria and HIV/AIDs resulted in a relatively lower ranking of MDD and dysthymia (5). 
 
GBD 2010’s capacity to generate country-level burden as well as regional estimates was especially 
relevant for MDD, which has been linked to risk factors such as conflict (175, 182), IPV and CSA 
(10), the levels of which vary between countries. Nevertheless, it’s important to stress that variation 
(or in some cases lack of variation) in burden estimates and rankings may reflect the true 
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distribution of burden, a lack of available epidemiological data, or outliers that can occur by chance 
in any distribution. The nature of the DisMod-MR modelling strategy used was such that if raw 
epidemiological data were not available for a given country, prevalence estimates were imputed on 
the basis of random effects for country, region, and super-region and fixed effects for country-level 
covariates such as the mortality rate due to conflict. In the case of MDD, as previously stated, our 
literature review was able to capture prevalence data from conflict countries such as Afghanistan 
and Iraq. To improve the predictive power of our DisMod-MR model, we included conflict and post 
conflict status covariates to guide the DisMod-MR estimation of MDD prevalence for regions with 
no data (175). This strategy does not replace high quality primary data but we preferred computing 
burden estimates for these countries/regions rather than excluding them entirely from this global 
health exercise. The global availability of the raw epidemiological data for MDD and dysthymia has 
been summarised in Table S1, Appendix Four as well as in previous publications (150, 151). Any 
utilization of GBD country-level estimates will have to take these data into consideration (183-185). 
As the updating of GBD continues we hope the scrutiny of these country-level findings will 
promote primary data collection on the epidemiology of depressive disorders, particularly in 
developing countries where data are sparse. 
 
We found no evidence of deaths attributable to dysthymia; this was consistent with our 
investigations into the epidemiology of dysthymia, finding no excess mortality attributable to the 
disorder (151). We found evidence for an elevated risk for mortality in those diagnosed with MDD 
(59, 175); however, since a health outcome could only occur once in the GBD cause list, MDD 
related deaths from suicide and IHD were captured under the headings of intentional injuries and 
cardiovascular disease in the GBD capstone papers (5). In this article, we’ve attributed a fraction of 
these DALYs to MDD using counterfactual estimation and GBD 2010 CRA methodology (10). The 
addition of these outcomes would have shifted MDD from 11th to eighth leading cause of DALYs, 
further supporting the prioritisation of depressive disorders in the prevention and management of 
wider aspects of health.  
 
It is worth noting that we were unable to quantify burden for all the outcomes of MDD and 
dysthymia. As a result, it is likely that the burden estimates presented here still underestimate the 
true burden of depressive disorders. Although there is literature linking stroke, diabetes, and 
vascular dementia/Alzheimer’s disease to MDD, there was insufficient evidence at the time of our 
review for a causal relationship and more studies are needed to support these tentative associations 
(88). For instance, many studies relied on symptom scales rather than DSM/ICD criteria to capture 
people with MDD and are hence likely to overestimate the strength of these associations. As more 
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rigorous evidence is made available we aim to quantify the burden due to MDD as a risk factor of 
other causes. Furthermore, for both suicide and IHD, meta-analyses relied on data from two 
countries that met our inclusion criteria. There is also uncertainty as to the extent to which these 
effect sizes are generalizable to different populations and GBD regions; this too is an area for 
further research. 
 
New to GBD 2010 was the capability of propagating uncertainty from the epidemiological data 
points through to burden estimates. While this also included uncertainty introduced by the 
adjustment of data points for study quality variables, the true uncertainty may be larger yet as we 
did not account for the rather crude nature of the study quality covariates as binary variables applied 
equally at all ages and both genders. The aim of GBD 2010 was to provide an empirical platform 
for consistently comparing the global burden attributable to different diseases and injuries. Given 
that MDD and dysthymia represented only two out of 291 causes included in the study, it was not 
surprising that some elements of the burden methodology could not be completely tailored to them. 
With ongoing improvements to the GBD methodology and the growing availability of 
epidemiological data, we will be able to add to our understanding of the global burden of depressive 
disorders.  
 
It is also worth acknowledging that our findings were reliant on the validity of the disability weights 
used. Although the methodology used to quantify disability largely improved on what was used in 
GBD 1990, some areas could benefit from further refinement. The health state definitions and 
subsequent lay descriptions for MDD and dysthymia may not have been representative of all 
participants’ experiences of the disorder. Further research is required into whether different health 
state definitions would change disability weights and, ultimately, burden estimates. Analyses of the 
disability weight surveys suggested a high degree of consistency between disability weights from 
the country surveys and the internet survey. In spite of responses coming from a heterogeneous 
sample of individuals (e.g., a high proportion of highly educated individuals from the internet-based 
survey and the opposite from the population-based survey from Tanzania), the strength of the 
correlation between disability weights was at least 0·9 across all surveys except in Bangladesh 
where it was 0·75 (12). That said, although these high correlations lend support to the argument that 
the disability weights used can be generalized across countries, replication of the disability weights 
survey in other settings is required for clearer conclusions.  
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Our review of the literature also indicated that there was much less reported on the severity of MDD 
and dysthymia compared to other areas of the disorders’ epidemiology. Moreover, the available 
literature differed vastly in sampling methods and survey instruments hence capturing different 
conceptualisations of severity with no general consensus in distinguishing between mild, moderate, 
and severe states of MDD (186). For instance, severity distributions obtained from the WMHS 
study group indicated the majority of cases with MDD were classified as severe. The skew towards 
classifying cases as severe was partly due to the algorithm used to group answers to questions from 
the Sheehan Disability Scale and/or the Quick Inventory of Depressive Symptomatology (17, 187, 
188) and partly due to the inclusion of additional criteria related to comorbid health states rendering 
the classification as unusable for GBD purposes  (17, 106, 187, 188). So instead, we turned to data 
from the MEPS, NESARC, and NSMHWB, which provided a less skewed distribution of cases and 
allowed us to derive severity distributions while also controlling for comorbidity. However, these 
three surveys were from two high income countries, limiting the global representativeness of our 
severity distributions and making it impossible to quantify any effect of treatment on severity. 
There is a clear need for further investigations with comparable methods into the severity 
distribution of MDD and dysthymia and the variation thereof between countries and by levels of 
access to care. 
 
Conclusions 
Our findings not only highlight the fact that depressive disorders are a global health priority but also 
that it is important to understand variations in burden by disorder, country, region, age, sex, and 
year when setting global health objectives. Furthermore, estimating the burden attributable to MDD 
as a risk factor for other health outcomes allows for a more accurate estimate of burden and 
reinforces the importance of implementing cost-effectiveness interventions to reduce its ubiquitous 
burden. Ongoing improvements to the GBD methodology and access to more epidemiological data 
will enhance the precision of our burden estimates and add to our understanding of the global 
burden of depressive disorders. 
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Chapter review 
Chapter Five estimated DALYs, YLDs, and YLLs due to MDD as part of GBD 2010 (thesis aim 
two). Given the lack of deaths and YLLs estimated for MDD, burden attributable to MDD but 
allocated to other diseases and injuries in GBD 2010 was also quantified. Findings showed that 
MDD was a significant contributor to the burden originally assigned to suicide and IHD.  
 
Given the literature presented in Chapter Two showed that other mental and substance use disorders 
also lead to an increased risk of suicide, the next chapter estimates the burden attributable to a 
number of different mental and substance use disorders as risk factors for suicide. It is important 
from a public health perspective to not only estimate the burden attributable to MDD as a risk factor 
for other health outcomes, but also to consider the relative impacts of MDD compared to other 
mental and substance use disorders. With that in mind, the aim of Chapter Six was to investigate the 
effect of all mental and substance used disorders (as a group) as well as the contribution of MDD 
(and other individual mental disorders) on suicide burden.  
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Chapter Six: The burden attributable to mental and substance use disorders as risk factors 
for suicide: Findings from the global burden of disease study 2010  
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Chapter summary 
Background 
The GBD 2010 study identified mental and substance use disorders as the 5
th
 leading contributor of 
burden in 2010, measured by DALYs. This estimate was incomplete as it excluded burden resulting 
from the increased risk of suicide captured elsewhere in GBD 2010’s mutually exclusive list of 
diseases and injuries. Here, we estimate suicide DALYs attributable to mental and substance use 
disorders. 
 
Method 
RR estimates of suicide due to mental and substance use disorders and the global prevalence of each 
disorder were used to estimate PAFs. These were adjusted for global differences in the proportion 
of suicide due to mental and substance use disorders compared to other causes then multiplied by 
suicide DALYs reported in GBD 2010 to estimate attributable DALYs (with 95% uncertainty).  
 
Results 
Mental and substance use disorders were responsible for 22.5 million (14.8-29.8 million) of the 
36.2 million (26.5-44.3 million) DALYs allocated to suicide in 2010. Depression was responsible 
for the largest proportion of suicide DALYs (46.1% (28.0%-60.8%)) and anorexia nervosa the 
lowest (0.2% (0.02%-0.5%)). DALYs occurred throughout the lifespan, with the largest proportion 
found in Eastern Europe and Asia, and males aged 20-30 years. The inclusion of attributable suicide 
DALYs would have increased the overall burden of mental and substance use disorders (assigned to 
them in GBD 2010 as a direct cause) from 7.4% (6.2%-8.6%) to 8.3% (7.1%-9.6%) of global 
DALYs, and would have changed the global ranking from 5
th
 to 3
rd
 leading cause of burden. 
 
Conclusion 
Capturing the suicide burden attributable to mental and substance use disorders allows for more 
accurate estimates of burden. More consideration needs to be given to interventions targeted to 
populations with, or at risk for, mental and substance use disorders as an effective strategy for 
suicide prevention.  
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Introduction 
There has been growing recognition of the importance of mental and substance use disorders as 
contributors to health loss in all countries. GBD 2010 is the largest and most recent effort to 
quantify this by systematically integrating YLLs and YLDs into DALYs for diseases, injuries and 
risk factors (5, 6, 10-13) 
GBD 2010 presented  age-, sex-, year-, country-, and region-specific DALYs for 291 diseases and 
injuries as well as for 67 risk factors (5, 6, 10-13)using improved methodology compared to 
previous GBD studies (1, 16).  Mental and substance use disorders explained 7.4 % (95% 
uncertainty interval: 6.2-8.6%) of total DALYs in 2010, confirming them as the leading disease 
category of YLDs, and the 5
th
 leading category of DALYs globally (19, 189, 190). This estimate 
reflects ‘direct burden’ where mental and substance use disorders are the direct cause of health loss, 
but excludes the excess (attributable) burden resulting from the increased risk of mortality and 
disability due to subsequent health outcomes captured elsewhere in the mutually exclusive disease 
and injury categories in GBD 2010. Jointly considering the direct and the attributable burden of 
mental and substance use disorders provides an estimation of the putative causal relationship 
between the disorders and other health outcomes. This is of clinical and policy relevance as it 
clearly delineates the disability and mortality that potentially can be modified by interventions to 
prevent and treat mental and substance use disorders. 
Here, we expand on the published GBD 2010 findings by estimating the additional burden 
attributable to mental and substance use disorders as risk factors for suicide.  Suicide, defined as 
deaths caused by intentional, self-inflicted poisoning or injury (39), was the 13
th
 leading cause of 
YLLs worldwide in 2010 (5, 11). Nearly 1 million people complete suicide every year with over 
50% aged between 15 and 44 years  (74, 191). Over 80% of suicides occur in low to middle income 
countries and close to 50% occur in India and China alone (191, 192). Suicide from firearms, car 
exhaust and poisoning are more common in high income countries and suicide from pesticide 
poisoning, hanging and self-immolation are more common in low to middle income countries (193). 
It is important to consider these differences in the global epidemiology of suicide while quantifying 
the suicide burden attributable to mental and substance use disorders. 
The link between mental and substance use disorders and suicide is well documented (74, 82, 83, 
90, 191-193) and authors such as Prince and colleagues argued (74) that failure to include suicide as 
part of mental and substance use disorder estimates in the previous GBD studies (1, 16) led to an 
underestimate of the extent of the burden.  A literature review and meta-analysis by Harris and 
Barraclough showed that of the 249 studies and 44 mental disorders assessed, 36 disorders were 
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associated with an increased risk of suicide (82). Li and collaborators also found that the risk of 
suicide was 7.5 (6.2-9.0) times higher in males and 11.7 (9.7-14.1) times higher in females with a 
mental or substance use disorder compared to males and females with no disorder. Depression and 
bipolar disorder accounted for the highest risk (83). Even when other risk factors such as adverse 
marital effects, employment and socio-economic status were considered, mental and substance use 
disorders remain strongly associated with suicide (83, 92) 
Quantifying the suicide burden attributable to mental and substance use disorders also corrects for 
the low burden from premature mortality (YLLs) directly attributed to mental and substance use 
disorders in GBD 2010. Although mental and substance use disorders were identified as a leading 
cause of global burden, YLDs contributed to 95% of DALYs (5, 19). In spite of evidence of excess 
mortality attributable to many mental and substance use disorders,  only substance use disorders, 
anorexia nervosa, and schizophrenia  are recognized as  underlying causes of death in the ICD-10 
cause of death guidelines (39) used in GBD 2010. Even for those disorders, few deaths were 
captured in the vital registrations used in the estimation of YLLs, as this typically involves the 
cumbersome task of disentangling the effect of multiple mental, substance and physical disorders to 
identify primary cause of death.  
 
Investigating mental and substance use disorders as risk factors for fatal outcomes like suicide 
allows us to circumvent this problem by making use of GBD 2010’s CRA methodology (10). 
Rather than rely on certification and coding practices in mortality registration systems, this method 
allows quantification of the difference in population health in a counterfactual with a theoretical 
minimum level of exposure (10). We make use of this method here to calculate the suicide burden 
attributable to mental and substance use disorders, and examine variations by region, country, age, 
year and disorder.  
 
Methods                                                                                                                                                                   
The suicide burden attributable to mental and substance use disorders was estimated by comparing 
the current health status with a theoretical-minimum-risk exposure defined as the counterfactual 
status of the absence of mental and substance use disorders. PAFs were determined from the 
prevalence of exposure to each disorder and the RR of suicide (10). For each disorder this involved:  
 Reviewing the strength of the evidence for a causal relationship between the disorder and 
suicide. 
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 Expanding on existing systematic reviews of the literature quantifying the effect size for the 
disorder as a risk factor for suicide. The preferred metric was population-representative RR 
estimates. 
 Pooling all RR estimates using meta-analysis. 
 Combining the pooled RR estimate with GBD 2010 prevalence estimates to generate PAFs 
by age, sex, country, and year. 
 Adjusting PAFs for global differences in suicide attributable to mental and substance use 
disorders versus differences attributable to other causes. 
 Multiplying PAFs by suicide YLLs reported in GBD 2010 to estimate attributable burden.   
 
Case definition 
GBD methods suggest that for each risk factor-outcome pairing, there should be (1) sufficient data 
to enable estimation of relative effect sizes as well as (2) sufficient evidence for a causal effect (10). 
A literature review by Baxter and collaborators (88) as well as other studies summarised in the 
previous section (74, 82, 83, 90, 191-193) investigating mental and substance use disorders as risk 
factors for other health outcomes found sufficient evidence to meet these two conditions for suicide.  
Mental and substance use disorders investigated were those included in GBD 2010 for which there 
was evidence of an increased risk of suicide (19, 82, 83). These were MDD, bipolar disorder, 
schizophrenia, anxiety disorder, anorexia nervosa, alcohol dependence, amphetamine dependence, 
cocaine dependence and opioid dependence. All disorders were defined using the DSM (38) or ICD 
diagnostic criteria (39). Suicide was defined as cases meeting ICD-10 cause of death codes for 
intentional self-inflicted poisoning or injury (X60-X84) (39). In some countries a large proportion 
of injury-related deaths are coded as ‘underdetermined intent’ for cultural, religious or medico-legal 
reasons. GBD 2010 developed a method to redistribute these deaths to specific underlying causes, 
including suicide (5). Although GBD 2010 also considered the effects of attempted suicide as ‘non-
fatal self-harm’ (5), this was not investigated in this paper. 
Literature search to identify relative-risk estimates                                                                                                                                                                            
We used data sources from recent  and methodologically comparable systematic reviews of the 
association between suicide and mental and substance use disorders (83, 194-196), specifically 
affective disorders, anxiety disorders, schizophrenia (14 studies from these 3 disorder groups) (83), 
cocaine, opioid, and amphetamine dependence (24 studies) (194, 195), s and alcohol dependence 
(12 studies) (196).  We expanded the Li and collaborators systematic review and replicated the 
literature search (83)  to collect data for bipolar disorder and MDD separately (rather than affective 
disorders combined), and anorexia nervosa which was not included in the original review.  The 
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search strategy used was in keeping with the PRISMA statement (121)  (See Text S1, Appendix 
Five for the PRISMA checklist and flow diagram). Electronic databases (Medline and Embase) 
were searched between 1966 and 2010.  A secondary search of reference lists and the grey literature 
was also conducted. Studies were included that; (1) considered mental and substance use disorders 
as a risk factor associated with suicide; (2) reported a RR with 95% uncertainty, or  provided 
sufficient information for these to be calculated; (3) were individual-level case-control or cohort 
studies where a clear temporal association between exposure and outcome could be determined; (4) 
had a minimum follow up period of 1 year and; (5) included disorders based on ICD  (39) or DSM 
(38) nomenclature  to ensure consistency in case definitions. Sex-specific data were preferred but 
non sex-specific estimates were included (e.g. for substance use disorders) where data were sparse. 
For each study, information on study methodology, quality and findings were extracted into a 
Microsoft Excel spreadsheet. See Table S1, Appendix Fice for a summary of the study variables 
extracted. 
 
Meta-analysis of relative-risk estimates  
For each disorder (except alcohol dependence for which a pooled estimate was available (196)), 
MetaXL software, an add-in for Microsoft Excel (197), was used to pool RR estimates from 
different studies. This was done for males and females separately and also combined.  RR estimates 
were pooled using a random effects model, and if there was sufficient data to do so, a quality effects 
model (198). Pooled RRs from the quality-effects model were preferred as these gave greater 
weight to studies of high quality versus studies of lesser quality, and avoided the anomaly of 
random effects models which revert to equal weighting regardless of sample size if heterogeneity is 
large (198-200). Study quality was assessed using a quality index which scored studies based on 
sampling design and representativeness and also the availability of age- and gender-specific 
estimates. It was limited to these items to reduce potential subjectivity within and between quality 
scores. To prevent inter-rater bias, all studies were rated by one researcher and a random sample of 
scores was checked by an independent researcher. The quality index and scores have been 
summarised in Table S1, Appendix Five. 
 
Prevalence of mental and substance use disorders 
We obtained the prevalence distribution of each mental and substance use disorder from the 
epidemiological disease models used in the calculation of direct burden (i.e. YLDs) in GBD 2010 
(19, 189). These were based on a separate literature review (presented in greater detail elsewhere 
(19, 142, 150, 201-203) conducted between 1980 to 2010 to capture studies reporting prevalence, 
incidence, remission, duration and all cause-excess mortality associated with mental and substance 
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use disorders. Point (current or past month) prevalence estimates of DSM/ICD defined disorders 
were required. Twelve-month prevalence estimates were accepted to maximize inclusion but 
adjusted towards the level of point prevalence using study-level covariates. Lifetime prevalence was 
excluded as it is more likely than point or period prevalence to be affected by recall bias (122, 123).  
GBD 2010’s DisMod-MR, a Bayesian meta-regression tool, was used to integrate these estimates 
into an epidemiological disease model. From the epidemiological inputs, DisMod-MR generated 
prevalence by sex and age for 187 countries, 21 world regions and 1990, 2005 and 2010 (13, 154). 
Prevalent cases for each disorder have been summarised in previous publications (13, 19, 189). 
 
Population attributable fractions 
PAFs were calculated from the DisMod-MR prevalence output (P) for each disorder and the pooled 
RR of suicide given exposure to the disorder. PAFs were calculated by age, sex, country, year and 
disorder (consistent with the format of GBD 2010 estimates) using the following formula (14): 
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Given the presence of comorbidity between mental and substance use disorders, disorder-specific 
PAFs cannot be summed to obtain the ‘joint effect’ of combined mental and substance use disorders 
on suicide. Instead, a joint PAF was estimated using the multiplicative method of adjusting for 
comorbidity between disorders (204). This can be understood as calculating the complement of the 
product of the complements of each individual PAF. The following formula was used where i  is the 
individual risk factor, and n is the total number of risk factors (10); 
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Ceiling values for joint population attributable fractions 
Although studies from high income countries have consistently shown that up to 90% of suicides 
occur as a result of an underlying mental or substance use disorder (90-92), there is also evidence to 
suggest that this proportion is substantially lower in China, Taiwan and India; where symptoms of  
‘dysphoric affect’ and ‘impulsivity’ (which do not  constitute  a mental and substance use disorder) 
are expressed through more lethal methods of self-harming such as pesticide poisoning and  self-
immolation (205-208). This in turn, increases the number of completed suicides occurring from 
self-harm behaviours (characteristically instigated as impulsive acts, without the presence of a 
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mental and substance use disorder or a clear intent to die) in these countries which would have 
resulted in an “attempted suicide” had such methods not been available  (206, 207). 
 
So as not to overestimate the total proportion of suicide burden attributable to mental and substance 
use disorders, we first portioned out global differences in suicide attributable to mental and 
substance use disorders from differences attributable to other causes. More specifically, the total 
proportion of suicide cases attributable to mental and substance use disorders in different countries 
was calculated and used to set a ceiling value (or upper threshold) for the joint PAFs. We examined 
reference lists of existing reviews for psychological autopsy studies (90-92) and conducted a 
supplementary literature search to capture additional data sources up to 2010. The psychological 
autopsy method is a retrospective assessment of causes of death which involves canvassing the 
views of individuals closest to the deceased and substantiating evidence from sources such as 
hospital and police records (209). The overall number of suicide cases attributable to mental and 
substance use disorders was extracted from these studies if DSM/ICD diagnostic criteria (38, 39) 
were used and the number of attributable suicide cases was reported for mental and substance use 
disorders as a group rather than for individual disorders. If gender was not recorded we also 
accepted combined estimates for males and females. Given that there were insufficient data to 
calculate ceiling values  individually for each country or region, we pooled estimates into 2 broad 
categories based on the percentage of suicide cases reported to be due to mental and substance use 
disorders. Meta-analyses based on quality effects models were used to generate separate pooled 
proportions for Group 1: China, India and Taiwan and Group 2: all other countries. 
These calculated proportions of suicide cases due to mental and substance use disorder were used to 
set the ceiling value of joint PAFs. All quantities of interest in GBD 2010 were calculated a 
thousand times in order to incorporate all sources of uncertainty. Similarly, we created a thousand 
draws of the ‘ceiling values’ based on the pooled estimates of mean and SE. When estimating the 
joint PAFs of suicide attributed to all mental and substance use disorders we did not allow PAF 
estimates in any of the one thousand draws to exceed the ceiling value in the corresponding draw. 
For draws that did exceed the ceiling, we scaled down each of the component mental and substance 
use disorder PAFs by the ratio of the ceiling to the combined PAF.  
 
Attributable burden    
The final step was to multiply PAFs by the corresponding GBD 2010 YLLs for suicide (5, 11) to 
calculate attributable burden. Since only completed suicides were considered in our analyses, only 
YLLs were included in attributable DALY estimates. To quantify 95% uncertainty around our final 
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burden estimate we calculated attributable YLLs and DALYs at the one thousand draw level and 
bounded the 95% uncertainty interval by the 2.5 and 97.5 centile values. All reporting of DALYs by 
region and country is based on age-standardised estimates using direct standardization to the global 
standard population proposed by the WHO in 2001 (169). 
 
Results 
Pooled relative-risk estimates 
Our search culminated in a dataset of 40 studies and 85 RR estimates covering 14 countries (Table 
S1 summarizes included studies). There was a statistically significant increased risk of suicide for 
all selected mental and substance use disorders (table 10).  The greatest risk was seen in MDD 
followed by schizophrenia, and alcohol dependence. The 95% confidence intervals around each 
pooled RR indicated high levels of uncertainty with statistical heterogeneity (as measured by the I
2
 
statistic) of up to 90%.  A statistically significant sex difference was only observed for alcohol 
dependence (Table S2, Appendix Five summarizes sex-specific pooled RRs) hence the overall 
pooled proportions for both sexes combined were used in PAF calculations.  Given that the one RR 
estimate for amphetamine dependence was not statistically different (i.e. occurred within 
overlapping 95% uncertainty) to the three estimates for cocaine dependence, we combined them to 
calculate a pooled RR for all psychostimulants. This was used to calculate PAFs for both disorders.  
Table 10. Pooled relative-risk of suicide in those diagnosed with a mental or substance use disorder. 
Disorder Number of studies Pooled relative risk 
(95% UI) 
Major depressive disorder 4 19.9 (9.5-41.7) 
Anxiety disorder 7 2.7 (1.7-4.3) 
Schizophrenia 4 12.6 (11.0-14.5) 
Bipolar disorder 4 5.7 (2.6-12.4) 
Anorexia nervosa 9 7.6 (2.2-25.6) 
Alcohol dependence
b 
12 9.8 (9.0–10.7) 
Opioid dependence 21 6.9 (4.5-10.5) 
Psychostimulant dependence 4 8.2 (3.9-16.9) 
Amphetamine dependence
a
 1 4.5(1.1-9.03) 
Cocaine dependence
a
 3 16.9(6.01-47.2) 
Note. 95% UI: 95% uncertainty interval; 
a
Due to lack of data, simultaneously pooled cocaine and amphetamine 
relative-risk estimates into an overall estimate for  psychostimulants which was applied to both disorders; 
b
Used 
reported pooled standardised mortality ratios from Wilcox et al (196)  for alcohol dependence. 
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Ceiling values for joint PAFs 
Out of 166 psychological autopsy studies reviewed, 43 studies and 57 estimates covering 20 
countries were used to calculate ceiling value for joint PAFs (Table S3, Appendix Five summarizes 
included studies). In China, India and Taiwan (group 1), 68.3% (55.2%-80.0%) of suicide cases was 
due to mental and substance use disorders which was lower than in all other countries (group 2), 
where  84.5% (78.6%-89.6%) of suicide cases were due to mental and substance use disorders. 
These two pooled proportions were used as the ceiling values for joint PAFs from China, India and 
Taiwan (Group 1) and all other countries (Group 2) respectively. Note that there was considerable 
heterogeneity between studies. As we found no statistically significant sex difference, the overall 
pooled proportions were used in PAF calculations (Table S4, Appendix Five summarizes sex-
specific pooled proportions). 
 
Attributable burden 
Mental and substance use disorders were responsible for 22.5 million (14.8-29.8 million) of the 
36.2 million (26.5-44.3 million) DALYs allocated to suicide in 2010, amounting to 62.1% (43.8%-
75.3%) of total suicide DALYs. The proportion of attributable suicide DALYs in 1990 was almost 
identical to that in 2010 (62.1% (44.5%-75.4%)). The remainder of this section focuses on 2010 
estimates with 1990 estimates summarised in Table S5, Appendix Five. There were twice as many 
mental and substance use disorders attributable suicide DALYs for males (14.9 million (9.5-20.1 
million)) compared to females (7.6 million (4.4-10.6 million)). For all disorders, this sex difference 
was consistent throughout the lifespan. Attributable suicide DALYs were apparent from those aged 
≥ 5 years, with the highest proportion occurring between those aged 20-30 years (Figure 15). 
 
The proportion of suicide DALYs explained by mental and substance use disorders was reasonably 
consistent between regions and within the range of the ceiling values presented in the previous 
section. When considered in terms of absolute DALYs, Asia South and Asia East had the highest 
burden attributable to mental and substance use disorders, given their large population size. In terms 
of age-standardized rates, Europe Eastern had the highest burden (almost 3 times higher than the 
global mean) and Sub-Saharan Africa West the lowest (6 times lower than the global mean) (Figure 
16, Table S5, Appendix Five summarizes attributable DALYs by disorder, region, age and sex). 
 
95 
 
 
 
Note. Plot 1 shows attributable DALYs as proportion of suicide DALYs. Plot 2 shows attributable DALYs as a rate per 
100,000                                                                                                                                          
Figure 15. Suicide DALYs attributable to mental and substance use disorders by age and sex, in 
2010. 
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Note. Plot 1 shows attributable DALYs as proportion of suicide DALYs. Plot 2 shows attributable DALYs as a rate per 
100,000; AP-HI: Asia Pacific, High Income, As-C: Asia Central, AS-E: Asia East, AS-S: Asia South, A-SE: Asia 
Southeast, Aus: Australasia, Caribb: Caribbean, Eur-C: Europe Central, Eur-E: Europe Eastern, Eur-W: Europe 
Western, LA-An: Latin America, Andean, LA-C: Latin America, Central, LA-Sth: Latin America, Southern, LA-Trop: 
Latin America, Tropical, Nafr-ME: North Africa/Middle East, Nam-HI: North America, High Income, Oc: Oceania, 
SSA-C: Sub-Saharan Africa, Central, SSA-E: Sub-Saharan Africa, East, SSA-S: Sub-Saharan Africa Southern, SSA-W: 
Sub-Saharan Africa, West. 
Figure 16. Suicide DALYs attributable to mental and substance use disorders by region, in 2010. 
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There were also differences in attributable suicide DALYs across countries (plot 1, figure 
17).  Attributable DALY rates were highest in Kazakhstan and lowest in Saudi Arabia, however 
many of the country level differences presented in plot 1 were within overlapping ranges of 
uncertainty (plot 2, figure 17).  Except for Guyana, Suriname and Zimbabwe, all countries with 
statistically higher attributable DALY rates than the global mean were from Eastern Europe and 
South Asia. Countries with statistically lower DALY rates than the global mean included those 
from South America, Oceania, Africa and the Middle East and parts of Asia. 
 
Plot 1: Map showing age standardized DALY rates (per 100,000) by country 
 
Plot 2: Map comparing country-specific DALY age standardized rates (per 100,000) to the global mean 
 
Note: Low: countries with statistically lower DALY rates than the global mean; middle: countries with statistically 
similar DALY rates to the global mean; high: countries with statistically higher DALY rates than the global mean. 
 
Figure 17. Suicide DALYs (rates per 100,000) attributable to mental and substance use disorders by 
country, in 2010. 
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Of the suicide DALYs attributable to mental and substance use disorders, MDD was responsible for 
the largest proportion (46.1% (28.0%-60.8%)), followed by alcohol dependence (13.25% (12.0%-
15.0%)), anxiety disorder (7.4% (3.0%-12.7%)), bipolar disorder (5.4% (1.8%-10.7%)), 
schizophrenia (4.7% (4.1%-5.3%)), amphetamine dependence (2.4% (0.9%-4.6%)), opioid 
dependence (1.9% (1.1%-2.9%)), cocaine dependence (0.9% (0.3%-1.8%)) and anorexia nervosa 
(0.2% (0.02%-0.5%))  (figure 18).  MDD explained the most suicide DALYs and anorexia nervosa 
the least across all age groups, sex and regions although most of the age and regional differences 
between disorders remained within wide and overlapping confidence intervals (Table S6, Appendix 
Five). 
 
 
Note. Absolute DALYs in 100,000. 
Figure 18. Suicide DALYs attributable to mental and substance use disorders by disorder, in 2010. 
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The additional burden attributable to suicide for each mental and substance use disorder (over and 
above the DALYs assigned to them as a direct cause) is also illustrated in figure 18. The inclusion 
of attributable suicide burden increased the fatal burden (YLLs) due to mental and substance use 
disorders from 0.5% (0.4%-0.7%) (assigned to them as a direct cause) to 1.8% (1.4% - 2.2%) of 
global YLLs and the overall burden (DALYs) of mental and substance use disorders from 7.4% 
(6.2%-8.6%) to 8.3% (7.1% - 9.6%) of global DALYs. Out of the 10 leading classes of diseases 
included in GBD 2010(5), mental and substance use disorders increased from the 5
th
 to the 3
rd
 
leading class of disease burden once the burden attributable to suicide was considered; exceeding 
the burden due to neoplasms (7.6% (7.0%-8.2%) of global DALYs) and neonatal conditions (8.1% 
(7.3%-9.0%) of global DALYs) but not cardiovascular and circulatory diseases (11.9% (11.1%-
12.7%) of global DALYs) and diarrhoea, LRI, meningitis, and other common infectious diseases 
(11.4% (10.4%-12.8%) of global DALYs). The global DALY ranking of individual disorders (as 
presented in GBD 2010’s publication series (5)) also increased when attributable suicide burden 
was included (table 11). Although within overlapping ranges of uncertainty, the ranking for alcohol 
dependence increased the most, from the 35
th
 (29
th
-45
th
) to the 28
th 
(26
th
-37
th
) leading cause of 
burden. 
Table 11. Global DALY proportions and rankings before and after the addition of attributable 
suicide burden, in 2010. 
 
 Before addition of attributable 
suicide burden 
(95% UI) 
After addition of attributable suicide 
burden 
(95% UI) 
Disorder Direct DALYs 
As a proportion of total 
DALYs 
Mean 
rank  
 
Direct plus attributable 
DALYs 
As a proportion of total 
DALYs 
Mean 
rank  
 
Major depressive 
disorder
a 
 
2.5% (1.9%-3.3%) 11 (7-14) 3.2% (2.5%-4.0%) 8 (4-11) 
Anxiety disorder
a 
 
1.1% (0.8%-1.5%) 26 (19-33) 1.2% (0.9%-1.6%) 25 (17-30) 
Alcohol dependence
a 
 
0.7% (0.5%-0.9%) 35 (29-45) 0.9% (0.7%-1.1%) 28 (26-37) 
Schizophrenia
a 
 
0.6% (0.4%-0.7%) 43 (36-57) 0.7% (0.5%-0.9%) 39 (30.5-
50) 
Bipolar disorder
a 0.5% (0.3%-0.8%) 46 (35-59) 0.6% (0.4%-0.8%) 44 (31-56) 
Mental and substance use 
disorders combined
b 
7.4% (6.2%-8.6%) 5 (3-6) 8.3% (7.1%-9.6%) 3 (3-6) 
Note. 95% UI: 95% uncertainty interval;  
a
Global ranking of direct burden for each disorder was from the official GBD 
2010 disease ranking for 2010 (5). Illicit drug use disorders have not been included here as the GBD 2010 official 
disease ranking investigated drug use disorders as group (rather than by specific drug types). Similarly, the ranking for 
anorexia nervosa was presented in addition to bulimia nervosa;
 b
The global ranking of direct burden of mental and 
substance use disorders as a group compares the direct burden of the 11 main classes of diseases in GBD 2010 (19). 
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Discussion 
 
Mental and substance use disorders are associated with an increased risk of suicide, a finding that is 
well established in the literature (82, 83, 196) but until now, not quantified in terms of a global 
comparison of disease burden. DALY rankings in GBD 2010 were based on a classification of 
mutually exclusive disease and injury categories (5, 19). Considering the additional burden due to 
mental and substance use disorders as a risk factor for suicide elevated mental and substance use 
disorders from the fifth to the third leading disease category of global burden in 2010. Few mental 
and substance use disorders are recognized as a primary cause of death in mortality registrations, 
and those that are recognised are often under-represented. The data presented here provide a more 
comprehensive insight into the magnitude of the burden due to these disorders. 
 
Mental and substance use disorders were the cause of two-thirds of all suicide DALYs reported in 
GBD 2010. Aside from emphasising these as a debilitating group of disorders, our findings 
highlight the importance of prioritising the prevention, early detection and effective management of 
mental and substance use disorders – particularly MDD – as a key suicide prevention 
strategy. Presenting the differences in attributable burden between regions and countries also 
provides a beginning for developing policies or intervention strategies that are applicable at the 
national level. Such interventions can be described as ‘selective’, in the sense that they target 
subgroups of the population whose members have yet to manifest suicidal behaviours, but exhibit 
risk factors (in this case, mental and substance use disorders) that predispose them to do so in the 
future.  These can be contrasted with ‘universal’ interventions, which target whole populations with 
the aim of favourably shifting proximal and distal risk (and protective) factors across the entire 
population, and ‘indicated interventions’ which are designed for individuals already exhibiting 
suicidal behaviours (210). 
Typically, countries that have put in place national suicide prevention strategies have funded a 
range of universal, selective and indicated interventions, in recognition of the variety of risk and 
protective factors associated with suicide (211). However our findings suggest that a relatively 
greater emphasis on selective interventions targeting individuals with mental and substance use 
disorders may be applicable.  By way of example, equipping general practitioners to detect, 
diagnose and manage MDD is likely to have benefits, particularly because many individuals with 
MDD will receive care from a general practitioner rather than a specialist mental health 
provider.  This was one of the few interventions for which there was good evidence of effectiveness 
as a suicide prevention strategy in a recent review by Mann and colleagues (212). That said, 
ensuring that care from general practitioners is evidence-based requires further consideration, given 
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findings that rates of minimally adequate treatment for depression are lower among patients treated 
solely by general practitioners or in the general medical care sector, compared to those treated by 
specialist mental health providers (213, 214). 
However universal and indicated interventions have their place, particularly in low and middle 
income countries where mental and substance use disorders were associated with a lesser proportion 
of the burden of suicide.  In these countries, universal interventions for example restricting access to 
means (e.g., pesticides) is worth pursuing given that they are relatively cheap to implement, can 
have a broad community reach and are known to be effective (212). 
Although within overlapping bounds of uncertainty, we found that attributable suicide DALY rates 
among young people aged 15-19 years were approaching those of the adult age groups. Although 
males had higher rates of attributable burden in most age groups, female rates were higher between 
the ages of 10 and 19 years. These age-related findings support the importance of school-based 
prevention programs which include a focus on mental health targeted to at-risk adolescents. The 
sex-difference in attributable burden also needs to be considered when formulating prevention 
strategies for this age group.  Although evidence of a reduction in suicide behaviours has not been 
demonstrated, there is evidence for the effectiveness of school-based programs in  reducing the 
effect of risk factors such as depression (211, 215). A recent systematic review of interventions 
targeting adolescents or young adults at risk of suicide identified individual cognitive behavioural 
therapy-based interventions and attachment-based family therapy as promising interventions, 
requiring further investigation (216). 
As there was insufficient data to (1) obtain pooled RR estimates for all countries or regions included 
in GBD 2010 and (2) clearly detect differences in RR estimates between all countries/regions, the 
pooled RR estimates used to estimate PAFs were assumed to be constant across age, sex and 
country.  Instead, the variation in attributable DALYs across countries was driven by (a function of 
both) the prevalence of mental and substance use disorders and the amount of burden accounted for 
by suicide in each country.  In addition, given evidence for differences in the underlying causes of 
suicide in China, India and Taiwan (205-208), where it has been well documented that the ease of 
availability of particularly lethal means of self-harm such as pesticides may influence patterns of 
suicide, we constrained the maximum proportion of suicide attributable to mental and substance use 
disorders to a ceiling value of 68.3%. In spite of this, some Asian countries were amongst those 
with the highest rates of attributable suicide burden due to the high rates of suicide in those 
countries. This emphasizes the fact that although there may be other risk factors for suicide, the 
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prioritisation of mental and substance use disorders in the prevention of suicide remains a global 
priority.    
 
The maximum proportion of suicide attributable to mental and substance use disorders in all other 
countries was constrained to a ceiling value of 84.5%. The studies categorized as “all other 
countries” were mainly from North America, Western Europe and Australia and, although we had 
data for three low to middle income countries (Colombia, Pakistan and Indonesia), this pooled 
proportion might not be appropriate for use in Sub-Saharan Africa where we found no data. It is 
possible that these countries have a different distribution of suicides attributable to mental and 
substance use disorders but more cross-national RR data are required before we can incorporate this 
in our findings. Islamic countries, for instance from North Africa/Middle East, were amongst the 
countries with the lowest proportion of attributable burden, despite being allocated the higher 
ceiling value of 84.5%. In contrast to the high rates of depression in the Middle East, rates of 
suicide were low. The lowest rate of suicide recorded in GBD 2010 was from Saudi Arabia. Stigma 
around suicide due to religious beliefs and legislative prohibition (i.e. suicide being considered as a 
criminal offence) can lead to fewer cases of suicide being recorded as a cause of death in countries 
from the Middle East. For similar reasons, the degree of psychopathology underpinning suicide 
cannot be as clearly assessed in these countries (217, 218).  These issues may have biased our 
estimates of attributable burden. The large bounds of uncertainty presented reflect this to some 
extent; however, more data are required on the distribution and aetiology of suicide in these 
countries to improve estimates.  
 
Like all population-based analyses, a number of methodological limitations need to be considered 
here. The ceiling values for suicide attributable to mental and substance use disorders were derived 
from psychological autopsy studies. As these collect retrospective data after the individual had died, 
they are limited by the accuracy of coroners’ reports and systematic bias from interviewees (209).  
Although the pooled RR estimates used were derived from more representative population-based 
prospective cohort studies, there were only a few estimates available for most disorders. We applied 
the same pooled RR across all countries, sex and age groups for each disorder to reduce errors in 
estimates as a result of paucity in the data. It is possible that this masked differences in the 
distribution of attributable suicide DALYs. More representative population cohort studies are now 
emerging from low and middle income countries such as India (192). We hope that the scrutiny of 
data presented here will encourage more and better quality data collection for mental and substance 
use disorders as risk factors for suicide. Until then, it is important to consider the uncertainty around 
our final estimates in interpreting these findings.  
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CRA methodology assumes a causal relationship between the exposure and outcome (10). In 
support for this, the RR estimates used here showed that mental and substance use disorders were 
significantly associated with suicide risk, even when other risk factors such as socio-economic 
factors (e.g. adverse marital, employment and socio-economic status) were considered (83, 92).  
Another assumption was that the proportion of suicide burden attributable to mental and substance 
use disorders was estimated while holding all other independent risk factors constant. We estimated 
the joint effect of all mental and substance use disorders on suicide while adjusting for comorbidity 
between these disorders, the next step would be to explore the joint effect of mental and substance 
use disorder with other risk factors of suicide. Finally, PAF calculations were sensitive to the 
exposure distribution used.  Here we used DisMod-MR to pool the prevalence of each disorder 
based on the raw epidemiological data that were available (8, 19). Although this provided consistent 
prevalence estimates by country, region, age, sex, and year, in some cases DisMod-MR was 
required to adjust for considerable heterogeneity in the raw data. This was, to some extent, 
incorporated in our analyses through the 95% uncertainty intervals around all prevalence estimates 
propagated to the final attributable burden estimates.  
 
Conclusions 
Mental and substance use disorders were responsible for two thirds of the suicide burden in 2010, 
adding a further 22 million DALYs to their global burden. More consideration needs to be given to 
interventions targeted to populations with, or at risk for, mental and substance use disorders as an 
effective strategy for suicide prevention.  
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Chapter review 
Chapter Six estimated the proportion of suicide burden in GBD 2010 that could be allocated to 
mental and substance use disorders (thesis aim three). MDD explained almost half of all suicide 
burden, surpassing the impact of all the other mental and substance use disorders investigated. This 
further contributed to our understanding of MDD as a significant contributor of the world’s burden. 
 
This chapter concludes the presentation of published materials in this thesis. The next chapter 
explores the risk factors of MDD. In the meta-regression of MDD prevalence presented in Chapter 
Three, variables investigated could only explain 57.7% of variability in prevalence. The aim here 
was to add to the epidemiological profile of MDD by investigating other potential determinants of 
its distribution. Efforts to establish potentially avertable risk factors to MDD can also inform the 
setting of  preventative intervention strategies for MDD in the population, which is currently 
lacking (28). 
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Chapter Seven: An exploration of the risk factors of major depressive disorder and how they 
explain its distribution in the population 
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Chapter summary 
This chapter explores the risk factors of MDD, an area of unexplained variability in the 
epidemiological profile of MDD proposed in this thesis. Although there is considerable literature on 
the risk factors of mental disorders, for most of these risk factors there are insufficient data to fully 
quantify their association with MDD and/or establish causality. The aim here was to identify risk 
factors for which there are sufficient data to quantify an association with MDD, discuss how these 
risk factors can impact on the global distribution of MDD and highlight areas requiring further 
research. 
 
The work presented in Chapters Three and Four illustrated the effect of war or conflict on the 
prevalence of MDD, whereby countries exposed to conflict had higher rates of MDD. In addition to 
this, GBD 2010’s risk factor analysis published in late 2012 highlighted CSA and IPV as risk 
factors for MDD. In this chapter, a working example of how CSA and IPV (both of which are 
globally more common in women) can impact on the sex difference in MDD is presented. Globally, 
there were 298,000,000 prevalent cases of MDD in 2010 of which 187,000,000 were women. 
Findings suggest that CSA and IPV have the potential to explain up to 63·7% (46·2%-80·2%) of 
this sex difference. This finding emphasizes the need to investigate how interventions to ameliorate 
the increased risk from CSA and IPV can be incorporated into prevention programs for MDD.  
Nonetheless, given key omissions in the data, these findings are preliminary until further research 
can be accumulated. Caveats of this work are presented and include lack of data on IPV in males as 
well as lack of data to quantify how the observed effect of CSA and IPV on the sex difference of 
MDD interacts with other risk factors.   
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Introduction 
According to the definition proposed in Chapter One, an epidemiological profile of MDD should 
quantify who in the general population has the disorder, who has recovered, and who has died as a 
result of MDD. It should also identify characteristics of those with and without MDD, behaviours 
that place people at risk, and their health outcomes. 
 
Whist the work presented in previous chapters on the prevalence, incidence, duration, mortality and, 
burden provide us with ample data to explore the distribution and impact of MDD in the population, 
to complete the epidemiological profile of MDD, there also needs to be a quantification of its risk 
factors. The systematic review of the global prevalence of MDD and well as the model put in place 
to identify the methodological determinants of prevalence in Chapter Three began to explore some 
of the unexplained variability in the prevalence of MDD by quantifying how much of the variability 
in the prevalence of MDD reported between studies was ‘real’ and how much could be explained by 
methodological factors. With only 57.7% of variability in prevalence explained by this model, there 
is scope to further explore how other ecological factors can impact on the prevalence of MDD. 
Aside from adding to the epidemiological profile of MDD, this work offers potential and 
possibilities for the prevention of MDD.  
 
What do we know about the risk factors of major depressive disorder? 
Risk factors can be classed into categories such as biological, psychosocial, economic or 
environmental. Although there have been a number of such variables identified as risk factors for 
MDD (20-25), for most of them, there are insufficient data to fully quantify their association with 
MDD. Furthermore, the majority of this research focuses on symptoms of depression (rather than a 
clinical diagnosis of MDD) from which the association between a risk factor and MDD can be 
overestimated.  
 
Examples of potential socioeconomic or environmental risk factors for MDD are linked to macro-
issues such as economic instability, poverty, war and inequity. Individuals living in poor 
socioeconomic conditions have been found to have higher levels of psychiatric symptoms including 
depression (219). However, as these individuals have limited access to resources (e.g. food, shelter, 
education, health) and often live without the basic liberties (e.g. freedom of speech or choice) found 
in populations living in higher socio-economic conditions, it is difficult to identify which of these 
factors are directly associated with MDD (20-25). 
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Analysis of MDD prevalence in Chapters Three and Four contributed to this work by exploring the 
extent to which war and conflict impacted on the distribution of MDD. The significant association 
between exposure to war or conflict and an elevated risk of MDD has been well established (147, 
148, 167, 168, 220). Additionally, the work presented in Chapters Three and Four showed that 
countries containing populations at war or conflict displayed higher rates of MDD compared to 
other countries. Although this assisted in explaining some of the variability in the prevalence of 
MDD between countries, the estimation of prevalence at the country level likely diluted the effect 
of conflict on the prevalence of MDD given the more localised geographical nature of many 
conflicts. For a more in-depth understanding of the effect of war or conflict on the distribution of 
MDD, a post-doctoral avenue for research collaboration (discussed in the next chapter) has been 
developed to investigate the distribution of MDD within specific conflict affected populations.  
 
Examples of biological or psychosocial risk factors can be hereditary, hormonal, interpersonal or 
related to one’s lifestyle (20-25). Imbalances in the production or transmission of neurotransmitters 
(e.g. serotonin, dopamine, noradrenaline) are postulated in individuals diagnosed with MDD but a 
biological marker for the occurrence of MDD has yet to be identified (20-25). Similarly, there is 
literature to suggest that lifestyle factors such as diet, sleep and exercise are associated with MDD 
although the underpinnings of these risk factor and their association with MDD have yet to be fully 
quantified  (221).   
 
CSA and IPV have also been identified as risk factors for MDD. Longitudinal studies have provided 
evidence for a statistically significant association between CSA and IPV (respectively) and incident 
MDD (10, 222-225). This includes evidence from longitudinal twin studies (which typically offer 
the best means of detecting confounding effects between early life risk factors) showing a causal 
link between traumatic events and an increased risk of MDD (97-99). GBD 2010’s review of the 
published and unpublished literature for risk factor-outcome pairings for which there was sufficient 
evidence to estimate attributable burden included only CSA and IPV as risk factors for MDD (10). 
Merits for inclusion were assessed using criteria (e.g. 1. relevance of the risk factor to disease 
burden or policy; 2. availability of data to estimate the global distribution of the risk factor and 
effect sizes; 3. availability and strength of the evidence for causal effects) which were in line with 
accepted frameworks for establishing causality in epidemiological research (86).  CSA was defined 
as all forms of sexual abuse occurring before the age of 18. This included both contact forms (e.g. 
rape) and non-contact forms (e.g. non-contact exposure of genitalia, threatened sexual violence) 
(226, 227). IPV was defined as physical and/or sexual violence perpetrated since the age of 15 by a 
current or ex-intimate partner (227).  
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How can abuse and violence impact on the distribution of major depressive disorder? 
In GBD 2010, CRA methodology was used to quantify the global proportion of MDD cases 
attributable to CSA and IPV respectively (10). As explained in Chapter Six, this methodology 
makes use of a ‘hypothetical minimum’ as an alternative distribution of exposure against which loss 
of health can be quantified. In this instance, the proportion of MDD prevalent cases averted given a 
counterfactual absence of ever having experienced CSA or IPV was investigated (10). Findings 
showed that  CSA accounted for 5.1% and IPV for 11.4%  of MDD DALYs respectively (10).   
 
In many countries, particularly low- to middle-income countries where there are high levels of 
gender inequality, women are considerably more likely to be exposed to CSA and IPV than men. 
Furthermore, women are likely to experience more chronic patterns of abuse and violence, more 
controlling and threatening behaviour and are more likely to be injured and killed by abuse and 
violence  than men (100-102). Consequently, it is conceivable that the sex difference in exposure to 
CSA and IPV also impacts on the sex difference in MDD. 
One of the most robust (103-110, 228, 229) and cited (230) findings in mental health epidemiology 
is that MDD is up to 2 times more prevalent in females compared to males. This sex-difference 
typically emerges during adolescence, and is driven by incident depression rather than differences 
across its duration or reoccurrence (103, 105, 106). However, despite the consistency of this finding 
across countries and ethnicity, we are yet to fully understand why it exists (103, 104, 106). 
Although there is  sufficient evidence to rule out artefactual factors (e.g. differences in help-seeking 
behaviour and bias in recall and measurement) as the only explanation to the sex difference in 
depression,  the remaining explanations  are inconsistent and difficult to interpret (103, 107-110). 
Reviews of this literature suggest that the sex difference in the prevalence of MDD can be best 
explained through an integrated etiological model comprising biological, social and psychological 
risk factors (103, 107-110). Women have a greater vulnerability to depression during the 
reproductive years, which could be due to psychosocial or biological factors, or a combination of 
these factors.  Biologically, gonadal hormones and associated biological changes with puberty 
and/or pregnancy may increase vulnerability to depression. Psychosocially, gender-role stereotypes, 
discrimination and exposures to traumatic life events differ between men and women.  Adverse life 
events such as trauma activate stress hormones which in turn modulate central neurotransmissions, 
including serotonin, a neurotransmitter linked to depression (103, 107). Furthermore, women suffer 
more of the socioeconomic disadvantages associated with depression, which along with role 
limitations and expectations reduce feelings of mastery and control, further increasing their 
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likelihood of depression (108, 110, 231-235). That said, causal pathways between these risk factors 
and the sex difference in depression, or their integration into an etiological model, are far from 
established. Evaluating the impact of CSA and IPV on MDD can contribute to this work. 
 
CSA and IPV have the potential to alter the sex difference in the distribution of MDD in two ways 
(1) through sex differences in  exposure to CSA and IPV, i.e. more women are exposed to CSA 
and/or IPV and therefore at greater risk of MDD; and (2) through sex differences in sensitivity to 
the effects of CSA and/or IPV, for instance women may be more likely than men to develop MDD 
after being exposed to IPV (236).  Although previous endeavours to quantify this association exist, 
they were typically restricted to sub-clinical presentations of MDD which tend to overestimate the 
effect of CSA and IPV on clinically diagnosed MDD or, community-level data which were not 
representative at the national or global level. For instance, Cutler and collaborators’ review of the 
literature showed that in spite of significant variability and data limitations, up to 35% of the sex 
difference in depression could be explained by CSA alone (237). Dunn and collaborators’  
investigations of data  from 5,692 participants in the US’ National Comorbidity Survey Replication, 
found that adjusting for exposure to sexual assault and rape, led to a 15.2% and 12.6% reduction 
respectively in effect-size between sex and the distribution of depression (236).  
 
A working example quantifying the impact of abuse and violence on major depressive disorder  
In keeping with the analytical approach presented in previous chapters, we make use of GBD 2010 
CRA methods (10) here to quantity the potential impact of CSA and IPV on the sex difference in 
MDD.  This work has been titled as a ‘working example’ because in some instances, we have relied 
on assumptions or the substitution of less ideal data due to the lack of the required data to derive 
estimates. Given these caveats, this working example represents a preliminary analysis of the effect 
of CSA and IPV on the sex difference in MDD. As was the case for conflict as a risk factor for 
MDD, the work on CSA and IPV as risk factors for MDD highlights a post-doctoral avenue for 
research to be supplemented as more and better quality data are made available. 
 
In this case, the hypothetical minimum required for CRA analyses was the proportion of MDD 
prevalent cases averted given a counterfactual absence of ever having experienced CSA and IPV in 
the population. Given the evidence showing that females who experience CSA are more likely to 
experience IPV than non-abused females and, those who experience multiple types of abuse 
including CSA and IPV have a higher risk of MDD than those exposed to only CSA or only IPV 
(238-242), in the present analysis we chose to investigate the combined effect of CSA and IPV on 
the sex difference in MDD.  
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Data sources 
Findings from existing reviews of the literature were used to obtain data on the global prevalence of 
MDD, CSA, and IPV respectively; as well as the effect size of CSA and IPV as risk factors for 
MDD. 
 
The prevalence distribution of MDD (as estimated by DisMod-MR) was obtained from Chapter 
Four. Equivalent DisMod-MR prevalence data for CSA and IPV were obtained from published 
works of GBD 2010 (175, 226, 243). DisMod-MR prevalence was derived using data from 
published systematic reviews of the literature to capture studies reporting on the point prevalence, 
incidence, remission, duration, and excess-mortality of MDD (reported in Chapters Three and 
Four); and the lifetime prevalence of CSA and IPV respectively (150, 175, 226, 243). DisMod-MR, 
GBD 2010’s Bayesian meta-regression tool was used to pool these epidemiological estimates into 
an internally consistent epidemiological model which also adjusted for study- and country-level 
variability in the input data and predicted epidemiological estimates for countries with no data (13, 
154). The global DisMod-MR prevalence estimates for CSA, IPV and MDD used here have been 
summarised in table 12.  
 
Table 12. DisMod-MR global prevalence of MDD, CSA and, IPV by sex. 
 
 Prevalence % (95% Uncertainty interval) 
Female Male 
    MDD
a 5.5% (5.0%-6.0%)  3.2% (3.0% 3.6%) 
    CSA
b 8.2% (8.0%-8.5%) 5.5% (5.3%-5.6%) 
    IPV
b 29.4% (27.7%-31.2%) - 
Note. Prevalence estimates presented for 2010; DisMod-MR modeled the 
a
point prevalence of MDD and the 
b
lifetime 
prevalence of CSA and IPV; IPV prevalence was estimated for females only; Source of data: GBD 2010 analysis of 
DisMod-MR prevalence output by age, country and region (10, 13, 175, 243). 
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We made use of pooled RR estimates quantifying the risk of MDD in those experiencing CSA 
and/or IPV from the two published systematic reviews and meta-analyses (222, 224). Devries and 
collaborators’ meta-analysis of CSA as a risk factor for MDD included 16 studies and produced a 
pooled RR of 1.7 (1.5-1.9) (226). Beydoun and collaborators’ meta-analysis of IPV as a risk factor 
for MDD included 34 studies and produced a higher pooled RR of 2.7 (2.2-3.3) (222). Studies were 
accepted if they used a case cohort/series design and representative samples of the previous 
population. Cases of MDD, CSA and IPV were included based on the case definitions previously 
presented. Final estimates were adjusted for the quality of the definition of CSA/IPV used. 
Estimates derived from sub-clinical presentations of depression (depressive symptoms rather than 
DSM/ICD diagnoses) were not included to avoid an overestimation of the effect of CSA and IPV on 
MDD. 
 
Paucity in the risk data constrained the scope of the rest of the analyses. Although the DisMod-MR 
prevalence data points were stratified by age, sex, country and region, all analyses were restricted to 
the global level, for all age groups combined, as there were insufficient data to quantify changes in 
the risk of MDD after CSA and IPV by country, region, or age. Similarly, the same pooled RR of 
MDD given exposure to CSA was applied to males and females as there was no statistically 
significant sex difference detected in the risk of MDD (226). For IPV, the pooled RR estimate was 
based on data for females (222). For the purposes of this paper, the risk of MDD after IPV in males 
was set to 1 based on insufficient evidence for a statistically significant association between IPV 
and MDD in males (100-102). A literature review by Devries and colleagues (224) investigating the 
effect of IPV on the incidence of depressive symptoms found no clear evidence for a relationship 
between IPV and depressive symptoms in males, however very few studies reported data for males. 
In many countries, particularly low to middle income countries where there are high levels of 
gender inequality, women are considerably more likely to be exposed to IPV than men. 
Furthermore, whilst both men and women are exposed to IPV, the type of violence experienced and 
their reactions can be different (100-102). Findings from a self-administered survey among 
university students from North-East Italy showed that whilst exposure to IPV can lead to a 
statistically significant increase in depressive symptoms in women, this was not the case in men 
where the only significant health outcome was an increase in negative self-evaluations of health 
(101).  
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Accounting for dual exposure to child sexual abuse and intimate partner violence  
To prevent any double counting of females with a history of both CSA and IPV, we estimated the 
prevalence and risk of MDD after single and after dual exposure to CSA and IPV.   
 
The DisMod-MR prevalence output for CSA and IPV were not adjusted for dual exposure, i.e. the 
prevalence of CSA also contained those experiencing IPV and vice versa. We made use of data 
from the WHO  multi-country study on women’s health and domestic violence (244) which 
conducted standardised population-based household surveys of women aged 15–49 years from 10 
different countries to collect data on their  experiences of physical and sexual abuse. Of the 24097 
women surveyed, 2387 of them had experienced both CSA and IPV (245). Meta-XL (a meta-
analysis add in tool for Microsoft Excel (197)), was used to pool the proportion of women with 
lifetime experience of IPV or CSA who have dual exposure across the 10 countries surveyed based 
on a quality-effects model (198-200). The quality-effects model gives greater weighting to 
estimates of higher quality versus those of lower quality and avoids the limitation in random-effects 
models of returning to equal weighting irrespective of sample size if heterogeneity is large (198-
200). Quality was assessed following a previously established quality index for epidemiological 
surveys (246), with the quality rankings summarised in table 13. Assuming no differences between 
world regions, the pooled proportions of cases of IPV also experiencing CSA were used to derive 
the prevalence of dual exposure to CSA and IPV which was then subtracted from the DisMod-MR 
CSA and IPV prevalence estimates (presented in Table 12) to derive the prevalence of single 
exposures (i.e. CSA only and IPV only; see Figure S1, Appendix Six for an illustration of this).  
 
As was the case for prevalence, the previously reported pooled RRs of MDD after exposure to CSA 
and IPV (222, 224) needed to be adjusted for dual exposure. In a two-step process we estimated the 
equivalent effect of a change in psychological functioning (mean score of depression) after dual 
exposure to CSA and IPV on the reported pooled RRs. At step one we made use of data presented 
by Messman-Moore and collaborators (241) showing differences in women’s mean depression 
scores after no exposure to CSA or IPV (control group), exposure to IPV only, CSA only, or CSA 
and IPV  combined (see table 14). Based on an approach presented in the Australian Burden of 
Disease Study (247) and the South African Burden of Disease Study (248), the reported mean 
depression scores and SEs (241) were used to calculate Hedges’ adjusted g for the standardized 
mean difference (an effect size) (249) which were then converted into, first ORs  (250, 251) then 
RRs (252, 253) of depression for each exposure group.  At step two, these RRs along with the 
estimated prevalence of dual exposure to CSA and IPV were used to proportionately redistribute the 
pooled RR of MDD after CSA (from Devries and collaborators (226)) and after IPV (from Beydoun 
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and collaborators (222)) into three separate RRs quantifying the risk MDD after CSA only, IPV 
only and CSA and IPV combined.  
 
Estimating population attributable fractions          
The estimated RRs of MDD given CSA only, IPV only, and CSA and IPV combined were paired 
with their corresponding prevalence estimates  to calculate PAFs using the following formula (10, 
254) 
    
 (    )
 (    )   
 
Where, ‘P’ is the prevalence of exposure to the risk factor and ‘RR’ is the relative-risk of MDD 
given CSA and IPV from published meta-analyses, adjusted for dual exposure to CSA and IPV. 
PAFs were applied to prevalent cases of MDD to estimate male and female MDD cases attributable 
to CSA and IPV worldwide.  
 
Estimating uncertainty 
Monte Carlo simulation–modelling techniques were used to present uncertainty ranges around point 
estimates reflecting the main sources of sampling uncertainty in the calculations using Ersatz 
software version 1.2 (255). Beta distributions were specified for prevalence estimates. For the RR 
input variables we used the Ersatz function “ErRelativeRisk” (255). 
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Table 13. Proportion of females with lifetime experience of IPV or CSA who also have dual exposure to both CSA and IPV. 
 
Setting Sample size CSA cases  
(% also experiencing IPV, 95% uncertainty 
interval) 
IPV cases 
(% also experiencing CSA, 95% uncertainty 
interval) 
Quality score 
 ( /1) 
Bangladesh  city 1,603 406 (69.4%, 60.5%-79.3%) 733 (38.5%, 34.2-43.5) 0.9 
Bangladesh  province 1,527 448 (78.1%, 69.1%-87.8%) 820 (42.7%, 38.3-47.2) 0.9 
Brazil city 1,172 139 (43.2%, 31.6%-56.4%) 272 (22.1%, 16.4-28.6) 0.9 
Brazil province 1,473 179 (57.0%, 45.1%-72.0%) 438 (23.3%, 18.9-28.5) 0.9 
Ethiopia province 3,016 1137 (70.9%, 65.5%-76.6%) 1602 (50.3%, 46.9-53.9) 0.8 
Japan city 1,371 135 (27.1%, 18.8-38.0) 196 (18.9%, 13.0-26.0) 0.7 
Namibia  city 1,500 130 (51.5%, 38.1-67.9) 491 (13.6%, 10.6-17.3) 0.8 
Peru city 1,414 317 (57.7%, 48.8-68.4) 556 (32.9%, 28.1-38.4) 0.9 
Peru province 1,837 292 (69.9%, 59.0-82.2) 1,059 (19.9%, 16.8-22.0) 0.9 
Samoa SMA 1,640 56 (50.0%, 30.6-77.7) 555 (5.0%, 3.3-7.0) 1 
Serbia & Montenegro city 1,456 34 (38.2%, 19.5-68.6) 282 (4.6%, 2.5-7.4) 0.8 
Thailand city 1,536 133 (39.0%, 28.0-53.3) 431 (12.1%, 8.9-15.7) 0.9 
Thailand province 1,282 86 (56.9%, 39.8-79.7) 485 (10.1%, 7.4-13.3) 0.9 
Tanzania city 1,820 171 (45.5%, 34.7-58.2) 596 (13.1%, 10.3-16.1) 0.9 
Tanzania province 1,450 125 (60.5%, 45.3-80.3) 702 (10.8%, 8.5-13.3) 0.9 
Total 24,097 3,788 (QE: 58.6%, 51.5-65.5; RE: 55.3%, 46.9-
63.5)
a 
9,218 (QE: 20.4%, 13.8-27.9; RE:19.5%, 12.4-
27.6)
a 
 
Note. 
a
Estimates were pooled in a meta-analysis with a  quality-effects design (QE) and random-effects design (RE) respectively;  Pooled proportions of dual exposure from the 
quality effects model were used in analyses. Pooled proportions from the random effects model have been included for comparison purposes only. Source of data: WHO’s multi-
country study on women’s health and domestic violence (244, 245)  
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Table 14. Estimating the difference in risk of depression after single, and dual exposure to CSA and IPV. 
 
Step One 
 Exposure group Reported mean value
a
  Reported SE
a
  
 
Hedges’ adjusted g 
(effect size)  
From effect size to 
OR 
 
From OR to RR 
 control exposure control exposure Hedges’ g SE OR (95% 
uncertainty) 
RR (95% 
uncertainty) 
Child sexual abuse only  0.79 1.03 0.04 0.1 0.35 0.15 1.89 (1.37-2.54) 1.80(1.34-2.36) 
Intimate partner violence 
only 
0.79 1.04 0.04 0.05 0.36 0.09 1.92 (1.61-2.28) 1.83 (1.56-2.16) 
Child sexual abuse and  
intimate partner violence 
0.79 1.27 0.04 0.09 0.69 0.14 3.52(2.67-4.58) 3.13 (2.45-3.92) 
Step Two 
Exposure group Reported RR of MDD 
(not adjusted for dual exposure to CSA and IPV) 
Adjusted RR of MDD 
(adjusted for dual exposure to CSA and IPV) 
Child sexual abuse  1.7(1.5-2.0)  1.1 (1.0-1.3) 
Intimate partner violence  3.1(2.5-3.9) 2.2 (1.9-2.8) 
Child sexual abuse and  
intimate partner violence 
- 3.0 (2.7-3.7) 
Note. OR: odds ratio; 
a
Source of data: Reported mean differences of depression score (and standard error) (241) 
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Findings 
Globally, there were 298,000,000 prevalent cases of MDD in 2010 of which 187,000,000 were 
women and 111,000,000 men (175). This was equivalent to 67.9% (95% uncertainty: 59.0%-77.3%) 
more females diagnosed with MDD than males in 2010. 
 
CSA and IPV explained an estimated 57,000,000 prevalent cases of MDD, equivalent to 19·2% 
(14·9%-23·2%) of total MDD cases. The majority of cases occurred in females, with CSA and IPV 
resulting in 53,000,000 females with MDD (equivalent to 28·4% (21·7%-34·9%) of all females 
with MDD). CSA alone resulted in an additional 4,000,000 males with MDD (equivalent to 3·6% 
(3·5%-3·7%) of all males with MDD). As previously explained, MDD cases explained by IPV in 
males was set to 0. Figure 19 illustrates the proportion of MDD cases explained by CSA and IPV.  
 
 
Note. CSA: Child sexual abuse; IPV: intimate partner violence; Cases presented as a proportion of males and female 
cases of MDD combined. 
 
Figure 19. Global prevalence of MDD in 2010 by sex and the proportion in males and females 
attributed to CSA and IPV. 
 
In the counterfactual of no exposure to IPV and CSA over the lifetime of the 2010 global 
population, there would have been 134,000,000 females and 107,000,000 males with MDD (i.e. 
after accounting for MDD cases attributable to CSA and IPV). There were 24·6% (13·5%-36·5%) 
more females with MDD than males in this counterfactual of no exposure to IPV and CSA over the 
lifetime. This was a statistically significant decrease from the baseline estimate of 67·9% (59·0%-
77·3%) more females with MDD than males (before accounting for cases due to CSA and IPV). 
Overall, this translated to CSA and IPV explaining 63·7% (46·2%-80·2%) of the sex difference in 
1.3% 
36.0% 
44.8% 
17.8% 
Male cases due to CSA
Male cases remaining
Female cases remaining
Female cases due to CSA and IPV
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MDD. Figure 20 illustrates the sex difference in MDD after accounting for cases due to CSA and 
IPV. 
 
 
Note. This distribution of MDD cases has now been adjusted for the proportion of cases explained by child sexual 
abuse and intimate partner violence. 
 
Figure 20. Sex distribution in the global prevalence of MDD in 2010, adjusted for CSA and IPV. 
 
 
Limitations of this work and requirements for more concrete conclusions 
Although our findings suggest a statistically significant decrease in the sex difference in MDD after 
accounting for cases with CSA and IPV, the 95% uncertainty intervals around these estimates were 
large. Measuring exposures to abuse and violence in the population is challenging and particularly 
sensitive to methodological factors that impact on the accuracy of participant responses. As such, 
key limitations and areas of uncertainty need to be considered and explored in further analysis 
before definite conclusions can be drawn surrounding the extent to which CSA and IPV explain the 
sex difference in MDD. 
 
 As has been the case in previous publications (224), we found a paucity of data on the health 
impacts of CSA and IPV in males. There was insufficient evidence to detect a significant 
sex difference in the association between CSA and MDD. Additionally, there was no clear 
evidence in the literature to suggest an association between IPV and MDD in males (224). 
The gaps in the current research base required the use of past conventions (10) in setting the 
number of male cases of MDD explained by IPV to 0 which may have overestimated the 
extent to which IPV explained the sex difference in MDD. That said, the literature that is 
available suggests that although IPV can affect both males and females, globally, it is more 
common in females. Females are also more likely to experience more severe forms of IPV. 
For instance, they are likely to experience more chronic patterns of violence, more 
44.5% 
55.5% 
Male
Female
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controlling and threatening behavior and are more likely to be injured and killed by their 
intimate partners (256, 257). In view of this, it is plausible that females are 
disproportionately at risk for MDD from IPV. There is also evidence to suggest that males 
and females respond differently to experiences of IPV (100-102), which may further explain 
the lack of an association between IPV and MDD in males. However, until more research 
investigating the association between IPV and MDD in males is made available, these 
remain hypothetical and our findings need to be interpreted with caution. 
 
 We investigated the combined (rather than individual) effect of CSA and IPV on the sex 
difference in MDD. This was in response to evidence showing that females who experience 
CSA are more likely to experience IPV than non-abused females (238-242), and those who 
experience multiple types of abuse, including CSA and IPV, have a higher risk of MDD 
than those exposed to only CSA or only IPV. Based on previously outlined definitions, 
individuals are first exposed to CSA during early childhood and IPV from 15 years onwards. 
As such, it may be argued that CSA rather than IPV is the critical risk factor to the sex 
difference in MDD.  On the other hand, we found that IPV (1) had a higher global 
prevalence compared to CSA (29.4% vs. 8.2% in females) and (2) led to a higher risk of 
MDD after exposure compared to CSA (RR of 2.9 vs 1.8). As these prevalence and RR 
estimates  served as inputs in our CRA analyses, overall IPV would have likely explained a 
larger proportion of the sex difference in MDD than CSA. More data on differences between 
the combined and individual health impacts of CSA and IPV by age, is required for us to 
clarify the impact of only CSA or IPV on the sex difference in MDD.  
 
 The majority of our prevalence data on dual exposure to CSA and IPV came from 
developing countries and we assumed that the proportion of dual exposure to lifetime 
experiences of CSA and IPV in females, was globally applicable. Similarly, the data used to 
estimate the added risk of MDD after dual exposure to CSA and IPV were collected from a 
single study of psychological functioning among college women in the USA which may not 
be fully representative of the impact of dual exposure to CSA and IPV on MDD. Though 
admittedly data were sparse, these adjustments to account for the combined exposure state 
of having experienced both CSA and IPV were key to avoid overestimating the proportion 
of MDD cases explained when both of these risk factors are present. 
 
 Finally, the impact of CSA and IPV in females with MDD may be mediated by any number 
of biological, psychosocial, or cultural factors. There is a need for more integrative models 
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as it is unlikely the CSA and IPV impact on the sex difference of MDD in isolation.  It is 
conceivable that across cultural settings or the life span, other risk factors (e.g. child 
physical abuse, emotional abuse and neglect; community violence including adult sexual 
assault by acquaintances or strangers; and bullying in childhood and adolescence) may 
impact on the sex difference in MDD. In further elucidating the mechanisms behind sex 
differences in MDD, future research should also attempt to control for the confounding 
effect of comorbidity (e.g. the confounding or mediating effects of post-traumatic stress 
disorder or the excess of anxiety disorder in women, both of which are also associated with 
IPV (77, 235, 258)), differences in psychological coping styles (259, 260), gendered 
division of labor, gender roles, socioeconomic status, and sex discrimination (108, 110, 231-
234, 260). Integrated stress-diathesis models of depression are favored, as the sex gradient in 
the prevalence of MDD is likely multifactorial and the factors inter-dependent. The present 
study provides the template from which this work can be done. As more data on the 
relationship between CSA, IPV and MDD are made available, we can quantify when these 
two risk factors begin to alter the sex pattern in MDD, how their effect changes across place 
and time, and how they interact with other risk factors. 
 
Conclusion 
Although CSA and IPV are established risk factors for MDD, the present findings also highlight 
their potentially significant contribution to the sex difference in MDD; an observation which 
although well cited (230) has yet to be fully explained in the literature.  Given the size of the global 
burden of MDD (190), particularly in females, there is a need to  investigate how interventions to 
ameliorate the increased risk from  CSA and IPV can be incorporated into prevention programs  for 
MDD; and also how interventions for the treatment of MDD in women exposed to CSA and IPV 
can be improved.  That said, given the caveats discussed, these findings are preliminary until further 
research on this topic is accumulated, particularly around how the observed effect of CSA and IPV 
on the sex difference of MDD interacts with other risk factors and changes across age, place and 
time.  The work presented here provides a template from which such further work can be done. It 
also adds to the epidemiological model of MDD formulated in this thesis by illustrating how risk 
factors of MDD can impact on its global distribution and by extension, burden in the population. 
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Chapter review 
Chapter Seven explored risk factors for which there are sufficient data to quantify an association 
with MDD, discussed how two of these risk factors can impact on the global distribution of MDD 
and highlighted areas of this literature requiring further research. The data presented here calls for 
more consideration to be given to experiences of abuse, war and violence when setting intervention 
and prevention strategies for MDD, particularly for women.   
 
This chapter also concluded the presentation of original data in this thesis. Chapter Eight 
amalgamates findings across all previous chapters and illustrates how they contribute to the 
epidemiological profile of MDD. Other implications, limitations and areas for future research are 
also discussed.   
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Chapter Eight: Discussion  
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Chapter summary 
The research presented in this thesis focused on formulating a complete epidemiological profile for 
MDD. Although there is considerable literature on the different elements of the epidemiology of 
MDD, until now, there has been little effort placed in integrating these into a comprehensive global 
profile. Such a profile assists in the identification of people in need of prevention and treatment 
services for MDD. Additionally, policy-makers need to be provided with complete and current 
information about the nature of the disorder in order to distribute health funds adequately between 
(1) MDD and other diseases and (2) between the treatment, rehabilitation, prevention, and 
promotion of MDD (28).  
 
By making use of a systematic review with strict inclusion criteria it was possible to capture data on 
the prevalence, incidence, duration, and excess-mortality associated with MDD from high quality 
epidemiological surveys (Chapter Three). Bayesian meta-regression statistical modelling techniques 
were used to integrate these epidemiological estimates into an internally consistent disease model 
for MDD and estimate data for parts of the world with little or no raw data available (Chapter Four). 
This made it possible to quantify the burden of MDD (in terms of DALYs, YLDs, YLLs) by sex, 
year, age, country and region (Chapter Five). To supplement vital registry data which can only 
assign deaths due to MDD to the direct physical cause (restricting the estimation of YLLs in 
Chapter Five), the additional burden attributable to MDD as a risk factor for suicide was also 
estimated (Chapter Six). To complete the epidemiological profile of MDD, an investigation into the 
risk factors of MDD was presented, with a working example of how two established risk factors ― 
CSA and IPV― can impact on the distribution of MDD. 
 
Figure 21 expands on the epidemiological profile presented in figure 1 (Chapter One) using the data 
compiled in Chapters Three to Seven. 
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General population
CSA and IPV account for  aprox. 16.7% 
(13.8%-21.5%) of MDD cases.                                         
A positive association between conflict status 
and MDD prevalence also found (effect size: 
1.07(1.02-1.12).
Existing cases of MDD (point prevalence):
 4.4% (4.1%-4.7%); 
Deaths in the general population from causes 
other than MDD
New episodes  of MDD (incidence): 7.3 (7.1-
7.5) per 100 person years
Excess Deaths due to MDD: 2,223,840 
deaths; corresponds to a pooled excess-risk of 
mortality of :1.9 (1.7-2.2)
Cases recovered 
from MDE 
(remission):
1.45(1.3-1.6): 
based on a 
duration of 37.7 
weeks
MDD accounts for 
44.9%(28.02%-
57.2%) of global 
suicides and  
2.9%(1.5%-4.5%) of 
global IHD cases
Deaths in people with MDD due 
to other causes
Direct burden of MDD:
63 million DALYs
Additional burden due to MDD as a risk factor 
for other health outcomes:
 20 million DALYs
Aim One Aim Two Aim Three Aim Four
 This attributable burden would increase the overall 
burden of depressive disorders from 3.0%(2.2%-3.8%) 
to 3.8%(3.0%-4.7%) of global DALYs. 
Broken line represents areas with most uncertainty and 
requiring more research
Note. Figure adapted from an existing incidence-prevalence-mortality model (9). 
 
Figure 21. Illustration of the completed epidemiological profile of MDD. 
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Summary of findings and contributions to the literature 
Chapter Three presented on the state of the literature on the global distribution of MDD. A 
systematic literature review identified 116 prevalence and 4 incidence studies. The majority of the 
data for prevalence was from Western Europe and North America with much less from Non-
Western regions. Overall, 57.7% of the variability between prevalence estimates could be explained 
by elements of study design and methodology. Whilst there were various naturalistic studies 
estimating the annual incidence of MDD, very few were follow-up studies based on representative 
community samples. Although MDD has been defined as an episodic disorder, most incidence 
studies excluded participants with past episodes of MDD at baseline (63-67). Consequently, annual 
incidence estimates presented in the litertaure tended to underestimate the true incidence of MDD.  
 
Understanding the global distribution of MDD is central to investigating its health impacts in the 
population. The analysis of heterogeneity across prevalence highlighted variables that need to be 
considered in future research involving collection, analysis and interpretation of prevalence data.  It 
also highlighted variability in the prevalence of MDD that was an artefact of differences in data 
collection and assessment and, alternatively due to ‘real’ differences in the disorder’s epidemiology. 
The aim of the next chapter was to correct for the former and to retain the latter in order to present a 
more accurate summary of the global distribution of MDD. 
  
Chapter Four made use of Bayesian meta-regression techniques to model the distribution of MDD 
while (1) adjusting for known sources of variability and (2) dealing with missing data. Using the 
data presented in Chapter Three, this model produced estimates of prevalence, incidence, duration, 
remission and excess-mortality for MDD for 187 countries, 21 regions, males and females, 20 age 
groups and 3 time points. There were 298 million cases of MDD globally at any point in time in 
2010. The global point prevalence was very similar across time (4.4%, 4.2-4.7% in 1990, 4.4%, 4.1-
4.7% in 2005 and 2010), challenging previous claims of an ‘epidemic’ of depression (261). In 
regards to age and sex differences, females had higher prevalence of MDD (5.5%, 5.0-6.0%) 
compared to males (3.2%, 3.0-3.6%) and prevalence was lowest, but still evident in early childhood 
and highest between 20 and 64 years. There was a second peak in prevalence between 75 and 85 
years, which further added to our understanding of the distribution of MDD across the lifespan.  
Historically, individuals aged 75 years or over were not well represented in population surveys 
which typically excluded people living in aged-care facilities or non-private households (70, 172, 
173). As such, the prevalence of MDD in this age group has not always been accurately reflected in 
summary estimates of prevalence. Prevalence from high-income regions was lower than prevalence 
from low- to middle-income regions, particularly regions in conflict. Analyses revealed a significant 
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effect of conflict, whereby populations at war or conflict displayed higher rates of MDD. This 
further contributed to our knowledge of the risk factors of MDD and drivers of the global 
differences in its distribution. Modelled prevalence by country also provided the basis from which 
further research of this effect of conflict could be conducted (182).  
To address limitations to the raw incidence data highlighted in Chapter Three, incidence was 
estimated using data available for the prevalence, duration and excess mortality of MDD. When 
compared to the raw incidence data, the estimated annual incidence of an episode of MDD was 
about one and a half times higher, consistent with an average duration of 37.7 weeks (27). Although 
estimating missing data was less optimal than using high quality raw data, the work presented in 
Chapter Four enabled all countries and age groups to be included in Chapter Five’s burden 
calculations. This strategy was preferred as not quantifying prevalence would be equivalent to 
assuming 0% prevalence (and therefore burden) of MDD in countries or age groups where no raw 
data was available.  
Chapter Five identified MDD as the second leading cause of YLDs in 2010, when compared to 290 
other diseases and injuries.  Although previous estimation of burden exists for MDD, regular 
updating provides policy makers with a way to keep track of the size of the burden and how it 
compares with other diseases and injuries. Findings reinforced depression as both a current and 
future public health priority. Despite of the lack of direct YLLs computed for MDD, it remained a 
leading cause of DALYs, emphasizing the importance of non-fatal health outcomes in quantifying 
disease burden. Although the rate of MDD was not increasing between 1990 and 2010, increasing 
life expectancy due to better reproductive health, nutrition and control of communicable diseases 
means that more of the population are reaching the age where MDD is most prevalent (5, 6). 
 
A comparison of burden between MDD and dysthymia highlighted MDD as the leading contributor 
to the burden of depressive disorders, accounting for 85% of its YLDs and DALYs in 2010. This 
was driven by the high prevalence estimates reported in Chapter Three, and high levels of disability 
found to be associated with MDD (13). MDD DALY and YLD rates followed the same sex and age 
pattern seen in the prevalence data, with estimates highest in Afghanistan and lowest in Japan. The 
capacity to compare burden by country was especially relevant for MDD, which has been linked to 
risk factors such as conflict (148), IPV (222, 224) and, CSA (224), the levels of which vary between 
countries. Country-level differences in prevalence and burden estimates for a given disease may 
also be driven by differences in access and quality of prevention and treatment strategies available. 
Although it was not possible to fully assess this in the thesis, it is unlikely that differences in 
prevention and treatment would have considerably impacted on the prevalence and burden of MDD 
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given that access to treatment remains exceedingly low in low to middle income countries and, even 
in high income countries, current intervention strategies can only reduce the burden of MDD 
between 10% to 30% (3, 26, 27).    
 
In addition to burden that can be directly attributed to MDD, Chapter Six quantified the surplus 
burden due to MDD and other mental and substance use disorders as risk factors for suicide. Mental 
and substance use disorders were responsible for 22.5 million (14.8-29.8 million) of the 36.2 
million (26.5-44.3 million) DALYs allocated to suicide in 2010. This surplus burden elevated them 
from the 5
th
 to 3
rd
 leading cause of global burden (DALYs). Within mental and substance use 
disorders, MDD explained almost half of all suicide DALYs (46.1%, 28.0%-60.8%), the highest 
proportion when compared to all other mental and substance use disorders.  Aside from 
emphasising MDD as a debilitating disorder, findings emphasized the importance of prioritising the 
prevention, early detection and effective management of MDD as a key suicide prevention strategy. 
They also illustrated how the lack of direct YLLs estimated for mental and substance use disorders 
in GBD 2010 should not be interpreted as having little or no excess risk of mortality in those with 
these disorders.   
 
Chapter Seven explored the risk factors of MDD, an area of this disorder’s epidemiology for which 
there is a paucity of high quality, quantitative data. War or conflict, CSA, and IPV (all potentially 
avertable risk factors) were discussed as risk factors for which there was sufficient evidence to infer 
a positive association with MDD. A working example investigating the impact of CSA and IPV on 
the sex difference in MDD showed that these two risk factors combined had the potential to explain 
up to 63·7% (46·2%-80·2%) of the sex difference in MDD however this estimate is preliminary and 
subject to change as further research is accumulated. Nonetheless, having presented on the 
ubiquitous burden associated with MDD in previous chapters, the data presented here provides an 
opening for the further development of prevention and intervention strategies for MDD. They also 
add to existing aetiological models for MDD (103, 107-110) by further elucidating mechanisms 
behind its occurrence. 
 
Translating research into practice 
Having established the global distribution and size of the burden associated with MDD, the next 
logical question is how can we use this data to reduce the burden of MDD? Reduction in disease 
burden can be reached by: (1) decreasing incidence, (2) decreasing duration, (3) reducing disorder 
severity, and (4) reducing the number of deaths due to the disorder (19, 28). Although a 
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comprehensive service system should be equipped to provide evidence-based interventions 
targeting each of these avenues for burden reduction, this is rarely, if ever, the case for MDD.  
Cost-effectiveness analysis is typically used for comparing the cost of a given health intervention 
against its associated health gains (262). In this case, it can also help inform the allocation of 
resources between the different approaches (1 to 4 above) to the burden reduction of MDD. In cost-
effectiveness analysis, the DALY can be used as a unit of measurement to quantify the proportion 
of disease burden that can be averted (i.e. the number of DALYs that can be gained) from a given 
intervention. From this, a dollar value per DALY averted can also be estimated provided there is 
sufficient cost data available for a given intervention. Such cost-effectiveness analyses of 
intervention strategies targeting reductions in the duration, severity and deaths associated with 
MDD exist but as previously mentioned, depending on the population coverage of these strategies, 
can only reduce burden by 10% to 30% (3, 26, 27). Although this highlights MDD as a condition 
where disease prevention can be critical, there is also much left to establish by way of effective 
prevention strategies (28). 
 
In regards to prevention strategies, this thesis highlighted the importance of investigating how 
interventions to ameliorate the increased risk from abuse and violence can be incorporated into 
prevention programs for MDD. These could include parenting, social and gender norm change 
interventions to reduce violence against children and women (263). Findings also highlighted the 
importance of considering the role of CSA and IPV in the clinical formulation and treatment 
planning of MDD. There is evidence linking a history of childhood trauma and abuse to earlier 
onset and more chronic forms of depression, longer episode duration (264-267) and, poorer 
response to psychological and pharmacological treatments (268, 269). As such, for women 
diagnosed with MDD, there may be value in considering their lived experience and social context 
when delivering depression-focused psychotherapies to address not just their symptoms but also 
their response to any specific contributing adverse life event.  
 
In regards to reducing the number of deaths associated to MDD, Chapters Four and Five highlighted 
the importance of prioritising the prevention, early detection and effective management of MDD as 
suicide and IHD prevention strategies. Such strategies can be ‘selective’ and target those in the 
population who have yet to display suicidal behaviour or symptoms of IHD but have been 
diagnosed with MDD hence are at risk to do so; ‘universal’ and target the entire population with the 
aim of favourably shifting proximal and distal risk (and protective) factors across the entire 
population; or ‘indicated’ which specifically targets individuals already exhibiting suicidal 
behaviours or symptoms of IHD (210).   
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Presenting findings at the age, sex, and country level facilitated the selection and tailoring of 
intervention strategies for MDD. For instance, by estimating prevalence and disease burden for the 
entire lifespan, ages at which intervention would be most beneficial can be elucidated. The 
prevalence of MDD was evident from the ages of three onwards, but peaked during early adulthood. 
This provided further rationale for setting early intervention strategies for MDD.  There is evidence 
to suggest that the integration of stress, anxiety and depression management courses into high 
school curriculums can be effective in preventing depression but further research is needed for 
clearer conclusions (270). The impact of conflict on MDD also highlighted populations most in 
need of global resources for MDD. Using data from Chapter Four, Charlson and collaborators 
estimated the required service response to severe presentations of MDD and PTSD in a post conflict 
Libyan population. Based upon service coverage targets, approximately 154 full-time equivalent 
staff would be required; an amount which would involve substantially more resources to be 
designated to mental health in the region than what is currently available (182). 
 
Strengths and limitations of the evidence 
A key constraint in this thesis was the lack of raw epidemiological data available for MDD. Bounds 
of uncertainty were estimated for all high level findings in the thesis. It is important to consider 
these when interpreting findings, particularly where missing data were most apparent. For instance, 
when interpreting the modelled incidence output in Chapter Four which was entirely estimated 
using data from other epidemiological parameters; when comparing differences in prevalence and 
burden between countries, particularly from less developed parts of the world; and when examining  
the  risk factors of MDD. Although there were a number of ecological variables linked with the 
occurrence of MDD, there were sufficient data to quantify an association between war or conflict, 
CSA, and IPV (respectively) and MDD. Although a working example of the extent to which CSA 
and IPV could impact on the sex difference in MDD was presented, this work needs to be 
interpreted with caution given the lack of data available for (1) CSA and IPV in males and (2) the 
impact of other risk factors which are yet to be established. 
 
The definition of MDD used in this thesis was restricted to cases meeting clinical diagnosis using   
DSM and ICD criteria (38, 39). This was done to ensure consistency and comparability between 
estimates. That said, DSM and ICD definitions of MDD are predominantly based on Western 
presentations of the illness and may not be sensitive to its cross-cultural presentations (4, 52, 120). 
For instance, some languages do not include words to describe concepts such as ‘sadness’ or 
‘depression’. As such, it is likely that epidemiological surveys in these cultures attributed cases of 
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MDD to other illnesses (8, 32, 271), which would have underestimated its occurrence and burden. 
Further research into the cross-cultural validity of DSM/ICD diagnostic criteria is essential for 
clearer conclusions. Furthermore, included epidemiological data were based on either DSM-IV-TR, 
ICD-10 or earlier versions of DSM and ICD. As new population surveys of MDD using DSM-5 
diagnoses are made available, the impact of DSM-5 diagnostic criteria (43) on the epidemiological 
profile of MDD presented here will require further investigation.  
 
The accuracy of burden estimates relied on the representativeness of disability weights estimated 
for MDD by GBD 2010’s disability weights survey (12). This pairwise comparison of health states 
required lay vignettes of no more than 35 words in length for each condition which may not have 
been sufficient to capture all participants’ experiences of MDD. Furthermore, disability and health 
states in GBD 2010 intended to capture ‘within the skin’ loss to health, welfare loss was not 
considered. This is a significant omission for MDD where effects of the illness extend to economic, 
social, and academic functioning. Although it is outside the scope of GBD studies to consider 
welfare loss to health as this largely obscures the comparability of burden estimates between 
settings; replication of the disability weights survey, testing the effect of different lay descriptions 
of health states, as well as their validity between countries is required.   
 
The effect of MDD on suicide and IHD and similarly, the effects of CSA and IPV on MDD were 
quantified using CRA methodology which stipulates that attributable burden is estimated while 
holding all other independent risk factors constant (10). In reality, the effect of CSA and IPV on 
MDD and similarly, MDD on suicide and IHD may be multifactorial and the factors inter-
dependent. In further elucidating the epidemiological profile of MDD, future research should 
explore the effects of other biological, psychosocial, environmental or economic factors. This thesis 
makes available a template from which this work can be done.  
 
Avenues for future research 
This thesis brought together data on the epidemiology of MDD, including the estimation of burden 
for MDD. Responses to findings thus far have been positive with several avenues for further 
research already underway. Prevalence output from Chapters Three and Four have facilitated 
further investigation into the global availability of epidemiological data for mental disorders and 
how this changes across the lifespan (272, 273); time trends in the prevalence of common mental 
disorders (261); and the distribution of MDD in conflict affected populations (182). The published 
systematic review of prevalence and incidence data from Chapter Three was ranked as one of the 
most cited papers published in Psychological Medicine for the year 2013 (274).  
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Burden estimates from Chapter Five also received considerable interest from the media (see Text 
S1, Appendix Seven) and are currently being used in the 3rd Edition of Disease Control Priorities in 
Developing Countries (DCP3) Project. DCP3 is aimed at evaluating the cost and effectiveness of 
interventions for leading causes of disease burden which will also facilitate the calculation of up to 
date estimates of dollars per DALY averted for MDD (273).  The work presented in Chapter Seven 
provided post-doctoral avenues for research pertaining to the quantification of other risk factors of 
MDD and the extent to which they impact on its distribution. For example, other forms of abuse are 
now being investigated as risk factors for MDD (275), an area of research which can further 
contribute to the working example of CSA and IPV as risk factors for MDD and ultimately,  the 
setting of effective prevention strategies for MDD. 
 
In order to remain up to date with the literature and provide decision-makers with the most 
representative picture of their population’s health, the process of estimating disease burden is 
constantly evolving. For instance, burden of disease inputs presented in Chapters Three to Five also 
featured in WHO’s recently published global burden of disease estimates (also termed  ‘global 
health estimates’) for 2002-2011 (276). WHO’s iteration of burden of disease estimates drew on 
data and methodology used in GBD 2010 with some key revisions made to GBD 2010’s method for 
a number of causes. Although final DALY rankings changed given changes made to other causes, 
estimated DALYs for depressive disorders were derived using GBD 2010 inputs and hence were 
very similar to the DALYs reported here (Chapter Five reported 74.3 million DALYs in 2010 and 
WHO reported 74.9 million DALYs in 2011 due to depressive disorders) (276).  
 
IHME which lead the GBD 2010 initiative has also endeavoured to make available yearly burden of 
disease estimates. The next update to burden estimates will be published in late 2014 (GBD 2013). 
For MDD, this work has been focused on improving some of the issues raised in this thesis. For 
instance, it will incorporate new data on the distribution of MDD, thereby providing the opportunity 
to further validate the modelled epidemiological data presented in this thesis, particularly for 
regions were no raw epidemiological data were available. It will also expand upon the disease 
modelling strategy to investigate other unexplained sources of variability in the model and 
ultimately reduce the uncertainty around the prevalence and burden estimates. 
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Conclusion 
The research presented in this thesis reviewed the literature on the global distribution of MDD from 
which (1) a statistical model of the prevalence, incidence, duration and excess mortality associated 
with MDD and (2) YLDs due to MDD were generated. CRA methodology was then used to 
investigate (1) YLDs and YLLs that could be re-assigned to MDD as a risk factor for suicide and 
IHD and (2) the proportion of MDD prevalent cases that could potentially be explained by CSA and 
IPV. The epidemiological model compiled as a result of this work showed that MDD is a highly 
prevalent disorder, leading to an increased risk of mortality. It is present across the lifespan but is 
more common in females aged 20 to 64 years, from conflict affected populations. High prevalence 
estimates and disability associated with MDD culminated in it being identified as a significant 
contributor to the world’s disease burden.  It was the second leading global cause of non-fatal 
burden in 2010 and was also a significant contributor the burden assigned to suicide and IHD. 
These findings emphasize the importance of including MDD as a public-health priority. They also 
provide several opportunities to set intervention strategies to reduce its ubiquitous burden. For 
instance, presenting MDD prevalence and burden estimates by age, sex, year, and country facilitates 
the selection and tailoring of intervention strategies for MDD.  Research on the risk factors of MDD 
also revealed that abuse, war, and violence have the potential to play a significant role in the 
distribution of MDD. This highlighted the importance of investigating how interventions to 
ameliorate the increased risk from abuse, war, and violence can be incorporated into prevention 
programs for MDD. In regards to reducing the number of deaths associated to MDD, findings also 
highlighted the importance of prioritising the prevention, early detection and effective management 
of MDD, as suicide and IHD prevention strategies. A key constraint in this thesis was the lack of 
raw epidemiological data available. Furthermore, the definition of MDD used was restricted to 
cases meeting clinical diagnosis as per DSM and ICD criteria which may not be fully representative 
of non-Western presentations of MDD. As more data are made available, the epidemiological 
profile presented here can be expanded upon to investigate other unexplained sources of variability 
in the model and, ultimately reduce the uncertainty around estimates presented. This thesis provides 
the template from which this work can be done. 
  
134 
 
List of References 
 
1. Murray CJL, Lopez AD, editors. The Global Burden of Disease: a comprehensive 
assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected 
to 2020. Cambridge: Harvard University Press; 1996. 
2. Chisholm D, Diehr P, Knapp M, Patrick D, Treglia M, Simon G. Depression status, medical 
comorbidity and resource costs. Evidence from an international study of major depression in 
primary care (LIDO). Br J Psychiatry. 2003;183:121-31. 
3. Chisholm D, Sanderson K, Ayuso-Mateos JL, Saxena S. Reducing the global burden of 
depression: population-level analysis of intervention cost-effectiveness in 14 world regions. Br J 
Psychiatry. 2004;184:393-403. 
4. Wang PS, Angermeyer M, Borges G, Bruffaerts R, Tat Chiu W, G DEG, et al. Delay and 
failure in treatment seeking after first onset of mental disorders in the World Health Organization's 
World Mental Health Survey Initiative. World Psychiatry. 2007;6(3):177-85. 
5. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-
adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic 
analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197-223. 
6. Salomon JA, Wang H, Freeman MK, Vos T, Flaxman AD, Lopez AD, et al. Healthy life 
expectancy for 187 countries, 1990–2010: a systematic analysis for the Global Burden Disease 
Study 2010. Lancet. 2012;380:2144-62. 
7. Last JM, editor. A dictionary of epidemiology 4ed. New York: Oxford University Press; 
2001. 
8. Whiteford1 HA, Ferrari AJ, Baxter AJ, Charlson FJ, Degenhardt L. How did we arrive at 
burden of disease estimates for mental and illicit drug use disorders in the Global Burden of Disease 
Study 2010? Current Opinion in Psychiatry. 2013;26(4):376-83. 
9. Barendregt JJ, Van Oortmarssen GJ, Vos T, Murray CJ. A generic model for the assessment 
of disease epidemiology: the computational basis of DisMod II. Popul Health Metr. 2003;1(1):4. 
10. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, et al. A comparative risk assessment of 
burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 
1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 
2012;380:2224-60. 
11. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and 
regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic 
analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095-128. 
12. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, et al. Common values 
in assessing health outcomes from disease and injury: disability weights measurement study for the 
Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2129-43. 
13. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with 
disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis 
for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163-96. 
14. Bonita R, Beaglehole R, Kjellstrom T. Basic Epidemiology. 2nd ed. Geneva: World Health 
Organization; 2006. 
15. Ustun TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. Global burden of 
depressive disorders in the year 2000. British Journal of Psychiatry. 2004;184:386–92. 
16. World Health Organization. The global burden of disease: 2004 update. Geneva: World 
Health Organization, 2008. 
17. Kessler RC, Ustun TB, editors. The WHO World Mental Health Surveys: global 
perspectives on the epidemiology of mental disorders. New York: Cambridge University Press; 
2008. 
18. Harris EC, Barraclough B. Excess mortality of mental disorder. British Journal of 
Psychiatry. 1998;173(JULY):11-53. 
135 
 
19. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. The Global 
Burden of Mental and Substance Use Disorders, 2010. The Lancet. 2013;382(9904):1575-86. 
20. Beard JR, Tracy M, Vlahov D, Galea S. Trajectory and socioeeonomic predictors of 
depression in a prospective study of residents of New York City. Annals of Epidemiology. 
2008;18(3):235-43. 
21. Colman I, Ataullahjan A. Life Course Perspectives on the Epidemiology of Depression. Can 
J Psychiatry. 2010;55(10):622-32. 
22. Gilman SE, Kawachi I, Fitzmaurice GM, Buka SL. Socioeconomic status in childhood and 
the lifetime risk of major depression. Int J Epidemiol. 2002;31(2):359-67. 
23. Koster A, Bosma H, Kempen GI, Penninx BW, Beekmanb AT, Deegc DJ, et al. 
Socioeconomic differences in incident depression in older adults: the role of psychosocial factors, 
physical health status, and behavioral factors. Journal of Psychosomatic Research. 2006;61:619-27. 
24. Wang JL, Schmitz N, Dewa CS. Socioeconomic status and the risk of major depression: the 
Canadian National Population Health Survey. J Epidemiol Community Health. 2010;64(5):447-52. 
25. Zimmerman FJK, Katon W. Socioeconomic status, depression disparities, and financial 
strain: what lies behind the income-depression relationship? . Health Ecconomics. 2005;14:1197-
215. 
26. Andrews G, Sanderson K, Corry J, Lapsley HM. Using epidemiological data to model 
efficiency in reducing the burden of depression. The journal of mental health policy and economics. 
2000;3(4):175-86. 
27. Vos T, Haby MM, Barendregt JJ, Kruijshaar M, Corry J, Andrews G. The burden of major 
depression avoidable by longer-term treatment strategies. Archives of general psychiatry. 
2004;61(11):1097-103. 
28. Andrews G. Reducing the burden of depression. Can J Psychiatry. 2008;53(7):420-7. 
29. Evans K, McGrath J, Milns R. Searching for schizophrenia in ancient Greek and Roman 
literature: a systematic review. Acta psychiatrica Scandinavica. 2003;107(5):323-30. 
30. Okasha A, Okasha T. Notes on mental disorders in Pharaonic Egypt. History of Psychiatry 
2000;11:413–24. 
31. Bhugra D, Mastrogianni A. Globalisation and mental disorders. Overview with relation to 
depression. Br J Psychiatry. 2004;184:10-20. 
32. Cheng AT. Case definition and culture: Are people all the same? Br J Psychiatry. 
2001;179:1-3. 
33. Gureje O, Lasebikan VO, Kola L, Makanjuola VA. Lifetime and 12-month prevalence of 
mental disorders in the Nigerian Survey of Mental Health and Well-Being. Br J Psychiatry. 
2006;188:465-71. 
34. Henningsen P, Zimmermann T, Sattel H. Medically unexplained physical symptoms, 
anxiety, and depression: a meta-analytic review. Psychosom Med. 2003;65(4):528-33. 
35. Patel V. Cultural factors and international epidemiology. British medical bulletin. 
2001;57:33-45. 
36. Patel V, Winston M. 'Universality of mental illness' revisited: assumptions, artefacts and 
new directions. Br J Psychiatry. 1994;165(4):437-40. 
37. Segall MH, Lonner WJ, Berry JW. Cross-cultural psychology as a scholarly discipline. Am 
Psychol 1998;53:1101–10. 
38. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV-TR). Fourth Edition, Text Revision ed. Washington DC: American Psychiatric 
Association; 2000. 
39. World Health Organization. The ICD-10 Classification of Mental and Behavioural 
Disorders. Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 
1992. 
40. Brown TA, Barlow DH. A proposal for a dimensional classification system based on the 
shared features of the DSM-IV anxiety and mood disorders: implications for assessment and 
treatment. Psychological assessment. 2009;21(3):256-71. 
136 
 
41. Kendler KS, Gardner CO, Jr. Boundaries of major depression: an evaluation of DSM-IV 
criteria. The American journal of psychiatry. 1998;155(2):172-7. 
42. Moore MT, Brown TA. Are there meaningful differences between major depressive 
disorder, dysthymic disorder, and their subthreshold variants? The Journal of nervous and mental 
disease. 2012;200(9):766-72. 
43. American Psychiatric Association. Diagnostic and statistical manual of mental disorders : 
DSM-5. 5 ed. Washington DC: American Psychiatric Association; 2013. 
44. Parker G. Opening Pandora's box: how DSM-5 is coming to grief. Acta psychiatrica 
Scandinavica. 2013;128(1):88-91. 
45. World Health Organization. The International Classification of Diseases 11th Revision is 
due by 2017 2014. Available from: http://www.who.int/classifications/icd/revision/en/. 
46. Ustun TB, Kessler RC. Global burden of depressive disorders: the issue of duration. British 
Journal of Psychiatry. 2002;181:181–3. 
47. Paykel ES, Brugha T, Fryers T. Size and burden of depressive disorders in Europe. Eur 
Neuropsychopharmacol. 2005;15(4):411-23. 
48. Lepine J, Gastpar M, Mendlewicz J, Tylee A. Depression in the community: The first pan-
European study. DEPRES (Depression Research in European Society). International Clinical 
Psychopharmacology. 1997;12(1):19–29. 
49. Chiu E. Epidemiology of depression in the Asia Pacific region. Australas Psychiatry. 
2004;12 Suppl:S4-10. 
50. Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, et al. Cross-
national epidemiology of major depression and bipolar disorder. JAMA: The Journal Of The 
American Medical Association. 1996;276(4):293-9. 
51. Weich S, Araya R. International and regional variation in the prevalence of common mental 
disorders: do we need more surveys? Br J Psychiatry. 2004;184:289-90. 
52. Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, et al. Cross-
national epidemiology of DSM-IV major depressive episode. BMC medicine. 2011;9:90. 
53. Chang SM, Hahm BJ, Lee JY, Shin MS, Jeon HJ, Hong JP, et al. Cross-national difference 
in the prevalence of depression caused by the diagnostic threshold. J Affect Disord. 2008;106(1-
2):159-67. 
54. Chen R, Hu Z, Qin X, Xu X, Copeland JR. A community-based study of depression in older 
people in Hefei, China--the GMS-AGECAT prevalence, case validation and socio-economic 
correlates. Int J Geriatr Psychiatry. 2004;19(5):407-13. 
55. Phillips MR, Zhang J, Shi Q, Song Z, Ding Z, Pang S, et al. Prevalence, treatment, and 
associated disability of mental disorders in four provinces in China during 2001–05: an 
epidemiological survey. The Lancet. 2009;373:2041–53. 
56. Carta MG, Angst J. Epidemiological and clinical aspects of bipolar disorders: controversies 
or a common need to redefine the aims and methodological aspects of surveys. Clin Pract 
Epidemiol Ment Health. 2005;1(1):4. 
57. Helzer JE, Robins LN, McEvoy LT, Spitznagel EL, Stoltzman RK, Farmer A, et al. A 
comparison of clinical and diagnostic interview schedule diagnoses. Physician reexamination of 
lay-interviewed cases in the general population. Archives of general psychiatry. 1985;42(7):657-66. 
58. Jorm AF. National surveys of mental disorders: are they researching scientific facts or 
constructing useful myths? Aust N Z J Psychiatry. 2006;40(10):830-4. 
59. Baxter AJ, Page A, Whiteford HA. Factors influencing risk of premature mortality in 
community cases of depression: a meta-analytic review. Epidemiology Research International. 
2011;2011(Article ID 832945):12 pages. 
60. Cuijpers P, Smit F. Excess mortality in depression: a meta-analysis of community studies. J 
Affect Disord. 2002;72(3):227-36. 
61. van den Akker M, Schuurman AG, Ensinck KT, Buntinx F. Depression as a risk factor for 
total mortality in the community: a meta-analysis. Archives of Public Health. 2003;61(6):313-32. 
137 
 
62. Wulsin LR, Vaillant GE, Wells VE. A systematic review of the mortality of depression. 
Psychosom Med. 1999;61(1):6-17. 
63. Alhasnawi S, Sadik S, Rasheed M, Baban A, Al-Alak MM, Othman AY, et al. The 
prevalence and correlates of DSM-IV disorders in the Iraq Mental Health Survey (IMHS). World 
Psychiatry. 2009;8(2):97-109. 
64. Eaton WW, Kramer M, Anthony JC, Dryman A, Shapiro S, Locke BZ. The incidence of 
specific DIS/DSM-III mental disorders: data from the NIMH Epidemiologic Catchment Area 
Program. Acta psychiatrica Scandinavica. 1989;79(2):163-78. 
65. Lewinsohn PM, Hops H, Roberts RE, Seeley JR, Andrews JA. Adolescent 
psychopathology: I. Prevalence and incidence of depression and other DSM-III-R disorders in high 
school students. J Abnorm Psychol. 1993;102(1):133-44. 
66. Mogga S, Prince M, Alem A, Kebede D, Stewart R, Glozier N, et al. Outcome of major 
depression in Ethiopia: population-based study. Br J Psychiatry. 2006;189:241-6. 
67. Patten SB. The duration of major depressive episodes in the Canadian general population. 
Chronic Dis Can. 2001;22(1):6-11. 
68. Spijker J, de Graaf R, Bijl RV, Beekman AT, Ormel J, Nolen WA. Duration of major 
depressive episodes in the general population: results from The Netherlands Mental Health Survey 
and Incidence Study (NEMESIS). Br J Psychiatry. 2002;181:208-13. 
69. Brhlikova. P, Pollock. AM, Manners R. Global Burden of Disease estimates of depression – 
how reliable is the epidemiological evidence? Journal of the Royal Society of Medicine. 
2010;104:25-35. 
70. Copeland JRM, Beekman ATF, Dewey ME, Hooijer C, Jordan A, Lawlor BA, et al. 
Depression in Europe. Geographical distribution among older people. British Journal of Psychiatry. 
1999;174(APR.):312-21. 
71. World Bank. World Development Report 1993. Investing in health: World development 
indicators. New York: World Bank,, 1993. 
72. Murray CJL, Salomon JA, Mathers C. A critical examination of summary measures of 
population health. Bulletin of the World Health Organisation. 2000;78(8):981-94. 
73. Ayuso-Mateos JL. Global burden of bipolar disorder in the year 2000: Version 1. World 
Health Organization, 2000. 
74. Prince M, Patel V, Saxena S, Maj M, Maselko J, Phillips MR, et al. No health without 
mental health. The Lancet. 2007;370:859–77. 
75. Patten SB, Bilsker D, Goldner E. The evolving understanding of major depression 
epidemiology: implications for practice and policy. Can J Psychiatry. 2008;53(10):689-95. 
76. Kruijshaar ME, Hoeymans N, Spijker J, Stouthard ME, Essink-Bot ML. Has the burden of 
depression been overestimated? Bull World Health Organ. 2005;83(6):443-8. 
77. Breslau N, Peterson EL, Schultz LR, Chilcoat HD, Andreski P. Major depression and stages 
of smoking. A longitudinal investigation. Archives of general psychiatry. 1998;55(2):161-6. 
78. Dierker LC, Avenevoli S, Stolar M, Merikangas KR. Smoking and depression: an 
examination of mechanisms of comorbidity. The American journal of psychiatry. 2002;159(6):947-
53. 
79. Scott KM, McGee MA, Oakley Browne MA, Wells JE, New Zealand Mental Health Survey 
Research T. Mental disorder comorbidity in Te Rau Hinengaro: the New Zealand Mental Health 
Survey. Aust N Z J Psychiatry. 2006;40(10):875-81. 
80. Roeloffs CA, Fink A, Unutzer J, Tang L, Wells KB. Problematic substance use, depressive 
symptoms, and gender in primary care. Psychiatric services. 2001;52(9):1251-3. 
81. Degenhardt L, Hall W, Lynskey M, Coffey C, Patton G. The association between cannabis 
use and depression: a review of the evidence. In: D.J. C, Murray R, editors. Marijuana and 
Madness: Psychiatry and Neurobiology. NY, USA: Cambridge University Press; 2004. 
82. Harris EC, Barraclough B. Suicide as an outcome for mental disorders: A meta-analysis. 
British Journal of Psychiatry. 1997;170:205-28. 
138 
 
83. Li Z, Page A, Martin G, Taylor R. Attributable risk of psychiatric and socio-economic 
factors for suicide from individual-level, population-based studies: a systematic review. Soc Sci 
Med. 2011;72(4):608-16. 
84. Gross AL, Gallo JJ, Eaton WW. Depression and cancer risk: 24 years of follow-up of the 
Baltimore Epidemiologic Catchment Area sample. Cancer causes & control : CCC. 2010;21(2):191-
9. 
85. Charlson FJ, Stapelberg NJC, Baxter A, Whiteford HA. Should Global Burden of Disease 
Estimates Include Depression as a Risk Factor for Coronary Heart Disease? BMC medicine. 
2011;9(47):1-6. 
86. Bradford-Hill A. The environment and disease: association or causation? . Proc R Soc Med 
1965;58:293-300. 
87. Hofler M. The Bradford Hill considerations on causality: a counterfactual perspective. 
Emerg Themes Epidemiol. 2005;2:11. 
88. Baxter AJ, Charlson FJ, Somerville AJ, Whiteford HA. Mental disorders as risk factors: 
assessing the evidence for the global burden of disease study. BMC medicine. 2011;9(134):1-7. 
89. Charlson FJ, Moran AE, Freedman G, Norman RE, Stapelberg NJC, Baxter AJ, et al. The 
contribution of major depression to the global burden of ischaemic heart disease: a comparative risk 
assessment. BMC medicine. 2013;11(250):doi: 10.1186/741-7015-11-250. 
90. Arsenault-Lapierre G, Kim C, Turecki G. Psychiatric diagnoses in 3275 suicides: a meta-
analysis. BMC Psychiatry. 2004;37(4):1-11. 
91. Cavanagh JT, Carson AJ, Sharpe M, Lawrie SM. Psychological autopsy studies of suicide: a 
systematic review. Psychological Medicine. 2003;33:395-405. 
92. Yoshimasu K, Kiyohara C, Miyashita K. Suicidal risk factors and completed suicide: meta-
analyses based on psychological autopsy studies. Environmental Health and Preventive Medicine 
2008;13:243-56. 
93. Gluckman P, Beedle A, Hanson M. Principles of evolutionary medicine. Oxford: Oxford 
University Press; 2009. 
94. Brune M, Belsky J, Fabrega H, Feierman HR, Gilbert P, Glantz K, et al. The crisis of 
psychiatry - insights and prospects from evolutionary theory. World Psychiatry. 2012;11(1):55-7. 
95. World Health Organization. Guidelines for medico-legal care for victims of sexual violence. 
Geneva: World Health Organization, 2003. 
96. Chang JC, Cluss PA, Ranieri L, Hawker L, Buranosky R, Dado D, et al. Health care 
interventions for intimate partner violence: what women want. Women's health issues : official 
publication of the Jacobs Institute of Women's Health. 2005;15(1):21-30. 
97. Hyde JS, Mezulis AH, Abramson LY. The ABCs of depression: integrating affective, 
biological, and cognitive models to explain the emergence of the gender difference in depression. 
Psychological review. 2008;115(2):291-313. 
98. Kendler KS, Thornton LM, Prescott CA. Gender differences in the rates of exposure to 
stressful life events and sensitivity to their depressogenic effects. The American journal of 
psychiatry. 2001;158(4):587-93. 
99. Kendler KS, Karkowski LM, Prescott CA. Causal relationship between stressful life events 
and the onset of major depression. The American journal of psychiatry. 1999;156(6):837-41. 
100. Anderson K. Perpetrator or victim? Relationships between intimate partner violence and 
well-being. Journal of Marriage and Family. 2002;64(4):851–63. 
101. Romito P, Grassi M. Does violence affect one gender more than the other? The mental 
health impact of violence among male and female university students. Soc Sci Med. 
2007;65(6):1222-34. 
102. Tjaden P, Thoennes N. Prevalence and consequences of male-to-female and female-to-male 
intimate partner violence, as measured by the national violence against women survey. Violence 
Against Women. 2000;6(2):142–61. 
103. Accortt EE, Freeman MP, Allen JJB. Women and Major Depressive Disorder: Clinical 
Perspectives on Causal Pathways. Journal of Women's Health. 2008;17(10):1583-90. 
139 
 
104. Bebbington P. The origins of sex differences in depressive disorder: bridging the gap. 
International Review of Psychiatry. 1996;8:295-332. 
105. Essau CA, Lewinsohn PM, Seeley JR, Sasagawa S. Gender differences in the developmental 
course of depression. J Affect Disord. 2010;127(1-3):185-90. 
106. Kessler RC. Epidemiology of women and depression. Journal of Affective Disorders. 
2003;74:5-13. 
107. Kuehner C. Gender differences in unipolar depression: an update of epidemiological 
findings and possible explanations. Acta psychiatrica Scandinavica. 2003;108:163-74. 
108. Nolen-Hoeksema S. Gender Differences in Depression. Current Directions in Psychological 
Science 2001;10:173-6. 
109. Nolen-Hoeksema S. The Etiology of Gender Differences in Depression.  Understanding 
depression in women: Applying empirical research to practice and policy. Washington, DC: 
American Psychological Association; US; 2006. p. 9-43. 
110. Piccinelli M, Wilkinson G. Gender differences in depression : Critical review. British 
Journal of Psychiatry. 2000;177:486-92. 
111. Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS, et al. Grand challenges in 
global mental health. Nature. 2011;475(7354):27-30. 
112. Murray CJL, Lopez AD, Black R, Mathers CD, Shibuya K, Ezzati M, et al. Global Burden 
of Disease 2005: call for collaborators. The Lancet. 2007;370(9582):109-10. 
113. Global Burden of Disease. Global Burden of Diseases, Injuries and Risk Factors Study 
Operations Manual 2009. Available from: http://www.globalburden.org/gbdops.html. 
114. Salomon JA. New disability weights for the global burden of disease. Bulletin of the World 
Health Organization 2010;88(12):879. 
115. Salomon JA, Murray CJ, Ustun B, Chatterji S. Health state valuations in summary measures 
of population health. In: Murray CJ, Evans DB, editors. Health systems performance assessment: 
debates, methods and empiricism. Geneva: World Health Organization 2003. p. 408-36. 
116. Kessler RC. The World Health Organization International Consortium in Psychiatric 
Epidemiology (ICPE): initial work and future directions -- the NAPE Lecture 1998. Nordic 
Association for Psychiatric Epidemiology. Acta psychiatrica Scandinavica. 1999;99(1):2-9. 
117. Skapinakis P, Lewis G. Epidemiology in community psychiatric research: common uses and 
methodological issues. Epidemiol Psichiatr Soc. 2001;10(1):18-26. 
118. Wittchen HU. Epidemiological research in mental disorders: lessons for the next decade of 
research--the NAPE Lecture 1999. Nordic Association for Psychiatric Epidemiology. Acta 
psychiatrica Scandinavica. 2000;101(1):2-10. 
119. Seedat S, Scott KM, Angermeyer MC, Berglund P, Bromet EJ, Brugha TS, et al. Cross-
national associations between gender and mental disorders in the World Health Organization World 
Mental Health Surveys. Archives of general psychiatry. 2009;66(7):785-95. 
120. Simon GE, Goldberg DP, Von Korff M, Ustun TB. Understanding cross-national 
differences in depression prevalence. Psychol Med. 2002;32(4):585-94. 
121. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred reporting items for 
systematic reviews and meta-analyses: the PRISMA Statement. PLoS Med. 2009;6(7):e1000097. 
122. Kruijshaar ME, Barendregt J, Vos T, de Graaf R, Spijker J, Andrews G. Lifetime prevalence 
estimates of major depression: An indirect estimation method and a quantification of recall bias. 
European Journal of Epidemiology. 2005;20:103–11. 
123. Moffitt TE, Caspi A, Taylor AJ, Kokaua J, Milne BJ, Polanczyk G, et al. How common are 
common mental disorders? Evidence that lifetime prevalence rates are doubled by prospective 
versus retrospective ascertainment. Psychological Medicine. 2010;40:899–909. 
124. Simon GE, VonKorff M. Recall of psychiatric history in cross-sectional surveys: 
Implications for epidemiologic research. Epidemiologic Reviews. 1995;17(1):221-7. 
125. Susser E, Shrout PE. Two plus two equals three? Do we need to rethink lifetime prevalence? 
A commentary on ‘How common are common mental disorders? Evidence that lifetime prevalence 
140 
 
rates are doubled by prospective versus retrospective ascertainment’ by Moffitt et al. (2009). 
Psychological Medicine. 2010;40:895–7. 
126. United Nations. World Population Prospects: The 2006 Revision, Highlights. Working 
Paper No. ESA/P/WP.202. Department of Economic and Social Affairs, Population Division, 2007. 
127. Sterne JAC, Egger M, Sutton AJ. Meta-Analysis Software.  Systematic Reviews in Health 
Care: BMJ Publishing Group; 2008. p. 336-46. 
128. Baker WL, White CM, Cappelleri JC, Kluger J, Coleman CI. Understanding heterogeneity 
in meta-analysis: the role of meta-regression. Int J Clin Pract. 2009;63(10):1426-34. 
129. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: 
multivariate approach and meta-regression. Stat Med. 2002;21(4):589-624. 
130. Tabachnick BG, Fidell LS, editors. Using multivariate statistics. 5 ed. Boston: 
Pearson/Allyn & Bacon; 2007. 
131. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-
analyses. BMJ. 2003;327(7414):557-60. 
132. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: An 
update. Contemporary Clinical Trials. 2007;28:105–14. 
133. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials. 
1986;7:177-88. 
134. Stata: Data Analysis and Statistical Software. Stata 12 help for predict 2011. Available 
from: http://www.stata.com/help.cgi?predict. 
135. Ihara K, Muraoka Y, Oiji A, Nadaoka T. Prevalence of mood disorders according to DSM- 
III -R criteria in the community elderly residents in Japan. Environmental Health and Preventive 
Medicine. 1998;3(1):44-9. 
136. Lopes Cardozo B, Bilukha OO, Gotway CA, Wolfe MI, Gerber ML, Anderson M. Mental 
health of women in postwar Afghanistan. Journal of Women's Health. 2005;14(4):285-93. 
137. Angst J, Gamma A, Gastpar M, Lepine JP, Mendlewicz J, Tylee A. Gender differences in 
depression. Epidemiological findings from the European DEPRES I and II studies. Eur Arch 
Psychiatry Clin Neurosci. 2002;252(5):201-9. 
138. Culbertson FM. Depression and gender. An international review. Am Psychol. 
1997;52(1):25-31. 
139. Bromet EJ, Gluzman SF, Paniotto VI, Webb CPM, Tintle NL, Zakhozha V, et al. 
Epidemiology of psychiatric and alcohol disorders in Ukraine: Findings from the Ukraine World 
Mental Health Survey. Social Psychiatry and Psychiatric Epidemiology. 2005;40(9):681-90. 
140. Faravelli C, Degl'Innocenti BG, Aiazzi L, Incerpi G, et al. Epidemiology of mood disorders: 
A community survey in Florence. Journal of Affective Disorders. 1990;20(2):135-41. 
141. Stefansson GE, Bjornsson JK, Gudmundsdottir A. Period prevalence rates of specific mental 
disorders in an Icelandic cohort. Soc Psychiatry Psychiatr Epidemiol. 1994;29:119-25. 
142. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of 
schizophrenia. PLoS Medicine. 2005;2(5):e141. 
143. Hollander AC, Ekblad S, Mukhamadiev D, Muminova R. The validity of screening 
instruments for posttraumatic stress disorder, depression, and other anxiety symptoms in Tajikistan. 
The Journal of nervous and mental disease. 2007;195(11):955-8. 
144. Horwitz AV, Wakefield JC. The loss of sadness: How psychiatry transformed normal 
sorrow into depressive disorder. New York: Oxford University Press; 2007. 
145. Ventevogel P, De Vries G, Scholte WF, Shinwari NR, Faiz H, Nassery R, et al. Properties of 
the Hopkins Symptom Checklist-25 (HSCL-25) and the Self-Reporting Questionnaire (SRQ-20) as 
screening instruments used in primary care in Afghanistan. Soc Psychiatry Psychiatr Epidemiol. 
2007;42(4):328-35. 
146. Hollifield M, Warner TD, Lian N, Krakow B, Jenkins JH, Kesler J, et al. Measuring trauma 
and health status in refugees: a critical review. JAMA. 2002;288(5):611-21. 
141 
 
147. Rodin D, van Ommeren M. Commentary: Explaining enormous variations in rates of 
disorder in trauma-focused psychiatric epidemiology after major emergencies. Int J Epidemiol. 
2009;38(4):1045-8. 
148. Steel Z, Chey T, Silove D, Marnane C, Bryant RA, van Ommeren M. Association of torture 
and other potentially traumatic events with mental health outcomes among populations exposed to 
mass conflict and displacement: a systematic review and meta-analysis. JAMA. 2009;302(5):537-
49. 
149. Institute for Health Metrics and Evaluation. Burden of Disease 2012. Available from: 
http://www.healthmetricsandevaluation.org/research/team/burden-disease#/overview. 
150. Ferrari AJ, Somerville AJ, Baxter AJ, Norman R, Patten SB, Vos T, et al. Global variation 
in the prevalence and incidence of major depressive disorder: a systematic review of the 
epidemiological literature. Psychol Med. 2013;43(3):471-81. 
151. Charlson FJ, Ferrari AJ, Somerville AJ, Norman R, Patten SB, Vos T, et al. The 
epidemiological modelling of dysthymia: Application for the Global Burden of Disease 2010 Study. 
Journal of Affective Disorders. 2013;151:111-20. 
152. Attanayake V, McKay R, Joffres M, Singh S, Burkle F, Jr., Mills E. Prevalence of mental 
disorders among children exposed to war: a systematic review of 7,920 children. Med Confl Surviv. 
2009;25(1):4-19. 
153. Fisher J, Tran T, La BT, Kriitmaa K, Rosenthal D. Common perinatal mental disorders in 
northern Viet Nam: community prevalence and health care use. Bull World Health Organ. 
2010;88(10):737-45. 
154. Flaxman AD, Vos T, Murray CJL, editors. An integrative metaregression framework for 
descriptive epidemiology. Washington: University of Washington Press, In press; 2014. 
155. Vos T, Mathers C, Herrman H, Harvey C, Gureje O, Bui D, et al. The burden of mental 
disorders in Victoria, 1996. Soc Psychiatry Psychiatr Epidemiol. 2001;36(2):53-62. 
156. Vos T, Mathers CD. The burden of mental disorders: a comparison of methods between the 
Australian burden of disease studies and the Global Burden of Disease study. Bull World Health 
Organ. 2000;78(4):427-38. 
157. Maharaj RG, Alli F, Cumberbatch K, Laloo P, Mohammed S, Ramesar A, et al. Depression 
among adolescents, aged 13-19 years, attending secondary schools in Trinidad: prevalence and 
associated factors. West Indian Med J. 2008;57(4):352-9. 
158. Roberts B, Damundu EY, Lomoro O, Sondorp E. Post-conflict mental health needs: a cross-
sectional survey of trauma, depression and associated factors in Juba, Southern Sudan. BMC 
Psychiatry. 2009;9:7. 
159. Uwakwe R. The pattern of psychiatric disorders among the aged in a selected community in 
Nigeria. Int J Geriatr Psychiatry. 2000;15(4):355-62. 
160. Eaton WW, Anthony JC, Gallo J, Cai G, Tien A, Romanoski A, et al. Natural history of 
Diagnostic Interview Schedule/DSM-IV major depression. The Baltimore Epidemiologic 
Catchment Area follow-up. Archives of general psychiatry. 1997;54(11):993-9. 
161. Kendler KS, Walters EE, Kessler RC. The prediction of length of major depressive 
episodes: results from an epidemiological sample of female twins. Psychol Med. 1997;27(1):107-
17. 
162. Lewinsohn PM, Clarke GN, Seeley JR, Rohde P. Major depression in community 
adolescents: age at onset, episode duration, and time to recurrence. J Am Acad Child Adolesc 
Psychiatry. 1994;33(6):809-18. 
163. McLeod JD, Kessler RC, Landis KR. Speed of recovery from major depressive episodes in a 
community sample of married men and women. J Abnorm Psychol. 1992;101(2):277-86. 
164. Howson C, Urbach P. Scientific reasoning : the Bayesian approach. Chicago, IL, US: Open 
Court Publishing Co; 1989. 
165. Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and 
interpreted? Statistics in Medicine 2002;21(11):1559–73. 
142 
 
166. Luby JL. Preschool Depression: The Importance of Identification of Depression Early in 
Development. Curr Dir Psychol Sci. 2010;19(2):91-5. 
167. Karam E, Bou Ghosnb M. Psychosocial consequences of war among civilian populations. 
Current Opinion in Psychiatry. 2003;16:413-9. 
168. Karam EG, Mneimneh ZN, Dimassi H, Fayyad JA, Karam AN, Nasser SC, et al. Lifetime 
prevalence of mental disorders in Lebanon: first onset, treatment, and exposure to war. PLoS Med. 
2008;5(4):e61. 
169. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R, Inoue M. Age 
standardization of rates: A new WHO standard. GPE Discussion Paper Series: No.31, World Health 
Organization, 2001. 
170. United Nations. World Population Prospects - The 2010 Revision. New York: United 
Nations, 2011. 
171. Luppa M, Sikorski C, Luck T, Ehreke L, Konnopka A, Wiese B, et al. Age- and gender-
specific prevalence of depression in latest-life--systematic review and meta-analysis. J Affect 
Disord. 2012;136(3):212-21. 
172. Beekman ATF, Deeg DJJ, Van Tilburg T, Smith JH, Hooijer C, Van Tilburg W. Major and 
minor depression in later life: A study of prevalence and risk factors. Journal of Affective 
Disorders. 1995;36(1–2):65–75. 
173. Kurlowicz LH. Depression in later life: dispelling the myths. J Psychosoc Nurs Ment Health 
Serv. 2005;43(1):16-9. 
174. Mathers CD, Stein C, Ma Fat D, C. R, Inoue M, Tomijima N, et al. Global Burden of 
Disease 2000: Version 2 methods and results. Geneva: World Health Organization, 2002. 
175. Ferrari AJ, Charlson FJ, Norman R, Flaxman AD, Patten SB, Vos T, et al. The 
epidemiological modelling of major depressive disorder: Application for the Global Burden of 
Disease Study 2010 PLoS One. 2013;8(7):1-14. 
176. Agency for Healthcare Research and Quality. United States Medical Expenditure Panel 
Survey 2000-2009. Rockville, United States: Agency for Healthcare Research and Quality; 2012. 
177. U.S. National Institutes of Health National Institute on Alcohol Abuse and Alcoholism. 
National Epidemiologic Survey on Alcohol and Related Conditions Wave 1 and Wave 2 Bethesda, 
Maryland, United States: National Institutes of Health; 2013 [22/08/2013]. Available from: 
http://www.niaaa.nih.gov/. 
178. Australian Bureau of Statistics. National Survey of Mental Health and Wellbeing of Adults 
1997 Canberra, Australia: Australian Bureau of Statistics; 2008 [22/08/2013]. Available from: 
http://www.abs.gov.au/AUSSTATS/abs@.nsf/allprimarymainfeatures/D5A0AC778746378FCA257
4EA00122887?opendocument. 
179. Ware JE, Kosinski M, Keller SD, QualityMetric Incorporated, New England Medical Center 
Hospital. Health Assessment Lab. SF-12 : how to score the SF-12 physical and mental health 
summary scales. Lincoln, R.I, Boston, Mass: QualityMetric Inc, Health Assessment Lab; 2002. 
180. Eaton WW, Kalaydjian A, Scharfstein D, Mezuk B, Ding Y. Prevalence and incidence of 
depressive disorder: the Baltimore ECA follow-up, 1981–2004. Acta psychiatrica Scandinavica. 
2007;116:182–8. 
181. Fu TS, Lee CS, Gunnell D, Lee WC, Cheng AT. Changing trends in the prevalence of 
common mental disorders in Taiwan: a 20-year repeated cross-sectional survey. Lancet. 
2012;381:235-41. 
182. Charlson FJ, Steel Z, Degenhardt L, Chey T, Silove D, Marnane C, et al. Predicting the 
Impact of the 2011 Conflict in Libya on Population Mental Health: PTSD and Depression 
Prevalence and Mental Health Service Requirements. PLoS One. 2012;7(7):e40593. 
183. GBD 2010 Country Collaboration. GBD 2010 country results: a global public good. Lancet. 
2013;381:965-70. 
184. Jessop EG. Health in the UK: could do even better? Lancet. 2013;381:970-2. 
185. Murray CJL, Richards MA, Newton JN, Fenton LA. UK health performance: fi ndings of 
the Global Burden of Disease Study 2010. Lancet. 2013;381:997-1020. 
143 
 
186. McKnight PE, Kashdan TB. The importance of functional impairment to mental health 
outcomes: a case for reassessing our goals in depression treatment research. Clin Psychol Rev. 
2009;29(3):243-59. 
187. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. International 
Clinical Psychopharmacology. 1996;11(Suppl 3):89−95. 
188. Sheehan KH, Sheehan DV. Assessing treatment effects in clinical trials with the discan 
metric of the Sheehan Disability Scale. Int Clin Psychopharmacol. 2008;23(2):70-83. 
189. Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Hall WD, et al. The 
global burden of disease attributable to illicit drug use: Results from the GBD 2010 study. The 
Lancet. 2013;382(9904):1564-74. 
190. Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Murray CJL, Vos T, et al. Burden of 
depressive disorders by country, sex, age and year: Findings from the Global Burden of Disease 
Study 2010. PloS Medicine. 2013;10(11):e1001547. doi:10.1371/journal.pmed. 
191. Phillips MR, Cheng HG. The changing global face of suicide. Lancet. 
2012;379(9834):2318-9. 
192. Patel V, Ramasundarahettige C, Vijayakumar L, Thakur JS, Gajalakshmi V, Gururaj G, et 
al. Suicide mortality in India: a nationally representative survey. Lancet. 2012;379(9834):2343-51. 
193. Vijayakumar L. Suicide and mental disorders in Asia. International Review of Psychiatry. 
2005;17(2):109–14. 
194. Degenhardt L, Singleton J, Calabria B, McLaren J, Kerr T, Mehta S, et al. Mortality among 
cocaine users: A systematic review of cohort studies. Drug and Alcohol Dependence. 2011;113:88-
95. 
195. Singleton J, Degenhardt L, Hall W, Zabransky T. Mortality among people who use 
amphetamines: A systematic review of cohort studies. Drug & Alcohol Dependence. 2009;105:1-8. 
196. Wilcox HC, Conner KR, Caine ED. Association of alcohol and drug use disorders and 
completed suicide: an empirical review of cohort studies. Drug Alcohol Depend. 2004;76 
Suppl:S11-9. 
197. Epigear. MetaXL 2012 [15/08/2013]. Available from: 
http://www.epigear.com/index_files/metaxl.html. 
198. Doi SA, Thalib L. A quality-effects model for meta-analysis. Epidemiology 2008;19(1):94-
100  
199. Barendregt JJ, Doi SA. MetaXL User Guide: Version 1.0. Wilston, Australia: EpiGear 
International Pty Ltd; 2010. Available from: http://www.epigear.com/index_files/metaxl.html  
200. Doi SA, Barendregt JJ, Mozurkewich EL. Meta-analysis Of heterogenous clinical trials: An 
empirical example. . Contemporary Clinical Trials. 2011;32:288-98. 
201. Baxter AJ, Scott K, Vos T, Whiteford HA. Global prevalence of anxiety disorders: A 
systematic review and meta-regression Psychological Medicine. 2012;43(5):897-910. 
202. Degenhardt L, Bucello C, Calabria B, Nelson P, Roberts A, Hall W, et al. What data are 
available on the extent of illicit drug use and dependence globally? Results of four systematic 
reviews. Drug Alcohol Depend. 2011;117(2-3):85-101. 
203. Ferrari AJ, Baxter AJ, Whiteford HA. A systematic review of the global distribution and 
availability of prevalence data for bipolar disorder. Journal of Affective Disorders. 2010;34(1-3):1-
13. 
204. Haagsma JA, van Beeck EF, Polinder S, Toet H, Panneman M, Bonsel GJ. The effect of 
comorbidity on health-related quality of life for injury patients in the first year following injury: 
comparison of three comorbidity adjustment approaches. Popul Health Metr. 2011;9:10. 
205. Conner KR, Phillips MR, Meldrum S, Knox KL, Zhang Y, Yang G. Low-planned suicides 
in China. Psychol Med. 2005;35(8):1197-204. 
206. Phillips MR. Rethinking the role of mental illness in suicide. The American journal of 
psychiatry. 2010;167(7):731-3. 
144 
 
207. Yang GH, Phillips MR, Zhou MG, Wang LJ, Zhang YP, Xu D. Understanding the unique 
characteristics of suicide in China: national psychological autopsy study. Biomedical and 
environmental sciences : BES. 2005;18(6):379-89. 
208. Zhang J, Xiao S, Zhou L. Mental disorders and suicide among young rural Chinese: A case-
control psychological autopsy study. American Journal of Psychiatry. 2010;167:773-81. 
209. Isometsa ET. Psychological autopsy studies – a review. European Psychiatry. 2001;16:379-
85. 
210. Silverman MM, Maris RW. The prevention of suicidal behaviors: an overview. Suicide & 
life-threatening behavior. 1995;25(1):10-21. 
211. Scott A, Guo B. For which strategies of suicide prevention is there evidence of 
effectiveness? Copenhagen: World Health Organization, 2012. 
212. Mann JJ, Apter A, Bertolote J, Beautrais A, Currier D, Haas A, et al. Suicide prevention 
strategies: a systematic review. JAMA. 2005;294(16):2064-74. 
213. Briffault X, Morvan Y, Rouillon F, Dardennes R, Lamboy B. [Use of services and treatment 
adequacy of major depressive episodes in France]. L'Encephale. 2010;36 Suppl 2:D48-58. 
214. Gabilondo A, Rojas-Farreras S, Rodriguez A, Fernandez A, Pinto-Meza A, Vilagut G, et al. 
Use of primary and specialized mental health care for a major depressive episode in Spain by 
ESEMeD respondents. Psychiatric services. 2011;62(2):152-61. 
215. Katz C, Bolton SL, Katz LY, Isaak C, Tilston-Jones T, Sareen J. A Systematic Review of 
School-Based Suicide Prevention Programs. Depression and anxiety. 2013. 
216. Robinson J, Hetrick SE, Martin C. Preventing suicide in young people: systematic review. 
Aust N Z J Psychiatry. 2011;45(1):3-26. 
217. Khan MM. Suicide prevention and developing countries. J R Soc Med. 2005;98(10):459-63. 
218. Pritchard C, Amanullah S. An analysis of suicide and undetermined deaths in 17 
predominantly Islamic countries contrasted with the UK. Psychol Med. 2007;37(3):421-30. 
219. Saxena S, Jane-Llopis E, Hosman C. Prevention of mental and behavioural disorders: 
implications for policy and practice. World Psychiatry. 2006;5(1):5-14. 
220. Karam EG, Friedman MJ, Hill ED, Kessler RC, McLaughlin KA, Petukhova M, et al. 
Cumulative traumas and risk thresholds: 12-month PTSD in the World Mental Health (WMH) 
surveys. Depression and anxiety. 2014;31(2):130-42. 
221. Lopresti AL, Hood SD, Drummond PD. A review of lifestyle factors that contribute to 
important pathways associated with major depression: diet, sleep and exercise. J Affect Disord. 
2013;148(1):12-27. 
222. Beydoun HA, Beydoun MA, Kaufman JS, Lo B, Zonderman AB. Intimate partner violence 
against adult women and its association with major depressive disorder, depressive symptoms and 
postpartum depression: a systematic review and meta-analysis. Soc Sci Med. 2012;75(6):959-75. 
223. Chen LP, Murad MH, Paras ML, Colbenson KM, Sattler AL, Goranson EN, et al. Sexual 
abuse and lifetime diagnosis of psychiatric disorders: systematic review and meta-analysis. Mayo 
Clinic proceedings Mayo Clinic. 2010;85(7):618-29. 
224. Devries KM, Mak JY, Child J, Falder G, Bacchus L, Astbury J, et al. Is childhood sexual 
abuse associated with incident depression?  A systematic review of twin and longitudinal studies. 
Submitted for review. 2014. 
225. Maniglio R, Maniglio R. Child sexual abuse in the etiology of depression: A systematic 
review of reviews. Depression & Anxiety. 2010;27(7):631-42. 
226. Devries KM, Mak JY, Bacchus L, Lim S, Petzold M, Child J, et al. The global prevalence of 
childhood sexual abuse. In preparation. 2014. 
227. World Health Organization, London School of Tropical Hygiene and Medicine, South 
African Medical Research Council. Global and regional estimates  of violence against women: 
Prevalence and health effects of intimate partner violence and non-partner sexual violence. Geneva, 
Switzerland: World Health Organization, 2013. 
228. Nolen-Hoeksema S. Sex Differences in Unipolar Depression: Evidence and Theory. 
Psychological Bulletin. 1987;101(2):259-82. 
145 
 
229. Weissman MM, Klerman GL. Sex differences and the epidemiology of depression. Archives 
of general psychiatry. 1977;34(1):98-111. 
230. Lipsman N, Lozano AM. The most cited works in major depression: the 'Citation classics'. J 
Affect Disord. 2011;134(1-3):39-44. 
231. Cyranowski JM, Frank E, Young E, Shear MK. Adolescent onset of the gender difference in 
lifetime rates of major depression: a theoretical model. Archives of general psychiatry. 
2000;57(1):21-7. 
232. Hankin BL, Abramson LY. Development of gender differences in depression: an elaborated 
cognitive vulnerability-transactional stress theory. Psychol Bull. 2001;127(6):773-96. 
233. Maier W, Gansicke M, Gater R, Rezaki M, Tiemens B, Urzua RF. Gender differences in the 
prevalence of depression: a survey in primary care. J Affect Disord. 1999;53(3):241-52. 
234. Nolen-Hoeksema S, Girgus JS. The emergence of gender differences in depression during 
adolescence. Psychol Bull. 1994;115(3):424-43. 
235. Parker G, Hadzi-Pavlovic D. Is any female preponderance in depression secondary to a 
primary female preponderance in anxiety disorders? Acta psychiatrica Scandinavica. 
2001;103(4):252-6. 
236. Dunn EC, Gilman SE, Willett JB, Slopen NB, Molnar BE. The impact of exposure to 
interpersonal violence on gender differences in adolescent-onset major depression: results from the 
National Comorbidity Survey Replication (NCS-R). Depression and anxiety. 2012;29(5):392-9. 
237. Cutler SE, Nolen-Hoeksema S. Accounting for sex differences in depression through female 
victimization: Childhood sexual abuse. Sex Roles. 1991;24(7-8):425-38. 
238. Carlson BE, McNutt LA, Choi DY. Childhood and adult abuse among women in primary 
health care: effects on mental health. Journal of interpersonal violence. 2003;18(8):924-41. 
239. Follette VM, Polusny MA, Bechtle AE, Naugle AE. Cumulative trauma: the impact of child 
sexual abuse, adult sexual assault, and spouse abuse. Journal of traumatic stress. 1996;9(1):25-35. 
240. McGuigan WM, Middlemiss W. Sexual abuse in childhood and interpersonal violence in 
adulthood: a cumulative impact on depressive symptoms in women. Journal of interpersonal 
violence. 2005;20(10):1271-87. 
241. Messman-Moore TL, Long PJ, Siegfried NJ. The revictimization of child sexual abuse 
survivors: an examination of the adjustment of college women with child sexual abuse, adult sexual 
assault, and adult physical abuse. Child maltreatment. 2000;5(1):18-27. 
242. Mouzos J, Makkai T. Women’s experiences of male violence, findings from the Australian 
component of the International Violence Against Women Survey (IVAWS). Canberra: Australian 
Institute of Criminology, 2004. 
243. Devries KM, Mak JYT, García-Moreno C, Petzold M, Child JC, Falder G, et al. The global 
prevalence of intimate partner violence against women. Science. 2013;340(6140):1527-8. 
244. Garcia-Moreno C, Jansen HA, Ellsberg M, Heise L, Watts CH, Health WHOM-cSoWs, et 
al. Prevalence of intimate partner violence: findings from the WHO multi-country study on 
women's health and domestic violence. Lancet. 2006;368(9543):1260-9. 
245. Devries KM, Garcia-Moreno C. Co-occurence of CSA and IPV in women: Data from the 
World Health Organization’s multi-country study on women’s health and domestic violence 
(Personal Communication). 2013. 
246. Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in 
prevalence studies: modification of an existing tool and evidence of interrater agreement. Journal of 
clinical epidemiology. 2012;65(9):934-9. 
247. Begg SJ, Vos T, Barker B, Stanley L, Lopez AD. Burden of disease and injury in Australia 
in the new millennium: measuring health loss from diseases, injuries and risk factors. The Medical 
journal of Australia. 2008;188(1):36-40. 
248. Norman R, Bradshaw D, Lewin S, Cairncross E, Nannan N, Vos T, et al. Estimating the 
burden of disease attributable to four selected environmental risk factors in South Africa. Reviews 
on environmental health. 2010;25(2):87-119. 
146 
 
249. Egger M, Smith GD, Altman DG, editors. Systematic reviews in health care: meta-analysis 
in context London: BMJ Publishing Group; 2001. 
250. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Converting Among Effect Sizes. In: 
Borenstein M, Hedges LV, Higgins JPT, Rothstein HR, editors. Introduction to Meta-Analysis 
Chichester, West Sussex, U.K. ; Hoboken: John Wiley & Sons; 2009. 
251. Hasselblad V, Hedges LV. Meta-analysis of screening and diagnostic tests. Psychol Bull. 
1995;117(1):167-78. 
252. Epigear. OR2RR 2013. Available from: http://www.epigear.com/index_files/or2rr.html. 
253. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort 
studies of common outcomes. JAMA. 1998;280(19):1690-1. 
254. Greenland S, Robins JM. Conceptual problems in the definition and interpretation of 
attributable fractions. American journal of epidemiology. 1988;128(6):1185-97. 
255. Barendregt JJ. Ersatz Version 1.2 Brisbane, Australia2012. Available from: 
http://www.epigear.com. 
256. Abrahams N, Mathews S, Martin LJ, Lombard C, Jewkes R. Intimate partner femicide in 
South Africa in 1999 and 2009. PLoS Med. 2013;10(4):e1001412. 
257. Krug EG, Mercy JA, Dahlberg LL, Zwi AB. The world report on violence and health. 
Lancet. 2002;360(9339):1083-8. 
258. Goodwin RD. Anxiety disorders and the onset of depression among adults in the 
community. Psychol Med. 2002;32(6):1121-4. 
259. Nolen-Hoeksema S. Responses to depression and their effects on the duration of depressive 
episodes. J Abnorm Psychol. 1991;100(4):569-82. 
260. Parker G, Brotchie H. Gender differences in depression. Int Rev Psychiatry. 
2010;22(5):429-36. 
261. Baxter AJ, Scott KM, Ferrari AJ, Norman R, Vos T, Whiteford HA. Challenging the myth 
of an "epidemic" of common mental disorders: trends in the global prevalence of anxiety and 
depression between 1990 and 2010. Depression & Anxiety. 2014;31(6):506-16. 
262. Musgrove P, Fox-Rushby J. Cost-Effectiveness  Analysis for Priority Setting. In: Jamison 
D, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al., editors. Disease Control 
Priorities in  Developing Countries. 2 ed. New York: Oxford University Press; 2006. p. 271-85. 
263. Heise LL. What works to prevent partner violence ?: An evidence overview. London: Strive, 
London School of Hygiene and Tropical Medicine 2011. 
264. Heim C, Newport DJ, Mletzko T, Miller AH, Nemeroff CB. The link between childhood 
trauma and depression: insights from HPA axis studies in humans. Psychoneuroendocrinology. 
2008;33(6):693-710. 
265. Kaplan MJ, Klinetob NA. Childhood emotional trauma and chronic posttraumatic stress 
disorder in adult outpatients with treatment-resistant depression. The Journal of nervous and mental 
disease. 2000;188(9):596-601. 
266. Lara ME, Klein DN, Kasch KL. Psychosocial predictors of the short-term course and 
outcome of major depression: a longitudinal study of a nonclinical sample with recent-onset 
episodes. J Abnorm Psychol. 2000;109(4):644-50. 
267. Weiss EL, Longhurst JG, Mazure CM. Childhood sexual abuse as a risk factor for 
depression in women: psychosocial and neurobiological correlates. The American journal of 
psychiatry. 1999;156(6):816-28. 
268. Asarnow JR, Emslie G, Clarke G, Wagner KD, Spirito A, Vitiello B, et al. Treatment of 
selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators 
of treatment response. J Am Acad Child Adolesc Psychiatry. 2009;48(3):330-9. 
269. Lewis CC, Simons AD, Nguyen LJ, Murakami JL, Reid MW, Silva SG, et al. Impact of 
childhood trauma on treatment outcome in the Treatment for Adolescents with Depression Study 
(TADS). J Am Acad Child Adolesc Psychiatry. 2010;49(2):132-40. 
270. Andrews G, Szabo M, Burns J. Preventing major depression in young people. Br J 
Psychiatry. 2002;181:460-2. 
147 
 
271. Yang LH, Link BG. Comparing diagnostic methods for mental disorders in China. Lancet. 
2009;373(9680):2002-4. 
272. Baxter AJ, Patton G, Scott KM, Degenhardt L, Whiteford HA. Global epidemiology of 
mental disorders: what are we missing? PLoS One. 2013;8(6):e65514. 
273. Erskine HE, Baxter AJ, Ferrari AJ, Patton G, Whiteford HA, Scott J. Will somebody thing 
of the children?;The coverage of epidemiological data for mental disorders in youth. In progress. 
2014. 
274. Psychological Medicine. Most-cited papers from 2013 2014. Available from: 
http://view.emarketing.cambridge.org/?j=fe8b1779746600747d&m=fe9f15707765037974&ls=fdf2
10707361037b73117073&l=fed417717561057c&s=fe241779726d057e711172&jb=ffcf14&ju=fe5
01377766d01787113&r=0. 
275. Norman RE, Moore SE, Ferrari AJ, Scott JG, Dunne M, Erskine H, et al. Burden 
attributable to child maltreatment in Australia. In progress. 2014. 
276. World Health Organization. WHO methods and data sources for global burden of disease 
estimates 2000-2011. Global Health Estimates Technical Paper WHO/HIS/HSI/GHE/2013.4. 
Geneva, Switzerland: Department of Health Statistics and Information Systems, WHO, 2013. 
 
 
  
148 
 
Appendices 
 
Appendix One 
Supplementary text to the Acknowledgements section  
As this thesis also included the estimation of burden estimates for the Global Burden of Disease 
Study 2010 (GBD 2010), I would like to acknowledge all core and collaborating members of the 
GBD 2010 expert group for mental and substance use disorders who provided advice and assistance 
during the course of the study. 
 
The mental and illicit drug use disorder expert group was made up of the following core members: 
Louisa Degenhardt, Harvey A Whiteford, John McGrath, Wayne Hall, Guilherme Polanczyk, 
Martin Prince, Shekhar Saxena, Oye Gureje, Ronald Kessler, Cille Kennedy, and Maria Elena 
Medina-More. The alcohol use disorders expert group was made up of the following core members: 
Guilherme Borges, Gerhard Gmel, Kate Graham, Charles Parry, Vladimir Poznyak, Jürgen Rehm, 
Robin Room. 
 
I would also like to acknowledge all other collaborating members who provided assistance to the 
mental and substance use disorder expert group, particularly James Scott, Jon-Paul Khoo, Jed Blore, 
Amanda Brown, Chiara Bucello, Bianca Calabria, Georgia Carstensen, Bianca Garcia, Yong Yi 
Lee, Bradley Mathers, Jennifer McLaren, Keryl Mitchener, Paul Nelson, Jayadeep Patra, An Pham, 
Svetlana Popova, Anna Roberts, Roman Scheurer, Adele Somerville, and Allison Ventura for their 
assistance in conducting the systematic reviews and/or the provision of expert advice. I would also 
like to acknowledge the World Mental Health Surveys Consortium for their contribution, led by 
Ronald Kessler and the following collaborators: Koen Demyttenaere, Ronny Bruff aerts, José 
Posada-Villa, Jean-Pierre Lepine, Viviane Kovess-Masfety, Matthias Angermeyer, Herbert 
Matschinger, Daphna Levinson, Giovanni de Girolamo, Norito Kawakami, Elie Karam, Maria 
Elena Medina Mora, Hans Ormel, Peter de Jonge, Ron de Graaf, Kate Scott, Elisabeth Wells, Oye 
Gureje, David Williams, Jordi Alonso, Josep Maria Haro Abad, and Evelyn Bromet. 
 
 
 
 
 
 
 
 
 
 
149 
 
Supplementary text to Chapter One 
 
Formulating a complete epidemiological profile  of major depressive disorder (MDD)
Investigating the global distribution, risk factors and outcomes of MDD in the population and implications for the Global Burden of Disease 2010 study
The global distribution and burden  
of MDD
Chapter 3/Paper 1
Literature review of the prevalence, 
incidence, duration and excess 
mortality of MDD in the population
Chapter 4/Paper 2
Modelling the distribution of MDD  by 
country, region, age , sex and year.
Chapter 5/Paper 3
Global Burden of depressive disorders
The risk factors of MDD The outcomes of MDD
Chapter 7/Discussion chapter
An exploration of the risk factors of 
MDD
Chapter 6/Paper 4
Burden of  MDD  (as well as  other 
mental and substance use disorders)  
as a risk factor for  suicide 
Concluding chapter
Illustrate the applicability and relevance of this epidemiological profile of MDD  and areas for future research
Burden of MDD  as a risk factor for 
ischemic heart disease
 
Note. Blue boxes represent PhD aims. Orange boxes represent PhD deliverables. The white box represents work that 
was not part of the PhD but was informed by PhD outputs. 
 
Figure S1. Outline of PhD.
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Appendix Two 
Supplementary text to Chapter Three 
 
Table S1. Summary of epidemiological parameters required for the burden estimation of MDD. 
Parameter Definition 
Prevalence The proportion of the population with  MDD*  at a specific point in time 
(point prevalence) or during a specified time period (6-, 12-month 
prevalence)  
Incidence The number of new cases of MDD in the population in one year (rate)  
Duration The average length of a MDE*  
 
Excess mortality 
rate 
The rate of dying in people with MDD compared to the general population. 
This can be presented as a relative risk (ratio of observed death in the 
sample to expected death in the population) or a standard mortality ratio 
(ratio of observed deaths in the sample to expected death in a population of 
standard composition in terms of age, sex, etc)  
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Table S2.Summary of included studies for prevalence 
 
       Study Country Coverage Age 
range 
Cohort 
size 
Response rate 
Midyear Depression 
subtype 
Diagnostic 
criteria/tool 
Parameter 
Type 
Sex Prevalence %  
(95% uncertainty)  
Europe, Western       
    
            
Aalto-Setala et al., 
2001 
Finland National 20-24 
647 excellent 
1995 MDD DSM4/SCAN Point Female 7.80(2.90-12.70) 
        
    
        Male 5.40(0.001-11.05) 
Almqvist et al., 1999 Finland National 8-9 
5813 excellent 
1989 MDD DSM3R/CDI Point Female 4.70(4.66-4.74) 
        
    
        Male 7.80(7.76-7.84) 
Andrade et al., 2003 Germany Community 14-25 
3021 average 
1995 MDD DSM4/CIDI Point Total 1.30(0.91-1.69) 
  Netherlands National 18-64 
7076 average 
1996 MDD DSM3R/CIDI Point Total 2.70(2.31-3.09) 
Angst et al., 1990 Switzerland Community 28-28 
4547 average 
1988 MDD + dep 
NOS 
DSM3/SPIKE 12 months Female 18.30(11.09-25.51) 
        
    
        Male 7.40(2.44-12.36) 
Ayuso-Mateos et al., 
2001 
Finland Community 18-64 
1950 average 
2000 MDD ICD10/SCAN Point Female 4.99(3.90-11.00) 
  Ireland Community 18-64 
472 average 
2000 MDD ICD10/SCAN Point Female 8.01(3.90-43.90) 
  Norway Community 18-64 
3050 average 
2000 MDD ICD10/SCAN Point Female 9.52(3.80-23.80) 
  Spain Community 18-64 
1250 average 
2000 MDD ICD10/SCAN Point Female 1.80(1.00-3.10) 
  United 
Kingdom 
Community 18-64 
2140 average 
2000 MDD ICD10/SCAN Point Female 8.14(10.10-39.02) 
  Finland Community 18-64 
1950 average 
2000 MDD ICD10/SCAN Point Male 2.91(1.20-6.10) 
  Ireland Community 18-64 
472 average 
2000 MDD ICD10/SCAN Point Male 5.58(1.20-13.90) 
  Norway Community 18-64 
3050 average 
2000 MDD ICD10/SCAN Point Male 5.17(2.30-8.80) 
  Spain Community 18-64 
1250 average 
2000 MDD ICD10/SCAN Point Male 2.00(0.70-5.30) 
  United 
Kingdom 
Community 18-64 
2140 average 
2000 MDD ICD10/SCAN Point Male 6.83(2.40-10.00) 
Barry et al., 2009 Ireland National 18-99 
10364 average 
2007 MDD DSM4/CIDI 12 months Female 8.00(7.00-9.00) 
        
    
    DSM4/CIDI   Male 6.00(4.98-7.02) 
Beekman et al., 1995 Netherlands National 55-85 
3056 average 
1993 MDD + dep 
NOS 
DSM3/DIS Point Female 17.10(14.41-19.79) 
        
    
        Male 12.40(9.97-14.83) 
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Bracke and Bracke, 
1998 
Belgium National 16-99 
8744 average 
1992 MDD RDC/HDL Point Female 8.70(7.45-9.95) 
        
    
        Male 4.30(3.40-5.20) 
Carta et al., 2002 France Community 18-99 
2260 average 
1995 MDD ICD10/CIDI Point Total 5.90(5.00-7.00) 
  Italy Community 18-99 
1040 average 
1995 MDD ICD10/CIDI Point Total 6.50(5.10-8.20) 
Copeland et al., 1999 Netherlands Community 65-84 
4051 excellent 
1993 MDD DSM3/GMS Point Female 2.10(1.54-2.66) 
  Germany Community 70-99 
516 poor 
1992 MDD DSM3/GMS Point Female 5.80(3.47-8.13) 
  Ireland Community 65-99 
936 excellent 
1993 MDD DSM3/GMS Point Female 0.30(0.001-0.74) 
  Iceland National 85-87 
800 excellent 
1983 MDD DSM3/GMS Point Female 4.40(3.64-5.16) 
  United 
Kingdom 
Community 65-99 
654 excellent 
1994 MDD DSM3/GMS Point Female 2.80(1.17-4.43) 
  Germany Community 85-99 
358 excellent 
1992 MDD DSM3/GMS Point Female 12.30(8.35-16.25) 
  Italy Community 65-99 
202 excellent 
1991 MDD DSM3/GMS Point Female 8.00(3.26-12.74) 
  Spain Community 65-99 
1080 excellent 
1989 MDD DSM3/GMS Point Female 5.00(3.22-6.78) 
  Netherlands Community 65-84 
4051 excellent 
1993 MDD DSM3/GMS Point Male 1.40(0.81-1.99) 
  Germany Community 70-99 
516 poor 
1992 MDD DSM3/GMS Point Male 5.40(1.61-9.19) 
  Ireland Community 65-99 
936 excellent 
1993 MDD DSM3/GMS Point Male 1.70(0.23-3.17) 
  Iceland National 85-87 
800 excellent 
1983 MDD DSM3/GMS Point Male 2.20(0.49-3.91) 
  United 
Kingdom 
Community 65-99 
654 excellent 
1994 MDD DSM3/GMS Point Male 3.10(0.99-5.21) 
  Germany Community 85-99 
358 excellent 
1992 MDD DSM3/GMS Point Male 5.10(0.001-10.21) 
  Italy Community 65-99 
202 excellent 
1991 MDD DSM3/GMS Point Male 1.30(0.001-4.21) 
  Spain Community 65-99 
1080 excellent 
1989 MDD DSM3/GMS Point Male 2.80(1.50-4.10) 
Donnelly, 1995 United 
Kingdom 
Regional 11-15 
887 average 
1993 MDD NS/CDI Point Total 12.00(8.90-15.10) 
Faravelli et al., 1990 Italy Community 15-99 
1000 excellent 
1987 MDD + dep 
NOS 
DSM3/Clinic
al IV 
12 months Female 14.34(10.04-18.64) 
        
    
        Male 7.35(3.91-10.79) 
        
    
      Point Female 5.96(3.06-8.86) 
        
    
        Male 2.60(0.50-4.70) 
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Frojd et al., 2007 
Finland Community 15-16 
3278 excellent 
2003 MDD NS/CDI Point Total 9.00(7.58-10.72) 
Frojd et al., 2007 
    17-18 
2070 average 
2005   NS/CDI     9.00(7.00-10.78) 
Goodwin et al., 2007 France Regional 65-99 
7869 average 
2000 MDD DSM4/MINI Point Female 2.30(1.68-2.92) 
        
    
        Male 0.70(0.28-1.12) 
Green et al., 2005 United 
Kingdom 
National 5-16 
7977 average 
2004 MDD ICD10/DAW
BA 
Point Female 1.10(0.62-1.58) 
        
    
        Male 0.60(0.26-0.94) 
Jenkins et al., 1997 United 
Kingdom 
National 16-65 
9792 average 
1993 MDD ICD10/CIS-R Point Female 2.70(2.30-3.10) 
        
    
        Male 1.80(1.40-2.20) 
Jylha et al., 2006 Finland Community 20-70 
441 poor 
2003 MDD NS/BDI Point Total 21.60(16.03-27.17) 
Kirby et al., 1997 Ireland Community 65-99 
1232 excellent 
1995 MDD DSM3/GMS Point Female 0.50(0.001-1.21) 
        
    
        Male 0.90(0.001-2.19) 
Kringlen et al., 2001 Norway National 18-65 
2066 poor 
1996 MDD DSM3R/CIDI 12 months Female 9.70(7.94-11.46) 
        
2066 poor 
        Male 4.10(2.92-5.28) 
Lepine et al., 1997 Belgium National 18-99 
8076 excellent 
1995 MDD + dep 
NOS 
DSM3R/MIN
I 
Point Female 7.90(6.70-9.10) 
  France National 15-99 
14517 excellent 
1995 MDD + dep 
NOS 
DSM/MINI Point Female 13.70(12.56-14.84) 
  Germany National 14-99 
16184 excellent 
1995 MDD + dep 
NOS 
DSM/MINI Point Female 6.60(5.83-7.37) 
  Netherlands National 16-99 
7811 excellent 
1995 MDD + dep 
NOS 
DSM/MINI Point Female 12.30(10.74-13.86) 
  Spain National 15-99 
16132 excellent 
1995 MDD + dep 
NOS 
DSM/MINI Point Female 9.80(8.86-10.74) 
  United 
Kingdom 
National 16-99 
15743 excellent 
1995 MDD + dep 
NOS 
DSM/MINI Point Female 12.70(11.68-13.72) 
  Belgium National 18-99 
8076 excellent 
1995 MDD + dep 
NOS 
DSM3R/MIN
I 
Point Male 5.10(4.12-6.08) 
  France National 15-99 
14517 excellent 
1995 MDD + dep 
NOS 
DSM/MINI Point Male 7.70(6.81-8.59) 
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 Lepine et al., 1997 Germany National 14-99 
16184 excellent 
1995 MDD + dep 
NOS 
DSM/MINI Point Male 4.60(3.93-5.27) 
  Netherlands National 16-99 
7811 excellent 
1995 MDD + dep 
NOS 
DSM/MINI Point Male 7.80(6.63-8.97) 
  Spain National 15-99 
16132 excellent 
1995 MDD + dep 
NOS 
DSM/MINI Point Male 5.60(4.87-6.33) 
  United 
Kingdom 
National 16-99 
15743 excellent 
1995 MDD + dep 
NOS 
DSM/MINI Point Male 10.30(9.28-11.32) 
Levav et al., 1993 Israel National 24-33 
4914 excellent 
1985 MDD + dep 
NOS 
RDC/SADS Point Female 5.18(2.97-7.39) 
        
    
        Male 4.55(1.69-7.41) 
        
    
      12 months Total 6.15(4.34-7.96) 
Meltzer et al., 2000 United 
Kingdom 
National 5-15 
10438 excellent 
1999 MDD ICD10/DAW
BA 
Point Female 0.70(0.37-1.03) 
        
    
        Male 0.60(0.30-0.90) 
Oldehinkel et al., 1999 Germany Community 14-17 
1395 excellent 
1996 MDD DSM4/CIDI 12 months Female 4.50(2.74-6.26) 
        
    
        Male 2.40(1.03-3.77) 
Pahkala et al., 1995 Finland Community 65-99 
1022 excellent 
1990 MDD DSM3R/Clini
cal IV 
Point Female 2.20(0.53-3.87) 
        
    
        Male 2.00(0.001-4.00) 
Pirkola et al., 2005 Finland National 30-99 
6005 excellent 
2001 MDD DSM4/CIDI 12 months Female 6.30(5.09-7.51) 
        
    
        Male 3.40(2.42-4.38) 
Ponizovsky and 
Grinshpoon, 2009 
Israel National 21-99 
4858 average 
2004 MDD DSM4/CIDI 12 months Total 5.76(4.81-6.71) 
Ritchie et al., 2004 France Community 65-99 
1863 excellent 
2000 MDD DSM4/MINI Point Female 4.00(2.90-5.20) 
        
    
        Male 1.80(0.90-2.80) 
Saunders et al., 1993 United 
Kingdom 
Community 65-99 
5222 excellent 
1990 MDD DSM3/GMS Point Female 3.14(0.55-5.73) 
        
    
        Male 2.55(0.85-4.24) 
Simon et al., 2002 France Community 18-64 
5447 average 
2002 MDD DSM4/CIDI Point Total 13.50(10.90-16.00) 
  Germany Community 18-64 
5447 average 
2002 MDD DSM4/CIDI Point Total 5.30(3.90-6.70) 
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 Simon et al., 2002 Germany Community 18-64 
5447 average 
2002 MDD DSM4/CIDI Point Total 9.90(6.60-13.10) 
  Greece Community 18-64 
5447 average 
2002 MDD DSM4/CIDI Point Total 7.30(4.60-9.90) 
  Italy Community 18-64 
5447 average 
2002 MDD DSM4/CIDI Point Total 4.60(2.90-6.30) 
  Netherlands Community 18-64 
5447 average 
2002 MDD DSM4/CIDI Point Total 14.40(11.30-17.60) 
  United 
Kingdom 
Community 18-64 
5447 average 
2002 MDD DSM4/CIDI Point Total 17.10(14.40-19.80) 
Singleton et al., 2001 United 
Kingdom 
National 16-74 
8580 average 
2000 MDD ICD10/CIS-R Point Female 2.80(2.08-3.52) 
  United 
Kingdom 
National 16-74 
8580 average 
2000 MDD ICD10/CIS-R Point Male 2.30(1.65-2.95) 
Stefansson et al., 1994 Iceland National 55-57 
862 average 
1988 MDD + dep 
NOS 
DSM3/DIS 12 months Female 6.90(3.39-10.41) 
        
    
        Male 3.60(1.08-6.12) 
        
    
      Point Female 5.10(2.05-8.15) 
        
    
        Male 2.10(0.16-4.04) 
Verhulst et al., 1997 Netherlands National 13-18 
2227 average 
1995 MDD DSM3R/DIS
C 
Point Total 0.40(0.001-0.99) 
Weissman et al., 1996 France Community 18-64 
1746 average 
1988 MDD DSM3/CIDI 12 months Total 4.50(3.23-5.77) 
  Germany Community 24-64 
481 average 
1981 MDD DSM3/CIDI 12 months Total 5.00(2.79-7.21) 
Europe, 
Central/Eastern 
      
    
            
Aluoja et al., 2004 Estonia National 15-79 
4677 average 
1997 MDD ICD10/EST-
Q 
Point Female 14.90(11.37-18.43) 
        
    
        Male 6.70(0.001-19.83) 
Bromet et al., 2005 Ukraine National 18-99 
4725 average 
2002 MDD DSM4/CIDI 12 months Female 11.34(9.71-12.97) 
        
    
        Male 4.87(3.93-5.81) 
        
    
      Point Female 6.60(5.33-7.87) 
        
    
        Male 2.61(1.94-3.28) 
Pakriev et al., 1998 Russian 
Federation 
Community 18-65 
855 excellent 
1995 MDD ICD10/CIDI 12 months Female 35.40(19.08-51.72) 
        
    
        Male 14.50(2.09-26.91) 
Andrade et al., 2003 Czech 
Republic 
National 18-79 
1534 average 
1999 MDD DSM4/CIDI Point Total 1.00(0.41-1.59) 
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Basoglu et al., 2005 Croatia Community 18-65 
256 excellent 
2001 MDD DSM4/SCID 12 months Total 11.00(5.45-16.55) 
        
    
      Point Total 10.00(4.67-15.33) 
Szadoczky et al., 1998 Hungary National 18-64 
2953 excellent 
1996 MDD DSM3R/DIS 12 months Female 9.02(5.30-11.80) 
        
    
        Male 5.79(2.50-8.10) 
        
    
      Point Female 3.15(1.40-5.70) 
        
    
        Male 1.68(0.50-4.40) 
Australasia       
    
            
Australian Bureau of 
Statistics, 2007 
Australia National 16-85 
8800 excellent 
2007 MDD ICD10/CIDI 12 months Female 5.2(4.28-5.92) 
        
    
        Male 3.10(2.27-3.93) 
Feehan et al., 1994 New Zealand Community 17-19 
930 excellent 
1991 MDD DSM3/DISC 12 months Total 13.30(11.10-15.90) 
        
    
      Point Total 3.40(2.30-4.80) 
Fergusson et al., 1993 New Zealand Community 15-15 
986 average 
1992 MDD DSM3R/DIS
C 
12 months Total 2.20(1.30-3.10) 
        
    
      Point Total 0.50(0.10-0.90) 
Hawthorne et al., 2008 Australia Regional 15-69 
3010 average 
1998 MDD DSM4/PRIM
E-MD 
Point Female 8.35(6.18-10.52) 
        
    
        Male 5.56(3.77-7.35) 
Hawthorne et al., 2008       
3015   
2004       Female 10.92(8.46-13.37) 
        
      
      Male 5.81(3.97-7.65) 
Kashani et al., 1983 New Zealand Community 9-9 
641 excellent 
1982 MDD DSM3/K-
SADS 
12 months Total 1.10(0.001-2.80) 
        
    
      Point Total 1.80(0.001-3.60) 
McGee et al., 1990 New Zealand Community 15-15 
943 excellent 
1988 MDD DSM3/DISC 12 months Total 1.90(1.00-2.80) 
        
    
      Point Total 1.20(0.50-1.90) 
Sawyer et al., 2007 Australia National 13-17 
1490 average 
1997 MDD DSM4/DISC 12 months Female 4.40(2.29-6.51) 
        
    
        Male 3.70(1.72-5.68) 
Wells et al., 2006 New Zealand National 16-99 
7435 average 
2004 MDD DSM4/CIDI 12 months Female 7.10(6.30-7.80) 
        
    
        Male 4.20(3.50-5.00) 
Wilhelm et al., 2003 Australia National 18-75 
10641 average 
1997 MDD ICD10/CIDI Point Female 4.20(3.61-4.79) 
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North America       
    
            
Andrade et al., 2003 Canada Regional 18-99 
6902 excellent 
1991 MDD DSM4/CIDI Point Total 1.90(1.31-2.49) 
Bland et al., 1988 Canada Regional 18-99 
3258 average 
1985 MDD DSM3/DIS Point Female 3.90(2.92-4.88) 
        
    
      Point Male 2.50(1.72-3.28) 
        
    
      12 months Female 5.90(4.72-7.08) 
        
    
      12 months Male 3.40(2.42-4.38) 
Blazer et al., 1994 United States 
of America 
National 15-54 
8098 excellent 
1991 MDD DSM3R/CIDI Point Female 5.90(4.72-7.08) 
        
    
        Male 3.80(2.82-4.78) 
Cohen et al., 1993 United States 
of America 
Regional 10-20 
776 average 
1985 MDD DSM3R/DIS
C 
Point Female 4.29(2.53-6.05) 
        
    
        Male 2.00(0.43-3.57) 
Costello et al., 1996 United States 
of America 
Regional 9-13 
4500 excellent 
1994 MDD DSM3R/CAP
A 
Point Total 1.11(0.67-1.55) 
Fleming et al., 1989 Canada Regional 6-16 
2852 excellent 
1983 MDD DSM3/CBCL Point Female 1.42(0.59-2.24) 
        
    
        Male 0.96(0.001-1.95) 
Garrison et al., 1992 United States 
of America 
Community 12-14 
3283 excellent 
1987 MDD DSM3/K-
SADS 
12 months Female 3.22(1.99-4.46) 
        
    
        Male 1.59(0.71-2.47) 
Gum et al., 2009 United States 
of America 
National 18-99 
9282 average 
2002 MDD DSM4/CIDI 12 months Female 8.50(7.72-9.28) 
        
    
        Male 4.70(4.11-5.29) 
Kessler and Walters, 
1998 
United States 
of America 
National 15-24 
1769 excellent 
1991 MDD DSM3R/CIDI 12 months Female 22.44(17.26-27.62) 
        
    
        Male 12.81(8.67-16.95) 
        
    
      Point Female 8.54(5.33-11.75) 
        
    
        Male 
4.75(2.28-7.21) 
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Kessler et al., 1993 United States 
of America 
National 25-54 
8098 excellent 
1991 MDD + dep 
NOS 
DSM3R/CIDI 12 months Female 11.81(9.26-14.36) 
        
    
        Male 
6.78(4.43-9.13) 
Lewinsohn et al., 1993 United States 
of America 
Regional 14-18 
1710 average 
1988 MDD DSM3R/K-
SADS 
Point Female 
3.37(2.19-4.55) 
  
          
  
  
  
  
Male 
1.71(0.83-2.59) 
      15-19 
1508 average 
1989 MDD DSM3R/SAD
S-LIFE 
Point Female 
3.58(2.31-4.85) 
        
    
    
  
  Male 
2.80(1.62-3.98) 
Mojtabai and Olfson, 
2004 
United States 
of America 
National 50-99 
9747 excellent 
1996 MDD DSM3R/CIDI 12 months Female 
8.50(7.80-9.30) 
        
    
        Male 4.10(3.50-4.70) 
Newman et al., 1998 Canada Regional 65-99 
1119 excellent 
1996 MDD DSM3/GMS Point Female 14.10(11.16-17.04) 
        
    
        Male 7.30(4.56-10.04) 
        
    
1994 MDD DSM4/GMS Point Total 0.86(0.27-1.45) 
Offord et al., 1996 Canada Regional 15-64 
8115 average 
1994 MDD DSM3R/CIDI 12 months Female 5.40(4.42-6.38) 
        
    
        Male 2.80(2.02-3.58) 
Patten, 2001 Canada National 12-99 
70538 average 
1997 MDD DSM4/CIDI 12 months Female 5.24(5.40-8.00) 
        
    
        Male 2.77(1.90-3.20) 
Patten et al., 2003 Canada Regional 18-99 
501 average 
2000 MDD DSM4/CIDI 12 months Female 13.20(9.10-17.30) 
        
    
        Male 7.40(4.20-10.60) 
Regier et al., 1988 United States 
of America 
Regional 18-99 
18571 average 
1982 MDD DSM3/DIS Point Female 2.90(2.51-3.29) 
        
    
        Male 1.60(1.21-1.99) 
Simon et al., 2002 United States 
of America 
Community 18-64 
5447 average 
2002 MDD DSM4/CIDI Point Total 6.40(4.60-8.20) 
South America       
    
            
Andrade et al., 2003 Mexico Community 18-54 
1734 average 
1995 MDD DSM3R/CIDI Point Total 2.20(1.02-3.38) 
Benjet et al., 2009 Mexico Community 12-17 
3005 average 
2005 MDD DSM4/CIDI 12 months Total 4.80(3.90-5.70) 
Kohn et al., 2005 Honduras Community 15-99 
800 excellent 
1999 MDD DSM4/Sx 
Scale 
Point Total 18.09(14.22-21.96) 
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Medina-Mora et al., 
2005 
Mexico National 18-65 
5826 average 
2002 MDD DSM4/CIDI 12 months Total 3.70(3.11-4.29) 
Slone et al., 2006 Mexico Regional 18-92 
2509 average 
2000 MDD DSM4/CIDI 12 months Female 7.60(6.20-9.00) 
        
    
        Male 4.30(3.10-5.50) 
        
    
      Point Female 5.70(4.50-6.90) 
        
    
        Male 3.30(2.20-4.40) 
Andrade et al., 2003 Chile Regional 15-99 
2978 excellent 
1996 MDD DSM3R/CIDI Point Total 3.30(2.52-4.08) 
Araya et al., 2001 Chile Community 16-64 
3870 excellent 
1997 MDD ICD10/CIS-R Point Female 8.00(6.50-9.80) 
        
    
        Male 2.70(1.40-5.10) 
Simon et al., 2002 Chile Community 18-64 
5447 average 
2002 MDD DSM4/CIDI Point Total 26.30(16.90-35.80) 
Andrade et al., 2002 Brazil Community 18-99 
1464 average 
1995 MDD ICD10/CIDI 12 months Female 9.20(7.04-11.36) 
        
    
        Male 4.30(2.54-6.06) 
        
    
      Point Female 5.40(4.22-6.58) 
        
    
        Male 3.20(1.44-4.96) 
Costa et al., 2007 Brazil Community 75-99 
392 excellent 
1999 MDD ICD10/SCAN Point Female 18.80(12.20-28.00) 
        
    
        Male 7.90(3.10-18.50) 
Fleitlich-Bilyk and 
Goodman, 2004 
Brazil Community 7-14 
1251 excellent 
2001 MDD DSM4/DAW
BA 
Point Total 1.00(0.20-1.90) 
Simon et al., 2002 Brazil Community 18-64 
5447 average 
2002 MDD DSM4/CIDI Point Total 18.30(14.20-22.30) 
Canino et al., 1987 Puerto Rico National 18-64 
1513 excellent 
1984 MDD DSM3/DIS Point Female 3.30(2.12-4.48) 
        
    
        Male 2.40(1.22-3.58) 
Canino et al., 2004 Puerto Rico National 4-17 
1897 excellent 
2000 MDD DSM4/DISC 12 months Total 3.00(2.00-4.50) 
Maharaj et al., 2008 Trinidad and 
Tobago 
Community 13-19 
1290 excellent 
2003 MDD DSM4/BDI Point Female 29.70(24.96-34.44) 
        
    
        Male 19.40(14.55-24.25) 
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Africa/Middle East       
    
            
Afifi et al., 2006 Oman National 14-20 
5409 excellent 
2004 MDD NS/CDI Point Female 19.40(17.22-21.58) 
        
    
        Male 14.70(12.78-16.62) 
Alhasnawi et al., 2009 Iraq National 18-99 
4332 excellent 
2007 MDD DSM4/CIDI 12 months Total 3.90(3.12-4.68) 
Al-Jawadi and Abdul-
Rhman, 2007 
Iraq Community 1-15 
3079 excellent 
2004 MDD DSM4/Dx IV Point Female 1.90(0.86-2.94) 
        
    
        Male 1.20(0.45-1.95) 
Andrade et al., 2003 Turkey National 18-54 
6095 average 
1996 MDD DSM3R/CIDI Point Total 3.10(2.32-3.88) 
Bostanci et al., 2005 Turkey Community 16-99 
504 excellent 
2000 MDD NS/BDI 12 months Female 23.60(15.24-31.96) 
        
    
        Male 28.00(20.59-35.41) 
Ghanem et al., 2009 Egypt National 18-65 
14640 excellent 
2003 MDD + dep 
NOS 
DSM4/MINI Point Total 5.22(4.70-5.74) 
Karam et al., 2006 Lebanon National 18-99 
2857 average 
2003 MDD DSM4/CIDI 12 months Total 4.90(3.53-6.27) 
Simon et al., 2002 Turkey Community 18-64 
5447 average 
2002 MDD DSM4/CIDI Point Total 10.70(7.70-13.70) 
Bolton et al., 2002 Rwanda Community 18-85 
368 excellent 
1999 MDD DSM4/HSCL Point Female 17.70(12.90-22.50) 
        
    
        Male 11.20(5.70-16.70) 
Bolton et al., 2004 Uganda Community 18-99 
368 excellent 
2000 MDD DSM4/HSCL Point Female 21.40(17.10-25.40) 
        
    
        Male 20.20(14.90-25.40) 
Kebede and Alem, 
1999 
Ethiopia Community 15-99 
10203 average 
1994 MDD ICD10/CIDI Point Female 3.40(1.39-5.41) 
        
    
        Male 1.40(0.19-2.61) 
Ovuga et al., 2005 Uganda Community 18-84 
939 excellent 
2003 MDD NS/BDI Point Female 24.50(17.56-31.44) 
        
    
        Male 13.90(9.98-17.82) 
Roberts et al., 2009 Sudan Community 18-99 
1242 excellent 
2007 MDD DSM/HSCL Point Female 58.73(55.19-62.18) 
        
    
        Male 40.85(36.69-45.14) 
Shaaban and Baashar, 
2003 
Sudan Community 12-19 
1107 excellent 
2005 MDD + dep 
NOS 
DSM4/PSE Point Female 12.90(10.04-15.76) 
Bhagwanjee et al., 
1998 
South Africa Community 18-99 
354 excellent 
1996 MDD DSM4/Clinic
al IV 
Point Total 4.80(1.57-8.03) 
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Hollifield et al., 1990 Lesotho Community 19-93 
356 average 
1987 MDD DSM3/DIS Point Female 14.50(7.76-21.24) 
        
    
        Male 8.80(1.90-15.70) 
Adewuya et al., 2006 Nigeria Community 15-41 
1206 excellent 
2004 MDD DSM4/MINI 12 months Total 2.70(1.37-4.03) 
Adewuya and Ologun, 
2006 
Nigeria Community 13-18 
1095 average 
    NS/BDI Point Total 9.00(6.54-11.46) 
Amoran et al., 2007 Nigeria Regional 15-99 
1105 excellent 
2004 MDD DSM4/SCID Point Female 5.70(3.19-8.21) 
        
    
        Male 4.80(1.82-7.78) 
Coleman,2006 Gambia Regional 15-54 
1348 average 
1999 MDD ICD10/PSE Point Female 10.30(8.30-12.70) 
Gureje,2006 Nigeria National 18-99 
1090 average 
2001 MDD DSM4/CIDI 12 months Total 1.00(0.80-1.20) 
Simon et al., 2002 Nigeria Community 18-64 
5447 average 
2002 MDD DSM4/CIDI Point Total 4.00(2.60-5.50) 
Uwakwe, 2000 Nigeria Community 60-99 
164 excellent 
1995 MDD DSM3/GMS Point Female 21.80(5.99-37.61) 
        
164 excellent 
    DSM3/GMS   Male 16.50(6.40-26.60) 
Asia, East/Southeast       
    
            
Chen et al., 2004 China Community 65-99 
1736 excellent 
2001 MDD DSM3/GMS Point Female 2.18(1.34-3.34) 
        
    
        Male 2.33(1.41-3.61) 
Chong et al., 2001 Taiwan Regional 65-99 
1350 excellent 
1997 MDD DSM3/GMS Point Total 5.90(4.70-7.30) 
Hwu et al., 1996 Taiwan National 18-99 
11004 excellent 
1984 MDD DSM3/DIS 12 months Female 1.30(0.86-1.74) 
        
    
        Male 0.60(0.31-0.89) 
Keqing et al., 2008 China Regional 18-95 
20716 excellent 
2005 MDD DSM4/SCID Point Female 3.15(2.82-3.48) 
        
    
        Male 2.25(1.96-2.53) 
Lu et al., 2008 China Regional 15-99 
5033 excellent 
2006 MDD DSM4/CIDI 12 months Female 1.47(1.01-1.93) 
        
    
        Male 0.75(0.41-1.09) 
        
    
      Point Female 1.13(0.72-1.54) 
        
    
        Male 0.62(0.31-0.93) 
Phillips et al., 2009 China Regional 18-99 
63004 excellent 
2003 MDD DSM4/SCID Point Female 2.6(2.28-2.97) 
        
    
        Male 1.55(1.29-1.85) 
Shen et al., 2006 China Regional 18-70 
5201 average 
2002 MDD DSM4/CIDI 12 months Total 2(1.412-2.588) 
Simon et al., 2002 China Community 18-64 
5447 average 
2002 MDD DSM4/CIDI Point Total 2.50(1.60-3.40) 
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Yang et al., 2004 Taiwan Community 12-16 
2440 excellent 
1999 MDD DSM4/K-
SADS 
Point Female 4.30(0-10.50) 
        
    
        Male 0.50(0-1.40) 
Vietnamese survey 
data, 2006 (personal 
correspondence from 
Prof Theo Vos) 
Vietnam National 0-99 78290 average 2006 MDD ICD10/MINI 12 months Female 3.68(3.41-3.95) 
        
    
        Male 1.22(1.06-1.38) 
Asia, South       
    
            
Lopes Cardozo et al., 
2005 
Afghanistan National 15-99 
699 excellent 
2002 MDD DSM4/HSCL Point Female 73.00(57.03-88.97) 
        
    
        Male 59(48.04-69.96) 
Nisar et al., 2004 Pakistan Community 18-99 
1200 excellent 
2000 MDD ICD10/MINI Point Female 7.50(5.34-9.66) 
Scholte et al., 2004 Afghanistan Regional 15-99 
1011 average 
2003 MDD DSM4/HSCL Point Female 58.4(54.2-62.6) 
        
    
        Male 16.1(12.8-19.4) 
Simon et al., 2002 India Community 18-64 
5447 average 
2002 MDD DSM4/CIDI Point Total 8.60(6.10-11.1) 
Srinath et al., 2005 India Community 4-16 
2064 excellent 
1998 MDD ICD10/DISC Point Total 0.10(0.001-0.33) 
Subedi et al., 2004 Nepal Community 50-99 
653 excellent 
1997 MDD DSM3R/Sx 
Scale 
Point Female 5.1(0.001-11.38) 
        
    
        Male 3.60(0.001-9.41) 
Asia Pacific, High 
Income 
      
    
            
Cho et al., 2007 Korea Regional 18-64 
6275 average 
2001 MDD DSM4/CIDI 12 months Female 2.50(1.72-3.28) 
        
    
        Male 0.80(0.21-1.39) 
Fones et al., 1998 Singapore Regional 13-65 
3020 average 
1996 MDD ICD10/CIDI 12 months Total 5.50(4.32-6.68) 
Ihara et al., 1998 Japan Community 65-99 
1965 excellent 
1993 MDD + dep 
NOS 
DSM3R/SCI
D 
Point Female 4.00(2.03-5.97) 
        
    
        Male 0.05(0.001-0.32) 
Kawakami et al., 2004 Japan Community 20-99 
1029 poor 
1998 MDD DSM3R/CIDI Point Female 1.40(0.01-2.79) 
        
    
        Male 0.90(0.001-2.16) 
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Kawakami et al., 2005 Japan Regional 20-99 
1664 poor 
2003 MDD DSM4/CIDI 12 months Total 2.90(2.10-3.70) 
Nakao et al., 2006 Japan Community 20-65 
1066 excellent 
2004 MDD + dep 
NOS 
DSM4/HAM-
D 
Point Total 11.50(8.72-14.28) 
Simon et al., 2002 Japan Community 18-64 
5447 average 
2002 MDD DSM4/CIDI Point Total 1.60(0.70-2.50) 
Weissman et al., 1996 Korea Regional 18-64 
5100 average 
1984 MDD DSM3/CIDI 12 months Total 2.30(1.87-2.73) 
Note. MDD: Major depressive disorder; dep NOS: depression not otherwise specified; DSM: Diagnostic and statistical manual of mental disorders; ICD: International Clarification 
of Diseases;  Clinical IV: Clinical interview; DIS: Diagnostic Interview Schedule; GMS: Geriatric Mental State Schedule; SADS: Schedule for Affective Disorders and 
Schizophrenia; MINI: Mini International Neuropsychiatric Interview; SCID: Structured Clinical Interview for DSM Disorders; BDI: Beck’s depression inventory: CAPA: The child 
and Adolescent Psychiatric Assessment; CBCL: Child Behaviour Checklist; CDI: Children’s Depression Inventory; CIDI: Composite International Diagnostic Interview; CIS-R: 
Revised clinical interview schedule; DAWBA: Development and Wellbeing Assessment; EST-Q: Emotional State Questionnaire, HAM-D: Hamilton Depression Rating Scale; HDL; 
Modified version of the global depression scale of the Health and Daily living Form; HSCL: Hopkins Symptoms Check List; PRIME-MD: Primary Care Evaluation of Mental 
Disorders; PSE: Present State Examination; SCAN: Schedule for Clinical Assessment in Neuropsychiatry; SPIKE: Semi-structured diagnostic instrument; Sx Scales: other symptom 
scales 
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Table S3. Summary of included studies for incidence 
 
Study Country Coverage Age range Cohort 
size 
Response 
rate 
Midyear Depression 
subtype 
Diagnostic 
criteria/tool 
Sex Annual 
incidence % 
(Standard 
error)  
North America                     
Patten, 2001 Canada National 12-99 70538 average 1997 MDD DSM4/CIDI Male 2.46 (0.04) 
                  Female 3.50 (0.04) 
Eaton et al., 1989 USA Regional 18-99 10861 average 1985 MDD DSM3/DIS Male 1.98(0.22) 
                  Female 1.59(0.57) 
Lewinsohn et al., 
1993 USA Regional 15-19 1508 average 1997 MDD 
DSM3R/SA
DS Male 4.53(0.82) 
Africa                 Female 7.14(1.05) 
Mogga et al., 2006 Ethiopia Regional 18-52 423 average 2000 MDD DSM4/CIDI Total 2.40(1.53) 
                      
Note. MDD: Major depressive disorder; dep NOS: depression not otherwise specified; DSM: Diagnostic and statistical manual of mental disorders; DIS: Diagnostic Interview 
Schedule; SADS: Schedule for Affective Disorders and Schizophrenia; CIDI: Composite International Diagnostic Interview 
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Table S4.  Table showing adjusted( adjusted for study level determinants) and unadjusted point 
prevalence  by region. 
 
 Unadjusted
a 
Adjusted(model 2)
b 
Region Prevalence  
(95% CI) 
Weight (%)
c 
Prevalence 
 (95% CI) 
Weight
c
 (%) 
North America (n=19) 4.2(3.5-5.2) 15.5 3.7(3.1-4.3) 14.5 
South America (n=13) 6.1(4.4-8.4) 9.5 4.0(3.5-4.7) 9.1 
Western Europe (n=33) 5.0(4.6-5.4) 36.4 4.7(4.2-5.1) 37.6 
Eastern/Central Europe (n=6) 6.7(4.6-9.9) 5.1 5.1(4.2-6.1) 5.5 
Australasia (n=9) 3.8(2.7-4.9) 7.4 4.1(2.9-5.7) 7.2 
Africa/Middle East (n=21) 8.6(5.8-12.8) 12.8 6.6(5.3-8.3) 12.1 
East/Southeast Asia (n=10) 1.8(1.4-2.3) 7.1 4.0(3.4-4.6) 7.0 
Asia South (n=6) 14.5(7.6-27.5) 2.9 8.6(5.2-14.0) 3.2 
Asia Pacific (n=8) 2.6(1.6-4.2) 3.4 5.6(4.2-7.4) 4.0 
All regions (n=125) 5.0(4.7-5.3) 100 4.7(4.4-5.0) 100 
Note. All I
2
 statistics >50%; n: number of studies in each group. 
a
Unadjusted results represent meta-analysis of reported 
prevalence estimates without countrolling for the effect of study-level variables.
 b
Adjusted model 2 results represent meta-
analysis of predicted prevalence estimates contolling for study-level variables. 
c
Random effects weights.  
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Appendix Three 
 
Supplementary text to Chapter Four 
 
Text S1. PRISMA checklist and flow diagram for the literature search to identify epidemiological data.  
This paper used data from an existing systematic review of the literature which has been published 
elsewhere (1-3).  The PRISMA checklist and flowchart (4), for this systematic review has been 
summarised below. 
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Section/topic  # Checklist item  Reported on page #  
TITLE  
 
Title  1 Identify the report as a systematic review, meta-analysis, or both.  N/A. This was reported in the specific review papers 
(1-3). 
ABSTRACT  
 
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions 
and implications of key findings; systematic review registration number.  
Page 2 
INTRODUCTION  
 
Rationale  3 Describe the rationale for the review in the context of what is already known.  Pages 3-4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
Pages 3-4 
METHODS  
 
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
N/A 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
Summary provided on pages 5-6 with more details in 
specific review papers (1-3). 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
Summary provided on page 5 with more details in 
specific review papers (1-3). 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
Summary provided on page 5 with more details in 
specific review paper (1-3). 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
Summary provided on pages 5-6 with more details in 
specific review papers (1-3). 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
Summary provided on pages 5-6 with more details in 
specific review papers (1-3). 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
Summary provided on pages 5-6 with more details in 
specific review papers  (1-3). 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
Strategies for adjusting study- and country-level 
sources of variability discussed on page 8 with 
additional analyses reported in the specific review 
papers (1-3). 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  Page 5  
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
Summary provided on pages 6-8 with more details in 
specific review papers  (1-3). 
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Section/topic  # Checklist item  Reported on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  
Strategies for adjusting study- and country-level 
sources of variability discussed on page 8 with 
additional analyses reported in the specific review 
papers (1-3). 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified.  
Pages 7-8 with additional analyses reported in specific 
review papers  (1-3). 
RESULTS  
 
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
Summary provided on pages 6-7 and figure 2, with 
more details in specific review papers (1-3). 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up 
period) and provide the citations.  
Summary provided on pages 5-6 with more details in 
specific review papers (1-3).   
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Results for adjusting study- and country-level sources 
of variability discussed on page 9 and figures 3-5. 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for 
each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Summarised in figure 2 with more details in specific 
review papers (1-3).   
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  Findings of Bayesian meta regression presented on 
pages 9-10 and figures 6-8. 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Results for adjusting study- and country-level sources 
of variability discussed on page 9 and figures 3-5. 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see 
Item 16]).  
Pages 9-10. 
DISCUSSION  
 
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
Pages 11-12  
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
Pages 12-13 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future 
research.  
Page 13 
FUNDING  
 
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of 
funders for the systematic review.  
See Section 8 of online submission entitled ‘Additional 
Information’ 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
doi:10.1371/journal.pmed1000097  
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PRISMA 2009 Flow Diagram 
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Additional records identified through other 
sources 
(n =  36) 
Records after duplicates removed 
(n =32615) 
Records screened 
(n =32615) 
Records excluded 
(n = 31643) 
 
 
Reaso 
Full-text articles assessed for 
eligibility 
(n = 972) Full-text articles excluded, 
(n =836) 
Main reasons for exclusion; 
 
 Only secondary data 
cited. 
 
 Incomplete reporting. 
 
 Epidemiological 
estimates not 
reported. 
 
 Sample not 
representative. 
 
 Only lifetime 
prevalence reported. 
 
 Clinical diagnostic 
criteria not used. 
 
 Study used the same 
sample as other 
studies. 
 
Studies included in qualitative 
synthesis 
(n = 136) 
Studies included in quantitative 
synthesis  
(n = 129) 
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Table S1. Raw and modelled prevalence output for all 21 GBD regions, by sex, 2010 
 
This table compares the modelled prevalence output to the raw prevalence data points for each 
GBD region. This assists in verifying the level consistency between DisMod-MR’s estimated 
prevalence and reported prevalence estimates obtained from the systematic review of the literature. 
 
As explained in chapter four, if no data were available for a particular region, then DisMod-MR 
relied on data points from neighbouring regions in the same GBD super-region to estimate 
prevalence. Table S1 also groups regions by super-regions so that modelled prevalence and data 
points can also be compared between regions in the same super region. 
 
Regional plots are presented separately for males and females, for 2010. In each plot, blue crosses 
show the individual, sex-specific data points available for that region, with the horizontal line 
showing the age range for the data point and the vertical line showing the range of uncertainty 
around the data point. The dotted line shows prevalence output from stage 1 of the modelling 
process. This is the line of best fit based on data for that parameter only. The numerous blue vertical 
lines show uncertainty around stage 1 estimates. The solid blue line shows output from stage 2 of 
the modelling process. This is the line of best fit based on data from all parameters and represents 
the final output for that parameter. The grey area shows uncertainty around stage 2 estimates. The 
solid red line represents ages below the minimum age of onset applied.  
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High income 
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Sub-Saharan Africa 
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Note. Prevalence interpreted as a proportion where 0.01 equates to 1% 
 
Figure S1. Regional point prevalence of MDD by age and sex, 1990 
  
 187 
 
 
  
Note. Prevalence interpreted as a proportion where 0.01 equates to 1% 
 
Figure S2. Regional point prevalence of MDD by age and sex, 2005 
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Appendix Four 
 
Supplementary text to Chapter Five 
 
 
GBD 2010 publications hierarchy
Level 1 papers
Papers presenting DALYs, YLDs, YLLs simultaneously for all 291 diseases and injuries 
Level 2 papers
Paper presenting DALYs, YLDs and YLLs for mental and 
substance use disorders as a group 
Level 3 papers
Papers presenting DALYs, YLDs, YLLs 
for individual mental and substance use 
disorders 
(E.g. current paper)
 
 
Figure S1: Illustration of the GBD 2010 publications hierarchy 
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Plot 1: World map showing age-standardised YLD rates (per 100,000) by country 
 
Plot 2: World map marking countries with statistically higher or lower YLD rates compared to the global mean 
 
Note. YLD: years lived with disability; Low: statistically lower YLD rates compared to global mean; Middle: YLD rates 
not statistically different to global mean; High: statistically higher YLD rates compared to global mean. 
 
Figure S2. YLD rates (per 100,000) by country for depressive disorders in 1990 
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Table S1: Summary of epidemiological data obtained from the systematic review of the literature and included in the DisMod-MR modelling 
of major depressive disorder and dysthymia.  
 Major depressive disorder Dysthymia 
Region Studies Number of estimates Studies Number of estimates 
Prevalence Incidence Duration Excess-
mortality 
Prevalence Incidence Remission Excess-
mortality 
Asia Pacific, High Income [1-8] 15 - - - [1-8] 12 - - - 
Asia, Central - - - - - - - - - - 
Asia, East [6,9-16] 59 - - - [9-12] 19 - - - 
Asia, South [6,17,18 ,19 ] 6 - - - - - - - - 
Asia, Southeast [20] 16 - - - - - - - - 
Australasia [21-30] 41 - - 1 [21-30] 13 - - - 
Caribbean [31,32] 6 - - - [31,32] 1 - - - 
Europe, Central [33-35] 23 - - - - - - - - 
Europe, Eastern [36-38] 13 - - - [36-38] 6 - - - 
Europe, Western [6,7,35,39-74] 170 - 1 6 [50,57,61-67,75,76]  35 - 2 0 
Latin America, Andean - - - - - - - - - - 
Latin America, Central [35,77-80] 8 - - - [79,80] 2 - - - 
Latin America, Southern [6,35,81] 4 - - - - - - - - 
Latin America, Tropical [6,82-84] 11 - - - [6,82-84] 8 - - - 
North Africa/Middle East [6,35,85-92] 22 - - - {[6,35,85-92] 3 - - - 
North America, High Income [6,35,93-116] 122 18 4 6 [94,99,100,102,104,
111,117] 
38 3 1 - 
Oceania - - - - - - - - - - 
Sub-Saharan Africa, Central - - - - - - - - - - 
Sub-Saharan Africa, East [118-123] 9 1 - 1 [118-123] 2 - - - 
Sub-Saharan Africa, 
Southern 
[124,125] 3 - - - [125] 1 - - - 
Sub-Saharan Africa, West [6,126-130] 16 - - - [126] 1 - - - 
Note. Some studies reported more than one estimate
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Table S2: Age standardised point prevalence (%) by region and country for major depressive 
disorder(MDD)  and dysthymia in 2010. 
 MDD Dysthymia 
Region Country Prevalence 
95% uncertainty 
interval 
Prevalence 
95% uncertainty 
interval 
Caribbean 5.16% 4.29% 6.21% 1.54% 1.41% 1.71% 
 
St Lucia 4.25% 2.82% 6.02% 1.54% 1.31% 1.81% 
 
Suriname 5.37% 3.54% 7.78% 1.54% 1.31% 1.80% 
 
Trinidad and Tobago 5.50% 3.64% 7.78% 1.56% 1.31% 1.84% 
 
Saint Vincent and 
Grenadines 5.36% 3.66% 7.53% 1.53% 1.30% 1.80% 
Europe, Central 4.09% 3.51% 4.79% 1.62% 1.48% 1.77% 
 
Albania 5.17% 3.48% 7.45% 1.62% 1.37% 1.90% 
 
Bulgaria 4.58% 3.09% 6.54% 1.62% 1.34% 1.92% 
 
Bosnia & Herzegovina 3.56% 2.47% 5.17% 1.61% 1.35% 1.88% 
 
Czech Republic 3.23% 2.28% 4.36% 1.61% 1.36% 1.91% 
 
Croatia 7.06% 5.06% 9.67% 1.62% 1.38% 1.92% 
 
Hungary 3.31% 2.59% 4.13% 1.62% 1.38% 1.92% 
 
Poland 3.91% 2.70% 5.56% 1.62% 1.36% 1.90% 
 
Romania 4.28% 2.99% 5.99% 1.61% 1.36% 1.88% 
 
Serbia 4.01% 2.68% 5.76% 1.62% 1.36% 1.90% 
 
Slovak Republic 3.60% 2.44% 5.13% 1.62% 1.38% 1.91% 
 
Slovenia 4.52% 3.02% 6.56% 1.62% 1.39% 1.92% 
 
Macedonia 5.23% 3.57% 7.56% 1.62% 1.35% 1.93% 
 
Montenegro 6.02% 3.90% 9.07% 1.61% 1.36% 1.90% 
Europe, Eastern 5.88% 4.51% 7.63% 1.59% 1.50% 1.70% 
 
Belarus 6.56% 4.42% 9.49% 1.60% 1.35% 1.87% 
 
Estonia 6.75% 5.15% 8.79% 1.61% 1.36% 1.90% 
 
Lithuania 4.79% 3.27% 6.53% 1.60% 1.36% 1.89% 
 
Latvia 6.21% 4.21% 9.06% 1.61% 1.35% 1.87% 
 
Moldova 4.39% 2.87% 6.50% 1.60% 1.36% 1.89% 
 
Russian Federation 6.52% 4.67% 9.05% 1.59% 1.47% 1.71% 
 
Ukraine 3.91% 2.98% 5.15% 1.61% 1.50% 1.73% 
Europe, Western 4.66% 4.28% 5.05% 1.49% 1.40% 1.58% 
 
Andorra 6.49% 4.15% 9.63% 1.51% 1.29% 1.81% 
 
Austria 5.01% 3.42% 7.37% 1.51% 1.29% 1.77% 
 
Belgium 3.98% 3.10% 5.04% 1.51% 1.28% 1.77% 
 
Switzerland 6.16% 4.26% 8.76% 1.50% 1.37% 1.64% 
 
Cyprus 5.75% 3.89% 8.21% 1.51% 1.28% 1.77% 
 
Germany 4.85% 4.05% 5.81% 1.52% 1.39% 1.65% 
 
Denmark 5.07% 3.45% 7.28% 1.50% 1.28% 1.77% 
 
Spain 4.33% 3.50% 5.26% 1.48% 1.35% 1.62% 
 
Finland 5.98% 4.91% 7.15% 1.65% 1.51% 1.79% 
 
France 4.80% 4.03% 5.65% 1.47% 1.35% 1.60% 
 
United Kingdom 3.12% 2.70% 3.58% 1.47% 1.34% 1.62% 
 
Greece 4.87% 3.56% 6.57% 1.51% 1.27% 1.77% 
 
Ireland 4.05% 3.28% 4.92% 1.49% 1.36% 1.61% 
 
Iceland 4.74% 3.33% 6.36% 1.50% 1.27% 1.77% 
 
Israel 4.58% 3.49% 5.73% 1.50% 1.30% 1.74% 
 
Italy 4.84% 3.97% 5.89% 1.46% 1.33% 1.59% 
 
Luxembourg 6.55% 4.24% 9.59% 1.51% 1.27% 1.77% 
 
Malta 6.58% 4.28% 9.68% 1.50% 1.26% 1.78% 
 
Netherlands 8.03% 6.69% 9.55% 1.47% 1.35% 1.60% 
 
Norway 5.94% 4.63% 7.57% 1.47% 1.35% 1.60% 
 
Portugal 4.32% 2.98% 6.11% 1.51% 1.28% 1.77% 
 
Sweden 4.76% 3.31% 6.75% 1.50% 1.26% 1.75% 
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 MDD Dysthymia 
Region Country Prevalence 
95% uncertainty 
interval 
Prevalence 
95% uncertainty 
interval 
Latin America, Andean 4.58% 3.60% 5.81% 1.54% 1.38% 1.71% 
 
Bolivia 3.94% 2.73% 5.86% 1.55% 1.32% 1.82% 
 
Ecuador 4.38% 3.04% 6.26% 1.54% 1.31% 1.81% 
 
Peru 4.89% 3.36% 7.06% 1.53% 1.29% 1.79% 
Latin America, Central 4.40% 3.76% 5.15% 1.50% 1.41% 1.61% 
 
Colombia 6.31% 4.27% 9.02% 1.51% 1.29% 1.77% 
 
Costa Rica 4.68% 3.15% 6.48% 1.49% 1.27% 1.74% 
 
Guatemala 5.35% 3.65% 7.56% 1.51% 1.28% 1.79% 
 
Honduras 9.22% 6.83% 12.23% 1.50% 1.28% 1.77% 
 
Mexico 2.96% 2.30% 3.78% 1.50% 1.42% 1.58% 
 
Nicaragua 5.15% 3.53% 7.51% 1.51% 1.28% 1.77% 
 
Panama 4.66% 3.13% 6.70% 1.50% 1.27% 1.76% 
 
El Salvador 5.38% 3.67% 7.66% 1.52% 1.30% 1.80% 
 
Venezuela 5.06% 3.48% 7.07% 1.51% 1.27% 1.77% 
Latin America, Southern 4.80% 3.65% 6.37% 1.52% 1.35% 1.71% 
 
Argentina 5.16% 3.57% 7.40% 1.53% 1.29% 1.77% 
 
Chile 3.99% 3.01% 5.19% 1.51% 1.29% 1.76% 
 
Uruguay 4.65% 3.22% 6.62% 1.52% 1.29% 1.82% 
Latin America, Tropical 5.50% 4.39% 6.82% 1.53% 1.44% 1.62% 
 
Brazil 5.47% 4.34% 6.87% 1.53% 1.44% 1.62% 
 
Paraguay 6.39% 4.16% 9.63% 1.53% 1.30% 1.77% 
North Africa/Middle East 7.35% 6.54% 8.23% 1.53% 1.44% 1.62% 
 
Afghanistan 22.50% 17.38% 29.32% 1.46% 1.23% 1.73% 
 
United Arab Emirates 8.12% 5.45% 11.54% 1.36% 1.15% 1.62% 
 
Bahrain 8.62% 5.88% 12.12% 1.42% 1.20% 1.65% 
 
Algeria 7.34% 5.12% 10.35% 1.47% 1.25% 1.73% 
 
Egypt 5.29% 3.91% 7.13% 1.47% 1.35% 1.59% 
 
Iran (Islamic Republic of) 7.00% 4.97% 9.90% 1.47% 1.24% 1.74% 
 
Iraq 4.48% 3.42% 5.81% 1.46% 1.35% 1.59% 
 
Jordan 7.73% 5.24% 10.97% 1.47% 1.25% 1.71% 
 
Kuwait 7.51% 5.11% 10.72% 1.42% 1.21% 1.67% 
 
Lebanon 5.27% 3.90% 7.06% 1.49% 1.37% 1.61% 
 
Libya 9.27% 6.13% 13.42% 1.47% 1.26% 1.72% 
 
Morocco 6.85% 4.72% 9.60% 1.48% 1.25% 1.73% 
 
Oman 5.25% 3.77% 7.03% 1.42% 1.21% 1.64% 
 
Occupied Palestinian Territory 9.01% 6.01% 13.31% 1.47% 1.24% 1.74% 
 
Qatar 7.99% 5.31% 11.78% 1.35% 1.15% 1.58% 
 
Saudi Arabia 5.90% 4.10% 8.30% 1.43% 1.21% 1.68% 
 
Syrian Arab Republic 7.02% 4.57% 10.26% 1.47% 1.26% 1.72% 
 
Tunisia 7.07% 4.71% 10.48% 1.47% 1.24% 1.73% 
 
Turkey 6.74% 5.32% 8.54% 1.47% 1.24% 1.72% 
 
Yemen 7.11% 4.89% 9.96% 1.47% 1.25% 1.73% 
North America, High Income 4.44% 3.76% 5.21% 1.57% 1.46% 1.69% 
 
Canada 4.35% 3.62% 5.22% 1.59% 1.48% 1.72% 
 
United States 4.45% 3.71% 5.34% 1.57% 1.45% 1.69% 
Oceania 4.72% 3.50% 6.31% 1.62% 1.43% 1.85% 
 
Fiji 3.46% 2.26% 5.07% 1.61% 1.36% 1.89% 
 
Micronesia (Fed. States of) 4.36% 2.96% 6.21% 1.62% 1.38% 1.91% 
 
Kiribati 5.73% 3.79% 8.57% 1.62% 1.37% 1.90% 
 
Marshall Islands 5.71% 3.80% 8.25% 1.62% 1.37% 1.91% 
 
Papua New Guinea 5.02% 3.41% 7.14% 1.63% 1.38% 1.90% 
 
Solomon Islands 3.44% 2.25% 5.05% 1.61% 1.36% 1.91% 
 
Tonga 4.43% 3.08% 6.42% 1.63% 1.37% 1.91% 
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 MDD Dysthymia 
Region Country Prevalence 
95% uncertainty 
interval 
Prevalence 
95% uncertainty 
interval 
Oceania  4.72% 3.50% 6.31% 1.62% 1.43% 1.85% 
 
Vanuatu 4.40% 2.94% 6.25% 1.61% 1.37% 1.92% 
 
Samoa 4.37% 2.94% 6.47% 1.62% 1.37% 1.91% 
Sub-Saharan Africa, Central 5.70% 4.41% 7.31% 1.59% 1.42% 1.78% 
 
Angola 5.03% 3.41% 7.09% 1.59% 1.35% 1.87% 
 
CAF 5.71% 3.92% 8.53% 1.58% 1.34% 1.86% 
 
Congo, Dem. Rep. 5.79% 3.97% 8.15% 1.59% 1.35% 1.85% 
 
Congo 6.45% 4.45% 9.21% 1.58% 1.35% 1.84% 
 
Gabon 7.20% 4.93% 10.31% 1.58% 1.34% 1.87% 
 
Equatorial Guinea 7.05% 4.79% 10.32% 1.57% 1.33% 1.84% 
Sub-Saharan Africa, East 5.43% 4.81% 6.16% 1.56% 1.46% 1.66% 
 
Burundi 6.06% 4.25% 8.53% 1.57% 1.33% 1.87% 
 
Comoros 5.78% 3.94% 8.40% 1.56% 1.32% 1.84% 
 
Djibouti 6.70% 4.58% 9.62% 1.57% 1.34% 1.83% 
 
Eritrea 6.61% 4.51% 9.73% 1.58% 1.33% 1.86% 
 
Ethiopia 3.61% 2.65% 4.75% 1.56% 1.47% 1.64% 
 
Kenya 5.15% 3.61% 7.22% 1.56% 1.31% 1.85% 
 
Madagascar 5.11% 3.54% 7.39% 1.57% 1.33% 1.85% 
 
Mozambique 4.58% 3.03% 6.51% 1.58% 1.34% 1.86% 
 
Malawi 5.77% 3.85% 8.41% 1.56% 1.32% 1.87% 
 
Rwanda 7.31% 5.43% 9.77% 1.57% 1.31% 1.83% 
 
Sudan 7.09% 5.19% 9.38% 1.56% 1.33% 1.82% 
 
Somalia 6.34% 4.40% 9.08% 1.56% 1.31% 1.82% 
 
Tanzania 6.35% 4.32% 9.25% 1.57% 1.33% 1.82% 
 
Uganda 6.35% 4.84% 8.31% 1.56% 1.33% 1.82% 
 
Zambia 5.80% 3.86% 8.65% 1.57% 1.34% 1.84% 
Sub-Saharan Africa, Southern 5.01% 3.96% 6.33% 1.59% 1.49% 1.69% 
 
Botswana 7.42% 4.78% 10.90% 1.59% 1.35% 1.87% 
 
Lesotho 6.28% 4.38% 8.79% 1.61% 1.36% 1.88% 
 
Namibia 5.00% 3.38% 7.16% 1.60% 1.34% 1.87% 
 
Swaziland 5.76% 3.79% 8.47% 1.61% 1.36% 1.87% 
 
South Africa 4.55% 3.38% 6.06% 1.59% 1.50% 1.68% 
 
Zimbabwe 6.50% 4.35% 9.54% 1.60% 1.34% 1.89% 
Sub-Saharan Africa, West 4.18% 3.69% 4.72% 1.53% 1.44% 1.62% 
 
Benin 3.92% 2.61% 5.69% 1.54% 1.30% 1.80% 
 
Burkina Faso 3.95% 2.58% 5.93% 1.55% 1.32% 1.83% 
 
Cote d'Ivoire 5.05% 3.45% 7.16% 1.52% 1.30% 1.78% 
 
Cameroon 4.39% 2.99% 6.24% 1.53% 1.28% 1.80% 
 
Cape Verde 5.02% 3.32% 7.58% 1.54% 1.30% 1.80% 
 
Ghana 4.38% 2.93% 6.30% 1.52% 1.28% 1.79% 
 
Guinea 4.45% 3.07% 6.13% 1.53% 1.31% 1.81% 
 
Gambia 5.07% 3.66% 6.87% 1.54% 1.30% 1.82% 
 
Guinea-Bissau 3.91% 2.53% 5.62% 1.53% 1.30% 1.81% 
 
Liberia 4.60% 3.11% 6.65% 1.54% 1.30% 1.80% 
 
Mali 5.72% 3.79% 8.35% 1.54% 1.31% 1.81% 
 
Mauritania 4.99% 3.48% 7.01% 1.54% 1.31% 1.80% 
 
Niger 4.38% 3.08% 6.20% 1.53% 1.30% 1.79% 
 
Nigeria 3.69% 2.95% 4.65% 1.52% 1.44% 1.61% 
 
Senegal 4.47% 3.01% 6.38% 1.54% 1.30% 1.81% 
 
Sierra Leone 5.65% 3.90% 8.01% 1.54% 1.31% 1.80% 
 
Sao Tome and Principe 6.51% 4.35% 9.46% 1.54% 1.32% 1.82% 
 
Chad 5.16% 3.49% 7.32% 1.54% 1.30% 1.80% 
 
Togo 4.49% 3.10% 6.23% 1.54% 1.30% 1.80% 
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Table S3. Regional DALY and YLD rankings with 95% uncertainty intervals for depressive disorders in 1990 
 
  
  
YLDs DALYs 
MDD Dysthymia MDD Dysthymia 
Order  Mean Rank 
(95% UI) 
Order  Mean Rank 
(95% UI) 
Order  Mean Rank 
(95% UI) 
Order 
  
Mean Rank 
(95% UI) 
Global 2 2.2 (1-3) 19 19.5 (12-27) 15 15.2 (11-18) 59 58.6 (48-69.5) 
Asia Pacific, High Income 4 3.2 (2-5) 20 19.3 (13-27) 10 10.0 (6-15.5) 37 37.8 (29-51) 
Asia Central 2 1.8 (1-3) 20 20.4 (14-28.5) 10 10.2 (8-13) 49 49.2 (40-62) 
Asia East 2 2.0 (1-3) 20 17.3 (9-24) 12 12.6 (6-19.5) 44 42.2 (30.5-55) 
Asia South 3 3.1 (2-4) 24 23 (13-34) 20 20.4 (13-27) 62 61.7 (48.5-79) 
Asia Southeast 2 1.8 (1-3) 18 19 (10-30) 11 10.8 (6-16.5) 50 51.5 (43-64) 
Australasia 2 2.8 (2-7) 21 20.3 (14-27) 7 8.2 (5-15) 37 37.6 (25.5-52) 
Caribbean 2 1.6 (1-3) 23 22.1 (15-29) 7 10 (7-15) 58 55.5 (43-66) 
Europe Central 2 2.0 (2-2) 21 19.6 (14-26.5) 7 6.7 (4-10) 46 43.6 (30-57) 
Europe Eastern 2 1.7 (1-2) 20 19.4 (14-26.5) 5 5.3 (3-9) 46 45.6 (36-58) 
 Europe Western 2 2.1 (2-3) 20 20.0 (14-26) 5 5.2 (4-8.5) 37 38.5 (29-54) 
Latin America, Andean 1 1.6 (1-3) 24 23.2 (16-32) 10 10.3 (5-16) 50 50.6 (42-65) 
Latin America, Central 1 1.1 (1-2) 20 20.2 (13-30) 8 8.4 (5-12) 48 46.6 (37-59) 
Latin America, Southern 2 1.6 (1-3) 19 20.6 (14-28) 7 5.9 (3-9) 49 50.5 (38-63) 
 Latin America, Tropical 2 1.8 (1-3) 22 21.0 (13-28) 10 9.7 (7-13) 47 47.6 (40-58) 
North Africa/Middle East 2 1.9 (1-3) 23 22.3 (16-31) 8 8.4 (7-10) 53 53.7 (43-68) 
North America, High Income 2 2.7 (1-5) 20 19.4 (13-27) 8 7.5 (3-11) 39 39.3 (31-50) 
Oceania 2 2.0 (1-4) 25 23.7 (16-34) 17 18.7 (10-28) 65 64.5 (53-77) 
Sub-Saharan Africa, Central 2 2.0 (1-3) 30 28.5 (18-38) 22 22.1 (16-27) 70 67.2 (56-80) 
Sub-Saharan Africa, East 2 2.2 (1-3) 23 23.9 (16-37) 21 21.1 (17-26) 66 66.4 (54-81.5) 
Sub-Saharan Africa Southern 2 2.0 (1-4) 23 23.1 (14-34) 11 12.2 (7-18) 55 55.1 (45-69) 
Sub-Saharan Africa, West 3 2.8 (2-4) 29 26.9 (18-36) 24 23.0 (17-27) 69 66.2 (55-78) 
Note. YLDs: years lived with disability; DALYs: Disability adjusted life years; MDD: Major depressive disorder; 95% UI: 95% uncertainty interval; Mean Rank: YLD and DALY 
ranks were estimated for MDD and dysthymia then simulated 1000 times to estimate 95% uncertainty ranges. The 95% bounds of uncertainty represent the 25
th
 and 975
th
 value of 
the 1000 draws; Order: Regional YLDs and DALYs for MDD and dysthymia were ordered by their mean rank across 1000 draws.  
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Appendix Five 
 
Supplementary text to Chapter Six 
 
Text S1. PRISMA checklist and flow diagram for the literature search to identify relative-risk estimates                   
                                                                                                                                                       
We used data sources from recent and methodologically comparable systematic reviews of the 
association between suicide and mental and substance use disorders (1-5), specifically affective 
disorders, anxiety disorders, schizophrenia (3), cocaine, opioid, and amphetamine dependence (1, 2, 4) 
and alcohol dependence (5).  We expanded the Li and collaborators systematic review and replicated 
the literature search (3) to collect data for bipolar disorder and MDD separately (rather than affective 
disorders combined), and anorexia nervosa which was not included in the original review. 
The PRISMA checklist and flowchart (6), for this literature search have been summarised below. The 
information presented amalgamate the search for data previously reported (1-5), as well as the 
expansion of the Li and collaborators systematic review (3) to collect data for bipolar disorder and 
MDD separately. 
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Section/topic  # Checklist item  Reported on page #  
TITLE  
 
Title  1 Identify the report as a systematic review, meta-analysis, or both.  N/A. This was reported in the specific review papers 
(1-5). 
ABSTRACT  
 
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions 
and implications of key findings; systematic review registration number.  
Page 2 
INTRODUCTION  
 
Rationale  3 Describe the rationale for the review in the context of what is already known.  Pages 3-4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
Pages 3-4 
METHODS  
 
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
N/A 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
Summary provided on pages 5-6 with more details in 
specific review papers (1-5). 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
Summary provided on page 6 with more details in Text 
S1 and the specific review papers (1-5). 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
Summary provided on page 6 with more details in the 
specific review papers (1-5). 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
Pages 5-6 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
Summary provided on page 6 with more details in 
Table S1 and the specific review papers (1-5). 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
Summary provided on pages 5-6 with more details in 
Table S1. 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
Strategies for adjusting study- and country-level 
sources of variability  through (1) the quality-effects 
model  and (2)  ceiling values for joint population 
attributable fractions discussed on pages  6-8 with more 
details in Tables S1, S2, S3, S4 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  Page 5 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
Pages 5, 6, 9 
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Section/topic  # Checklist item  Reported on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  
Strategies for adjusting study- and country-level 
sources of variability through (1) the quality-effects 
model and (2) ceiling values for joint population 
attributable fractions discussed on pages 6-8 with more 
details in Tables S1, S2, S3, S4. More strategies for 
addressing publication bias and selective reporting 
were presented in the specific review papers (1-5) 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified.  
Pages 6-7 discuss the sex-, region, and disorder-
specific analyses conducted. As-well as sensitivity 
analyses around the type of model used to pool 
estimates in the meta-analysis. 
RESULTS  
 
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
Summary provided on pages 9-10, Table S1, with a 
literature search flow diagram in Text S1.  
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up 
period) and provide the citations.  
Summary provided on pages 9-10 with more detail in 
Table S1. 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Pages 9-10, Tables S2 and S4 compare findings of the 
meta-analysis conducted using random- and quality-
effects models. 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for 
each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Pages 9-10, and Tables 1, S1, S2, S3, S4 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  Pages 9-10, and Tables 1, S1, S2, S3, S4 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Assessments for adjusting study- and country-level 
sources of variability through (1) the quality-effects 
model and (2) ceiling values for joint population 
attributable fractions presented in Tables S1, S2, S3, 
S4. More strategies for addressing publication bias and 
selective reporting were presented in specific review 
papers (1-5) 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see 
Item 16]).  
Assessments of findings by sex-, region, and disorder  
presented in Pages 9-10, Tables 1, S2, S4 
DISCUSSION  
 
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
Pages 12-15 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
Pages 14-15 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future 
research.  
Page 12-14 
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FUNDING  
 
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of 
funders for the systematic review.  
Funding information providing in the ‘Additional 
Information’ section of PloS One’s online submission 
form. 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
doi:10.1371/journal.pmed1000097 
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PRISMA 2009 Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through database 
searching  
(n = 7872) 
Sc
re
en
in
g 
In
cl
u
d
ed
 
El
ig
ib
ili
ty
 
Id
en
ti
fi
ca
ti
o
n
 
Additional records identified through other 
sources  
(n = 117) 
Records after duplicates removed  
(n =7989) 
Records screened  
(n =7989) 
Records excluded  
(n = 7504) 
 
 
Reaso 
Full-text articles assessed for 
eligibility  
(n = 485) Full-text articles excluded,  
(n = 430) 
Main reasons for exclusion; 
 
. Only secondary data cited. 
 
. Incomplete data to assess 
methodological quality 
 
. Effect-size not reported or insufficient 
data to estimate effect-size.  
 
. Sampling strategy or study type not 
representative. 
 
. Clinical diagnostic criteria not used. 
Studies included in qualitative 
synthesis  
(n = 55) 
Studies included in quantitative synthesis for 
mental disorders  
(n = depression: 4; anxiety disorder: 7; bipolar 
disorder: 4; schizophrenia: 4; anorexia nervosa: 
9) 
 
Studies included in 
quantitative synthesis for 
illicit drug use dependence  
(n = opioid: 21; cocaine: 3; 
amphetamine: 1) 
 
Studies included in quantitative 
synthesis for alcohol dependence  
(n = 12) 
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Table S1: Summary of studies reporting the relative-risk of suicide in those with mental and substance use disorders. 
 
Data source Country Disorder  Age Range  
(years) 
Epoch Range Sexa Relative-risk 
(95% UI) 
Quality 
score/1c 
Mental disorders        
Shaffer et al., 1996 [1] USA Major Depression 
Bipolar disorder                    
Anxiety disorders 
                             
0-19 
                       
 
1984-1986 
                               
 
M                          
F                          
M                           
F                                                    
M                 
F                          
16.1 (2.0-128.1)                                                     
- 
-                          
1.6 (0.1-26.5)                  
2.6 (1.1-6.0)               
0.7 (0.2-3.3) 
0.8 
Lesage et al., 1994 [2] Canada Major depression 
Major depression with psychotic features 
Bipolar disorder 
Bipolar NOS 
Depression NOS 
Generalized anxiety disorder 
Panic Disorder 
Agoraphobia 
Obsessive compulsive disorder 
Social phobia 
Somatoform disorder 
Anxiety NOS 
Schizophrenia 
Schizoaffective disorder  
Schizophrenia NOS 
18-35 1987-1989 M  
M 
 
M 
M 
M 
M 
                             
M 
M 
M 
                                                                                       
M 
M 
                              
M 
M                                         
M 
M                             
M 
11.2 (3.7-33.9) 
- 
 
1.0 (0.2-5.1) 
1 (0.1-16.3) 
- 
3.1 (0.3-30.3) 
                                  
- 
- 
2.0 (0.2-22.8) 
 
1.0 (0.1-16.3) 
2.0 (0.2-22.8) 
                             
3.1 (0.3-30.3) 
1.4 (0.3-6.3)                                  
- 
-
- 
0.6 
Waern et al., 2002 [2] Sweden Major depression 
Minor depression 
Anxiety disorders 
                                
65-99 1994-1996 M                              
F 
M                       
F 
M                        
F   
34.4 (7.5-157.1)               
28.7 (6.2-134.1) 
5.7 (1.4-22.6)                     
- 
2.6 (0.5-12.0)                        
6.6 (1.7-26.1) 
0.8 
Dutta et al., 2007 [3] United Kingdom Bipolar I disorder 16-99 1965-1999 M 
F 
12.76(5.13-26.29) 
4.27(0.11-23.78) 
0.9 
Brent et al., 1999 [4] USA Anxiety disorders 
                               
13-19 
                
1989-1994  M                         
F 
13.0 (1.7-100.2)           
2.8 (0.7-11.9) 
0.8 
Kreipe et al., 1989 [5] USA Anorexia Nervosa 12-19 1979-1984 F 20.41 (0.5-113.7) 0.6 
Keel et al., 2003 [6] USA Anorexia Nervosa 12-99 1987-2000 F 29.41 (8.0-75.3) 0.8 
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Data source Country Disorder  Age Range  
(years) 
Epoch Range Sexa Relative-risk 
(95% uncertainty 
interval) 
Quality 
score/1c 
Mental disorders        
Korndofer et al., 2003 [7] USA Anorexia Nervosa 10-57 1935-1989 M                                   
F 
-                                   
10.36 (1.3-37.4) 
0.9
Zipfel et al., 2000 [8] Germany Anorexia Nervosa 0-99 1974-1998 F 23.81 (2.9-86.0) 0.8 
Papadopoulos et al., 2009 [9] Sweden Anorexia Nervosa 10-40 1973-2003 F 13.98 (11.2-17.3) 0.8 
Moller-Madsen, 1998 [10] Denmark Anorexia Nervosa 0-99 1970-1994 M               
F 
31.75 (3.8-114.7)                
20.25 (11.6-32.9) 
0.9 
Signorini et al., 2007 [11] Italy Anorexia Nervosa 10-52 1994-2003 F 6.8 (0.2-37.9) 0.8 
Qin & Nordentoft, 2005 [12] Denmark Schizophrenia 0-99 1981-1997 M                       
F 
11.8 (10.9-12.8)                 
12.6 (11.4-13.9) 
0.8 
Riala et al., 2007 [13] Finland Schizophrenia 0-33   1966-2001 M 13.7 (5.2-36.1)                   
19.5 (4.2-90.8) 
0.9 
Illicit drug use disorders       
Pavarin, 2008 [14] Italy Cocaine dependence 0-99 1989-2004 P 10.3(00.01-32.2) - 
Tyndall et al., 2001 [15] Canada Cocaine dependence 14-61 1996-2004 P 15.1(4.01-31.0) - 
Fugelstad et al., 1997 [16] Sweden Amphetamine dependence 
Opioid dependence 
0-99 1985-1992 P 4.3(1.1-8.6) 
13.9(10.6-30.3) 
- 
Stenbacka et al., 2007 [17] Sweden Opioid dependence 14-47 1967-2003 P 8.03(5.6-10.7) - 
Miller et al., 2007 [18] Canada Opioid dependence 0-29 1996-2004 P 10.1(0.01-25.1) - 
Wang et al., 2005 [19] USA Cocaine dependence 0-99 1988-2001 P 3.04(0.01-7.8) 
 
- 
Goldstein et al., 1995 [20] USA Opioid dependence 13-60 1969-1993 P 3.2(1.3-5.1) - 
Soyka et al., 2006 [21] Germany Opioid dependence 17-62 1993-1994 P 7.2(0.01-17.8) - 
Fugelstad et al., 1998  [22] Sweden Opioid dependence 20-99 1986-1993 P 13.9(0.01-38.5) - 
Antolini et al., 2006 [23] Italy Opioid dependence 0-99 1975-1999 P 6.7(4.3-9.5) - 
Brancato et al., 1995 [24] Italy Opioid dependence 18-38 1985-1994 P 18.3(0.01-58.04) - 
Galli & Musicco., 1994 [25] Italy Opioid dependence 14-57 1980-1991 P 6.7(2.6-11.6) - 
Manfredi et al., 2006 [26] Italy Opioid dependence 10-62 1977-2002 P 6.5(2.4-11.6) - 
Eskild et al., 1993 [27] Norway Opioid dependence 15-44 1985-1991 P 13.3(5.6-23.6) - 
Odegard et al., 2007 [28] Norway Opioid dependence 18-54 1981-2003 P 11.9(6.9-18.5) - 
Rossow., 1994 [29] Norway Opioid dependence 16-67 1961-1992 P 16.2(12.3-20.4)  
Risser et al., 2001 [30] Austria Opioid dependence 0-99 1995-1997 P 5.7(0.01-16.8) - 
Bartu et al., 2004 [31] Australia Opioid dependence 18-50 1985-1998 P 1.5(1.1-1.97) - 
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Data source Country Disorder  Age Range  
(years) 
Epoch Range Sexa Relative-risk 
(95% uncertainty 
interval) 
Quality 
score/1c 
Illicit drug use disorders       
Degenhardt et al., 2009 [32] Australia Opioid dependence 20-40 1985-2005 P 4.98(4.5-5.5) - 
Digiusto et al.,  2004 [33] Australia Opioid dependence 0-99 1998-2202 P 13.6(0.01-47.3) - 
Tait et al., 2008 [34] Australia Opioid dependence 18-35 1997-2002 P 3.9(1.3-7.3) - 
Vlahov et al., 2005 [35] USA Opioid dependence 0-99 1988-2005 P 2.7(0.01-8.2) - 
Vlahov et al., 2008 [36] USA Opioid dependence    3.9(1.3-7.3) - 
Oppenheimer et al., 1994 
[37] 
United Kingdom Opioid dependence 17-52 1969-1981 P 4.8(0.01-12.6) - 
Alcohol dependencec        
Wilcox et al 2004c [38] USA, Kuwait, 
Sweden 
Spain, 
United Kingdom 
Alcohol use disorders - - P 9.8 (8.98–10.7)  
Note. NOS: Not otherwise specified;  aSex: Males (M), Female (F), Persons(P). bQuality scores calculated for mental disorders only due to insufficient data for substance use. Studies scored out of 8 where 
studies reporting gender specific estimates =2 and person estimates only=1; studies derived from population representative samples= 2 and hospitalised samples=1; studies covering the entire lifespan=2 and 
only a specific age group=1; studies using a prospective design=2 and a retrospective design=1. RR estimate for alcohol dependence obtained from an existing literature review and meta-analysis of 12 studies 
[39].  Due to paucity of data estimates based on clinical samples were also included for bipolar disorder and anorexia nervosa. The difference in representativeness of each sample was reflected in the quality 
indices. 
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Table S2:  Pooled relative-risk associated to mental and substance use disorders as a risk factor for 
suicide. 
 Pooled Relative-risk (95% UI) 
Disorder Overall  Male Female  
Major Depressive disorder QE: 19.9 (9.5-41.7) 
 
RE:18.6 (9.02-38.5) 
QE: 17.7  (7.6-41.2) 
 
RE:16.5 (7.2-37.5) 
QE: 28.7 (6.2-133.5) 
 
RE:28.7 (6.2-133.5) 
Bipolar Disorder QE: 5.7 (2.6-12.4) 
 
RE: 2.9 (0.7-11.7) 
QE:6.3 (2.6-15.2) 
 
RE: 2.8 (0.4-20.9) 
QE: 2.8 (0.1-19.2) 
 
RE:2.7 (0.4-18.4) 
Anxiety Disorder QE: 2.7  (1.7-4.3) 
 
RE:2.7 (1.7-4.3) 
QE:2.8 (1.6-5.2) 
 
RE:2.8 (1.6-5.02) 
QE: 2.4 (1.0-5.6) 
 
RE:2.4 (0.7-8.6) 
Anorexia Nervosa QE: 7.57 (2.24-25.62) 
 
RE:6.9 (4.1-11.5) 
QE:6.17 (3.00-12.65) 
 
RE:6.2 (2.8-11.8) 
QE: 8.63 (1.69-43.93) 
 
RE:7.7 (3.7-15.9) 
Schizophrenia QE: 12.6  (11.01-14.5) 
 
RE:12.1 (11.4-12.9) 
QE: 12.04 (10.3-14.03) 
 
RE:11.8 (10.9-12.8) 
QE: 13.4 (10.6-16.8) 
 
RE:12.6 (11.4-13.9) 
Alcohol dependencea RE: 9.8 (8.98–10.7) 
 
RE: 4.8 (4.4–5.2) RE: 16.9 (12.5–22.4) 
Cocaine dependence  RE: 16.9 (6.01-47.2) 
 
- - 
Opioid dependence RE: 6.9 (4.5-10.5)  
 
- - 
Amphetamine dependence RE: 4.5 (1.1-9.03) - - 
Note. 95% UI: 95% uncertainty interval; QE: Quality effects model estimate; RE: Random effects model estimate;  
a
Estimates for alcohol dependence were extracted from Wilcox et al [1]; There was sufficient data to calculate quality 
effects estimates for mental disorders only. There insufficient data to calculate sex specific estimates for illicit drug use 
disorders. 
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Table S3: Summary of studies reporting the proportion of suicide cases attributable to mental and substance use disorders. 
 
Data source Country Epoch 
range 
Age 
range 
Sex
a 
Proportion 
%
b 
Quality 
Score
c
 /1 
Included Disorders 
Foster et al., 1997 (1) Ireland 1992-1993 14-99 M 
 
F 
82.8 
 
100 
0.9 Mood, Substance, Psychotic, Anxiety, Somatoform, 
Organic Adjustment, Other axis l disorders 
Schneider et al., 2005 (2) Germany 1999-2000 0-99 M 
 
F 
90.4 
 
88.1 
0.7 Mood, Substance, Psychotic disorders 
Groholt et al., 1997 (3) Norway 1990-1992 8-19 M 
 
F 
74.7 
 
73.3 
0.8 Mood, Disruptive, Psychotic, Adjustment, Substance 
disorders  
Henriksson et al., 1993 (4) Finland 1987-1988 10-89 M 
 
F 
97.5 
 
100 
1.0 Mood, Substance, Psychotic, Organic , Anxiety, 
Adjustment, Personality disorders 
Asgard, 1990 (5) Denmark 1982-1982 15-99 
 
 
F 
 
 
99.0 
 
 
0.6 Mood, Psychotic , Substance, Anxiety, Adjustment, 
Organic disorders 
Runeson, 1989 (6) Sweden 1984-1989 15-29 P 98.3 0.4 Mood, Eating, Dementia, Substance, Psychotic , 
Anxiety, Somatization, Adjustment, Personality 
disorders 
Waern et al., 2002 (7) Sweden 1994-1996 65-97 P 96.5 0.4 Mood, Substance, Anxiety, Psychotic  disorders, 
dementia 
Boardman et al., 1999 (8) UK 1991-1995 14-89 P 71.2 0.6 Mood, Psychotic, Substance, Organic , Personality 
disorders,  
Cavanagh et al., 1999 (9) UK 1996-1998 N/S P 97.8 0.6 Mood, Psychotic, Anxiety, Substance, Personality 
disorders  
Harwood et al., 2001 (10) UK 1995-1998 60-99 P 77.0 0.6  Mood, Psychotic, Substance-related, Schizophrenia, 
Sexual, Adjustment, Somatoform,  Organic, Personality 
disorders 
Houston et al., 2001 (11) UK 1993-1995 15-24 P 70.4 0.4 Mood, Psychotic,  Substance, Anxiety, Somatoform, 
Gender identity, Eating disorders  
Appleby et al., 1999 (12) UK 1995-1996 13-35 P 90.5 0.3 N/S 
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Data source Country Epoch 
range 
Age 
range 
Sex
a 
Proportion 
%
b 
Quality 
Score
c
 /1 
Included Disorders 
Portzky et al., 2009 (13) Belgium 1997-2001 15-19 P 100 0.4 
 
Mood, Psychotic, Anxiety, Substance, Adjustment 
Hyperkinetic, Aspergers, Eating, Impulsive, Gender 
identity, Conduct, Body dysmorphic disorders 
Pompili et al., 2008 (14) Italy 1994-2004 15-96 P 48.9 0.3 
 
Mood, Substance, other disorders  
Isometsa et al., 1997 (15) Finland 1987-1988 10-89 P 99.1 0.8 
 
Mood, Substance, Psychotic, Organic , Anxiety, 
Adjustment, Personality, other axis I and II disorders 
Almasi et al., 2009 (16) Hungary 2002-2004 30-62 P 69.1 0.6 Mood, Psychotic, Anxiety, Eating disorders 
Arato et al., 1988 (17) Hungary 1985-1985 0-99 M 
 
F 
75.7 
 
61.9 
0.7 
 
Mood, Somatisation, Psychotic, Substance disorders 
Zonda, 2006 (18) Hungary N/S-N/S N/S P 81.0 0.2 Mood, Substance disorders 
Brent et al., 1999 (19) USA 1989-1991 13-19 M 
 
F 
82.4 
 
81.0 
0.7 
 
Mood, Anxiety, Substance, Conduct/ Antisocial 
disorders 
Shaffer et al., 1996 (20) USA 1984-1986 0-20 M 
 
F 
90.4 
 
92.0 
0.8 Mood, Psychotic, Anxiety, Substance, Adjustment, 
Disruptive , Eating disorders 
Conwell et al., 1991 (21) USA 1987-1988 50-92 M 
 
F 
86.7 
 
100 
0.7 
 
Mood, Substance, Anxiety, Dementia/ Delirium 
disorders 
Fowler et al., 1986 (22) USA 1981-1983 10-29 P 86.5 0.3 
 
Mood, Substance, Conduct, Psychotic, Adjustment, 
Personality disorders 
Rich et al., 1986 (23) USA 1981-1983 0-99 P 93.5 0.6 
 
Mood, Psychotic, Organic, Substance, Adjustment, 
Child-adolescent, Axis II disorders 
Shafii et al., 1988 (24) USA NS-NS 11-19 P 95.2 0.2 Mood, Other disorders 
Preville et al., 2005 (25) Canada 1998-1999 60-99 P 42.1 0.4 Mood, Anxiety, Substance disorders 
Lesage et al., 1994 (26) Canada 1987-1989 18-35 M 88.0 0.7 Mood, Psychotic, Substance, Organic , Anxiety, Sexual, 
Somatoform, Childhood developmental, Disruptive, 
Personality disorders 
McGirr et al., 2006 (27) Canada 2000-2005 28-57 M 
 
F 
93.4 
 
90.5 
0.7 Mood, Anxiety, Psychotic, Substance  disorders 
Palacioa et al., 2007 (28) Colombia N/S-N/S 19-42 P 89.8 0.3 Mood, Substance, Psychotic, Adaptive, Personality 
disorders 
Thacore et al., 2000 (29) Australia 1992-1996 16-86 P 60.1 0.4 Mood, Psychotic, Substance, Other disorders 
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Data source Country Epoch range Age 
range 
Sexa Proportion %b Quality Scorec /1 Included Disorders 
Graham et al., 1992 (30) Australia 1986-1988 15-59 P 57.1 0.6 Mood, Psychotic, Organic, Substance,  Conduct, Personality, Other 
disorders 
Kurihara et al., 2009 (31) Indonesia 2007-2007 13-87 P 80.0 0.6 
 
Mood, Psychotic, Anxiety, Substance, Adjustment disorders  
Chen et al 2006 (32) China-Hong 
Kong 
2002-2004 15-59 P 80.7 0.4 
 
Mood, Substance, Other disorders 
Chiu et al., 1994 (33) China-Hong 
Kong 
2000-2001 60-99 M 
 
F 
87.5 
 
84.2 
0.8 
 
Mood, Anxiety, Psychotic, Adjustment, Dementia, Somatoform, 
Substance disorders  
Zhang et al., 2010 (34) China 2005-2008 15-34 M 
 
F 
55.1 
 
39.3 
0.9 
 
Mood, Psychotic, Anxiety, Substance, Acute stress, Pathological 
gambling disorders 
Zhang et al., 2009 (35) China 2001-2003 0-99 M 
 
F 
72.9 
 
55.6 
0.8 
 
 
Mood, Psychotic, Anxiety, Substance disorders 
Phillips et a., 2002 (36) China 1995-2000 10-99 P 62.6 0.7 N/S 
Li et al., 2008 (37) China 1995-2000 15-24 P 44.7 0.6 N/S 
Zhang et al, 2004 (38) China 2001-2002 N/S P 75.8 0.4 
 
Mood, Anxiety, Psychotic, Substance, Eating disorders 
Cheng, 1995 (39) Taiwan 1989-1991 15-99 P 98.3 0.9 
 
Mood, Organic, Psychotic,  Substance, Mental retardation, Adjustment, 
Pathological gambling disorders 
Vijayakumar et al., 1999 (40) India 1994-1995 14-99 P 88.0 0.6 
 
Mood, Substance, Anxiety, Somatoform, Adjustment, Other disorders 
Gururaj et al., 2004 (41) India 2001-2002 0-99 P 42.8 0.4 N/S 
Khan et al., 2005 (42) India 2003-2003 15-35 P 36.0 0.3 N/S 
Khan et al., 2008 (43) Pakistan 2003-2003 N/S P 96.0 0.8 Mood, Psychotic , Adjustment, Acute stress reaction, Substance, 
Mental retardation, Personality disorders 
Note. 
a
Sex: Males (M), Female (F), Persons(P);  
b
Proportion of suicide cases occurring as a result of a mental and substance use disorders; 
c
 Studies scored out of 9 
where studies reporting male and female estimates =2, male or female estimates = 1, person estimates only=0; studies with a clearly reported sample and observation 
period = 2 and unreported sample and observation period =1; studies using national representative data =3, regionally-representative data =2, community-
representative data=1; studies covering the entire lifespan=2 and only a specific age group=1. 
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Table S4: Pooled proportion of suicide cases attributable to mental and substance use disorders  
 
Region Pooled proportion  
(95% UI) 
Number of 
studies 
Number of countries 
Group 1: China, India, Taiwan    
Overall  QE: 68.3% (55.2%-80.0%) 
 
RE: 69.4% (53.5%-83.4%) 
9 3 
Male QE: 63.4% (46.2%-79.1%) 
 
RE: 76.3% (50.1%-90.6%) 
1 3 
Female QE: 48.6% (29.1%-68.3%) 
 
RE: 61.0% (30.5%-87.9%) 
1 3 
Group 2: Other countries
a    
Overall QE: 84.5% (78.6%-89.6%) 
 
RE: 83.8% (76.5%-90.0%) 
34 17 
Male QE: 88.8% (84.1%-92.8%) 
 
RE: 87.9% (82.9%-92.1%) 
12 7 
Female QE: 93.3% (87.2%-97.6%) 
 
RE: 94.2% (86.5%-99.0%) 
12 8 
Note.95% UI: 95% uncertainty interval; QE: Quality effect model estimate, RE: Random effects model estimate;
 
a
Group 2 countries: Includes studies from Australia, USA, Canada, Colombia, Hungary, United Kingdom, Belgium, 
Italy, Germany, Sweden, Ireland, Norway, Finland, Indonesia, Pakistan. 
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Table S5: Suicide DALYs (i.e. YLLs) attributable to mental and substance use disorders in 1990 
and 2010 
 
 1990   2010  
YLL 95% UI YLL 95% UI 
 Mean Lower Upper Mean Lower  Upper 
By sex       
Male 11,400,000 7,700,000 15,800,000 14,900,000 95000,00 20,100,000 
Female 6,800,000 4,000,000 9,900,000 7,600,000 4,400,000 10,600,000 
By age             
5-9 years 20,000 10,000 40,000 20,000 10,000 30,000 
10-14 years 300,000 200,000 500,000 300,000 100,000 600,000 
15-19 years 2,200,000 1,300,000 3,100,000 2,500,000 1,500,000 3,800,000 
20-24 years 3,100,000 2,000,000 4,300,000 3,400,000 2,000,000 4,900,000 
25-29 years 2,600,000 1,700,000 3,500,000 2,900,000 1,900,000 4,000,000 
30-34 years 2,200,000 1,500,000 2,900,000 2,400,000 1,500,000 3,200,000 
35-39 years 1,900,000 1,300,000 2,600,000 2,200,000 1,400,000 3,100,000 
40-44 years 1,500,000 1,000,000 2,000,000 2,000,000 1,400,000 2,900,000 
45-49 years 1,100,000 800,000 1,600,000 1,800,000 1,200,000 2,500,000 
50-54 years 1,100,000 800,000 1,600,000 1,600,000 1,000,000 2,300,000 
55-59 years 800,000 500,000 1,200,000 1,200,000 700,000 1,800,000 
60-64 years 600,000 400,000 900,000 800,000 500,000 1,200,000 
65-69 years 400,000 200,000 600,000 500,000 300,000 800,000 
70-74 years 200,000 100,000 300,000 400,000 200,000 600,000 
75-79 years 200,000 100,000 200,000 300,000 100,000 400,000 
80 + years 100,000 100,000 200,000 200,000 100,000 300,000 
By region             
Asia Pacific, 
High Income 
600,000 400,000 1,000,000 800,000 400,000 1,200,000 
Asia, Central 300,000 200,000 400,000 400,000 200,000 500,000 
Asia, East 5,300,000 2,900,000 7,400,000 3,500,000 2,200,000 6,100,000 
Asia, South 4,000,000 2,600,000 6,000,000 8,800,000 4,800,000 12,600,000 
Asia, 
Southeast 
1,100,000 700,000 1,500,000 1,300,000 800,000 1,800,000 
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  1990   2010  
YLL 95% UI YLL 95% UI 
Mean Lower Upper Mean Lower  Upper 
By region       
Australasia 80,000 50,000 100,000 70,000 50,000 100,00
0 
Caribbean 100,000 100,000 100,000 100,000 100,000 100,000 
Europe, 
Central 
600,000 400,000 800,000 500,000 300,000 600,000 
Europe, 
Eastern 
2,000,000 1,400,000 2,700,000 1,800,000 1,200,000 2,800,000 
Europe, 
Western 
1,500,000 1,000,000 2,000,000 1,200,000 800,000 1,700,000 
Latin America, 
Andean 
50,000 40,000 70,000 90,000 50,000 100,000 
Latin America, 
Central 
200,000 160,000 400,000 400,000 200,000 500,000 
Latin America, 
Southern 
200,000 110,000 200,000 200,000 100,000 300,000 
Latin America, 
Tropical 
300,000 200,000 400,000 400,000 300,000 500,000 
North Africa / 
Middle East 
200,000 100,000 300,000 500,000 200,000 700,000 
North 
America, High 
Income 
1,100,000 700,000 1,400,000 1,100,000 800,000 1,500,000 
Oceania 20,000 10,000 30,000 30,000 20,000 50,000 
Sub-Saharan 
Africa, Central 
80,000 50,000 100,000 200,000 100,000 300,000 
Sub-Saharan 
Africa, East 
400,000 300,000 600,000 800,000 500,000 1,100,000 
Sub-Saharan 
Africa, 
Southern 
100,000 50,000 200,000 200,000 100,000 300,000 
Sub-Saharan 
Africa, West 
100,000 60,000 200,000 200,000 100,000 300,000 
By disorder             
Alcohol 
dependence 
4,200,000 3,200,000 5,300,000 4,900,000 3,600,000 6,300,000 
Amphetamine 
dependence 
700,000 300,000 1,400,000 900,000 300,000 1,700,000 
Anorexia 
nervosa 
40,000 10,000 100,000 60,000 10,000 200,000 
Anxiety 
disorder 
2,100,000 800,000 3,600,000 2,700,000 1,000,000 4,800,000 
Bipolar 
disorder 
1,600,000 500,000 3,300,000 2,000,000 600,000 4,000,000 
Cocaine 
dependence 
300,000 100,000 600,000 300,000 100,000 700,000 
Major 
depressive 
disorder 
13,500,000 8,000,000 18,900,000 16,700,000 9,900,000 23,300,000 
Opioid 
dependence 
500,000 300,000 800,000 700,000 400,000 1,100,000 
Schizophrenia 1,400,000 1,000,000 1,700,000 1,700,000 1,300,000 2,200,000 
Note. DALYs: Disability adjusted life years; YLLs: years of life lost; 95% UI: 95% uncertainty interval; Absolute YLLs 
rounded to 100,000 
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Table S6: Suicide DALYs (i.e. YLLs) attributable to each mental and substance use disorders in 2010 by region 
 
Region Alcohol use 
disorder 
Amphetamin
e dependence 
 Anorexia 
nervosa 
Anxiety 
disorder 
Bipolar 
disorder 
Cocaine 
dependence 
Major 
depressive 
disorder 
Opioid 
dependence 
Schizophrenia 
Asia Pacific, High Income         
Mean  190,000 30,000 10,000 90,000 70,000 20,000 520,000 30,000 70,000 
95% UI: Lower 250,000 70,000 40,000 170,000 160,000 50,000 860,000 70,000 90,000 
             Upper 110,000 10,000 2,000 30,000 20,000 10,000 240,000 10,000 40,000 
Asia, Central          
Mean  120,000 20,000 300 50,000 30,000 4,000 240,000 10,000 30,000 
95% UI: Lower 180,000 30,000 1,000 90,000 60,000 10,000 370,000 20,000 50,000 
             Upper 90,000 10,000 50 20,000 10,000 2,000 140,000 10,000 20,000 
Asia, East          
Mean 870,000 100,000 4,000 260,000 330,000 10,000 2,480,000 70,000 340,000 
95% UI: Lower 1,450,000 220,000 10,000 520,000 700,000 20,000 4,450,000 140,000 560,000 
             Upper 590,000 30,000 1,000 90,000 100,000 3,000 1,250,000 30,000 240,000 
Asia, South          
Mean  1,820,000 370,000 2,000 1,090,000 770,000 100,000 6,530,000 310,000 600,000 
95% UI: Lower 2,630,000 800,000 10,000 2,020,000 1,620,000 220,000 9,730,000 530,000 820,000 
             Upper 1,020,000 110,000 300 410,000 250,000 30,000 3,280,000 150,000 330,000 
Asia, Southeast          
Mean  210,000 90,000 1,000 140,000 120,000 4,000 970,000 30,000 100,000 
95% UI: Lower 300,000 180,000 2,000 270,000 250,000 10,000 1,430,000 50,000 150,000 
             Upper 160,000 30,000 100 50,000 40,000 1,000 570,000 10,000 70,000 
Australasia          
Mean 20,000 5,000 1,000 10,000 10,000 2,000 50,000 4,000 10,000 
95% UI: Lower 20,000 10,000 2,000 20,000 10,000 4,000 70,000 10,000 10,000 
             Upper 10,000 2,000 100 5,000 2,000 1,000 30,000 2,000 5,000 
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Region Alcohol use 
disorder 
Amphetamin
e dependence 
 Anorexia 
nervosa 
Anxiety 
disorder 
Bipolar 
disorder 
Cocaine 
dependence 
Major 
depressive 
disorder 
Opioid 
dependence 
Schizophrenia 
Caribbean          
Mean  20,000 3,000 200 10,000 10,000 5,000 70,000 3,000 10,000 
95% UI: Lower 30,000 10,000 1,000 20,000 20,000 10,000 90,000 10,000 10,000 
             Upper 20,000 1,000 30 4,000 2,000 2,000 40,000 1,000 5,000 
Europe, Central          
Mean  110,000 20,000 1,000 70,000 40,000 4,000 340,000 10,000 50,000 
95% UI: Lower 150,000 50,000 3,000 130,000 90,000 10,000 490,000 20,000 70,000 
             Upper 80,000 10,000 200 30,000 10,000 1,000 200,000 10,000 30,000 
Europe, Eastern          
Mean  540,000 30,000 2,000 160,000 150,000 10,000 1,410,000 50,000 130,000 
95% UI: Lower 850,000 80,000 10,000 360,000 320,000 30,000 2,240,000 110,000 210,000 
             Upper 400,000 10,000 300 50,000 50,000 5,000 820,000 30,000 90,000 
Europe, Western          
Mean 280,000 40,000 10,000 170,000 90,000 20,000 920,000 40,000 70,000 
95% UI: Lower 380,000 80,000 40,000 290,000 190,000 50,000 1,330,000 70,000 90,000 
             Upper 220,000 10,000 2,000 70,000 30,000 10,000 550,000 20,000 50,000 
Latin America, Andean          
Mean  30,000 3,000 100 10,000 10,000 4,000 60,000 3,000 10,000 
95% UI: Lower 40,000 10,000 200 30,000 10,000 10,000 90,000 10,000 10,000 
             Upper 20,000 1,000 10 4,000 2,000 1,000 30,000 1,000 3,000 
Latin America, Central          
Mean  80,000 20,000 1,000 60,000 40,000 10,000 300,000 10,000 30,000 
95% UI: Lower 100,000 50,000 2,000 100,000 80,000 20,000 430,000 20,000 40,000 
             Upper 60,000 10,000 100 20,000 10,000 3,000 160,000 10,000 20,000 
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Region Alcohol use 
disorder 
Amphetamin
e dependence 
 Anorexia 
nervosa 
Anxiety 
disorder 
Bipolar 
disorder 
Cocaine 
dependence 
Major 
depressive 
disorder 
Opioid 
dependence 
Schizophrenia 
Latin America, Southern          
Mean  40,000 10,000 1,000 30,000 20,000 10,000 150,000 10,000 10,000 
95% UI: Lower 60,000 20,000 2,000 60,000 40,000 20,000 210,000 10,000 20,000 
             Upper 30,000 3,000 100 10,000 10,000 3,000 90,000 3,000 10,000 
Latin America, Tropical          
Mean  80,000 20,000 200 60,000 30,000 20,000 310,000 10,000 30,000 
95% UI: Lower 120,000 40,000 1,000 100,000 70,000 40,000 430,000 20,000 50,000 
             Upper 50,000 10,000 30 20,000 10,000 10,000 190,000 4,000 10,000 
North Africa / Middle 
East 
         
Mean  40,000 20,000 2,000 80,000 40,000 10,000 400,000 20,000 40,000 
95% UI: Lower 50,000 50,000 10,000 160,000 90,000 30,000 580,000 40,000 50,000 
             Upper 20,000 10,000 300 30,000 10,000 4,000 190,000 10,000 20,000 
North America, High Income         
Mean 220,000 30,000 10,000 200,000 100,000 60,000 850,000 30,000 120,000 
95% UI: Lower 270,000 70,000 40,000 350,000 200,000 130,000 1,180,000 50,000 150,000 
             Upper 160,000 10,000 2,000 80,000 30,000 20,000 510,000 20,000 80,000 
Oceania          
Mean  10,000 1,000 10 4,000 3,000 200 20,000 1,000 2,000 
95% UI: Lower 10,000 3,000 40 10,000 10,000 400 40,000 2,000 10,000 
             Upper 4,000 300 2 1,000 1,000 40 10,000 300 1,000 
Sub-Saharan Africa, Central         
Mean  20,000 10,000 1,000 30,000 20,000 1,000 140,000 3,000 10,000 
95% UI: Lower 40,000 20,000 2,000 60,000 30,000 3,000 220,000 10,000 20,000 
             Upper 10,000 2,000 100 10,000 4,000 400 80,000 1,000 10,000 
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Region Alcohol use 
disorder 
Amphetamin
e dependence 
 Anorexia 
nervosa 
Anxiety 
disorder 
Bipolar 
disorder 
Cocaine 
dependence 
Major 
depressive 
disorder 
Opioid 
dependence 
Schizophrenia 
Sub-Saharan Africa, East          
Mean  110,000 40,000 100 120,000 70,000 10,000 650,000 20,000 50,000 
95% UI: Lower 150,000 80,000 200 220,000 140,000 10,000 930,000 30,000 60,000 
             Upper 70,000 10,000 10 50,000 20,000 2,000 380,000 10,000 30,000 
Sub-Saharan Africa, Southern         
Mean 60,000 10,000 100 20,000 20,000 2,000 160,000 10,000 10,000 
95% UI: Lower 90,000 20,000 300 50,000 40,000 5,000 240,000 10,000 20,000 
             Upper 40,000 4,000 10 10,000 5,000 1,000 80,000 2,000 10,000 
Sub-Saharan Africa, West          
Mean  20,000 10,000 10 20,000 20,000 2,000 140,000 4,000 10,000 
95% UI: Lower 20,000 20,000 40 50,000 40,000 4,000 220,000 10,000 20,000 
             Upper 10,000 3,000 2 10,000 5,000 1,000 80,000 2,000 10,000 
Note. DALYs: Disability adjusted life years; YLLs: years of life lost; 95% UI: 95% uncertainty interval; Absolute YLLs rounded to 100,000 
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Appendix Six  
 
Supplementary text to Chapter Seven 
 
 
 
Note. Figure has been scaled to approximate prevalence proportions; 
a
Prevalence of CSA and IPV in females estimated by DisMod-MR; 
b
Prevalence of dual exposure to CSA and 
IPV in females estimated from WHO’s multi-country study on women’s health and domestic violence. For the purposes of this paper, single and dual exposures to CSA and IPV in 
males did not need to be estimated given the lack of evidence for the association between IPV and depression in males. 
Figure S1. Illustration of the prevalence of single and dual exposure to lifetime child sexual abuse (CSA) and intimate partner violence (IPV) in 
females 
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Appendix Seven 
Supplementary text to Chapter Eight 
 
Text S1. Media coverage in response to the data presented in Chapter Three 
 
Source: News article, The Australian, 4
th
 August, 2012 
Title: Depression could be Third World disease 
Author: Stephen Matchett 
 
“DEPRESSION is a disease of developing countries rather than a unique affliction of 
consumer societies, according to the first global study of worldwide mental illness in a 
generation. 
 
A statistical analysis by a team led by University of Queensland researcher Alize Ferrari 
found North America, Western Europe and Australia have the lowest rates of major 
depressive disorders, while South Asia, Africa and the Middle East lead the world for 
incidences of major depressive disorders. 
 
However, a separate study by her colleague Amanda Baxter and other researchers identifies 
anxiety disorders as a disease of affluence, with Africans far less prone to them than Euro 
and Anglo cultures. The two papers are the first findings of a Bill & Melinda Gates 
Foundation research project at the University of Queensland led by Harvey Whiteford. 
His team is one of 54 expert groups around the world participating in the Global Burden of 
Disease project, which follows another World Health Organisation project in 1990. 
Professor Whiteford said the Gateses' motivation was to discover the effectiveness of 20 
years of global health spending. 
 
He said the increase in incidence of major depression in the developing world was a result of 
an improvement in basic health services. "Better maternal health and better infectious 
diseases control mean people in the developing world now live into the age group where 
mental health disorders emerge, which is the late teens and early 20s," he said. But 
traditional cultures can be better at dealing with anxiety, a sense of disquiet and foreboding 
out of proportion to real-world risk, thanks to strong systems of family support that 
encourage resilience among individuals. 
 
However, Professor Whiteford warns the apparent lower level of anxiety in poor and 
conflict ridden countries than in the West may be more apparent than real, saying Third 
World surveys show low levels of anxiety but higher incidences of medically unexplained 
complaints. "People are just as anxious but they report it as physical symptoms," he says. 
Professor Whiteford is optimistic that identifying the extent of anxiety and major depression 
will lead to treatments that reduce the social impact and individual burden of these illnesses. 
While about 20 per cent of depression cases are genetic -- and while both it and anxiety are 
triggered by factors as diverse as poverty, war and domestic violence – once the symptoms 
are identified medical treatment becomes possible. The WHO funded programs in the 
successor states to Yugoslavia to deal with the trauma of the wars in the region a decade ago 
and Professor Whiteford is in contact with Libyan officials looking to address the impact of 
the recent conflict. "Wars are like infectious disease. They run their course, with depression 
rising, and take decades to drop back," Professor Whiteford said. "Our research will show it 
is possible to measure the disease burden and then come up with ways to reduce it." All 54 
teams have filed their data to the Gates Foundation, with publication of their findings 
scheduled to start in November.” 
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Media coverage in response to the data presented in Chapter Five 
 
Source: News article, BBC News, 6
th
 November 2013 (See: http://www.bbc.co.uk/news/health-
24818048 ) 
Title: Depression-'Second biggest cause of disability' in world. 
Author: Helen Briggs 
 
“Depression is a big problem and we definitely need to pay more attention to it than we are 
now” 
Dr Alize Ferrari, University of Queensland 
Depression was ranked at number two as a global cause of disability, but its impact varied in 
different countries and regions. For example, rates of major depression were highest in 
Afghanistan and lowest in Japan. In the UK, depression was ranked at number three in terms 
of years lived with a disability. 
Dr Alize Ferrari from the University of Queensland's School of Population Health led the 
study. 
"Depression is a big problem and we definitely need to pay more attention to it than we are 
now," she told BBC News. 
"There's still more work to be done in terms of awareness of the disease and also in coming 
up with successful ways of treating it. 
"The burden is different between countries, so it tends to be higher in low and middle 
income countries and lower in high income countries." 
Policy-makers had made an effort to bring depression to the forefront, but there was a lot 
more work to be done, she added. 
"There's lots of stigma we know associated with mental health," she explained. 
"What one person recognizes as disabling might be different to another person and might be 
different across countries as well, there are lots of cultural implications and interpretations 
that come in place, which makes it all the more important to raise awareness of the size of 
the problem and also signs and how to detect it." 
The data - for the year 2010 - follows similar studies in 1990 and 2000 looking at the global 
burden of depression. 
Commenting on the study, Dr Daniel Chisholm, a health economist at the department for 
mental health and substance abuse at the World Health Organization said depression was a 
very disabling condition. 
"It's a big public health challenge and a big problem to be reckoned with but not enough is 
being done."Around the world only a tiny proportion of people get any sort of treatment or 
diagnosis." 
The WHO recently launched a global mental health action plan to raise awareness among 
policy-makers.” 
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Source: Info graphic, Everyday Health Staff , 7
th
 November 2013 (See: 
http://www.everydayhealth.com/depression/depression-a-leading-cause-of-disability-worldwide-
8061.aspx ) 
Title: Depression: A Leading Cause of Disability Worldwide. 
Author: Janet Kim and Jasmine Kim. 
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Web links to other media coverage of the data presented in Chapter Five: 
 
 
 http://www.washingtonpost.com/blogs/worldviews/wp/2013/11/07/a-stunning-map-of-
depression-rates-around-the-world/ 
 
 http://www.newsinmind.com/general-news/depression-second-biggest-cause-of-disability-
in-world 
 
 http://www.everydayhealth.com/depression/depression-a-leading-cause-of-disability-
worldwide-8061.aspx 
 
 http://www.cxvascular.com/nn-latest-news/neuro-news---latest-news/depression-was-
second-leading-cause-of-global-disability-burden-in-2010?highlight=depression 
 
 http://www.odt.co.nz/lifestyle/health-fitness/280195/depression-leading-cause-global-
disability 
 
 http://www.latimes.com/science/sciencenow/la-sci-sn-its-a-sad-sad-sad-sad-world-
depression-and-global-disability-20131105,0,1460569.story#axzz2lziRGLkO 
 
 http://www.globalhealthhub.org/2013/11/06/this-week-in-plos-medicine-global-burden-of-
depression-syphilis-treatment-in-pregnancy/ 
 
 http://www.healthline.com/health-news/mental-depression-a-leading-cause-of-global-
disability-110513 
 
 http://historypsychiatry.com/tag/plos-medicine/ 
 
 http://www.eurekalert.org/pub_releases/2013-11/plos-a103013.php 
 
 http://inagist.com/all/398395653459423232/ 
 
 http://www.medicalnewstoday.com/articles/268367.php 
 
 http://dementianews.wordpress.com/2013/11/06/burden-of-depressive-disorders-findings-
from-the-global-burden-of-disease-study-2010-bbc-news-plos-medicine/ 
 
 http://depression.about.com/b/2013/11/05/depression-is-second-leading-cause-of-disability-
study-says.htm 
 
 http://www.foxnews.com/health/2013/11/06/depression-second-leading-cause-disability-
worldwide/ 
 
 http://io9.com/which-countries-have-the-highest-rate-of-diagnosed-depr-1461353607 
 
 http://www.globalmentalhealth.org/depression-second-biggest-cause-disability-world 
 
 http://www.hypnotherapy-now.co.uk/depression/bbc-depression-second-biggest-cause-of-
disability-in-world/ 
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 http://allafrica.com/stories/201311251248.html 
 
 http://www.insidermedicine.com/archives/Depression_second_leading_cause_of_global_dis
ability_burden_7567.aspx 
 
 http://www.brainphysics.com/news/depression/depression-a-leader-in-global-disability 
 
 http://www.counselheal.com/articles/7548/20131107/experts-call-depression-the-second-
leading-cause-of-disability-in-the-world.htm 
 
 http://www.nursinginpractice.com/article/depression-should-be-global-priority 
 
 http://www.torontosun.com/2013/11/07/depression-is-the-second-biggest-cause-of-
disability-after-back-pain 
 
 http://sfoxwriting.com/2013/11/08/depression-second-biggest-cause-of-disability-in-world/ 
 
 http://www.medscape.com/viewarticle/813896 
 
 http://www.medtiblog.org/2013/11/07/depression-second-largest-cause-of-disability-
worldwide/ 
 
 http://www.philly.com/philly/health/mental-
health/HealthDay681887_20131106_Health_Highlights__Nov__6__2013.html 
 
 http://www.studentnewspaper.org/blog/2013/11/12/recent-report-highlights-global-extent-
of-depression/ 
 
 http://www.advisory.com/Daily-Briefing/2013/11/07/A-global-health-priority-Depression-
among-top-causes-of-disability 
 
 
 
 
 
